glucagon has been researched along with Diabetes Mellitus, Type 2 in 1631 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 152 (9.32) | 18.7374 |
| 1990's | 316 (19.37) | 18.2507 |
| 2000's | 428 (26.24) | 29.6817 |
| 2010's | 492 (30.17) | 24.3611 |
| 2020's | 243 (14.90) | 2.80 |
| Authors | Studies |
|---|---|
| Angarita, L; Bermúdez, V; Cabrera de Bravo, M; Cano, C; Chacín, M; D'Marco, L; Guerrero-Wyss, M; Manzano, A; Martínez, MS; Nava, M; Olivar, LC; Ortiz, R; Salazar, J | 1 |
| Hamajima, H; Hosojima, M; Kabasawa, H; Kitamura, T; Kobayashi, M; Mieno, E; Miyachi, A; Narita, I; Saito, A; Tanabe, N; Yoshizawa, Y | 1 |
| La Sala, L; Pontiroli, AE | 1 |
| Asadi, F; Dhanvantari, S | 1 |
| Del Prato, S; Gallwitz, B; Holst, JJ; Meier, JJ | 1 |
| Choi, YK; Jeon, JH; Kwon, OK; Park, JY; Park, KB | 1 |
| Mandarim-de-Lacerda, CA; Spezani, R | 1 |
| Forman, JL; Gasbjerg, LS; Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; Rosenkilde, MM; van Hall, G; Vilsbøll, T | 1 |
| Arends, R; Bosch, R; Hoefman, S; Petrone, M; Sijbrands, EJG; Snelder, N; Vicini, P | 1 |
| Dupont, G; Gonzalez-Velez, V; Romero-Campos, HE | 1 |
| Cabrera, O; Chepurny, OG; Echeverri, F; Ficorilli, J; Holz, GG; Leech, CA; Schwede, F; Shaw, J | 1 |
| Bao, J; Li, L; Liu, D; Lv, Y; Ni, M; Qi, L; Sj, P; Su, J; Wang, L; Wang, Q; Wei, Q; Xia, H | 1 |
| Holst, JJ | 7 |
| Ahrén, B; Alsalim, W; Göbl, C; Kahleova, H; Morettini, M; Salvatori, B; Tura, A | 1 |
| Bando, S; Fujimoto, K; Ichikawa, R; Miyatsuka, T; Motomiya, T; Shichiri, M; Taguchi, M; Taguchi, T; Takano, K | 1 |
| Alvarez, H; Builes-Montaño, CE; Garcia-Tirado, J; Lema-Perez, L | 1 |
| Kareenhalli, V; Somvanshi, PR; Tomar, M | 1 |
| Eisenberg, Y; Gimbar, RP; Lin, J; Maheswaran, AB | 1 |
| Arrojo E Drigo, R; Avrahami, D; Bautista, A; Briant, LJB; Camunas-Soler, J; Dai, XQ; Dos Santos, T; Johnson, J; Jones, RC; Kaestner, KH; Kim, SK; Light, PE; Lyon, J; MacDonald, PE; Manning Fox, JE; Michelakis, ED; Nie, A; Quake, SR; Rorsman, P; Smith, N; Spigelman, AF; Stein, RW; Walker, EM; Zhang, Y | 1 |
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
| Bao, J; Cheng, H; Li, L; Liu, D; Lv, Y; Qi, L; Qiu, Y; Su, J; Su, X; Sun, J; Wei, Q; Ye, Z; Yu, X; Zhang, Y | 1 |
| Aas Holm, L; Ängquist, L; Christiansen, M; de Retana Alzola, IF; Fonvig, CE; Frithioff-Bøjsøe, C; Hansen, T; Hartmann, B; Holm, JC; Holst, JJ; Jonsson, AE; Lund, MAV; Pedersen, O; Stinson, SE; Sørensen, TIA | 1 |
| Chang, R; Chen, LN; Chen, Y; Cong, Z; Dai, A; Feng, W; Hang, K; Liang, A; Ming, Q; Wang, M; Wang, MW; Wu, B; Xia, T; Xu, HE; Xu, P; Yang, D; Zhang, C; Zhang, Y; Zhao, F; Zhao, L; Zhou, Q; Zou, X | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; DeFronzo, RA; Gastaldelli, A; Lavryneko, O; Solis-Herrera, C; Triplitt, C | 1 |
| Aronson, R; Bandak, B; Hövelmann, U; Knudsen, KM; Pieber, TR; Plum-Mörschel, L; Tehranchi, R; Willard, J | 1 |
| Chepurny, OG; Collier, JJ; Cooney, RN; Holz, GG; Leech, CA; Meng, Q; Molnar, ME; Pruekprasert, N | 1 |
| Birnie, E; Burggraaf, B; Castro Cabezas, M; de Herder, WW; Fernández Arroyo, S; Huisbrink, J; Mulder, MT; Pouw, NMC; Rensen, PCN; van de Geijn, GM; van der Zwan, EM; van Vark-van der Zee, LC | 1 |
| Boulgaropoulos, B; Brunner, M; Haberlander, M; Moser, O; Obermayer-Pietsch, B; Pieber, TR; Raml, R; Sourij, H; Svehlikova, E | 1 |
| Biswas, B; Choubey, A; Dehury, B; Dogra, S; Dwivedi, DK; Gaur, P; Ghosh, S; Girdhar, K; Kumar, S; Mondal, P; Thakur, S | 1 |
| Dorn, GW; Fujimoto, K; Honzawa, N; Ikeuchi, Y; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Nishimura, R; Tabei, Y; Utsunomiya, K; Wada, E; Yokota-Hashimoto, H | 1 |
| Jain, G; Kumar, R; Pahadiya, H; Srivastava, S | 1 |
| Coskun, T; DeVries, JH; Haupt, A; Heise, T; Li, J; Mari, A; Mather, KJ; Milicevic, Z; Pratt, EJ; Thomas, MK; Urva, S | 1 |
| Chalk, R; Gough, S; Rorsman, P; Spiliotis, II | 1 |
| Starling, S | 1 |
| Barbot, M; Basso, D; Ceccato, F; Giordano, C; Guarnotta, V; Mondin, A; Regazzo, D; Scaroni, C | 1 |
| Dan, K; Fushimi, Y; Iwamoto, H; Iwamoto, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kubo, M; Mune, T; Nakanishi, S; Nakao, E; Sanada, J; Shimoda, M; Sugisaki, T; Takahashi, K; Tatsumi, F; Wamata, R | 1 |
| Martens, P; Mathieu, C; Vanassche, T | 1 |
| Cherney, DZI; Drucker, DJ; Udell, JA | 1 |
| Cao, J; Chang, X; Gao, M; Jiang, C; Yin, Z; Zhang, D; Zhang, J; Zhao, Y; Zheng, R | 1 |
| An, Z; Cai, J; Ge, S; Gu, T; Guo, H; Guo, Y; Lin, D; Lu, Y; Sui, C; Wang, N; Ying, R; Zha, K; Zhao, Y; Zhou, Y | 1 |
| Casanueva-Álvarez, E; Cózar-Castellano, I; Fernández-Díaz, CM; González-Casimiro, CM; Kaestner, KH; Leissring, MA; Merino, B; Perdomo, G; Postigo-Casado, T; Quesada, I | 1 |
| Elmelund, E; Galsgaard, KD; Holst, JJ; Kjeldsen, SAS; Knop, FK; Richter, MM; Suppli, MP; Wewer Albrechtsen, NJ; Winther-Sørensen, M | 1 |
| Perry, RJ | 1 |
| Pan, X; Tao, S; Tong, N | 1 |
| Bommer, GT; Corbet, C; Drappier, M; Feron, O; Herinckx, G; Hue, L; Jacobs, R; Johanns, M; Messens, J; Rider, MH; Steinberg, GR; Tajeddine, N; Vertommen, D; Young, D | 1 |
| Holst, JJ; Laferrère, B; Mark, V; Prasad, M; Shah, A | 1 |
| Anderlova, K; Bendlova, B; Krejci, H; Pacini, G; Sladek, M; Sumova, A; Tura, A; Vankova, M; Vcelak, J; Vejrazkova, D | 1 |
| Deng, H; Feng, L; Han-Zhang, H; Jiang, H; Li, L; Liu, M; Ma, Q; Pang, S; Qian, L; Song, B; Yang, W; Yu, T; Zhang, Y | 1 |
| Bernstein, HG; Dobrowolny, H; Keilhoff, G; Steiner, J | 1 |
| Andrews, JC; Arora, P; Bailey, KR; Cobelli, C; Dalla Man, C; Laurenti, MC; Matveyenko, A; Rizza, RA; Vella, A | 1 |
| Arunagiri, A; Arvan, P; Chen, X; Mao, Y; Matson, K; Mohan, R; Schoenborn, J; Tang, X; Wang, Z; Zhang, S | 1 |
| Dai, S; Li, L; Liu, JY; Wang, N; Wang, X; Wu, W; Xu, ZH; Zhao, QX | 1 |
| Biancolin, AD; Brubaker, PL; Jeong, H; Mak, KWY; Yuan, Z | 1 |
| Billeter, AT; Israel, B; Kopf, S; Müller-Stich, BP; Nawroth, PP; Scheurlen, KM; Schirmacher, P; Straub, BK | 1 |
| Asadi, F; Chung, YH; Kong, C; Ng, XW; Piston, DW; Ustione, A | 1 |
| Story, LH; Wilson, LM | 1 |
| Ahlqvist, E; Artner, I; Asplund, O; Chandra, V; Groop, L; Hansson, O; Hatem, G; Ibberson, M; Ibrahim, H; Korsgren, O; Krus, U; Mansour-Aly, D; Marchetti, P; Mulder, H; Otonkoski, T; Ottosson-Laakso, E; Prasad, RB; Renström, E; Solimena, M; Storm, P; Tuomi, T; Wierup, N; Wollheim, C | 1 |
| Chapman, I; Giezenaar, C; Horowitz, M; Jones, KL; Lange, K; Oberoi, A; Rigda, RS; Soenen, S | 1 |
| Bunn, RC; Fowlkes, JL; McDonald, S; Popescu, I; Ray, P; Thrailkill, KM | 1 |
| Forman, JL; Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; Vilsbøll, T | 1 |
| Bojsen-Møller, KN; Deacon, CF; Hansen, AE; Hansen, ML; Holst, JJ; Johannesen, HH; Keller, SH; Kjaer, A; Klausen, TL; Löfgren, J; Loft, A; Madsbad, S; Martinussen, C; Svane, MS; Wewer Albrechtsen, NJ | 1 |
| Conlon, JM; Flatt, PR; Irwin, N; Klempel, N; Thomas, K | 1 |
| Bergman, JJGHM; Busch, CBE; Hemke, R; Holleman, F; Meiring, S; Nieuwdorp, M; van Baar, ACG | 1 |
| Aguilar-Ballester, M; González-Navarro, H; Hurtado-Genovés, G; Jiménez-Martí, E; Martínez-Hervás, S | 1 |
| Hüttl, M; Malinska, H; Markova, I; Miklankova, D; Stankova, B | 1 |
| Hosoe, S; Ishizaka, Y; Kageyama, Y; Katakami, N; Kawamori, D; Shimomura, I; Tanaka, T | 1 |
| Brubaker, PL | 1 |
| Sherr, J; Van Name, M | 1 |
| Artoni, RF; Caproni, P; Cleva, R; Estabile, PC; Kuga, R; Milléo, FQ; Mota, FC; Moura, EGH; Santo, MA | 1 |
| Castillejo-López, C; Cavalli, M; Deshmukh, AS; Diamanti, K; Eriksson, JW; Komorowski, J; Korsgren, O; Kumar, C; Mann, M; Mundt, F; Pan, G; Pereira, MJ; Wadelius, C | 1 |
| Eguchi, H; Fujita, Y; Horii, T; Ishibashi, C; Kawata, S; Kozawa, J; Miyagawa, JI; Nammo, T; Ozawa, H; Shimomura, I; Yoneda, S | 1 |
| Chen, X; Liu, H; Lu, Y; Lu, Z; Meng, F; Zhao, H | 1 |
| Han, C; Jiang, Y; Ma, W; Qiao, A; Qin, G; Yan, B; Zhou, J | 1 |
| Behrends, C; Blüher, M; Finan, B; Gancheva, S; Hass, D; Herzig, S; Jülg, J; Kahl, S; Krahmer, N; Kwon, Y; Miaczynska, M; Motzler, K; Müller, TD; Najafi, B; Novikoff, A; Okun, JG; Plettenburg, O; Roden, M; Schwarz, K; Seitz, S; Sekar, R; Wang, S; Warnke, AL; Yang, B; Zeigerer, A | 1 |
| Li, R; Zhang, R; Zhao, Q | 1 |
| Carr, RD; Chai, S; Ji, L; Rajpathak, S; Zhang, R; Zhang, Y; Zheng, Y | 1 |
| Chen, Y; Wang, MW; Yang, D | 1 |
| Campbell, JE; Capozzi, ME; D'Alessio, DA | 1 |
| Holst, JJ; Wewer Albrechtsen, NJ; Winther-Sørensen, M | 1 |
| Andreassen, KV; Henriksen, K; Karsdal, MA; Kayed, A; Khan, S; Melander, SA | 1 |
| Ast, J; Briant, LJB; Cuozzo, F; Hasib, A; Heising, S; Hewison, M; Hodson, DJ; Nasteska, D; Viloria, K | 1 |
| Grayson, BE; Harris, KK; Pride, Y; Smith, AM; Welch, BA | 1 |
| Abou-Samra, AB; Atkin, SL; Bettahi, I; Butler, AE; Halabi, NM; Moin, ASM; Pawar, K; Ramanjaneya, M; Sathyapalan, T | 1 |
| Atkinson, G; Betts, JA; Carter, S; Gonzalez, JT; Holst, JJ; Koumanov, F; Watkins, JD | 1 |
| Ajduk, A; Dobosz, AM; Dobrzyn, A; Dziewulska, A; Janikiewicz, J; Krogulec, E; Nieznańska, H; Szczepankiewicz, AA; Szpila, M; Wypych, D | 1 |
| Lefèbvre, PJ; Scheen, AJ | 1 |
| Gallwitz, B | 5 |
| Horowitz, M; Huang, W; Jones, KL; Rayner, CK; Wewer Albrechtsen, NJ; Wu, T; Xie, C | 1 |
| Biondi, G; Caruso, I; Cignarelli, A; D'Oria, R; Genchi, VA; Giorgino, F; Laviola, L; Marrano, N; Natalicchio, A; Perrini, S; Sorice, GP | 1 |
| Bhawal, R; Chen, W; Jing, H; Lidan, S; Qiang, Z; Qianqian, Z; Wenxi, W; Zhihong, Y | 1 |
| Aigner, E; Dalus, C; Furthner, D; Gramlinger, K; Julian, V; Lukas, A; Mangge, H; Maruszczak, K; Mörwald, K; Pixner, T; Schneider, AM; Stummer, N; Thivel, D; Weghuber, D | 1 |
| Aramandla, R; Bottino, R; Bradley, AM; Brissova, M; Caicedo, A; Cartailler, JP; Haliyur, R; Jenkins, R; Kang, H; Petronglo, J; Phillips, S; Powers, AC; Reinert, RB; Richardson, TM; Saunders, DC; Shrestha, S | 1 |
| Gulati, S; Misra, A; Pandey, RM; Sati, HC; Sharma, M; Tiwari, R; Upadhyay, AD | 1 |
| Aiken, J; Atherley, S; D'Souza, NC; Hoffman, EG; Liggins, R; Riddell, MC | 1 |
| Chen, X; DeFronzo, RA; Merovci, A; Tripathy, D | 1 |
| Gandasi, NR; Kothegala, L; Krieger, JP; Miranda, C; Singh, M | 1 |
| Abdelgani, S; Abdul-Ghani, M; Abu-Farha, M; Adams, J; Al-Mulla, F; Daniele, G; DeFronzo, RA; Del Prato, S; Khattab, A | 1 |
| Csanalosi, M; Kabisch, S; Kemper, M; Keyhani-Nejad, F; Markova, M; Meyer, NMT; Pfeiffer, AFH; Pivovarova-Ramich, O; Rohn, S; Schäfer, SM; Schuppelius, B; Zhang, J | 1 |
| Bartlett, PJ; Brumer, RP; Corrêa-Velloso, JC; Sandiford, OA; Thomas, AP; Thomas, SJ | 1 |
| Bailey, CJ; Flatt, PR; Klempel, NJ; Moffett, RC; Thomas, KG | 1 |
| Horowitz, M; Huang, W; Jalleh, RJ; Jones, KL; Rayner, CK; Sun, Y; Watson, LE; Wu, T; Xie, C | 1 |
| Achanta, K; Artner, I; Bertonnier-Brouty, L; Bsharat, S; Holmberg, D; Johansson, JK; Kokaia, Z; Monni, E; Prasad, RB; Schmidt-Christensen, A; Singh, T | 1 |
| Dai, Z; Dong, LQ; Liu, F; Liu, W; Ryu, J; Sun, LZ; Wang, Y; Xiao, Y; Yan, Y; Zhang, D; Zhang, R; Zhou, Z; Zou, H | 1 |
| Andersen, A; Hædersdal, S; Knop, FK; Vilsbøll, T | 1 |
| Birkenfeld, AL; Bornstein, SR; Hoffmann, C; Mantzoros, CS; Perakakis, N; Schwarz, PE; Solimena, M; Wolfrum, C | 1 |
| Frikke-Schmidt, R; Holst, JJ; Janus, C; Jensen, SBK; Juhl, CR; Knudsen, C; Lundgren, JR; Madsbad, S; Martinussen, C; Stallknecht, BM; Torekov, SS; Wiingaard, C | 1 |
| Müller, TD; Novikoff, A | 1 |
| Babu, S; Gowshika, K; Kumar, NP; Lakshan Raj, S; Mittal, R; Pandiarajan, AN; Putlibai, S; Rajamanickam, A; Ramanan, PV; Sasidaran, R; Selvaraj, N; Venkataraman, A | 1 |
| Ambery, P; Iqbal, N; Logue, J; Mallappa, A; Sjöström, CD | 1 |
| Doggrell, SA | 1 |
| Barber, TM; Hanson, P; Kyrou, I; Pelling, M; Randeva, H; Statham, L | 1 |
| Brissova, M; Pettway, YD; Saunders, DC | 1 |
| Golovina, EL; Grishkevich, IR; Kudlay, DA; Matveeva, MV; Podchinenova, DV; Samoilova, IG; Vaizova, OE | 1 |
| Coronel, R; Eroglu, TE; Folke, F; Gislason, GH; Halili, A; Júlíusdóttir, YK; Torp-Pedersen, C | 1 |
| Ai, W; Guo, S; Jiang, W; Li, X; Liao, W; Pan, Q; Shen, Z; Yang, W | 1 |
| Ahrén, B; Nogueiras, R; Tschöp, M | 1 |
| Nauck, MA; Nogueiras, R; Tschöp, MH | 1 |
| Alsina-Fernandez, J; Coskun, T; Du, Y; Haupt, A; Hemmingway, A; Loh, MT; Milicevic, Z; O'Farrell, L; Qu, H; Urva, S | 1 |
| Baek, S; Byeon, J; Choi, J; Hompesch, M; Kang, S; Shin, W | 1 |
| Bloom, SR; Campbell, JE; Cherrington, AD; Dean, ED; Finan, B; Gluud, LL; Holst, JJ; Knop, FK; Müller, TD; Tan, TM; Wewer Albrechtsen, NJ | 1 |
| Chen, L; Chen, W; Cui, W; Hu, X; Li, X; Shang, H; Sun, X; Wang, J; Wu, J; Xiao, RP; Yuan, Y; Zeng, F; Zhang, J; Zhang, X; Zheng, W | 1 |
| Asadi, J; Jazi, MS; Kiaei, M; Safarzad, M | 1 |
| Deane, A; Horowitz, M; Jalleh, RJ; Jones, KL; Plummer, MP; Umapathysivam, MM | 1 |
| Dukhande, VV; Vemana, HP | 1 |
| Haag, JD; Herges, JR; Kosloski Tarpenning, KA; Mara, KC; McCoy, RG | 1 |
| Agranovich, B; Assa, M; Avrahami, D; Bernal-Mizrachi, E; Cerasi, E; Glaser, B; Gottlieb, E; Helman, A; Jackson, F; Kadosh, L; Kogot-Levin, A; Leibowitz, G; Malka, A; Piran, R; Riahi, Y | 1 |
| Kampmann, U; Ovesen, PG; Rittig, N; Smedegaard, S; Støvring, H | 1 |
| Gasbjerg, LS; Holst, JJ; Knop, FK; Meier, JJ; Rosenkilde, MM | 1 |
| Andrews, RC; Bowman, P; Flanagan, SE; Hammersley, S; Hartmann, B; Hattersley, AT; Holst, JJ; Knight, BA; Leveridge, M; McDonald, TJ; Patel, KA; Shepherd, MH; Shields, BM; Spaull, SR | 1 |
| Dudka, I; Dudka, T; Khukhlina, O; Roshchuk, O; Voyevidka, O | 1 |
| Agamennone, V; Beulens, JWJ; Blom, MT; Groeneveld, L; Hoevenaars, F; Keijser, BJF; Muilwijk, M; Rutters, F; van den Broek, T | 1 |
| Almorza-Gomar, D; Bancalero-de Los Reyes, J; Díaz-Gómez, A; González-Domínguez, Á; Gracia-Romero, M; Pérez-Arana, GM; Prada-Oliveira, JA; Ribelles-García, A; Visiedo, F | 1 |
| Horowitz, M; Huang, W; Jones, KL; Rayner, CK; Sang, M; Sun, Z; Wewer Albrechtsen, NJ; Wu, T; Xie, C | 1 |
| Aiba, S; Baba, Y; Hirayama, K; Iga, R; Inaba, Y; Ishibashi, R; Ito, C; Kanayama, T; Kasahara, K; Koshizaka, M; Kuroda, Y; Maezawa, Y; Ohtani, R; Okano, K; Watanabe, S; Yokote, K | 1 |
| Martens, L; Pfeiffer, AFH; Zhang, J; Zheng, Y | 1 |
| De Vito, G; Krause, M | 1 |
| Akarlar, BA; Akyel, YK; Aydin, C; Baris, I; Ergun, C; Gören, AC; Gul, S; Gul, ZM; Guzel, M; Ipek, OS; Kavakli, IH; Okyar, A; Ozcan, O; Ozlu, N; Ozturk, N; Surme, S; Taskin, AC; Turkay, M | 1 |
| D'Alessio, DA; Marks, V | 1 |
| Alves, C; Casajoana, A; Fernández-Veledo, S; Gómez-Vaquero, C; Guerrero-Pérez, F; Hernández-Montoliu, L; López-Urdiales, R; Osorio, J; Pellitero, S; Perez-Maraver, M; Pujol-Gebelli, J; Vendrell, J; Vidal-Alabró, A; Vilarrasa, N; Virgili, N | 1 |
| Biba, U; Close, KL; Kurian, MJ; Teng, RW | 1 |
| Bagger, JI; Bergmann, NC; Christensen, MB; Knop, FK; Lund, A; Mathiesen, DS; Vilsbøll, T | 1 |
| Blaslov, K; Kruljac, I; Rahelić, D; Renar, IP; Režić, T; Vrkljan, M | 1 |
| Chen, S; Klein, S; Scherer, PE; Smith, GI; Stern, JH; Unger, RH | 1 |
| Abrahamson, MJ; Ashrafzadeh, S; Eldib, AH; Hamdy, O; Mottalib, A; Pober, DM; Polak, R; Tomah, S | 1 |
| Chen, Y; Hu, C; Hu, M; Hu, Y; Li, D; Li, X; Liao, S; Liu, B; Liu, J; Lu, Y; Lv, X; Qian, Q; Tan, M; Wang, Y; Wu, D; Xiong, X; Zhang, D; Zhang, Z | 1 |
| Ambery, PD; Cooper, AT; Heise, T; Hirshberg, B; Hornigold, DC; Klaus, B; Meier, JJ; Parker, VER; Petrone, M; Plum-Moerschel, L; Posch, MG; Robertson, D; Schlichthaar, H; Wang, T | 1 |
| Abe, T; Abiko, A; Bessho, R; Fujita, Y; Haneda, M; Ota, T; Sakagami, H; Sato, M; Takeda, Y; Takiyama, Y; Yanagimachi, T | 1 |
| Deng, B; Gilbert, RG; Liu, X; Liu, Y; Wang, K; Wu, Z; Yang, L; Zhang, Y | 1 |
| Hamajima, H; Inoue, E; Mieno, E; Miyachi, A; Nagai, Y; Nakagawa, T; Takahashi, M; Tanaka, Y; Yamamoto, Y | 1 |
| Fujikawa, T; Fukui, T; Goto, S; Hayashi, T; Hirano, T; Hiromura, M; Kohata, Y; Kushima, H; Mori, Y; Nagaike, H; Ohara, M; Sato, N; Terasaki, M; Yamagishi, SI; Yamamoto, T | 1 |
| Albaugh, VL; Bosompem, A; Flynn, CR; Gregory, JM; Sidani, RM; Tamboli, RA; Winnick, JJ | 1 |
| Barran, PE; Beavil, RL; Butterworth, S; Caton, PW; Choudhary, P; Cruickshank, JK; Fine, NHF; Hodson, DJ; Huang, GC; Lavery, GG; McGill, AT; Mills, CE; Pacholarz, KJ; Poppitt, SD; Sayers, SR; Silvestre, MP | 1 |
| Campbell, JE; El, K | 1 |
| DiMarchi, RD; Finan, B; Knerr, PJ; Mowery, SA; Perez-Tilve, D; Tschöp, MH | 1 |
| Erdmann, S; Kahle-Stephan, M; Kapitza, C; Meier, JJ; Menge, BA; Nauck, MA; Schenker, N; Schliess, F | 1 |
| Frier, BM; Mitchell, BD; Thieu, VT; Varnado, OJ | 1 |
| Bhowmick, DC; Cohen, J; Jeremic, A; Singh, T; Suarez Castellanos, I; Zderic, V | 1 |
| Almby, K; Eriksson, JW; Kamble, PG; Lundqvist, M; Pereira, MJ; Sarsenbayeva, A; Thombare, K | 1 |
| Alcala-Diaz, JF; Caballero-Villarraso, J; Gonzalez-Requero, A; Leon-Acuña, A; Lopez-Miranda, J; Luque, RM; Ordovas, JM; Pérez-Martinez, P; Pozuelo-Sanchez, I; Quesada, I; Roncero-Ramos, I; Vals-Delgado, C; Villasanta-Gonzalez, A; Yubero-Serrano, EM | 1 |
| Meng, S; Pesavento, TE; Singh, P; Taufeeq, M; Walsh, D; Washburn, K | 1 |
| Bergmann, NC; Christensen, MB; Dela, F; Gasbjerg, LS; Hartmann, B; Heimbürger, SM; Holst, JJ; Jessen, L; Knop, FK; Krogh, LSL; Lund, A; Vilsbøll, T | 1 |
| Cao, T; Carmichael, GG; Diano, S; Huang, X; Huang, Y; Jin, S; Sun, X; Taylor, HS; Yang, X | 1 |
| Gilon, P | 2 |
| Barg, S; Dibner, C; Gandasi, NR; Petrenko, V; Sage, D; Tengholm, A | 1 |
| Flatt, PR; Irwin, N; Moffett, RC; Tanday, N | 1 |
| Azhar, S; Bittner, A; Bittner, S; Chan, J; Cortez, Y; Dong, D; Han, L; Kraemer, FB; Peterson, RG; Shen, WJ; Umar, M | 1 |
| Adam, J; Alrifaiy, A; Benrick, A; Briant, LJB; Chibalina, MV; Denwood, G; Eliasson, L; Guida, C; Hamilton, A; Hill, TG; Ramracheya, R; Reimann, F; Rorsman, NJG; Rorsman, P; Salehi, A; Spilliotis, I; Tarasov, AI; Vergari, E; Walker, JN; Wernstedt Asterholm, I; Zhang, Q | 1 |
| Abbas, G; Al-Sibani, M; Hamaed, A; Haq, QMI; Hussain, H | 1 |
| Al-Jahdami, N; Anderson, SJ; Armour, SL; Carey, C; Ding, Y; Krasnogor, N; Lyon, J; MacDonald, P; Maheshwari, RR; Morgan, NG; Richardson, SJ; Shaw, JAM; White, MG | 1 |
| Dobrogorskaya, LN; Sidorin, VS; Zabrodskaya, YM | 1 |
| Matsuhisa, M; Nagai, Y; Nagashima, H; Nasu, R; Ohwaki, K; Takita, Y | 1 |
| Brill, AL; Butrico, GM; Cline, GW; Dufour, S; Ehrlich, BE; Goedeke, L; Guerra, MT; Nasiri, AR; Nathanson, MH; Nozaki, Y; Peng, L; Perry, RJ; Petersen, KF; Rabin-Court, A; Shulman, GI; Toussaint, K; Wang, Y; Zhang, D; Zhang, XM; Zhang, Y | 1 |
| Chen, SH; Chen, YW; Cheng, YN; Chien, PH; Ho, LC; Hsieh, TT; Kuo, LH; Leu, SY; Lien, IC; Shan, YS; Sung, JM; Tsai, PJ; Tsai, YS; Weng, WT; Yang, CC | 1 |
| Fukui, M; Hashimoto, Y; Imai, S; Kajiyama, S; Matsumoto, S; Miyawaki, T; Nitta, A; Ozasa, N; Saito, Y | 1 |
| Ding, W; Li, F; Xing, Y; Ye, SD; Zheng, HL | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Kawamori, D | 2 |
| Barg, S; Gandasi, NR; Lund, PE; Omar-Hmeadi, M; Tengholm, A | 1 |
| Abdel-Wahab, YH; Conlon, JM; Flatt, PR; Graham, GV | 1 |
| Fushimi, Y; Hirukawa, H; Horiya, M; Iwamoto, Y; Kaku, K; Kan, Y; Kaneto, H; Kinoshita, T; Kohara, K; Mashiko, A; Mizoguchi-Tomita, A; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Basu, A; Basu, R; Carter, RE; Yadav, Y | 1 |
| Fujita, Y; Haneda, M; Honjo, J; Takeda, Y; Yanagimachi, T; Yokoyama, H | 1 |
| Ng, JCM; Schooling, CM | 1 |
| Barr, A; Campbell, SA; Golec, DP; Hubert, M; Johnson, J; Light, PE; MacDonald, PE; Philippaert, K; Salamon, N | 1 |
| Khoo, B; Tan, TM | 1 |
| Kitamura, T; Kobayashi, M; Kusunoki, Y; Matsuo, T; Namba, M; Satoh, H; Tokushima, M; Watada, H | 1 |
| Bound, MJ; Ferrannini, E; Frascerra, S; Grivell, J; Horowitz, M; Jones, KL; Lange, K; Mari, A; Natali, A; Phillips, LK; Rayner, CK; Tricò, D; Watson, LE; Wu, T | 1 |
| Baldi, S; Frascerra, S; Mengozzi, A; Natali, A; Nesti, L; Tricò, D | 1 |
| Cai, HL; Chen, T; Cheng, M; Cheng, XB; Huang, HY; Lu, Y; Su, JB; Wang, X; Wang, XH; Wang, XQ; Xu, F; Zhang, DM; Zhang, XL; Zhao, LH | 1 |
| Chang, CA; Gu, X; Hang, Y; Kim, SK; Stein, RW; Tellez, K | 1 |
| Cui, X; Feng, J; Gu, L; Hong, T; Lang, S; Le, Y; Liu, J; Wang, H; Wei, R; Wei, T; Yang, J; Yang, K | 1 |
| Kracht, M; Müller-Ladner, U; Schmitz, ML | 1 |
| Iizuka, K; Kubota, S; Kuwata, H; Liu, Y; Seino, Y; Yabe, D | 1 |
| Fappi, A; Mittendorfer, B | 1 |
| Campos, CA; Deem, JD; Faber, CL; Morton, GJ; Taborsky, GJ | 1 |
| Morioka, I; Urakami, T; Yoshida, K | 1 |
| Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; van Hall, G; Vilsbøll, T | 1 |
| Anderson, JN; Bao, Y; Bartlett, JR; Bissonnette, S; Briant, AR; Carcel, C; Chan, K; Chen, H; Chen, L; Cheng, C; Chrétien, M; Conway Fitzgerald, A; Cyr, Y; Du, Y; El-Sayed, YY; Endo, T; Faraj, M; Fujimoto, K; Girsen, A; Goto, H; Hashimoto, D; Hayasaka, K; Hayase, E; Herrmann, N; Hidaka, D; Holst, JJ; Igbinosa, I; Iijima, H; Jeandidier, N; Jeong, DY; Jeong, GT; Joubert, M; Kagawa, I; Kahata, K; Kaushik, LK; Kim, SK; Kim, SR; Kuang, Y; Laird, M; Lamantia, V; Li, P; Li, Y; Li, Z; Lindsay, SE; Liu, X; Loizon, E; Lu, Z; Lyell, DJ; Ma, J; Magnani, CJ; Mahalingam, AK; Mandal, N; Mayer, G; Michimata, R; Ngo Sock, ET; Okada, K; Onozawa, M; Opigez, V; Palanisamy, M; Parienti, JJ; Park, YR; Pavlikova, B; Peyro Saint Paul, L; Ramsahye, N; Reyes, GA; Reznik, Y; Richardson, MT; Samo, IA; Sarkar, R; Shendge, AK; Shimizu, C; Shiratori, S; Steinberg, JR; Sugita, J; Sukwong, P; Sun, X; Sunagoya, K; Sunwoo, IY; Svendsen, B; Tang, L; Tang, Z; Teshima, T; Totée, C; Turner, BE; Unno, M; Vidal, H; Wang, C; Wang, M; Wang, S; Wang, X; Wang, Z; Wassef, H; Weeks, BT; Wong Chi Man, M; Xu, C; Xu, W; Yamamoto, S; Yu, H; Zhang, WY; Zhang, X; Zhong, Y | 1 |
| Ahrén, B; Pacini, G | 2 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Ali Mondal, S; Anne M, B; Basu, M; Chakrabarti, P; Das, K; Ghosh, I; Ghosh, S; Mukhopadhyay, P; Nargis, T; Pandit, K | 1 |
| Oredsson, S; Pierzynowska, K; Pierzynowski, S | 1 |
| Flatt, PR; Irwin, N; McCloskey, AG; McKillop, AM; Moffett, RC; Mohan, S | 1 |
| Abiru, N; Akazawa, S; Haraguchi, A; Horie, I; Ito, A; Kamada, A; Kawakami, A; Miwa, M; Nakashima, Y; Natsuda, S; Niri, T; Sako, A; Shigeno, R | 1 |
| Clausen, TD; Damm, P; Færch, K; Grarup, N; Hansen, T; Holst, JJ; Jonsson, A; Jørgensen, ME; Kelstrup, L; Mathiesen, ER; Pedersen, O; Stinson, SE; Torekov, SS; Witte, DR | 1 |
| Elovaris, RA; Feinle-Bisset, C; Hajishafiee, M; Heilbronn, LK; Horowitz, M; Jones, KL; Poppitt, SD | 1 |
| Akashi, T; Amo-Shiinoki, K; Bouchi, R; Fukuda, T; Harano, R; Hatanaka, M; Hoshii, Y; Ikeda, E; Kudo, A; Matsui, H; Nagano, H; Nishimura, W; Ogawa, Y; Okuya, S; Takagi, T; Takeda, K; Takeuchi, T; Tanabe, K; Tanabe, M; Tanaka, S; Tanizawa, Y; Yamada, T | 1 |
| Cameron, MD; Griffin, PR; Kamenecka, TM; Lin, H; Lin, L; Novick, SJ; Puigserver, P; Ruiz, C; Sharabi, K; Zhu, D | 1 |
| Schaumleffel, C | 1 |
| Hulman, A; Jessen, N; Mikkelsen, UR; Mose, M; Møller, N; Rittig, N; Smedegaard, SB; Wegener, G | 1 |
| Chen, X; DeFronzo, RA; Maldonado, E; Tripathy, D | 1 |
| Benninger, RKP; Caldwell, JH; Fontaine, AK; Kravets, V; Littich, SF; Mizoguchi, N; Piscopio, RA; Ramirez, DG; Schleicher, WE; Weir, RFF | 1 |
| Gabbay, RA; Kahn, PA; Lipska, K; Liu, S; McCoy, R | 1 |
| Chatterjee Bhowmick, D; Cohen, J; Jeremic, A; Singh, T; Suarez-Castellanos, I; Zderic, V | 1 |
| Bahl, V; Glaser, B; Kaestner, KH; Lee May, C; Perez, A | 1 |
| Birkenfeld, AL; Dannecker, C; Fritsche, A; Häring, HU; Heni, M; Hummel, J; Peter, A; Stefan, N; Vosseler, A; Wagner, R | 1 |
| Brown, JL; Campbell, JE; Capozzi, ME; Chazotte, BM; Clifford, A; D'Alessio, DA; El, K; Encisco, SE; Gray, SM; Jin, E; Knuth, ER; Merrins, MJ; Nunez, DJ; Sloop, KW; Svendsen, B | 1 |
| Hewison, M; Hodson, DJ; Viloria, K | 1 |
| Bagger, JI; Grøndahl, MFG; Holst, JJ; Knop, FK; Lund, A; Vilsbøll, T | 1 |
| Chen, T; Huang, HX; Huang, HY; Shen, LL; Su, JB; Wang, XQ; Xie, Y; Xu, F; Zhang, DM; Zhang, XL; Zhao, LH | 1 |
| Chen, H; Guan, Y; Li, P; Li, X; Shan, Y; Sun, H | 1 |
| Han, DJ; Jung, CH; Jung, JH; Kim, DH; Kim, YH; Ko, Y; Kwon, H; Lim, SJ; Mun, S; Shin, S | 1 |
| Ahrén, B | 6 |
| Cai, X; Hu, S; Ji, L; Li, L; Lin, C; Zhu, X | 1 |
| Deacon, CF; Holst, JJ; Kuhre, RE; Wewer Albrechtsen, NJ | 1 |
| Gomes Dos Santos, AL; Kinna, S; Ouberaï, MM; Sonzini, S; Welland, ME | 1 |
| Fujiwara, Y; Hamamoto, Y; Haraguchi, T; Ishitobi, M; Kubota, S; Kubota-Okamoto, S; Kurose, T; Kuwata, H; Murotani, K; Seino, Y; Usui, R; Yabe, D; Yamada, Y; Yamazaki, Y | 1 |
| Brown, GS; Diaz, M; Lackey, AI; Sato, PY; Snyder, J; Yuzhen, T | 1 |
| Agah, S; Bitarafan, V; Elovaris, RA; Feinle-Bisset, C; Horowitz, M; Lange, K; Ullrich, SS | 1 |
| Abelin, KU; Andersen, A; Bagger, JI; Baldassarre, MPA; Christensen, MB; Faber, J; Gislason, G; Holst, JJ; Knop, FK; Lindhardt, TB; Pedersen-Bjergaard, U; Vilsbøll, T | 1 |
| Flatt, PR; Gault, VA; Irwin, N; Lafferty, RA; O'Harte, FPM | 1 |
| Boriboun, C; Deng, J; Habegger, KM; Kim, T; Ma, W; Ma, YC; Qiao, A; Qin, G; Qiu, H; Richard, S; Song, Y; Xu, S; Yan, B; Yang, L; Zhang, C; Zhang, E; Zhang, J; Zhou, J | 1 |
| Hirano, T; Honzawa, N; Ikeuchi, Y; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Matsui, S; Obinata, H; Sasaki, T; Suga, T; Tsuneoka, H; Wada, E; Yokota-Hashimoto, H | 1 |
| Kieffer, TJ; Ramzy, A | 1 |
| Broughton, KS; LeMieux, MJ; Rao, M; Zumbro, EL | 1 |
| Cao, XY; Li, DL; Lu, JW; Wang, XY; Zeng, ZY | 1 |
| Li, W; Liu, R; Long, H; Sui, W; Wu, T; Zhang, M; Zhang, Y; Zhao, Y | 1 |
| Choi, H; Jun, HS; Lee, CY; Maeng, HJ; Mee Lee, K; Nguyen, TT; Park, EY; Shin, D | 1 |
| Bethea, M; Bozadjieva-Kramer, N; Sandoval, DA | 1 |
| Li, Q; Li, W; Liu, R; Long, H; Muhindo, EM; Sui, W; Wu, T; Zhang, M; Zhang, Y; Zhao, Y | 1 |
| Chen, G; Jog, R; Leff, T; Wang, J | 1 |
| Huang, Y; Li, N; Liang, R; Liu, M; Liu, T; Wang, J; Wang, S; Yang, J; Zhen, J | 1 |
| Chen, C; Chen, X; Chen, Y; Lin, Z; Lu, Y; Wan, H; Wang, C; Wang, N; Wang, Y; Xia, F; Zhang, W | 1 |
| Ameneiro, C; Beiroa, D; Bernardo, G; Bilbao, J; Bravo, SB; Carneiro, C; Cho, JW; Coppari, R; Cuñarro, J; Da Silva Lima, N; Dieguez, C; Dp Chantada-Vazquez, M; Fernandez, U; Fernández-Ramos, D; Ferno, J; Fidalgo, M; Fondevila, MF; Fruhbeck, G; Garcia-Vence, M; Gonzalez-Rellan, MJ; Guallar, D; Herzig, S; Iglesias, C; López, M; Lopitz-Otsoa, F; Martinez-Chantar, ML; Mato, JM; Millet, O; Müller, TD; Nogueiras, R; Novoa, E; Perez-Fernandez, R; Porteiro, B; Rodríguez, A; Sabio, G; Senra, A; Seoane, S; Tovar, S; Varela-Rey, M; Veyrat-Durebex, C; Vidal, A; Woodhoo, A; Yang, WH | 1 |
| Biggs, E; Foreman, R; Galvin, SG; Gribble, FM; Jermutus, L; Kay, RG; Larraufie, P; Meek, CL; Ravn, P; Reimann, F | 1 |
| Borg, MJ; Horowitz, M; Jones, KL; Rayner, CK; Wu, T; Xie, C | 1 |
| Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D | 1 |
| Angeletti, S; Cappelli, A; Del Toro, R; Fallucca, S; Guglielmi, C; Lachin, JM; Lauria, A; Maurizi, AR; Pozzilli, P | 1 |
| Lund, A | 1 |
| DeFronzo, R; Gaggini, M; Gastaldelli, A | 1 |
| Gylfe, E; Tengholm, A | 1 |
| Choi, H; Connelly, PW; Kramer, CK; Retnakaran, R; Zinman, B | 2 |
| Fujioka, Y; Izawa, S; Kato, M; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, T; Shoji, K; Sumi, K; Taniguchi, S; Yamamoto, K | 1 |
| Dibner, C; Petrenko, V | 1 |
| Cobelli, C; Dalla Man, C; Laurenti, MC; Matveyenko, A; Rizza, RA; Sharma, A; Varghese, RT; Vella, A | 1 |
| Junker, AE | 1 |
| Chen, S; Davidson, JA; Holland, WL; Lee, Y; Li, J; McCorkle, SK; Roth, MG; Scherer, PE; Unger, RH; Wang, MY; Wang, ZV; Yu, X | 1 |
| DiMarchi, R; Tschöp, M | 1 |
| Deem, JD; Morton, GJ; Muta, K; Scarlett, JM; Schwartz, MW | 1 |
| Holst, JJ; Knop, FK; Pedersen, J; Wewer Albrechtsen, NJ | 1 |
| Caron, MG; Chen, M; Chen, W; Cui, Y; Godlewski, G; Gurevich, VV; Kunos, G; Lee, RJ; Perry, NA; Rossi, M; Sakamoto, W; Urs, NM; Wess, J; Zhu, L | 1 |
| Díaz-Villaseñor, A; Palacios-González, B; Torres, N; Tovar, AR; Tovar-Palacio, C; Velázquez-Villegas, LA | 1 |
| Jung, H; Kim, MK; Kim, TK; Kim, TN; Kwon, MJ; Lee, E; Lee, SH; Park, JH; Rhee, BD; Shin, HM | 1 |
| Aboelmagd, O; Bernstein, L; Johar, D; Maher, A; Morsi, M | 1 |
| Breuer, TGK; Holst, JJ; Meier, JJ; Menge, BA; Mumme, L; Nauck, MA; Rohrer, S; Schenker, N | 1 |
| Dong, EW; Fonseca, VA; Htun, W; Mauvais-Jarvis, F; Wu, H; Wu, M; Zhang, Y | 1 |
| Hara, K; Inukai, T; Naruse, R; Suetsugu, M; Takebayashi, K; Terasawa, T; Tsuchiya, T | 1 |
| Marks, V | 1 |
| Ahmed, AR; Behary, P; Bloom, SR; Chahal, H; Holst, JJ; Kenkre, J; Miras, AD; Tan, T; Tharakan, G; Wewer Albrechtsen, NJ | 1 |
| Seufert, J | 1 |
| Eberhard, D; Heiss, C; Klüppel, C; Lammert, E; Mayatepek, E; Meissner, T; Mrugala, J; Welters, A; Wörmeyer, L | 1 |
| Ahn, CW; Kang, S; Kim, KR; Kim, M; Lee, M; Lee, S; Park, JS; You, J | 1 |
| Henquin, JC; Ibrahim, MM; Rahier, J | 1 |
| Kadowaki, T; Muto, S; Ouchi, Y; Seino, Y; Shimazaki, R | 1 |
| Christensen, M; Galsgaard, KD; Holst, JJ; Hædersdal, S; Junker, AE; Knop, FK; Lund, AM; Vilsbøll, T; Wewer Albrechtsen, NJ; Wibrand, F | 1 |
| Brull, JM; Cantonero Chamorro, C; Corbacho, AJ; Delgado, E; Duran, ML; Gómez-Gordo, L; González, MJ; Granados, MP; Hernández, MJ; Jardín, I; Jiménez, F; López, JJ; Martínez, M; Montero, R; Redondo, PC; Reyes Panadero, M; Rosado, JA; Tarancón Rubio, MJ | 1 |
| Girard, J | 7 |
| Cao, BY; Hu, XG; Jia, N; Li, R; Ma, YJ; Tian, HH; Wang, YY | 1 |
| Grøndahl, MF; Keating, DJ; Knop, FK; Vilsbøll, T | 1 |
| Ahlqvist, E; Almgren, P; Asplund, O; Groop, L; Hakaste, L; Holst, JJ; Krus, U; Laurila, E; Lindqvist, A; Melander, O; Nilsson, PM; Orho-Melander, M; Ottosson-Laakso, E; Prasad, RB; Sonestedt, E; Tuomi, T; Wierup, N | 1 |
| Bódis, K; Bönhof, G; Burkart, V; Markgraf, DF; Müssig, K; Püttgen, S; Roden, M; Strom, A; Szendroedi, J; Ziegler, D | 1 |
| Albrechtsen, NJW | 1 |
| Jiang, ZH; Li, CG; Li, CJ; Li, Z; Ni, CL; Sun, B; Tang, YZ; Yang, M; Zhu, YJ | 1 |
| DiMarchi, RD; Finan, B; Gelfanov, V; Knerr, PJ; Perez-Tilve, D; Tschöp, MH | 1 |
| Bowden, DW; Cox, AJ; Cripps, AW; Davoren, PM; Devereaux, B; West, NP; Zhang, P | 1 |
| Kim, GY; Kim, S; Ong, RKS; Shawa, H | 1 |
| Banning, F; Gar, C; Hesse, N; Hübener, C; Lechner, A; Moschko, S; Popp, D; Rottenkolber, M; Sacco, V; Seissler, J | 1 |
| Hædersdal, S; Knop, FK; Lund, A; Vilsbøll, T | 1 |
| Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
| Bjørnshave, A; Hermansen, K; Holst, JJ | 1 |
| Basfi-Fer, K; Carrasco, F; Codoceo, J; Inostroza, J; Pérez, A; Pérez-Bravo, F; Rojas, P; Ruz, M | 1 |
| Deacon, CF | 2 |
| Christensen, MB; Gabe, MBN; Gasbjerg, LS; Hartmann, B; Holst, JJ; Knop, FK; Rosenkilde, MM | 1 |
| Flatt, PR; Irwin, N; Pathak, V | 2 |
| Wewer Albrechtsen, NJ | 1 |
| Bloom, SR; Scott, RV | 1 |
| Bailey, CJ | 1 |
| Al Batran, R; Almutairi, M; Ussher, JR | 1 |
| Deutsch, GH; Fligner, CL; Frevert, CW; Gibson, RL; Hull, RL; McNamara, S; Ramsey, BW; Sanda, S | 1 |
| Trautmann, ME; Vora, J | 1 |
| Bäckhed, F; Brønden, A; Gabe, MN; Hansen, M; Holst, JJ; Knop, FK; Mikkelsen, K; Rehfeld, JF; Rosenkilde, M; Sonne, DP; Tremaroli, V; Våben, C; Vilsbøll, T; Wu, H | 1 |
| Attie, AD; Broman, AT; Coon, JJ; Freiberger, EC; Hebert, AS; Keller, MP; Kennedy, RT; Kwiecien, NW; Malec, PA; Mitok, KA; Rabaglia, ME; Schueler, KL; Stapleton, DS | 1 |
| Adams-Huet, B; Burgess, S; Li, X; Lingvay, I; Mari, A; Mitchell, L; Pop, LM; Zhao, TJ | 1 |
| Bøgevig, S; Christensen, MB; Holst, JJ; Knop, FK; Petersen, KM | 1 |
| Hull, RL; Parilla, JH; Zraika, S | 1 |
| Eguchi, H; Fujita, Y; Imagawa, A; Iwahashi, H; Kozawa, J; Nagano, H; Shimomura, I; Uno, S; Yoneda, S | 1 |
| Bagger, JI; Faurschou, A; Grøndahl, MF; Holst, JJ; Knop, FK; Lund, A; Rehfeld, JF; Vilsbøll, T | 1 |
| Ahrén, B; Farngren, J; Persson, M | 2 |
| Ceriani, V; Pontiroli, AE | 1 |
| Avogaro, A; Fadini, GP | 1 |
| Knop, FK | 2 |
| Ahnmark, A; Davidsson, P; Ericsson-Dahlstrand, A; Eriksson, JW; Hansson, SF; Jongsma Wallin, H; Karlsson, D; Magnone, MC; Pereira, MJ; Skrtic, S; Sörhede Winzell, M; Vachet, P; Zhou, AX | 1 |
| Horowitz, M; Rayner, CK | 1 |
| Bonikowska, K; Magnusson, P; Sjöholm, Å | 1 |
| Li, WH; Nan, M | 1 |
| Hornemann, S; Markova, M; Pfeiffer, AFH; Pivovarova, O; Rohn, S; Rudovich, N; Schneeweiss, R; Sucher, S; Thomann, R; Wegner, K | 1 |
| Bonner, C; Pattou, F; Saponaro, C | 1 |
| Basu, A; Basu, R; Carter, RE; Joshi, N; Miles, J; Rizza, RA | 1 |
| Annunziata, G; Barrea, L; Colao, A; Di Somma, C; Muscogiuri, G; Orio, F; Savastano, S; Vecchiarini, M | 1 |
| Buxbaum, JD; Fendrick, AM; He, X; Liu, D; Mitchell, BD | 1 |
| Calle, RA; Cobelli, C; Fryburg, DA; Gebauer, M; Ghosh, A; Raymond, RH; Robertson, RP; Ruetten, H; Shankar, SS; Staten, MA; Stefanovski, D; Vella, A; Wright, K | 1 |
| Eriksson, JW; Esterline, R; Johnsson, E; Kamble, PG; Katsogiannos, P; Langkilde, AM; Lundkvist, P; Pereira, MJ | 1 |
| Kondo, Y; Mitsumatsu, T; Okahata, S; Sakamoto, K; Shiba, T; Tanaka, S | 1 |
| Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Boland, BB; Boland, ML; Brown, C; Cann, J; Grimsby, JS; Grønlund, RV; Hansen, G; King, W; Rhodes, CJ; Rondinone, C; Sulikowski, M; Trevaskis, J | 1 |
| Chabosseau, P; Gromada, J; Rutter, GA | 1 |
| Alcala-Diaz, JF; Arenas-Larriva, AP; Camargo, A; Delgado-Lista, J; Jimenez-Lucena, R; Leon-Acuña, A; Lopez-Miranda, J; Malagon, MM; Ordovas, JM; Perez-Martinez, P; Rangel-Zuñiga, OA; Roncero-Ramos, I; Vals-Delgado, C | 1 |
| Cijevschi-Prelipcean, C; Dranga, M; Drug, V; Grigorescu, ED; Lăcătușu, CM; Mihai, BM; Mihai, C; Sporea, I | 1 |
| Adam, J; Ashcroft, FM; Brereton, M; Chibalina, MV; Hamilton, A; Haythorne, E; Knudsen, JG; Mulder, H; Ramracheya, R; Rorsman, P; Spégel, P; Tarasov, AI; Zhang, Q | 1 |
| Choi, D; Jung, CH; Kang, SK; Kim, BY; Kim, CH; Lee, B; Moh Moh, MA; Mok, JO | 1 |
| Bound, MJ; Checklin, HL; Clifton, PM; Grivell, J; Horowitz, M; Jones, KL; Phillips, LK; Rayner, CK; Watson, LE; Wu, T | 1 |
| Arriaga, Y; Beg, MS; Gupta, A; Karri, S; Khosama, L; Mansour, J; Meyer, J; Scherer, PE; Stern, JH; Syed, S; Verma, U | 1 |
| Bharmal, SH; Cervantes, A; DeSouza, SV; Pendharkar, SA; Petrov, MS; Singh, RG | 1 |
| Chen, L; Cui, W; Hou, N; Hu, X; Liu, Y; Ma, D; Shang, H; Sun, X; Wang, C; Wang, J; Xiao, RP; Xiao, Y; Yuan, Y; Zeng, F; Zhang, X; Zhang, Y; Zheng, W | 1 |
| Broberg, B; Christensen, KB; Feldt-Rasmussen, B; Fuglsang, S; Holst, JJ; Hornum, M; Idorn, T; Madsen, JL; Rydahl, C | 1 |
| Bajpai, S; Mitchell, BD; Osumili, B; Pöhlmann, J; Valentine, WJ | 1 |
| Freeman, J | 1 |
| Besse-Patin, A; Estall, JL; Jeromson, S; Laplante, M; Levesque-Damphousse, P; Secco, B | 1 |
| Basu, A; Basu, R; Keenan, DM; Veldhuis, JD | 1 |
| Alfieri, S; Capece, U; Carfì, A; Cefalo, CMA; Cinti, F; Ferraro, PM; Giaccari, A; Holst, JJ; Impronta, F; Mari, A; Mezza, T; Moffa, S; Pontecorvi, A; Quero, G; Sorice, GP | 1 |
| Galsgaard, KD; Gromada, J; Holst, JJ; Janah, L; Knop, FK; Pedersen, J; Suppli, MP; Vilstrup, H; Wewer Albrechtsen, NJ; Winther-Sørensen, M | 1 |
| Bhansali, A; Bhansali, S; Bhat, K; Dutta, P; Kochhar, R; Kurpad, AV; Mudaliar, S; Mukherjee, KK; Sachdeva, N; Shekhawat, VS; Sinha, SK; Vaiphei, K | 1 |
| Elsherbeny, A; Hosny, SS; Kamal, MM; Okba, A | 1 |
| Hirota, Y; Komada, H; Ogawa, W | 1 |
| Matschinsky, FM; Wilson, DF | 1 |
| Chambers, D; Harries, LW; Jeffery, N; Morgan, NG; Richardson, S | 1 |
| Accili, D; Damle, M; Egli, D; González, BJ; Kuo, T; Lazar, MA | 1 |
| Beverly, EA; Mort, SC; Rennie, RG; Ritholz, MD | 1 |
| Fujimoto, K; Ichikawa, R; Kitamura, T; Kobayashi, M; Motomiya, T; Shichiri, M; Takano, K | 1 |
| Abiru, N; Akazawa, S; Ando, T; Haraguchi, A; Hasegawa, Y; Higashijima, A; Horie, I; Ito, A; Kawakami, A; Masuzaki, H; Miura, K; Mori, Y; Natsuda, S; Nozaki, A; Yoshida, A | 1 |
| Fujita, Y; Fukui, K; Hosakawa, Y; Ishibashi, C; Iwahashi, H; Kimura, T; Kozawa, J; Shimomura, I; Yoneda, S | 1 |
| Ahlers, M; Laferrère, B; Levesque, K; Mark, V; Patel, K; Pierini, E; Rojas, B; Shah, A | 1 |
| Andries, A; Christensen, MM; Falkenhahn, M; Forman, JL; Friis, S; Holst, JJ; Jelsing, J; Jorsal, T; Juhl, CB; Knop, FK; Langholz, E; Larsen, PJ; Mortensen, B; Musholt, PB; Støving, RK; Sørensen, F; Theis, S; Vilsbøll, T; Vrang, N; Wandall, E; Wewer Albrechtsen, NJ; Worm, D; Ørskov, C | 1 |
| da Silva, MER; Dagogo-Jack, S; de Sousa, MV; Fukui, R; Krustrup, P; Zouhal, H | 1 |
| Javor, E; Lucijanic, M; Skelin, M | 1 |
| Bertero, E; Heymans, S; Maack, C; Sequeira, V | 1 |
| Khotskina, AS; Klimontov, VV; Korbut, AI; Orlov, NB; Zav'yalov, EL | 1 |
| Pontiroli, AE; Tagliabue, E | 1 |
| Fujimoto, K; Honzawa, N; Kitamura, T | 1 |
| Cho, YM; Kim, MY; Kim, S; Lee, JC; Oh, TJ; Park, KS; Shin, JY | 1 |
| Abdul-Ghani, MA | 1 |
| Czupryniak, L; Durczynski, A; Hogendorf, P; Nowicki, M; Strzelczyk, J; Szymanski, D; Wojciechowska-Durczyńska, K | 1 |
| Imagawa, A; Iwahashi, H; Kozawa, J; Okita, K; Shimomura, I; Yamagata, K | 1 |
| Checklin, HL; Horowitz, M; Jones, KL; Ma, J; Meyer, JH; Rayner, CK; Stevens, JE; Wishart, JM | 1 |
| Drucker, DJ; Sadry, SA | 1 |
| Bano, G | 1 |
| Bloom, SR; Bouvy, ND; Buurman, WA; de Jonge, C; Greve, JW; le Roux, CW; Rensen, SS; Schaper, NC; Verdam, FJ; Vincent, RP | 1 |
| Chang, J; Greenfield, JR; Horowitz, M; Rayner, CK; Samocha-Bonet, D; Wu, T | 1 |
| Casamitjana, R; Delgado, S; Flores, L; Jiménez, A; Lacy, A; Vidal, J | 1 |
| Honda, K; Kumagai, N; Muroya, Y; Shimodaira, M; Tsuzawa, K | 1 |
| Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
| Bojsen-Møller, KN; Dirksen, C; Hansen, DL; Holst, JJ; Jacobsen, SH; Jørgensen, NB; Kristiansen, VB; Madsbad, S; Naver, L; Worm, D | 1 |
| Becker, RH; Horowitz, M; Lorenz, M; Pfeiffer, C; Rütten, H; Ruus, P; Steinsträsser, A | 1 |
| Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W | 1 |
| Khan, SA; Nanduri, J; Prabhakar, NR; Wang, N | 1 |
| Buchner, K; Kaczmarek, P; Klussmann, S; Kolodziejski, P; Maasch, C; Nowak, KW; Pruszynska-Oszmalek, E; Purschke, WG; Sell, S; Strowski, MZ; Vater, A | 1 |
| Cheng, Y; Dong, L; Fu, X; Han, W; Hao, H; Hou, Q; Liu, H; Liu, J; Mu, Y; Shen, J; Ti, D; Tong, C; Zhao, Y | 1 |
| Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
| Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M | 1 |
| Otto-Buczkowska, E | 1 |
| Anselmino, M; Astiarraga, B; Baldi, S; Camastra, S; Ciociaro, D; Ferrannini, E; Gastaldelli, A; Holst, JJ; Mari, A; Muscelli, E; Nannipieri, M | 1 |
| Eng, K; Guey, LT; Haney, S; Tien, E; Tiwari, S; Zhao, J | 1 |
| Bolkent, S; Coskun, ZM | 1 |
| Ito, R; Matsuda-Nagasumi, K; Mori, I; Negoro, N; Takeuchi, K; Tsujihata, Y | 1 |
| Alssema, M; Dekker, JM; Eekhoff, EM; Gastaldelli, A; Hart, LM; Holst, JJ; Mari, A; Nijpels, G; Rijkelijkhuizen, JM; Scheffer, PG; Teerlink, T | 1 |
| Carlson, OD; de Cabo, R; Doyle, ME; Egan, JM; Farhang, K; Fiori, JL; Gadkaree, SK; González-Mariscal, I; Kim, W; Krzysik-Walker, SM; Mattison, JA; Moaddel, R; Pearson, KJ; Sanghvi, M; Shin, YK | 1 |
| Novikova, L; Robbins, DC; Schwasinger-Schmidt, T; Stehno-Bittel, L; Williams, SJ | 1 |
| Franklin, ZJ; Irwin, N; O'Harte, FP; Rafferty, EP | 1 |
| Balas, B; Balena, R; Boldrin, M; Bolli, GB; Charbonnel, B; Gastaldelli, A; Ratner, R; Rosenstock, J | 1 |
| Li, XC; Zhuo, JL | 2 |
| Abe, T; Fujitani, Y; Fukada, T; Fukunaka, A; Hara, A; Hirano, T; Hojyo, S; Imaizumi, MO; Kanazawa, A; Kawaguchi, M; Kawamori, R; Kawauchi, T; Kiyonari, H; Mita, T; Nagamatsu, S; Ogihara, T; Shimizu, T; Takeno, K; Tamaki, M; Tamura, Y; Uchida, T; Watada, H; Watanabe, T | 1 |
| Anselmino, M; Baldi, S; Barsotti, E; Bellini, R; Berta, R; Camastra, S; Colligiani, D; Ferrannini, E; Guarino, D; Mari, A; Moriconi, D; Nannipieri, M | 1 |
| Amer, A; Booth, T; Huang, GC; Marshall, HL; Rigby, R; Shaw, JA; White, MG; White, S | 1 |
| Feng, T; Gao, K; Hu, D; Li, C; Li, L; Ren, Y; Wang, B; Wang, C; Wang, J; Wang, Q; Wang, Y; Yin, L; You, H; Zhai, Y; Zhao, J | 1 |
| Birkenfeld, AL; Brachs, S; Erion, DM; Henkel, J; Kuna, M; Lieske, S; Neuschäfer-Rube, F; Pathe-Neuschäfer-Rube, A; Perry, RJ; Pesta, D; Pfeiffer, AF; Püschel, GP; Schupp, M; Shulman, GI; Tolkachov, A; von Loeffelholz, C; Willmes, DM | 1 |
| Boggi, U; Bugliani, M; Campani, D; Filipponi, F; Focosi, D; Marchetti, P; Marselli, L; Martino, L; Masiello, P; Masini, M; Olimpico, F; Scatena, F; Suleiman, M; Syed, F | 1 |
| Alvarez-Sanchez, SN; Carrillo-Vico, A; Guerrero, JM; Lardone, PJ | 1 |
| Ashcroft, FM; Bengtsson, M; Braha, O; Braun, M; Brereton, M; Collins, S; Galvanovskis, J; Gloyn, AL; Gonzalez, A; Gribble, F; Groschner, LN; Johnson, PR; Lahmann, C; Ramracheya, R; Reimann, F; Rorsman, NJ; Rorsman, P; Salehi, A; Tarasov, A; Travers, ME; Walker, JN; Zhang, Q | 1 |
| Cho, KY; Nakamura, A; Nomoto, H; Ono, Y | 1 |
| Bai, RX; Cui, Z; Li, YG; Pan, LZ; Song, MM; Xu, J; Yuan, HS; Zhong, ZQ; Zhou, L | 1 |
| Chowdhury, S; Crimmins, DL; Dunai, J; Griest, TA; Laciny, E; Ladenson, JH; Patterson, BW; Polonsky, KS; Reeds, DN; Rometo, DA; Tran, HD; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Chen, T; Clark, T; Dimattia, D; Dullea, R; Gandhok, H; Kreeger, J; Salatto, C; Sciabola, S; Stanton, R; Vage, C; Weng, Y | 1 |
| Korbonits, M; Pernicova, I | 1 |
| Albrechtsen, NW; Bak, MJ; Christensen, M; Deacon, CF; Dragsted, LO; Hartmann, B; Holst, JJ; Knop, FK; Pedersen, J; Vilsbøll, T | 1 |
| Calanna, S; Christensen, MB; Holst, JJ; Knop, FK; Vilsbøll, T | 1 |
| Calanna, S; Di Pino, A; Knop, FK; Piro, S; Purrello, F; Rabuazzo, AM; Scicali, R | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Fava, GE; Fonseca, VA; O'Malley, TJ; Wu, H; Zhang, Y | 1 |
| Becker, RH; Kapitza, C; Msihid, J; Stechl, J | 1 |
| Andreani, T; Belani, J; Bradley, P; Cao, Y; Chen, P; Cox, K; Dai, P; Dai, X; DeMong, D; Feng, KI; Gauuan, J; Greenlee, W; Grotz, D; Hwa, J; Kang, L; Kozlowski, J; Lachowicz, J; Lavey, B; Liang, M; Lin, P; Lin, SI; McNamara, P; Meng, T; Miller, M; Morrison, R; Patel, B; Sondey, C; Soriano, A; Stamford, A; Wong, J; Wong, M; Yang, DY; Yu, W; Zhai, Y; Zhang, H; Zhao, H; Zhou, G | 1 |
| Ishihara, H | 1 |
| Bang, CY; Choung, SY | 1 |
| Ahrén, B; Farngren, J; Foley, JE; Persson, M; Schweizer, A | 1 |
| Ahrén, B; Aronson, R; Bailey, CJ; Berria, R; Gautier, JF; Stager, W | 1 |
| Fujihara, M; Mizuta, M; Nakashima, N; Nakazato, M; Noma, K; Shiiya, T; Tsuchimochi, W; Ueno, H | 1 |
| Bagger, JI; Hansen, T; Holst, JJ; Knop, FK; Pedersen, O; Vilsbøll, T; Østoft, SH | 1 |
| Madison, LL; Muller, WA; Unger, RH | 1 |
| Rui, L | 1 |
| Bound, M; Checklin, H; Horowitz, M; Jones, KL; Lange, K; Marathe, CS; Rayner, CK; Standfield, S; Wishart, J | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Andreoli, AM; Bolli, GB; Candeloro, P; Cioli, P; Fanelli, CG; Lucidi, P; Marzotti, S; Porcellati, F; Schmidt, R | 1 |
| Ishida, H; Katsuta, H; Nishida, S; Ozawa, S; Sumitani, Y; Suzuki, K; Takahashi, K; Tanaka, T; Yoshimoto, K | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Daich, E; Shehadeh, N; Zuckerman-Levin, N | 1 |
| Holmes, D | 1 |
| Chow, SZ; Ehses, JA; Ellingsgaard, H; Hansen, AM; Herrera, PL; Ladefoged, M; Lynn, FC; Müller, W; Nackiewicz, D; Rabe, B; Rose-John, S; Speck, M; Voshol, PJ; Yoganathan, P | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 1 |
| Belinova, L; Dezortova, M; Hajek, M; Hill, M; Kahleova, H; Kazdova, L; Malinska, H; Oliyarnyk, O; Pelikanova, T; Skop, V; Trnovska, J; Tura, A | 1 |
| Charron, MJ; Du, XQ; Foda, ZH; Kleiner, RE; Leissring, MA; Liu, DR; Maianti, JP; McFedries, A; Saghatelian, A; Seeliger, MA; Tang, WJ | 1 |
| de Oliveira, Mda S; Geloneze, B; Novaes, FS; Pareja, JC; Tambascia, MA; Vasques, AC | 1 |
| Bagger, JI; Holst, JJ; Knop, FK; Lund, A; Vilsbøll, T | 2 |
| Christensen, CS; Karstoft, K; Pedersen, BK; Solomon, TP | 1 |
| Hompesch, M; Krentz, AJ; Morrow, L; Norjavaara, E; Petersson, M | 1 |
| Gu, JJ; Hou, LQ; Liu, YH; Zhao, TY | 1 |
| Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M | 1 |
| Holst, JJ; Knop, FK; Rehfeld, JF; Sonne, DP; Vilsbøll, T | 1 |
| Ang, M; Linn, T | 1 |
| Bowe, JE; Franklin, ZJ; Hauge-Evans, AC; Jones, PM; King, AJ; Persaud, SJ | 1 |
| Allister, EM; Cai, EP; Gaisano, HY; Luk, CT; Schroer, SA; Shi, SY; Wang, L; Wheeler, MB; Woo, M | 1 |
| Bokhari, S; Emmerson, P; Gupta, A; Meyer, C; Plummer, E | 1 |
| Berglund, ED; Charron, MJ; Evans, MR; Holland, WL; Lee, Y; Roth, MG; Scherer, PE; Unger, RH; Wang, MY; Yu, X | 1 |
| Denney, WS; Engel, SS; Fang, L; Kowalski, KG; Liu, R; Musser, BJ; Peng, JZ; Reitman, ML; Stoch, A; Stone, JA; Troyer, MD; Tsai, K; Xu, L | 1 |
| Pellitero, S; Puig-Domingo, M | 1 |
| Bhanot, S; Brandt, TA; Burggraaf, J; Cohen, AF; de Kam, ML; Geerts, BF; Morgan, ES; Romijn, JA; van Dongen, MG | 1 |
| Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Basu, A; Basu, R; Brett, J; Johnson, C; Joyner, M; Nandy, D; Svendsen, CB | 1 |
| Aguilar, R; Hehnke, U; Lajara, R; von Eynatten, M; Woerle, HJ | 1 |
| Qiu, YX; Shi, M; Wang, YG; Xu, T | 1 |
| Nakamura, S; Nakazato, M; Sakoda, H; Tsubouchi, C; Tsuchimochi, W; Ueno, H; Yamashita, E | 1 |
| Carr, MC; Hompesch, M; Jones-Leone, A; Matthews, J; Morrow, L; Reinhardt, RR; Young, M; Zhi, H | 1 |
| Arpa, M; Deyneli, O; Gunes, M; Haklar, G; Imeryuz, N; Sirikci, O; Temizkan, S; Yasar, M; Yavuz, DG; Yazici, D | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Castro e Sousa, F; Eickhoff, H; Louro, T; Matafome, P; Seiça, R | 1 |
| Andersson, LE; Axelsson, AS; Groop, LC; Mulder, H; Renström, E; Rosengren, AH; Spégel, P; Tang, Y | 1 |
| Abdulla, H; Atherton, PJ; Idris, I; Phillips, B; Smith, K; Wilkinson, D | 1 |
| Castellsague-Perolini, M; Grand-Guillaume-Perrenoud, L; Registe-Rameau, M | 1 |
| Furukawa, A; Ishihara, H; Kosuda, M; Nakazaki, M; Otsuka, Y; Yamaguchi, S | 1 |
| Al-Zoairy, R; Ciardi, C; Hermann, M; Khan, MI; Mittermair, C; Niederwanger, A; Pedrini, MT; Salzmann, K; Tatarczyk, T | 1 |
| Bagger, JI; Christensen, M; Knop, FK; Lund, A; Vilsbøll, T | 1 |
| Chen, L; Da Silva Xavier, G; Ferrer, J; French, PM; Hodson, DJ; Mcginty, JA; Mitchell, RK; Mondragon, A; Rutter, GA; Thorens, B | 1 |
| Baretić, M; Troskot, R | 1 |
| Deng, Y; Gu, W; Gu, Y; Hong, J; Liu, T; Ning, G; Shi, J; Sun, Z; Wang, C; Wang, W; Yao, S; Zhang, Y; Zheng, S | 1 |
| Holst, JJ; Karstoft, K; Knudsen, SH; Pedersen, BK; Solomon, TP; Winding, K | 2 |
| Katsuno, T; Kusunoki, Y; Matsuo, T; Miuchi, M; Miyagawa, J; Murai, K; Namba, M; Ochi, F; Tokuda, M | 1 |
| Escalada, FJ | 1 |
| Jiang, S; Lai, SS; Li, CJ; Lu, JM; Shen, N; Tao, WW; Wang, XX; Xu, N; Xue, B; Yu, X; Zhang, JL; Zhang, JZ | 1 |
| Benoit, YD; Gudas, LJ; Trasino, SE | 1 |
| Bräuner-Osborne, H; Iversen, H; Knudsen, SM; Nøhr, AC; Roed, SN; Waldhoer, M; Wismann, P | 1 |
| Almokayyad, RM; Gannon, MC; Nuttall, FQ | 1 |
| Hamamoto, S; Hashiramoto, M; Hirukawa, H; Kaku, K; Kaneto, H; Kimura, T; Kohara, K; Okauchi, S; Shimoda, M; Tawaramoto, K | 1 |
| Dela, F; Hansen, M; Helge, JW; Palsøe, MK | 1 |
| Dhanjal, JK; Goyal, S; Grover, A; Grover, S; Sundar, D | 1 |
| Gyldenløve, M; Holst, JJ; Knop, FK; Skov, L; Storgaard, H; Vilsbøll, T | 1 |
| Fujimoto, K; Hamamoto, Y; Hamasaki, A; Honjo, S; Ikeda, H; Koshiyama, H; Okamura, E; Tokumoto, S; Wada, Y; Yamaguchi, E | 1 |
| Deeg, MA; Fu, H; Garhyan, P; Kelly, RP; Lim, CN; Loh, MT; Pinaire, JA; Prince, MJ; Raddad, E | 1 |
| Bolze, S; Fouqueray, P; Mari, A; Pacini, G; Roden, M | 1 |
| Adriaenssens, AE; Andersson, LE; Bagge, A; Gribble, F; Mulder, H; Reimann, F; Sharoyko, VV; Spégel, P; Stamenkovic, JA; Wollheim, CB | 1 |
| Heden, TD; Kanaley, JA; Leidy, HJ; Liu, Y; Nyhoff, LM; Park, YM; Thyfault, JP | 1 |
| Chen, Y; Fu, Z; Hu, J; Sun, R; Tang, N; Wang, F; Wang, L; Yan, S | 1 |
| Eguchi, H; Fujita, Y; Imagawa, A; Iwahashi, H; Kozawa, J; Nagano, H; Okita, K; Shimomura, I; Uno, S; Yoneda, S; Yoshikawa, A | 1 |
| Kitamura, T | 1 |
| Bae, JH; Im, SS; Na, AY; Park, JH; Shim, HM; Song, DK | 1 |
| Cannone, M; D'Ascia, SL; Guise, TA; Lacampagne, A; Marks, AR; Marziliano, N; Pagano, G; Reiken, S; Santulli, G; Sardu, C; Trimarco, B; Xie, W | 1 |
| Campbell, JE; Drucker, DJ | 1 |
| Gao, K; Hu, D; Li, L; Ren, Y; Wang, B; Wang, J; Wang, Q; Wang, Y; Yan, G; You, H; Zhai, Y; Zhang, J; Zhang, M | 1 |
| Ahmed, L; Bantle, JP; Bessler, M; Billington, CJ; Connett, JE; Ikramuddin, S; Inabnet, WB; Korner, J; Nguyen, KT; Thomas, A; Vella, A; Wang, Q | 1 |
| Cho, WK; Jung, MH; Park, MS; Park, SH; Suh, BK | 1 |
| Bähr, I; Mühlbauer, E; Peschke, E | 1 |
| Bos, E; Carlotti, F; Clark, A; de Koning, EJ; Ellenbroek, JH; Engelse, MA; Hansen, BC; Koster, AJ; Rabelink, TJ; Roefs, MM; Song, H; Spijker, HS | 1 |
| Chen, MC; Hsieh, CH; Hsu, KC; Hung, CC; Wang, TY | 1 |
| Bagger, JI; Hansen, T; Hartmann, B; Holst, JJ; Knop, FK; Pedersen, O; Vilsbøll, T; Østoft, SH | 1 |
| Chang, BC; Chen, LM; Ren, HZ; Shan, CY; Wang, Y; Xu, YG; Yang, JH; Yang, YH; Zheng, MY | 1 |
| Farhy, LS; McCall, AL | 2 |
| Choi, H; Kramer, CK; Retnakaran, R; Zinman, B | 1 |
| Chang, B; Chen, L; Ren, H; Shan, C; Wang, Y; Xu, Y; Yang, J; Yang, Y; Zheng, M | 1 |
| Gao, K; Hu, D; Li, L; Luo, X; Wang, C; Wang, J; Zhang, J; Zhang, M; Zhao, J | 1 |
| Bindels, LB; Burkart, V; Hartmann, B; Henrich, B; Holst, JJ; Hwang, JH; Kolb, H; MacKenzie, C; Martinez, I; Nowotny, B; Nowotny, P; Pacini, G; Roden, M; Schloot, NC; Simon, MC; Stehle, P; Strassburger, K; Walter, J; Zivehe, F | 1 |
| Gyldenløve, M; Holst, JJ; Knop, FK; Skov, L; Vilsbøll, T; Zachariae, C | 1 |
| Balhuizen, A; Bennet, H; Dekker Nitert, M; Essén, S; Fex, M; Krus, U; Medina, A; Ottosson Laakso, E; Spégel, P; Storm, P; Wierup, N | 1 |
| Chen, H; Chen, Y; Liu, M; Luo, J; Wang, T; Wang, X; Yang, Y; You, P; Zhao, Y; Zheng, C; Zhou, W | 1 |
| Ahren, B; Bar-Dayan, Y; Froy, O; Jakubowicz, D; Landau, Z; Wainstein, J | 1 |
| Camilleri, M; Cobelli, C; Edens, KL; Farrugia, LP; Grothe, KB; Man, CD; Micheletto, F; Piccinini, F; Rizza, RA; Sathananthan, M; Shah, M; Vella, A | 1 |
| Hara, K; Kaku, H; Kato, T; Mitsuzaki, K; Muraishi, K; Nakayama, H; Nakayama, S; Ohki, T; Tajiri, Y; Tanaka, K; Tokubuchi, I; Tsuruta, M; Wada, N; Yamada, K | 1 |
| Østoft, SH | 1 |
| Hattersley, AT; Thorens, B | 1 |
| Merino, B; Quesada, I; Vieira, E | 1 |
| Ahrén, B; Alsalim, W; Bizzotto, R; Mari, A; Omar, B; Pacini, G; Tura, A | 1 |
| Bolkent, S; Coskun, ZM; Karabulut, S | 1 |
| Davidson, JA | 1 |
| Cagle, AP; He, X; Mitchell, BD; Settles, JA; Sturdy, IM | 1 |
| Cahen, DL; Kramer, MH; Muskiet, MH; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Augstein, P; Bandala-Sanchez, E; Campbell, P; Harrison, LC; Hawthorne, WJ; Heinke, P; Kay, TW; Loudovaris, T; Naselli, G; Rogers, K; Thomas, HE | 1 |
| Gupta, Y; Kalra, S | 1 |
| Kramer, CK; Retnakaran, R; Zinman, B | 1 |
| Bagger, JI; Knop, FK; Lund, A; Suppli, MP; Vilsbøll, T | 1 |
| Frandsen, CS; Madsbad, S; Østergaard, L | 1 |
| Ahmed, S; Fatima, N; Hafizur, RM; Hameed, A; Kabir, N; Nisar, M | 1 |
| Flint, A; Ingwersen, SH; Jacobsen, LV; Olsen, AK | 1 |
| Chang, ES; Chen, CY; Chen, SC; Chen, YC; Inui, A; Lee, WJ | 1 |
| Miuchi, M; Miyagawa, J; Namba, M | 1 |
| Benatti, FB; Harder-Lauridsen, NM; Krogh-Madsen, R; Lyngbæk, MP; Møller, K; Nielsen, ST; Pedersen, BK; Wedell-Neergaard, AS | 1 |
| Ahlkvist, L; Ahrén, B; Fosgerau, K; Omar, B; Valeur, A | 1 |
| Iwasaki, M; Kurose, T; Kuwata, H; Maeda, H; Minami, K; Murotani, K; Nakada, K; Nosaka, C; Seino, S; Seino, Y; Shimizu, S; Yabe, D | 1 |
| Chang, B; Cheng, J; Ren, H; Shan, C; Xu, Y; Yang, J; Yang, Y; Zheng, M | 1 |
| Accili, D; Bouchi, R; Cinti, F; Kim-Muller, JY; Marchetti, P; Marselli, L; Masini, M; Ohmura, Y; Ratner, LE; Sandoval, PR; Suleiman, M | 1 |
| Gluud, L; Holst, JJ; Junker, AE; Knop, FK; Vilsbøll, T | 1 |
| Davidson, JA; Holland, WL; Lee, Y; McCorkle, SK; Roth, MG; Scherer, PE; Unger, RH; Wang, MY; Yu, X | 1 |
| Bergsten, P; Cen, J; Ciba, I; Forslund, A; Kristinsson, H; Manell, H; Manukyan, L; Staaf, J; Stenlid, R | 1 |
| Scheen, AJ | 2 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| Cho, YM; Kim, EK; Kim, LK; Oh, TJ | 1 |
| Bi, X; Henry, CJ; Quek, R | 1 |
| Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR | 1 |
| Cogne, M; Gérard, P; Jarlet, E; Maiza, JC; Rollot, O; Schneebeli, S | 1 |
| Chang, B; Chen, L; Ren, H; Shan, C; Wang, X; Wang, Y; Xu, Y; Yang, J; Zheng, M | 1 |
| Åsberg, A; Egeland, EJ; Feldt-Rasmussen, B; Halden, TA; Hartmann, A; Holst, JJ; Hornum, M; Jenssen, T; Khiabani, HZ; Knop, FK; Midtvedt, K | 1 |
| Adams-Huet, B; Dimitrov, I; Harrison, LB; Hulsey, K; Jaster, AW; Lenkinski, RE; Li, X; Lingvay, I; Pedrosa, I; Pinho, DF; Pop, LM; Vanderheiden, A; Warshauer, JT; Yokoo, T; Yuan, Q | 1 |
| Chowdhury, MK; Coleman, JL; Morris, MJ; Shepherd, PR; Smith, GC; Smith, NJ; Wu, LE | 1 |
| Gromada, J; Harp, JB; Yancopoulos, GD | 1 |
| Christensen, MB | 1 |
| Briant, L; Rorsman, P; Salehi, A; Vergari, E; Zhang, Q | 1 |
| de la Peña, A; Del Prato, S; Karanikas, CA; Ludvik, B; Mari, A; Milicevic, Z; Pechtner, V; Shurzinske, L | 1 |
| Bergman, A; Erion, DM; Kazierad, DJ; Lee, DS; Rolph, T; Somayaji, V; Tan, B | 1 |
| Li, D; Li, Y; Lin, J; Sun, J | 1 |
| Franklin, ZJ; Hewage, CM; Irwin, N; McShane, LM; O'Flynn, D; O'Harte, FP | 1 |
| Billert, M; Kaczmarek, P; Kolodziejski, PA; Mackowiak, P; Nowak, KW; Pruszynska-Oszmalek, E; Sassek, M; Strowski, MZ; Szczepankiewicz, D | 1 |
| Birnbaum, MJ; Miller, RA | 1 |
| Cai, X; Chen, D; Clark, A; Johannessen, H; McCulloch, LJ; Olsen, MK; Ramracheya, RD; Rorsman, P; Wiggins, D; Zhao, CM | 1 |
| Deutsch, T; Dió, M; Mészáros, J | 1 |
| Agius, L | 2 |
| Hansen, JS; Lehmann, R; Pedersen, BK; Plomgaard, P; Weigert, C; Xu, G | 1 |
| Asmar, M; Boer, GA; Christensen, M; Hartmann, B; Holst, JJ; Nissen, A; Pedersen, J; Svendsen, B; Torekov, S; Windeløv, JA | 1 |
| Ahn, CH; Cho, YM; Oh, TJ | 1 |
| Yang, H; Yang, L | 1 |
| Fligner, CL; Foulis, AK; Hull, RL; Mei, Q; Mundinger, TO; Taborsky, GJ | 1 |
| Carrera-Bastos, P; Chanrai, M; Fontes-Villalba, M; Granfeldt, Y; Jönsson, T; Knop, FK; Lindeberg, S; Memon, AA; Picazo, Ó; Sundquist, K; Sunquist, J | 1 |
| Oestricker, L; Patterson, BW; Reeds, DN; Sterl, K; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Arslanian, S; Bacha, F; Hannon, T; Hughan, KS; Kim, JY; Lee, S; Michaliszyn, SF; Nasr, A; Tfayli, H | 1 |
| Chen, K; Chen, Y; Jia, S; Li, X; Lv, Q; Sun, C; Zhang, X | 1 |
| Chowdhury, S; Dunai, J; Kilpatrick, R; Oestricker, LZ; Patterson, BW; Reeds, DN; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Akagami, T; Ikawa, T; Inagaki, T; Katsuno, T; Kushida, A; Kusunoki, Y; Matsuo, T; Miuchi, M; Miyagawa, J; Namba, M; Tokuda, M | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Chanprasert, K; Chongjaroen, N; Hanchang, W; Kooptiwut, S; Plengvidhya, N; Semprasert, N; Sujjitjoon, J; Tangjittipokin, W; Yenchitsomanus, PT | 1 |
| Abels, M; Ahlqvist, E; Ahrén, B; Bennet, H; Dekker-Nitert, M; Dyachok, O; Fadista, J; Fex, M; Fred, RG; Groop, L; Hansson, O; Kask, L; Kuhar, MJ; Lindqvist, A; Lyssenko, V; Nagaraj, V; Poon, W; Renström, E; Riva, M; Sathanoori, R; Shcherbina, L; Sörhede-Winzell, M; Tengholm, A; Wierup, N; Wollheim, CB | 1 |
| Clemmensen, C; DiMarchi, RD; Finan, B; Gelfanov, V; Müller, TD; Perez-Tilve, D; Tschöp, MH | 1 |
| Casajoana, A; de Gordejuela, AG; Duran, X; Espinet, E; Galvao, M; López-Urdiales, R; Pérez, M; Pujol, J; Toro, S; Vendrell, J; Vilarrasa, N | 1 |
| Armas, D; Dilzer, S; Klein, D; Lasseter, K; Li, YX; Logan, D; Marschke, KB; Pipkin, JD; Plotkin, DJ; Vajda, EG; Wei, X; Zhi, L; Zhou, R | 1 |
| Ahrén, B; Færch, K; Hansen, T; Holst, JJ; Johansen, NB; Jonsson, A; Jørgensen, ME; Lauritzen, T; Pacini, G; Pedersen, O; Torekov, SS; Vistisen, D; Witte, DR | 1 |
| Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W | 1 |
| Dusaulcy, R; Gosmain, Y; Gribble, F; Handgraaf, S; Heddad-Masson, M; Philippe, J; Reimann, F; Skarupelova, S; Vesin, C; Visentin, F | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Norton, L; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Ceriello, A; Genovese, S; Gronda, E; Mannucci, E | 1 |
| Fischer, M; Hauber, M; Jarick, I; Krepak, Y; Lee-Barkey, YH; Schiffer, E; Stratmann, B; Tschoepe, D | 1 |
| Ishii, Y; Ito, H; Kon, K; Sakurai, T; Sasahara, M; Sasaoka, T; Takahara, S; Toyooka, N; Tsuneki, H; Wada, T; Yamazaki, M; Yanagisawa, M | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
| Wang, N; Wang, X; Xing, XY; Yang, WY; Yang, ZJ; Zhang, B; Zhang, JP | 1 |
| Biebermann, H; Brandt, S; Clemmensen, C; De Angelis, M; DiMarchi, R; Döring, Y; Finan, B; Fischer, K; Flamant, F; Fuchs, H; Gailus-Durner, V; Gauthier, K; Gelfanov, V; Habegger, KM; Healy, ME; Heikenwalder, M; Hofmann, SM; Hrabě de Angelis, M; Jall, S; Jastroch, M; Keuper, M; Kleinert, M; Köhrle, J; Liu, F; Liu, P; Lutter, D; Malehmir, M; Moreth, K; Müller, L; Müller, TD; Neff, F; Perez-Tilve, D; Rozman, J; Sánchez-Garrido, MA; Schramm, KW; Stemmer, K; Tschöp, MH; Tuckermann, J; Weber, A; Weber, C; Yang, B; Zhu, Z | 1 |
| Colao, A; de Angelis, C; Muscogiuri, G; Negri, M; Pivonello, C; Pivonello, R; Provvisiero, DP; Simeoli, C | 1 |
| Ahrén, B; Eto, T; Irie, S; Kurose, T; Kuwata, H; Murotani, K; Seino, S; Seino, Y; Shiramoto, M; Yabe, D | 1 |
| Chen, YY; Li, GW; Wang, X; Yang, ZJ; Zhang, B | 1 |
| Ahn, CH; Cho, YM; Kim, EK; Min, SH; Oh, TJ | 1 |
| Agrawal, S; Gupta, Y | 1 |
| Deeg, MA; Ding, Y; Fu, H; Garhyan, P; Hardy, TA; Kazda, CM; Kelly, RP; Landschulz, WH; Lewin, AJ; Lim, CN; Moller, DE; Shi, C; Watson, DE | 1 |
| Cui, X; de la Peña, A; Kapitza, C; Kelly, RP; Loghin, C; Zhang, X | 1 |
| Ahlqvist, E; Fritsche, A; Gallwitz, B; Groop, L; Hakaste, LH; Häring, HU; Heni, M; Machann, J; Schick, F; Stefan, N; Tuomi, T; Van Obberghen, E; Wagner, R | 1 |
| Bagger, JI | 1 |
| Andersen, G; Falk, A; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
| Bentley, NL; Bustamante, S; Chowdhury, MK; Das, A; Gilchrist, RB; Morris, MJ; Richani, D; Shepherd, PR; Smith, GC; Turner, N; Wu, LE | 1 |
| Angelin, B; Bonde, Y | 1 |
| Coppieters, K; Hasselby, JP; Kirk, RK; Knudsen, LB; Mortensen, PG; Pedersen, L; Pyke, C; von Herrath, MG | 1 |
| Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Triplitt, C | 1 |
| Fourmy, D | 1 |
| Chen, L; Chen, Q; Duan, Y; Liu, H; Wang, P; Xi, S | 1 |
| Ekelund, M; Groop, L; Hedenbro, J; Lindqvist, A; Pierzynowski, S; Wierup, N | 1 |
| Cao, T; Gao, L; Liang, Y; Qiao, Z; Wang, Y; Yang, D; Yu, B; Zhang, P; Zhang, X | 1 |
| Ackermann, AM; Briker, A; Heller, A; Kaestner, KH; Zhang, J | 1 |
| Guerci, B; Martin, CS | 1 |
| Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Ravikumar, B; Taylor, R | 1 |
| Choi, MS; Jeon, SM; Jeong, YJ; Kim, DJ; Kim, HJ; Kwon, JH; Lee, MK; Moon, KD; Park, YB | 1 |
| Li, WH; Sun, Q; Wang, H; Wang, T; Xiao, XH; Yang, GH; Yuan, T | 1 |
| Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
| Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P | 2 |
| DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P | 1 |
| Hoist, JJ; Lasalle, JR | 1 |
| Baskin, DG; Cummings, BP; Digitale, EK; Graham, JL; Griffen, SC; Havel, PJ; Reed, BJ; Stanhope, KL; Sweet, IR | 1 |
| Böni-Schnetzler, M; Donath, MY; Ehses, JA; Faulenbach, M | 1 |
| Bock, G; Camilleri, M; Cobelli, C; Dalla Man, C; Foley, JE; Giesler, PD; Ligueros Saylan, M; Rizza, RA; Serra, DB; Toffolo, G; Vella, A | 1 |
| Büchler, MW; Erbel, S; Esposito, I; Nawroth, PP; Reers, C; Ritzel, RA; Schmied, B | 1 |
| Burcelin, R | 1 |
| Brunner, Y; Couté, Y; Priego-Capote, F; Sanchez, JC; Schvartz, D | 1 |
| Holst, JJ; Højberg, PV; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T; Vølund, A; Zander, M | 1 |
| de la Peña, A; Fineman, M; Irie, S; Isaka, Y; Kothare, PA; Linnebjerg, H; Mace, K; Sakata, Y; Shigeta, H; Teng, CH; Uenaka, K; Yamamura, A; Yeo, KP | 1 |
| Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Simonsen, U; Vilsboll, T; Vølund, A | 1 |
| Heller, SR | 1 |
| Blackwood, A; Farooqi, IS; Greenfield, JR; Gribble, FM; Habib, AM; Henning, E; Holst, JJ; Keogh, JM; Reimann, F | 1 |
| Thorens, B | 6 |
| Ali, S; Drucker, DJ | 1 |
| Furrer, D; Kaufmann, K; Lutz, TA; Reusch, CE; Tschuor, F | 1 |
| Bokhari, S; Emerson, P; Gupta, A; Israelian, Z; Meyer, C | 1 |
| Addabbo, F; Chander, PN; Chen, J; Gobe, G; Goligorsky, MS; Kuo, MC; Li, H; Nasjletti, A; Ni, J; Park, HC; Patschan, D; Pelger, E; Zhang, F | 1 |
| Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Nilsson, PM; Persson, M; Schweizer, A | 1 |
| Bohannon, N | 1 |
| Barati, MT; Epstein, PN; Moore, JP; Portillo, J; Song, Y; Villafuerte, BC | 1 |
| Havale, SH; Pal, M | 1 |
| Amiel, SA; Cryer, PE | 1 |
| Carlson, OD; Charles, CP; Chia, CW; Egan, JM; Kim, HS; Kim, W; Melvin, DL; Shin, YK | 1 |
| Bermúdez-Silva, FJ; Nadal, A; Rodríguez de Fonseca, F; Suárez Pérez, J | 1 |
| Ceriello, A; Frost, GS; Lansink, M; Rouws, CH; van Laere, KM | 1 |
| Basu, A; Basu, R; Chandramouli, V; Landau, BR; Rizza, RA; Schumann, W | 1 |
| Gerrard, J; Jovanovic, A; Taylor, R | 1 |
| Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K | 2 |
| Bianchi, C; Gentilella, R; Rossi, A; Rotella, CM | 1 |
| Pratley, RE | 1 |
| Capparelli, E; Fineman, M; Gottschalk, M; Guan, X; Kothare, P; Malloy, J | 1 |
| Astrup, A; Brader, LJ; Hartvigsen, ML; Hermansen, K; Holst, JJ; Mortensen, LS; Schrezenmeir, J; Thomsen, C | 1 |
| Hauner, H; Holle, R; Kohlmann, T; Landgraf, W; Pirk, O; Scholten, T | 1 |
| Astrup, A; Brader, L; de Vrese, M; Hermansen, K; Holm, L; Holst, JJ; Mortensen, L; Schrezenmeir, J; Thomsen, C | 1 |
| Bremer, JP; Hallschmid, M; Jauch-Chara, K; Schmid, S; Schultes, B | 1 |
| Miyamoto, M | 1 |
| Born, D; Büchler, MW; Esposito, I; Friess, H; Giese, NA; Giese, T; Kleeff, J; Kolb, A; Rieder, S; Rudofsky, G; Werner, J | 1 |
| Amiel, SA; Choudhary, P; Emery, CJ; Heller, SR; Lonnen, K; MacDonald, IA; MacLeod, KM | 1 |
| Fukuda, S; Ishii, Y; Matsui, K; Matsushita, M; Miyajima, K; Nishizawa, E; Oda, T; Ohta, T; Sano, R; Sasase, T; Ueda, N; Yamamoto, H | 1 |
| Chen, ZX; Duan, HY; Lin, CJ; Lin, SD | 1 |
| Basu, S; Bjerve, KS; Frayn, KN; Grill, V; Mostad, IL; Sutton, P | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Fritsche, A; Häring, HU; Machicao, F; Staiger, H | 1 |
| Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Bryan, J; Harmon, JS; Oseid, EA; Robertson, RP; Slucca, M | 1 |
| Asmar, M; Deacon, CF; Hare, KJ; Holst, JJ; Knop, FK; Madsbad, S; Vilsbøll, T | 1 |
| Chakraborty, G; Lafontant, DE; Thumpayil, S; Toney, JH; Woubneh, W | 1 |
| Gibiansky, L; Kakkar, T; Komorowski, R; Lau, YY; Ma, P; Véniant, MM; Wang, G; Wang, J; Yan, H | 1 |
| Khoo, EY; Macdonald, IA; Mansell, P; Tsintzas, K; Wallis, J | 1 |
| Dirksen, C; Hansen, DL; Holst, JJ; Hvolris, LE; Madsbad, S; Naver, LS; Worm, D | 1 |
| Adeghate, E; Al-Salam, S; Hameed, R; Parvez, HS | 1 |
| Egefjord, L; Petersen, AB; Rungby, J | 1 |
| Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B | 1 |
| Luft, FC | 1 |
| Diamant, M; van Genugten, RE; van Raalte, DH | 1 |
| Hedrick, S; Inoue, H; Liu, Y; Miller, N; Montminy, M; Ravnskjaer, K; Vera, L; Viste, K; Wang, Y | 1 |
| Cauchi, S; Choquet, H; D'Aleo, V; Del Guerra, S; Froguel, P; Groves, CJ; Lupi, R; Marchetti, P; McCarthy, MI | 1 |
| Asmar, M; Deacon, CF; Hare, KJ; Holst, JJ; Knop, FK; Vilsbøll, T | 1 |
| Iki, K; Pour, PM; Saruc, M | 1 |
| Beauvieux, MC; Gallis, JL; Gin, H; Rigalleau, V; Schneiter, P; Tappy, L | 1 |
| Briscoe, VJ; Davis, SN; Gogitidze Joy, N; Hedrington, MS; Nicholson, W; Richardson, MA; Tate, DB; Wang, Z; Younk, L | 1 |
| Spellman, CW | 1 |
| Ahn, YR; Choi, DW; Choi, SH; Chung, JH; Heo, JS; Jang, KT; Kim, JH; Kim, KW; Kim, SW; Kim, SY; Kim, YS; Lee, MK; Lee, MS; Min, YK; No, HS; Oh, SH; Park, JY | 1 |
| Machnica, Ł; Otto-Buczkowska, E | 1 |
| Deacon, CF; Holst, JJ; Jacob, A; Meier, JJ; Menge, BA; Nauck, MA; Ritter, PR; Schmidt, WE | 1 |
| Dufresne, M; Fanjul, M; Gmyr, V; Hollande, E; Kerr-Conte, J; Lefebvre, B; Ratovo, G; Sengenès, C | 1 |
| Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R | 1 |
| Holst, JJ; Knop, FK; Krarup, T; Larsen, S; Madsbad, S; Vilsbøll, T | 2 |
| D'Alessio, DA | 1 |
| Baughman, R; Boss, A; Cassidy, J; Costello, D; Damico, C; Marino, MT; Richardson, PC; van Marle, S; van Vliet, A | 1 |
| Svec, F | 1 |
| Lele, RD | 1 |
| Arias, S; Bawa, B; Bose, M; Laferrère, B; Machineni, S; Olivan, B; Pi-Sunyer, FX; Scherer, PE; Teixeira, J | 1 |
| Rizza, RA | 1 |
| Garber, AJ | 1 |
| Hare, KJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 4 |
| Karasawa, H; Sakakibara, S; Shimamura, M; Shinagawa, A | 1 |
| Mühlbauer, E; Peschke, E; Schucht, H | 1 |
| He, YL; Ito, H; Sekiguchi, K; Terao, S; Yamaguchi, M | 1 |
| Knudsen, LB | 2 |
| Gustavsson, N; Han, W; Lao, Y; Radda, GK; Seah, T; Südhof, TC | 1 |
| Birzele, F; Bugliani, M; Caxaria, S; da Silva Xavier, G; Farhan, H; Gribble, FM; Hughes, S; Johnson, P; Kim, H; Marchetti, P; Marselli, L; Parker, H; Reimann, F; Rutter, GA; Rutter, J; Scharfmann, R; Siniakowicz, K; Sun, G; Weir, G | 1 |
| Bailey, A; Kernan, K; Lernmark, A; Moralejo, D; Osborne, W; Yanay, O | 1 |
| Gaidhu, MP; Gao, X; Gonzalez, R; Reingold, BK; Tsushima, RG; Unniappan, S | 1 |
| Ferrannini, E; Gastaldelli, A; Iozzo, P | 1 |
| Barbot-Trystram, L; Benabadji, S; Boitard, C; Larger, E; Philippe, MF; Vadrot, D | 1 |
| Carlson, OD; Chen, Z; Egan, JM; Fiori, JL; Kim, W; Lao, Q; Liu, Z; Napora, JK; Odetunde, JO; Shin, YK; Short, R; Xin, L | 1 |
| Korbas, S; Meier, JJ; Schneider, S; Ueberberg, S | 1 |
| MacDonald, PE; Rorsman, P | 1 |
| Chen, B; Ernsberger, P; Escobedo, LV; Hou, D; Koletsky, MS; Koletsky, RJ; Moore, A | 1 |
| Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Lager, I; Orn, T; Steen, L | 1 |
| Cersosimo, E; Cervera, A; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N; Petz, R; Sriwijilkamol, A; Triplitt, C; Wajcberg, E; Zuo, P | 1 |
| Gong, M; Li, Y; Tang, L; Xu, W; Zheng, X | 1 |
| Anderwald, CH; Balkau, B; Bonnet, F; Ducluzeau, PH; Gastaldelli, A; Konrad, T; Laville, M; Mari, A | 1 |
| Arasaki, CH; Carneiro, G; Geloneze, B; Silva, EA; Umeda, LM; Zanella, MT | 1 |
| Alvarez, JG; Denechaud, PD; Downes, M; Evans, RM; Mihaylova, MM; Montminy, M; Ravnskjaer, K; Shaw, RJ; Vasquez, DS; Yu, RT | 1 |
| Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O | 1 |
| Bagger, JI; Holst, JJ; Knop, FK; Vilsbøll, T | 1 |
| Henningsson, R; Jimenez-Feltstrom, J; Lundquist, I; Meidute Abaraviciene, S; Salehi, A | 1 |
| Elahi, D; Meneilly, GS; Stafford, S | 1 |
| Deacon, CF; Grüber, L; Holst, JJ; Jørgensen, SM; Meier, JJ; Menge, BA; Schmidt, WE; Veldhuis, JD | 1 |
| Damm, P; Nolan, CJ; Prentki, M | 1 |
| Grarup, N; Hainerová, IA; Hansen, T; Hartmann, B; Holst, JJ; Jørgensen, T; Kielgast, U; Kissow, H; Lauritzen, T; Lebl, J; Linneberg, A; Ma, L; Madsbad, S; Madsen, OD; Pedersen, O; Rosenkilde, M; Sandbaek, A; Torekov, SS; Wang, J; Witte, DR | 1 |
| Akiyama, M; Hambro, B; Hu, J; Kawamori, D; Kulkarni, RN | 1 |
| Christensen, M; de Heer, J; Holst, JJ; Kielgast, U; Knop, FK; Lund, A; Svendsen, B | 1 |
| Braun, M; Johnson, PR; Ramracheya, R; Rorsman, P; Walker, JN; Zhang, Q | 1 |
| Chimienti, F; Hardy, AB; Serino, AS; Wheeler, MB; Wijesekara, N | 1 |
| D'Alessio, D | 1 |
| Atta, M; Fontecave, M; Fujimura, A; Kaitsuka, T; Kimura, S; Matsui, H; Michiue, H; Suzuki, T; Tomizawa, K; Watanabe, S; Wei, FY; Yamagata, K | 1 |
| Hitman, GA | 1 |
| Besser, RE; Bowman, P; Hattersley, AT; Hope, SV; Jones, AG; Knight, BA; McDonald, TJ; Oram, RA; Shields, BM | 1 |
| Bettaieb, A; Cummings, BP; Dill, R; Graham, JL; Haj, FG; Havel, PJ; Morton, GJ; Stanhope, KL | 1 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Acitores, A; González, N; Gutiérrez-Rojas, I; Moreno, P; Nuche-Berenguer, B; Sancho, V; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Lindqvist, A; Ling, C; Nitert, MD; Riva, M; Sathanoori, R; Voss, U; Wierup, N | 1 |
| Cryer, PE | 3 |
| Aaboe, K; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T; Vølund, A | 1 |
| Kishimoto, M; Noda, M | 1 |
| Matsui, T; Yamagishi, S | 1 |
| Booker Porter, TK; Cirincione, BB; Darsow, T; Diamant, M; Fineman, MS; Kinninger, LA; Mace, KF; Trautmann, ME | 1 |
| Bagger, JI; Christensen, M; Knop, FK; Vilsbøll, T | 1 |
| Casamitjana, R; Flores, L; Ibarzabal, A; Lacy, A; Nicolau, J; Romero, F; Vidal, J | 1 |
| Conde, R; de Luis, D; Domingo, M; Gonzalez Sagrado, M; Pacheco, D; Primo, D; Romero, A | 1 |
| Gjedsted, J; Juhl, CB; Nielsen, MF; Schmitz, O | 1 |
| Burggraaf, J; Cohen, AF; de Kam, ML; Flameling, B; Geerts, BF; Gerhardt, CC; Kloek, J; Moerland, MM; Romijn, JA; van Dongen, MG | 1 |
| Stiefelhagen, P | 1 |
| Cobelli, C; Dalla Man, C; Micheletto, F; Sathananthan, A; Sathananthan, M; Smushkin, G; Vella, A; Zinsmeister, AR | 1 |
| Danielsson, A; Eriksson, JW; Johansson, L; Korsgren, O; Lindskog, C; Pontén, F | 1 |
| Bystrup, SK; Chen, X; Hermansen, K; Jeppesen, PB; O'Driscoll, L; Xiao, J | 1 |
| Crimmins, DL; Dunai, J; Ladenson, JH; Patterson, BW; Polonsky, KS; Reeds, DN; Tran, HD; Villareal, DT; Wallendorf, MJ; Wice, BM | 1 |
| Bojsen-Møller, KN; Clausen, TR; Dirksen, C; Holst, JJ; Hvolris, L; Jacobsen, SH; Jørgensen, NB; Lindqvist Hansen, D; Madsbad, S; Naver, L; Worm, D; Wulff, BS | 1 |
| Albrecht, E; Bähr, I; Mühlbauer, E; Peschke, E | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
| Alba, M; Astiarraga, B; Casolaro, A; Chen, Y; Ferrannini, E; Gastaldelli, A; Holst, J; Mari, A; Muscelli, E; Seghieri, G | 1 |
| Lundquist, I; Muhammed, SJ; Salehi, A | 1 |
| Candelore, MR; Dallas-Yang, Q; Guo, J; Jiang, G; Liang, R; McCann, PE; Miller, C; Parmee, ER; Qureshi, SA; Shang, J; Tata, JR; Tong, X; Tota, LM; Vincent, SH; Wright, MJ; Xiong, Y; Xu, SS; Yang, X; Zhang, BB | 1 |
| Carneiro, L; Derani, A; Göke, B; Schirra, J; Woerle, HJ | 1 |
| Bredenbröker, D; Brose, M; Fabbri, LM; Göke, B; Rabe, KF; Teichmann, P; Wouters, EF | 1 |
| Castagneto-Gissey, L; Mingrone, G | 1 |
| Cree-Green, M; Mizokami-Stout, K; Nadeau, KJ | 1 |
| Kanazawa, A | 1 |
| Abe, M; Akiba, J; Kage, M; Kawaguchi, T; Kawahara, A; Koga, H; Sakata, M; Sata, M; Taira, T; Taniguchi, E | 1 |
| Cai, XY; Li, PB; Lin, WL; Peng, W; Su, WW; Wang, YG | 1 |
| Inaba, W; Kamata, K; Mizukami, H; Takahashi, K; Tsuboi, K; Yagihashi, S | 1 |
| Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V | 1 |
| Butler, AE; Butler, PC; Gurlo, T; Hernandez, R; Matveyenko, AV; Robertson, RP | 1 |
| Basu, R; Cui, MH; Hawkins, M; Hwang, JH; Kehlenbrink, S; Kishore, P; Koppaka, S; Li, Y; Martin, M; Relwani, R | 1 |
| Han, W; Lee, P; Leong, W; Lim, M; Radda, GK; Tan, T | 1 |
| Boggi, U; Bugliani, M; D'Aleo, V; Del Guerra, S; Dotta, F; Filipponi, F; Grieco, FA; Kirkpatrick, CL; Lupi, R; Marchetti, P; Marselli, L; Piro, S; Purrello, F; Salvini, L; Sebastiani, G; Tinti, L; Wollheim, CB | 1 |
| Holzhütter, HG; König, M | 1 |
| Inoue, M | 1 |
| Hashimoto, N; Hirota, Y; Matsuda, T; Nakamura, T; Ogawa, W; Sakaguchi, K; Seino, S; Takabe, M | 1 |
| Fukunari, A; Iwasaki, S; Kakimoto, T; Kimata, H; Utsumi, H | 1 |
| Ghosh, S; Palika, R; Pullakhandam, R; Reddy, GB | 1 |
| Funahashi, T; Imagawa, A; Iwahashi, H; Kozawa, J; Okauchi, Y; Okita, K; Shimomura, I | 1 |
| van der Klauw, MM; Wolffenbuttel, BH | 1 |
| Cobelli, C; Dalla Man, C; Law, JH; Piccinini, F; Rizza, RA; Sathananthan, M; Smushkin, G; Vella, A; Zinsmeister, AR | 1 |
| Bue-Valleskey, J; Heathman, M; Schneck, K; Sinha, V; Yeo, KP; Zhang, X | 1 |
| Bauer, R; Karlsson, MO; Schneck, KB; Sinha, VP; Zhang, X | 1 |
| Bennett, MJ; Chen, J; Chen, P; Daikhin, Y; Doliba, N; Li, C; Liu, C; Matschinsky, FM; Naji, A; Nissim, I; Stanley, CA; Stokes, D; Yudkoff, M; Zhang, T | 1 |
| Chen, C; Chen, Z; Han, Y; Shen, J; Zhu, X | 1 |
| Birnbaum, MJ; Chu, Q; Foretz, M; Miller, RA; Viollet, B; Xie, J | 1 |
| Hewage, CM; Venneti, KC | 1 |
| Arafat, AM; Belli, S; Cheng, C; D'Alessio, D; DiMarchi, RD; Gelfanov, V; Habegger, KM; Hembree, JL; Heppner, KM; Hofmann, SM; Holland, J; Itoh, N; Kapps, M; Kharitonenkov, A; Konishi, M; Konkar, A; Krishna, R; Müller, TD; Ottaway, N; Perez-Tilve, D; Pfluger, PT; Seeley, RJ; Smiley, D; Spranger, J; Stemmer, K; Tschöp, MH; Woods, SC | 1 |
| Barosa, C; Basu, A; Basu, R; Carter, R; Dube, S; Jones, J; Rizza, RA | 1 |
| Kaya-Dagistanli, F; Ozturk, M | 1 |
| Casamitjana, R; Jiménez, A; Lacy, A; Viaplana-Masclans, J; Vidal, J | 1 |
| Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
| Deane, AM; Horowitz, M | 1 |
| Fukui, T; Hara, N; Hirano, T; Nagashima, M; Naito, H; Oono, K; Yamamoto, T | 1 |
| Gallwitz, B; Meier, JJ; Nauck, MA; Schmidt, WE | 1 |
| Bär, J; Demuth, HU; Hinke, SA; Hoffmann, T; Kühn-Wache, K; Manhart, S; McIntosh, CH; Pederson, RA; Wagner, L; Wermann, M | 1 |
| Baker, B; Chapman, I; Horowitz, M; Morris, H; Vozzo, R; Wishart, JM; Wittert, GA | 1 |
| Egan, JM; Elahi, D; Habener, JF; Meneilly, GS | 1 |
| Demuth, HU; Hinke, SA; McIntosh, CH; Pederson, RA | 1 |
| Holst, JJ; Krarup, T; Madsbad, S; Vilsbøll, T | 2 |
| Horowitz, M; Lee, A; Morley, JE; Patrick, P; Wishart, J | 1 |
| Bressler, P; Consoli, A; Defronzo, RA; Delprato, S; Giordano, M; Glass, L; Matsuda, M | 1 |
| Carr, RD; Deacon, CF; Gotfredsen, CF; Knudsen, LB; Larsen, MO; Rolin, B; Wilken, M | 1 |
| Carr, RD; Deacon, CF; Knudsen, LB; Larsen, MO; Ribel, U; Rolin, B; Sturis, J; Westergaard, L; Wilken, M | 1 |
| Taminato, T | 1 |
| Catala, J; Chanh, AP; Daumas, M; Hollande, E; Lasserre, B | 1 |
| Schiel, KA | 1 |
| Fineman, M; Kolterman, OG; Maggs, DG; Strobel, S; Weyer, C | 1 |
| Gottschalk, WK; Lenhard, JM | 1 |
| Chan, CB; Joseph, JW; Koshkin, V; Lowell, BB; Wang, J; Wheeler, MB; Zhang, CY | 1 |
| Nowotny, P; Raffesberg, W; Roden, M; Stingl, H; Waldhäusl, W | 1 |
| Walczak, IM | 1 |
| Egan, JM; Elahi, D; Meneilly, GS | 1 |
| Djuric, SW; Grihalde, N; Lin, CW | 1 |
| Baron, AD; Kim, D; Weyer, C | 1 |
| Chang, AM; Halter, JB | 1 |
| Bjerve, KS; Grill, VE; Mostad, IL; Qvigstad, E | 1 |
| Legakis, IN; Phenekos, C; Tzioras, C | 1 |
| Büsing, M; Klempnauer, J; Meier, JJ; Nauck, MA; Pox, C; Ritzel, R; Schmiegel, W | 1 |
| Agersø, H; Holst, JJ; Krarup, T; Vilsbøll, T | 1 |
| Ikuta, H; Nagakura, T; Tanaka, I; Yamazaki, K; Yasuda, N | 1 |
| Holst, JJ; Kjems, LL; Madsbad, S; Vølund, A | 1 |
| Bloomgarden, ZT | 3 |
| Mkrtumian, AM | 1 |
| Hermansen, K; Holst, JJ; Storm, H; Thomsen, C | 1 |
| Smith, SA; Tadayyon, M | 1 |
| Abbatecola, AM; Grella, R; Manzella, D; Paolisso, G; Ragno, E | 1 |
| D'Alessio, DA; Hanson, K; Prigeon, RL; Quddusi, S; Vahl, TP | 1 |
| Cancelas, J; Courtois, P; Malaisse, WJ; Sancho, V; Scott, FW; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Jiang, G; Zhang, BB | 1 |
| Gallwitz, B; Meier, JJ; Nauck, MA | 1 |
| Agger, A; Colombo, M; Gregersen, S; Hermansen, K; Jeppesen, PB; Jepsen, M; Kruhøffer, M; Orntoft, T; Rolfsen, SE; Xiao, J | 1 |
| Clodi, M; Ludvik, B; Nolan, JJ; Pacini, G; Prager, R; Thomaseth, K | 1 |
| Abdel-Halim, SM; Ahrén, B; Efendic, S; Ljungberg, O; Lukinius, A; Portela-Gomes, GM | 1 |
| Malaisse, WJ; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Choi, S; Kim, SW; Ko, KS; Lee, M; Oh, S | 1 |
| Boden, GH; Fisher, RS; Gonlachanvit, S; Hsu, CW; Knight, LC; Maurer, AH; Parkman, HP | 1 |
| Holst, JJ; Juul, AG; Krarup, T; Madsbad, S; Sonne, J; Vilsbøll, T; Vølund, A | 1 |
| Gallwitz, B; Goetze, O; Holst, JJ; Meier, JJ; Nauck, MA; Salmen, S; Schmidt, WE | 1 |
| Mark, M | 1 |
| D'Alessio, D; Vahl, T | 1 |
| An, B; Bloem, CJ; Chang, AM; Galecki, A; Halter, JB; Jakobsen, G; Smith, MJ; Sturis, J | 1 |
| Barazzoni, R; Cristini, M; Kiwanuka, E; Tessari, P; Vettore, M; Zanetti, M | 1 |
| Aisporna, M; Baron, AD; Bicsak, TA; Buse, JB; Fineman, MS; Gaines, E; Heintz, S; Kim, D; Kolterman, OG; Taylor, K; Wang, Y | 1 |
| Greig, NH; Perry, T | 2 |
| Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Henricsson, M; Lager, I; Orn, T; Steen, L; Sundkvist, G; Westermark, G; Westermark, P | 1 |
| Bryant, L; Feinle, C; Horowitz, M; Jones, KL; Lei, Y; Meyer, JH; O'Donovan, D; Pilichiewicz, A; Wishart, JM | 1 |
| Brand, CL; Carr, RD; Deacon, CF; Gotfredsen, CF; Knudsen, LB; Ribel, U; Rolin, B; Rømer, J; Sturis, J; Wassermann, K; Wilken, M | 1 |
| Beck-Nielsen, H; Hojlund, K; Holst, JJ; Hother-Nielsen, O; Staehr, P | 1 |
| Egan, JM; Elahi, D; Greig, N; Habener, JF; Meneilly, GS; Tildesley, H | 1 |
| Drucker, DJ | 3 |
| Chepurny, OG; Holz, GG | 1 |
| Hansen, T; Holst, JJ; Johansen, A; Knop, FK; Krarup, T; Larsen, S; Madsbad, S; Pedersen, O; Vilsbøll, T | 1 |
| Brazg, R; D'Alessio, DA; Ehlers, MR; Harley, RE; Kay, HD; Klaff, LJ; Mathisen, AL; Schneider, R | 1 |
| Bailey, CJ; Flatt, PR; Gault, VA; Green, BD; Greer, B; Harriott, P; Irwin, N; Mooney, MH; O'Harte, FP | 2 |
| Creutzfeldt, W; Meier, JJ; Nauck, MA | 1 |
| Gregersen, S; Hermansen, K; Holst, JJ; Jeppesen, PB | 1 |
| Dalgaard, M; Hermansen, K; Holst, JJ; Rasmussen, BM; Thomsen, C | 1 |
| Hooft, R | 1 |
| Nielsen, LL; Parkes, DG; Young, AA | 1 |
| Morrow, T | 1 |
| El-Ouaghlidi, A; Gallwitz, B; Gallwitz, JB; Holst, JJ; Nauck, MA; Schmidt, WE; Schmiegel, W; Senkal, M; Vethacke, A; Walberg, J | 1 |
| Clements, RH; Gonzalez, QH; Laws, HL; Long, CI; Wittert, G | 1 |
| Holst, JJ; Vilsbøll, T | 1 |
| Basu, R; Rizza, RA; Schwenk, WF | 1 |
| D'Alessio, DA; Vahl, TP | 1 |
| Rachman, J | 1 |
| Gallwitz, B; Holst, JJ; Meier, JJ; Michaely, M; Nauck, MA; Schmidt, WE; Senkal, M; Weyhe, D; Zumtobel, V | 1 |
| Bulotta, A; Di Mario, U; Nourparvar, A; Perfetti, R | 1 |
| Brock, B; Chandramouli, V; Degn, KB; Jakobsen, G; Juhl, CB; Landau, BR; Rungby, J; Schmitz, O; Sturis, J | 1 |
| Balci, H; Damci, T; Ilkova, H; Korugan, U; Osar, Z; Ozyazar, M; Yalin, S | 1 |
| Damm, P; Hansen, T; Hornnes, P; Jensen, DM; Lauenborg, J; Locht, H; Mølsted-Pedersen, L; Pedersen, O; Vestergaard, H | 1 |
| Kordella, T | 1 |
| Hjorth, SA; Jensen, AD; Vilsbøll, T; Ørskov, C | 1 |
| Ahrén, B; Holmes, D; Jansson, PA; Landin-Olsson, M; Schweizer, A; Svensson, M | 1 |
| Meier, JJ; Nauck, MA | 3 |
| Donahue, EP; Fujimoto, Y; Shiota, M | 1 |
| Habener, JF; List, JF | 1 |
| Roden, M; Stingl, H | 1 |
| Jakobsen, G; Madsbad, S; Matthews, DR; Ranstam, J; Schmitz, O | 1 |
| Edwards, CM | 1 |
| Baudys, M; Choi, S; Kim, SW | 1 |
| Camilleri, M; Rizza, RA; Vella, A | 1 |
| Wasada, T | 1 |
| Doran, S; Feinle-Bisset, C; Horowitz, M; Jones, KL; Meyer, JH; Morris, HA; O'Donovan, DG; Wishart, JM | 1 |
| Dou, H; Li, KS; Mao, JF; Yang, SS; Zhang, ZZ | 1 |
| Gromada, J; Holst, JJ | 1 |
| Donini, A; Facchiano, E; Patriti, A | 1 |
| Basu, A; Basu, R; Johnson, CM; Rizza, RA; Schwenk, WF | 1 |
| Christiansen, A; Holst, JJ; Madsbad, S; Zander, M | 1 |
| Astrup, A; Harder, H; Nielsen, L; Tu, DT | 1 |
| Rotella, DP | 1 |
| Frezza, EE | 1 |
| Allolio, B | 1 |
| Ahrén, B; Gutniak, MK; Holst, JJ; Nyström, T; Sjöholm, A; Zhang, F; Zhang, Q | 1 |
| Pronsati, MP | 1 |
| Deacon, CF; El-Ouaghlidi, A; Gabrys, B; Gallwitz, B; Holst, JJ; Hücking, K; Meier, JJ; Nauck, MA; Schmidt, WE | 1 |
| Bunck, MC; Diamant, M; Heine, RJ | 1 |
| Chujo, D; Mabuchi, H; Muramoto, H; Murase, Y; Otsuji, M; Sugihara, M; Yagi, K | 1 |
| Feinle-Bisset, C; Horowitz, M; Jones, K; Nauck, M | 1 |
| Ferrannini, E; Gastaldelli, A; Mari, A; Natali, A; Ostergard, T; Schmitz, O | 1 |
| Deacon, CF; Holst, JJ | 4 |
| Baggio, LL; Drucker, DJ | 2 |
| Hamann, A; Morcos, M; Nawroth, P | 1 |
| Baller, B; Meier, JJ; Nauck, MA | 1 |
| Holst, JJ; Orskov, C | 3 |
| Joy, SV; Rodgers, PT; Scates, AC | 1 |
| Caumo, A; Cobelli, C; Singhal, P; Taylor, R | 1 |
| Atsumi, Y; Matsuoka, K; Murata, C; Oka, Y; Suzuki, Y; Taniyama, M | 1 |
| Huang, A; Raskin, P | 1 |
| Brock, B; Gromada, J; Rorsman, P; Schmitz, O | 1 |
| Flatt, PR; Gault, VA; Green, BD; O'harte, FP | 1 |
| Brillantes, AM; Thearle, M | 1 |
| Beconi, M; Eiermann, GJ; Fisher, MH; He, H; Hickey, GJ; Kim, D; Kowalchick, JE; Leiting, B; Lyons, K; Marsilio, F; McCann, ME; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Wang, L; Weber, AE; Wu, JK; Wyvratt, MJ; Zhang, BB; Zhu, L | 1 |
| Anyaoku, V; Bloom, SR; Forbes, S; Ghatei, MA; Johnston, DG; Moonan, M; Murphy, KG; Patterson, M; Robinson, S | 1 |
| Feinle-Bisset, C; Gentilcore, D; Horowitz, M; Jones, KL; Morris, HA; Murolo, N; O'Donovan, D; Russo, A; Wishart, JM | 1 |
| McCarty, MF | 1 |
| Baron, AD; Fineman, MS; Kim, DD; Kolterman, OG; Nielsen, LL; Ruggles, JA; Shen, L | 1 |
| Berthault, MF; Cerasi, E; Chavanieu, A; Delagrange, P; Grassy, G; Kaiser, N; Ktorza, A; Leibowitz, G; Uçkaya, G | 1 |
| Ratner, RE; Uwaifo, GI | 1 |
| El-Ouaghlidi, A; Nauck, MA | 1 |
| Mentlein, R; Mest, HJ | 1 |
| Holst, JJ; Larsen, PJ | 1 |
| Drucker, DJ; Hansotia, T | 1 |
| Demuth, HU; McIntosh, CH; Pederson, R; Pospisilik, JA | 1 |
| Holst, JJ; Hücking, K; Kostic, Z; Nauck, MA; Pox, C; Ritzel, R; Schmiegel, W | 1 |
| Haselmann, KF; Nielsen, PF; Zubarev, RA | 1 |
| Ardill, J; Bell, PM; Duffy, NA; Flatt, PR; Lindsay, JR; McKillop, AM; O'Harte, FP | 1 |
| Bailey, CJ; Flatt, PR; Gault, VA; Green, BD; Irwin, N; O'Harte, FP | 1 |
| Purnell, JQ; Weyer, C | 1 |
| Chaikomin, R; Doran, S; Feinle-Bisset, C; Horowitz, M; Jones, KL; O'Donovan, D; Rayner, CK | 1 |
| Bardini, G; Brogi, M; Ciani, S; Cremasco, F; Dicembrini, I; Mannucci, E; Messeri, G; Ognibene, A; Petracca, MG; Pezzatini, A; Rotella, CM; Tesi, F | 1 |
| Albareda, M; Caballero, A; Cabezas, R; Carreras, G; Chico, A; Pérez, A; Rigla, M; Rodríguez-Espinosa, J | 1 |
| Ballantyne, GH; Gumbs, AA; Modlin, IM | 1 |
| Michael, MD; Moyers, JS; Sloop, KW | 1 |
| Giorgino, F; Laviola, L; Leonardini, A | 1 |
| Acitores, A; Arnés, L; González, N; Malaisse, WJ; Sancho, V; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Baillargeon, JP; Carpentier, AC; Cyr, D; Frisch, F; Généreux, P; Giguère, R; Patterson, BW | 1 |
| Björck, IM; Frid, AH; Holst, JJ; Nilsson, M | 1 |
| Laustsen, G | 1 |
| An, B; Feinglos, MN; Pi-Sunyer, FX; Saad, MF; Santiago, O | 1 |
| Choi, S; Kim, SW; Lee, M; Oh, S | 1 |
| Keating, GM | 1 |
| Jenssen, T; Toft, I | 1 |
| Inoue, T; Nagakura, T; Yamazaki, K; Yasuda, N | 1 |
| Ali, AA; Bhathena, SJ; Hansen, CT; Mohamed, AI; Velasquez, MT | 1 |
| Bernal-Mizrachi, E; Cras-Méneur, C; Ford, E; Grimm, AA; Imai, S; Moynihan, KA; Permutt, MA; Plueger, MM | 1 |
| Dostou, JM; Gerich, JE; Gosmanov, NR; Meyer, C; Szoke, E; Welle, SL; Wittlin, SD; Woerle, HJ | 1 |
| Ahn, JH; Cheon, HG; Jung, WH; Kim, HY; Kim, KR; Kim, SS; Rhee, SD; Yang, SD | 1 |
| Hanefeld, M; Henkel, E; Koehler, C; Leonhardt, W; Menschikowski, M | 1 |
| Ahrén, B; Dunning, BE; Foley, JE | 1 |
| Fetita, S; Gautier, JF; Salaün-Martin, C; Sobngwi, E | 1 |
| Drucker, DJ; Sinclair, EM | 1 |
| Bergstrom, C; Ipp, E; Linfoot, P | 1 |
| Carlson, O; Doyle, ME; Egan, JM; Juhaszova, M; Michopoulos, S; Petraki, K; Theodorakis, MJ | 1 |
| Bokhari, S; Cryer, PE; Gerich, JE; Gosmanov, NR; Israelian, Z; Meyer, C; Schorr, M; Szoke, E | 1 |
| Aisporna, M; Baron, AD; Fineman, MS; Kim, D; Nielsen, LL; Taylor, K | 1 |
| Gutniak, M; Malmberg, K; Olsson, A; Rydén, L; Thrainsdottir, I | 1 |
| D'Alessio, DA; Sandoval, DA; Seeley, RJ | 1 |
| Jobe, LJ; Martin, R; Ryan, GJ | 1 |
| Asghar, Z; Chan, CB; Chan, F; Leroith, D; Wheeler, MB; Yau, D | 1 |
| Deacon, CF; Holst, JJ; Madsbad, S; Zander, M | 1 |
| Demuth, HU; Kim, SJ; McIntosh, CH; Pederson, RA; Pospisilik, JA | 1 |
| Bartfai, T; Gaisano, H; Ostenson, CG; Sheu, L; Tibell, A | 1 |
| Groop, LC; Honkanen, EH; Isomaa, B; Sarelin, L; Tuomi, T | 1 |
| Barazzoni, R; Carnielli, V; Cogo, P; Gucciardi, A; Kiwanuka, E; Millioni, R; Puricelli, L; Tessari, P; Tiengo, A; Tosolini, M; Vettore, M; Zanetti, M | 1 |
| Bolli, GB; Fanelli, CG; Porcellati, F; Rossetti, P | 1 |
| Bokhari, S; Cryer, PE; Gerich, JE; Israelian, Z; Meyer, C; Schorr, M; Schwenke, DC; Szoke, E; Woerle, J | 1 |
| Ae Park, S; Cho, SY; Choi, MS; Jung, UJ; Kim, MJ; Lee, MK; Park, YB; Seo, JS; Sung, MK | 1 |
| Choi, MS; Jung, UJ; Kim, HJ; Kim, MJ; Lee, JS; Lee, MK; Noh, HJ; Park, HM; Park, KK; Park, SA; Park, YB | 1 |
| Bajaj, M; Briones, M | 1 |
| Pye, S; Radziuk, J | 1 |
| Dunning, BE; Foley, JE; Mänttäri, S; Matikainen, N; Mills, D; Schweizer, A; Taskinen, MR; Ulvestad, A | 1 |
| Birzin, ET; Cashen, DE; Jacks, TM; Nowak, KW; Patchett, AA; Rohrer, SP; Schaeffer, JM; Singh, V; Smith, RG; Strowski, MZ; Yang, L | 1 |
| Beruto, V; Di Girolamo, G; González, C; Keller, G; Santoro, S | 1 |
| Kurland, IJ; Pei, L; Tontonoz, P; Vaitheesvaran, B; Waki, H; Wilpitz, DC | 1 |
| Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K | 1 |
| Donahue, EP; Fujimoto, Y; Shiota, M; Torres, TP | 1 |
| Glinka, Y; Hunag, Y; Kumar, M; Prud'homme, GJ; Wang, Q | 1 |
| Iki, K; Pour, PM | 1 |
| Brand, CL; Fosgerau, K; Holst, JJ; Neschen, S; Nishimura, E; Shulman, GI; Sørensen, H | 1 |
| Ratner, RE; Want, LL | 1 |
| Lange, AJ | 1 |
| Mikhail, N | 1 |
| Catlin, RL; Donahue, EP; Shin, JS; Shiota, M; Torres, TP | 1 |
| Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
| Baldi, S; Buzzigoli, E; Casolaro, A; Ciociaro, D; Ferrannini, E; Frascerra, S; Gastaldelli, A; Mari, A; Nannipieri, M; Pettiti, M | 1 |
| Barucci, N; Burns, M; Buxton, JM; Clairmont, KB; Claus, TH; Livingston, JN; Ortiz, AA; Pan, CQ; Reynolds, JC; Roczniak, S; Whelan, JP; Yang, L | 1 |
| Doyle, ME; Egan, JM | 2 |
| Busse, FP; Denti, V; Stumvoll, M | 1 |
| Abdul-Ghani, M; DeFronzo, RA | 1 |
| Deacon, CF; Holst, JJ; Meier, JJ; Nauck, MA; Schmidt, WE | 1 |
| Harinck, HI; Romijn, JA; van Lennep, JR | 1 |
| Geelhoed-Duijvestijn, PH | 1 |
| Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Holberg, MA; Kirksaether, N; Lager, I; Orn, T; Steen, L; Sundkvist, G | 1 |
| Dunning, BE; Gerich, JE | 1 |
| Bullock, JM; Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Wang, Y | 1 |
| Dejgaard, A; Gredal, C; Hilsted, J; Rosenfalck, AM | 1 |
| Brooks-Worrell, B; Chiu, H; Felton, J; Goel, A; Palmer, JP | 1 |
| Gallo, S; Hanefeld, M; Henkel, E; Koehler, C; Siegert, G | 1 |
| Bhanot, S; Booten, SL; Cao, JX; Cox, AL; Finger, EA; Irizarry, AR; McKay, RA; Michael, MD; Monia, BP; Murray, SF; Showalter, AD; Siesky, AM; Sloop, KW; Zhang, HY | 1 |
| Holst, JJ; Højberg, PV; Knop, FK; Krarup, T; Larsen, S; Madsbad, S; Vilsbøll, T; Vølund, A | 1 |
| Ciechanowicz, A; Frankow, M; Majkowska, L; Parczewski, M; Pilarska, K; Safranow, K; Stefanski, A | 1 |
| Eichhorn, I; Göncz, E; Grötzinger, C; Hamprecht, B; Nowak, KW; Pfeiffer-Guglielmi, B; Pless, G; Plöckinger, U; Sauer, IM; Singh, V; Strowski, MZ; Wiedenmann, B; Zacharias, S | 1 |
| Aller, R; Conde, R; de Luis, DA; Delgado, A; González Sagrado, M; Izaola, O; Pacheco, D; Romero, A | 1 |
| Bates, HE; Elliott, ME; Goche Montes, D; Kiraly, MA; Matthews, SG; Riddell, MC; Vranic, M; Yue, JT | 1 |
| Ando, H; Kaneko, S; Kato, K; Kurita, S; Sakurai, M; Shimizu, A; Takamura, T; Tsuchiyama, N | 1 |
| Bollyky, J; Greenbaum, CJ | 1 |
| Kocić, G; Kocić, R; Pavlović, D; Pesić, M | 1 |
| Jayapaul, MK; Walker, M | 1 |
| Ferrannini, E; Flyvbjerg, A; Gabriel, R; Golay, A; Hojlund, K; Mitrakou, A; Muscelli, E; Natali, A | 1 |
| Hsiao, PH; Lee, JS; Tsai, WY; Tung, YC | 1 |
| Li, XC; Liao, TD; Zhuo, JL | 1 |
| Baller, B; Ellrichmann, M; Holst, JJ; Meier, JJ; Nauck, MA; Schmidt, WE; Vollmer, K | 1 |
| Charpentier, G; Gautier, JF; German, MS; Guillausseau, PJ; Kevorkian, JP; Louet, JF; Mauvais-Jarvis, F; Molokhia, M; Smith, SB; Urbanek, M; Vaisse, C; Vexiau, P; Virally, ML | 1 |
| Brismar, K; Efendic, S; Lehtihet, M | 1 |
| Asgharian, H; Dorkhan, M; Groop, L; Malm, G; Tripathy, D; Tuomi, T | 1 |
| Cersosimo, E; Cervera, A; DeFronzo, RA; Fernandez, M; Musi, N; Sriwijitkamol, A; Triplitt, C; Wajcberg, E; Zuo, P | 1 |
| Berggren, PO; Berman, DM; Cabrera, O; Caicedo, A; Echeverri, F; Fachado, A; Jacques-Silva, MC; Kenyon, NS; Khan, A; Poo, R; Ricordi, C | 1 |
| Banks, MR; Klein, S; Patterson, BW; Polonsky, KS; Villareal, DT | 1 |
| Chen, S; Grayburn, P; Orci, L; Ravazzola, M; Unger, RH; Wang, MY | 1 |
| Lebovitz, HE | 1 |
| Bawa, B; Colarusso, A; Egger, JR; Koshy, N; Kovack, B; Laferrère, B; Lee, H; McGinty, J; Olivan, B; Teixeira, J; Tran, H; Yapp, K | 1 |
| Aaboe, K; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Efendic, S; Jimenez-Feltstrom, J; Lundquist, I; Meidute Abaraviciene, S; Ostenson, CG; Salehi, A | 1 |
| Kowarski, AA; Levin, PA; McLaughlin, J | 1 |
| Germaniuk, IaL | 1 |
| Del Campo, F; Di Vincenzo, S; Ferlito, S; Fichera, C; Indelicato, G; La Vignera, A | 2 |
| Groop, L | 1 |
| Hübinger, A; Müller, HJ; Vogelberg, KH | 1 |
| Bressler, R; Johnson, DG | 1 |
| Broer, Y; Chamras, H; Picon, L; Portha, B; Rosselin, G | 1 |
| Reid, RL; Sandler, JA; Yen, SS | 1 |
| Parsons, SR | 1 |
| Boden, G; Hoeldtke, RD; Owen, OE; Soriano, M | 1 |
| Consoli, G; D'Onofrio, F; Giugliano, D; Passariello, N; Quatraro, A; Sgambato, S; Torella, R | 1 |
| de la Viña, S; Nash Raina, RE; Ordoñez Pérez, AJ; Sánchez Arriarán, MS; Serrano Ríos, M; Villalba Díaz, MT | 1 |
| Brogard, JM; Dorner, M; Pinget, M | 1 |
| de la Viña, S; Nash, RE; Ordóñez, AJ; Sánchez, MS; Serrano, M; Villalba, MT | 1 |
| Beard, JC; Halter, JB; Porte, D | 1 |
| Groop, L; Tolppanen, EM | 1 |
| Lohmann, D; Verlohren, HJ | 1 |
| Bolgiano, DC; Halter, JB; McKnight, B; Porte, D; Ward, WK | 1 |
| Hill, NE; Mookherjee, S; Patel, DG; Potts, JL; Raheja, KL; Smulyan, H; Vardan, S; Warner, R | 1 |
| Bergenstal, RM; Fang, VS; Gilden, JL; Herold, KC; Jaspan, JB; Moossa, AR; Polonsky, KS | 1 |
| Brass, EP; Ensinck, JW; Halter, JB; Robertson, RP | 1 |
| Acosta, AM; Arteaga, A; Costamaillere, L; Foradori, A; López, G; Pellegrino, MR; Velasco, N | 1 |
| Gerard, J; Lefebvre, PJ; Luyckx, AS | 1 |
| Giroix, MH; Kergoat, M; Picon, L; Portha, B | 1 |
| Bao, W; Berenson, GS; Radhakrishnamurthy, B; Srinivasan, SR | 1 |
| Hartmann, H; Nolte, W; Ramadori, G | 1 |
| Hansen, KW; Hermansen, K; Rasmussen, OW; Thomsen, C; Vesterlund, M | 1 |
| Koivisto, V | 1 |
| Fabris, S; Litchfield, A; Proietto, J; Thorburn, A | 1 |
| Prasanna, BM; Shah, P; Sidhu, SS; Srikanta, SS; Tandon, RK | 1 |
| Ballard, FJ; Berry, MN; Brinkman, M; Butler, RN; Clark, DG; Nestel, PJ; Oliver, JR; Owens, PC; Tomas, FM; Withers, RT | 1 |
| Campbell, LV; Chisholm, DJ; Furler, SM; Jenkins, AB; Kraegen, EW; Markovic, TP | 1 |
| Bergman, RN; Getty, L; Rebrin, K; Steil, GM | 1 |
| Deacon, CF; Holst, JJ; Nauck, MA; Pridal, L; Toft-Nielsen, M; Willms, B | 1 |
| Camilleri, M; Dinneen, S; Frank, JW; Rizza, RA; Saslow, SB; Thomforde, GM | 1 |
| Boden, G; Chen, X | 1 |
| Hasegawa, H; Iwasaki, Y; Kondo, K; Oiso, Y | 1 |
| Abiru, N; Akazawa, S; Ishibasi, M; Kawasaki, E; Matsumoto, K; Matsuo, H; Uotani, S; Yamamoto, H; Yamasaki, H; Yano, M | 1 |
| Araki, S; Hashiramoto, M; Ishida, Y; Kanda, E; Kasuga, M; Kazumi, T; Kishimoto, M | 1 |
| Langlois, WJ; Olefsky, JM; Pillay, TS | 1 |
| Carcassi, C; Contu, L; Hager, J; Hansen, L; Julier, C; Philippi, A; Poller, W; Vaisse, C; Velho, G; Vionnet, N | 1 |
| Bednarczyk-Kałuzny, M; Jonderko, G; Krzewiński, W; Kucharz, EJ; Straszecka, J | 1 |
| Weir, GC | 1 |
| Arai, Y; Imamura, K; Ishii, M; Kasai, F; Kikuchi, H; Kudoh, K; Nakamura, T; Takebe, K; Tandoh, Y; Yamada, N | 1 |
| Beljic, T; Miric, M | 1 |
| Brand, CL; Holst, JJ; Jørgensen, PN; Kristensen, JS; Rolin, B; Svendsen, I | 1 |
| Castillo, MJ; Lefebvre, PJ; Scheen, AJ | 3 |
| Beck-Nielsen, H; Henriksen, JE; Holm, N; Madsbad, S; Vaag, A | 1 |
| Bogardus, C; Esposito-Del Puente, A; Feinglos, MN; Kuhn, CM; Lillioja, S; McCubbin, JA; Surwit, RS | 1 |
| Fujita, M; Kodama, H; Yamaguchi, I; Yamazaki, M | 1 |
| Meneilly, GS; Milberg, WP; Tuokko, H | 1 |
| Amiel, SA | 1 |
| Bottazzo, GF; Buschard, K; Damm, P; Jakobsen, BK; Kühl, C; Mølsted-Pedersen, L; Shattock, M; Sodoyez-Goffaux, F; Svejgaard, A | 1 |
| Balasse, EO; Féry, F | 1 |
| Efendić, S; Gutniak, MK; Holst, JJ; Linde, B | 1 |
| Biolo, G; Bruttomesso, D; Fongher, C; Inchiostro, S; Panebianco, G; Tessari, P; Tiengo, A; Vedovato, M | 1 |
| Kelley, D; Mokan, M; Veneman, T | 1 |
| Pernet, A; Scheidegger, K | 1 |
| Brady, EJ; Cullinan, CA; Leibowitz, MD; Saperstein, R | 1 |
| Andersen, DK; Elahi, D; Fukagawa, NK; Habener, JF; McAloon-Dyke, M; Meneilly, GS; Minaker, KL; Sclater, AL | 1 |
| Andersen, PH; Bak, JF; Christiansen, JS; Lund, S; Møller, N; Orskov, L; Pedersen, O; Rasmussen, O; Schmitz, O | 1 |
| Colzi, G; Cresci, B; Galli, G; Giannini, S; Mannucci, E; Messeri, G; Piani, F; Rizzello, SM; Rotella, CM; Vannini, R | 1 |
| Chen, YD; Jaspan, JB; Jeng, CY; Polonsky, KS; Reaven, GM; Sheu, WH | 1 |
| Efendic, S; Ostenson, CG | 1 |
| Ishida, K; Mizuno, A; Sano, T; Shi, K; Shima, K | 1 |
| Fehmann, HC; Göke, B | 1 |
| Hansen, KW; Hermansen, K; Rasmussen, OW; Thomsen, C; Vesterlund, M; Winther, E | 1 |
| Habener, JF | 1 |
| De Sio, G; Ippoliti, M; Monteburini, T; Recchioni, A; Refe, A; Testa, I; Testa, R | 1 |
| Cavallero, E; Dachet, C; Jacotot, B; Mathe, D; Neufcour, D; Wirquin, E | 1 |
| Orwoll, E; Prince, M; Riddle, M | 1 |
| Leclercq-Meyer, V; Malaisse, WJ | 2 |
| Cozzolino, D; D'Onofrio, F; Di Maro, G; Lefebvre, PJ; Paolisso, G; Scheen, A; Varricchio, M | 1 |
| Waeber, G | 1 |
| Puhakainen, I; Yki-Järvinen, H | 1 |
| Keller, U; Laager, R | 1 |
| Ercan, N; Gannon, MC; Nuttall, FQ; Redmon, JB; Sheridan, KJ | 1 |
| Martin, IK; Wahren, J | 1 |
| Balázsi, I; Hargitai, G; Takács, J | 1 |
| Blackard, WG; Clore, JN | 1 |
| Caumo, A; Cobelli, C; Homan, M; Jensen, M; Katz, H; Rizza, R | 1 |
| Cheung, E; Meneilly, GS; Tuokko, H | 1 |
| Laitinen, J; Pyörälä, K; Siitonen, O; Uusitupa, M; Vanninen, E | 1 |
| Ercan, N; Gannon, MC; Nuttall, FQ; Westphal, SA | 1 |
| Fernlund, P; Gottsäter, A; Landin-Olsson, M; Lernmark, A; Sundkvist, G | 1 |
| Abourizk, NN; Lyons, RW; Madden, GM | 1 |
| Donnini, P; Franzetti, I; Gaiazzi, M; Uccella, R | 1 |
| Ditzler, TM; Gumbiner, B; Henry, RR; Joyce, M; Murata, C; Song, YM; Suh, KI | 1 |
| Thorens, B; Waeber, G | 1 |
| Ekstrand, A; Eriksson, J; Forsblom, C; Groop, L; Groop, PH; Teppo, AM; Widén, E | 1 |
| Goriya, Y; Iwama, N; Kajimoto, Y; Kamada, T; Katsura, M; Kawamori, R; Kubota, M; Shichiri, M; Yamasaki, Y | 1 |
| Durlach, V; Gross, A; Grulet, H; Hecart, AC; Leutenegger, M | 1 |
| Groop, L; Härkönen, M; Melander, A; Saloranta, C; Taskinen, MR; Widen, E | 1 |
| Creutzfeldt, W; Holst, JJ; Kleine, N; Nauck, MA; Orskov, C; Willms, B | 1 |
| Garrel, DR; Nadeau, MH; Pomerleau, J; Verdy, M | 1 |
| Ditzler, T; Glauber, HS; Gumbiner, B; Henry, RR; Lyon, R; Wallace, P | 1 |
| Creutzfeldt, W; Ebert, R; Heimesaat, MM; Holst, JJ; Nauck, MA; Orskov, C | 1 |
| Erkelens, DW; Hoekstra, JB; van der Feltz, M | 1 |
| Ceriello, A; Consoli, G; D'Onofrio, F; De Rosa, N; Giugliano, D; Minei, A; Quatraro, A | 1 |
| Alberti, KG; Berrish, TS; Cooper, BG; Elliott, C; Orskov, H; Reed, JW; Walker, M | 1 |
| Amagasaki, Y; Fushimi, T; Hasegawa, A; Hayashi, I; Iioka, Y; Kobayashi, M; Mizuiri, S; Tanaka, T | 1 |
| Hanafusa, T; Kono, N; Namba, M; Tarui, S | 1 |
| Rasmussen, O | 1 |
| Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AS; Walker, M | 1 |
| Feldman, EC; Kirk, CA; Nelson, RW | 1 |
| Erkelens, DW; Hackeng, WH; Lips, CJ; van Jaarsveld, BC | 1 |
| Arnold, R; Fuder, H; Göke, B; Kleist, P; Littke, T; Lücker, PW; Stridde, E; Theiss, U; Wieckhorst, G | 1 |
| Creutzfeldt, W; Holst, JJ; Nauck, MA; Orskov, C; Werner, J; Willms, B | 1 |
| Damm, P; Hornnes, P; Kühl, C; Mølsted-Pedersen, L | 1 |
| Daimon, M; Fukase, N; Igarashi, M; Manaka, H; Sasaki, H; Sugiyama, K; Takahashi, H; Tominaga, M; Yamatani, K | 1 |
| Grossman, EB; Gumbiner, B; Low, CC | 1 |
| Abrahamsen, N; Froguel, P; Hager, J; Hansen, LH; Jelinek, L; Kindsvogel, W; Nishimura, E | 1 |
| Alzaid, A; Basu, A; Caumo, A; Cobelli, C; Dinneen, S; Rizza, RA | 1 |
| Chase, J; Chen, W; Duleba, A; Perseghin, G; Price, TB; Rothman, DL; Shulman, GI; Shulman, RG | 1 |
| Bier, D; Bucci, A; Dailey, G; Gerich, J; Jansson, PA; Jenssen, T; Nurjhan, N; Perriello, G; Stumvoll, M; Welle, S | 1 |
| Hurel, S; Newkirk, J; Ofei, F; Sopwith, M; Taylor, R | 1 |
| Boden, G; Chen, X; Urbain, JL | 1 |
| Brand, CL; Holst, JJ; Jørgensen, PN; Svendsen, I | 1 |
| Butler, PC; Janson, J; Kreutter, DK; Nelson, RT; Roche, PC; Soeller, WC; Torchia, AJ | 1 |
| Cheli, V; Ciuchi, E; Giusti, R; Melga, P; Odetti, P; Prando, R | 1 |
| Camisasca, R; Pacchioni, M; Pontiroli, AE; Pozza, G | 1 |
| Creutzfeldt, WO; Holst, JJ; Kleine, N; Nauck, MA; Orskov, C; Willms, B | 1 |
| Gottsäter, A; Luzio, S; Owens, DR; Sundkvist, G | 1 |
| Morgan, LM | 1 |
| Gaillard, R; Jéquier, E; Lefèbvre, PJ; Paquot, N; Scheen, A; Schneiter, P; Tappy, L | 1 |
| Federlin, K; Göke, B; Linn, T; Schneider, K | 1 |
| Carroll, R; Chan, SJ; Gong, Q; Martin, S; Rouillé, Y; Steiner, DF | 1 |
| Diedrich, T; Knepel, W; Yildiz, N | 1 |
| Funakoshi, A; Ikeda, S; Jimi, A; Kanai, S; Kawanami, T; Kono, A; Masuda, M; Miyasaka, K; Nagai, T; Yasunami, Y | 1 |
| Fletcher, JM; Knapper, JM; Morgan, LM | 1 |
| Efendic, S; Guenifi, A; Gutniak, MK; Hellström, PM; Holst, JJ; Juntti-Berggren, L | 1 |
| Albert, SG; Bernbaum, M; Mooradian, AD; Plummer, S | 1 |
| de Kreutzenberg, SV; Del Prato, S; Lisato, G; Marchetto, S; Riccio, A; Tiengo, A; Turrin, M | 1 |
| Barrow, BA; Buchanan, KD; Gribble, FM; Levy, JC; Rachman, J; Turner, RC | 1 |
| Cooper, GJ; Tse, CA | 1 |
| Besedovsky, HO; del Rey, A; Klusman, I; Monge-Arditi, G | 1 |
| Kolterman, O; Moyses, C; Young, A | 1 |
| Nauck, M | 1 |
| Malaisse, WJ | 1 |
| Ligere, R; Martinsone, D; Martinsons, A | 1 |
| Efendic, S; Gutniak, M; Hamsten, A; Juntti-Berggren, L; Karpe, F; Pigon, J; Vignati, L | 1 |
| Edelman, SV; Henry, RR; Kelley, DE | 1 |
| Byrne, MM; Göke, B | 1 |
| Mineo, I; Nakagawa, C; Tarui, S | 1 |
| Bao, W; Berenson, GS; Srinivasan, SR | 1 |
| Beck-Nielsen, HB; Holst, JJ; Vaag, AA; Vølund, A | 1 |
| Mizuno, A; Noma, Y; Sano, T; Shima, K; Zhu, M | 1 |
| Graal, MB; Wolffenbuttel, BH | 1 |
| Elahi, D; Ryan, AS | 1 |
| Creutzfeldt, W; Holst, JJ; Nauck, MA; Orskov, C; Werner, J; Willms, B; Wollschläger, D | 1 |
| Castillo, MJ; Lefebvre, PJ; Paolisso, G; Scheen, AJ | 1 |
| Giacca, A; Kawamori, R; Lekas, M; Matsuhisa, M; Rodgers, CD; Shi, ZQ; Vranic, M; Wan, C | 1 |
| Hisatomi, A; Iguchi, H; Natori, S; Nawata, H; Ohashi, M; Umeda, F | 1 |
| Ahrén, B; Holst, JJ; Larsson, H | 1 |
| Atzeni, MM; Ciccarese, M; Li, LS; Luthman, H; Maioli, M; Manai, M; Massidda, A; Melis, MG; Pala, G; Pilosu, RM; Secchi, G; Tonolo, G | 1 |
| Alzaid, A; Basu, A; Bettini, F; Caumo, A; Cobelli, C; Gelisio, A; Rizza, RA | 1 |
| Barrow, BA; Levy, JC; Rachman, J; Turner, RC | 1 |
| Berghöfer, P; Fehmann, HC; Göke, B; Peterson, RG; Schneider, K | 1 |
| Hamada, Y; Hara, T; Hotta, N; Koh, N; Komori, T; Mori, K; Nakamura, J; Nakashima, E; Naruse, K; Sakakibara, F; Takeuchi, N | 1 |
| Kuikka, JT; Turpeinen, AK; Uusitupa, MI; Vanninen, E | 1 |
| Bolli, GB; Brunetti, P; Ciofetta, M; Del Sindaco, P; Lalli, C; Pampanelli, S; Perriello, G; Santeusanio, F; Volpi, E | 1 |
| Coleman, TG; Hall, JE; Montani, JP; Summers, RL; Woodward, LH | 1 |
| Bonadonna, RC; DeFronzo, RA; Del Prato, S; Groop, LC; Leonetti, F; Matsuda, M; Sheehan, P; Simonson, DC | 1 |
| Aarsen, M; Draeger, KE; Heine, RJ; Martini, C; van der Wal, PS; van Iperen, AM | 1 |
| Ishida, K; Kuwajima, M; Mizuno, A; Murakami, T; Noma, Y; Sato, I; Shima, K; Tateishi, K | 1 |
| Bloom, SR; Edwards, CM; Ghatei, MA; Khan, FA; Todd, JF; Wilding, JP | 1 |
| Jacob, HJ; Koike, G; Maget, B; Rivière, M; Shiozawa, M; Simon, JS; Svoboda, M; Szpirer, C; Szpirer, J; Vanvooren, P | 1 |
| Movassat, J; Portha, B; Saulnier, C; Serradas, P | 1 |
| Finney, LS; Finney, MO; Gonzalez, JM | 1 |
| Ihm, SH; Lee, KU; Park, JY; Park, SW; Yoo, HJ | 1 |
| Beermann, F; Birnbaum, MJ; Dériaz, N; Guillam, MT; Hümmler, E; Schaerer, E; Schmidt, A; Thorens, B; Wu, JY; Yeh, JI | 1 |
| Holst, JJ; Nauck, MA; Willms, B | 1 |
| Nishi, S; Taminato, T; Yagi, T | 1 |
| Basu, A; Dinneen, SF; Nielsen, MF; Rizza, RA; Schwenk, WF; Wise, S | 1 |
| Barg, Y; Gefel, D; Zimlichman, R | 1 |
| Langeberg, LK; Lester, LB; Scott, JD | 1 |
| Ahrén, B; Gutniak, MK; Holst, JJ; Juneskans, O; Larsson, H; Sanders, SW | 1 |
| Baloga, J; Bell, JM; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, JM; Roberts, A | 1 |
| Ito, C | 1 |
| Ahrén, B; Gutniak, M | 1 |
| Louw, J; Seier, J; Wolfe-Coote, SA; Woodroof, C | 1 |
| Alford, FP; Arackal, R; Barton, J; Best, JD; Boston, RC; Walters, JM; Ward, GM | 1 |
| Gromada, J; Holst, JJ; Rorsman, P | 1 |
| Arai, K; Hayashi, T; Hukuda, G; Kanazawa, M; Kanazawa, Y; Komeda, K; Nomoto, S; Notoya, Y; Shirabe, S; Tanaka, A | 1 |
| Arnold, R; Beglinger, C; Göke, B; Hildebrand, P; Katschinski, M; Leicht, P; Schirra, J | 1 |
| Bonner-Weir, S; Clark, J; Kubstrup, C; Levisetti, M; Pick, A; Polonsky, KS; Pugh, W | 1 |
| Ercan-Fang, N; Ercan-Fang, S; Gannon, MC; Grant, CT; Nuttall, FQ | 1 |
| Amiel, S; Hopkins, D; Korzon-Burakowska, A; Lomas, J; Macdonald, I; Matyka, K; Pernet, A | 1 |
| Aiache, JM; Cardot, JM; Saffar, F | 1 |
| Boyd, AE; Dillon, JS; Leng, XH; Ligon, BB; Wheeler, MB | 1 |
| Bungert, S; Gudat, U; Heinemann, L; Kemmer, F | 1 |
| Alford, FP; Beck-Nielsen, H; Henriksen, JE; Hew, LF; Rantzau, C; Vaag, A; Ward, GM | 1 |
| Kayo, T; Koizumi, A | 1 |
| Belfiore, F; Campione, R; Iannello, S | 1 |
| Creutzfeldt, W; Holst, JJ; Idowu, K; Nauck, MA; Willms, B | 1 |
| Bergmann, J; Holst, JJ; Nauck, MA; Ritzel, R; Schmiegel, W; Seifarth, C | 1 |
| Ahlgren, U; Edlund, H; Jonsson, J; Jonsson, L; Simu, K | 1 |
| Seeley, RJ; Woods, SC | 1 |
| Cryer, PE; Nielsen, MF; Rizza, RA; Wise, SD | 1 |
| Cseh, K; Salamon, D; Salamon, F; Simon, K; Speer, G; Winkler, G | 1 |
| Dostou, J; Gerich, J; Meyer, C; Mitrakou, A; Nadkarni, V; Stumvoll, M | 1 |
| Elahi, D; Meneilly, GS | 1 |
| Bajaj, M; Kinsley, BT; Levy, CJ; Simonson, DC | 1 |
| Arnold, R; Byrne, MM; Gliem, K; Göke, B; Katschinski, M; Polonsky, KS; Wank, U | 1 |
| Aharon, Y; Giacca, A; Hawkins, M; Mevorach, M; Rossetti, L; Shamoon, H | 1 |
| Dussoix, P; Froguel, P; Guenat, E; Jéquier, E; Philippe, J; Schneiter, P; Surmely, JF; Tappy, L; Temler, E; Vaxillaire, M | 1 |
| Bloom, SR; Edwards, CM; Ghatei, MA; Mather, HM; Todd, JF | 1 |
| Peterson, RG; Roth, MD; Shen, HQ | 1 |
| Moriyama, A; Otsuki, M; Shirohara, H; Tabaru, A | 1 |
| Asai, K; Iriyama, A; Kakumu, S; Kusunoki, M; Okabayashi, N; Sakakibara, H; Sato, Y; Usui, K; Yajima, M; Yamanouchi, K | 1 |
| Gutniak, M | 1 |
| Ercan-Fang, N; Fang, S; Gannon, MC; Nuttall, FQ; Westphal, SA | 1 |
| Koeslag, JH; Saunders, PT; Wessels, JA | 1 |
| Basu, R; Caumo, A; Cobelli, C; Nielsen, MF; Rizza, RA; Wise, S | 1 |
| D'Onofrio, F; Gambardella, A; Giugliano, D; Gualdiero, P; Howard, BV; Paolisso, G; Rizzo, MR; Saccomanno, F; Tagliamonte, MR | 1 |
| Holst, JJ; Nauck, MA; Ritzel, R; Sauerwald, A; Schmiegel, W | 1 |
| Bach, I; Holst, JJ; Nauck, MA; Orskov, C; Richter, S; Schmiegel, W; Weber, I | 1 |
| Marks, V; Morgan, L; Ranganath, L; Sedgwick, I; Wright, J | 1 |
| Nauck, MA | 2 |
| Harada, H; Hasegawa, T; Kyouda, T; Makino, I; Nakamura, K; Ohnishi, K; Yoneda, M; Yoshida, Y | 1 |
| Cseh, K; Hajós, P; Harmos, G; Kovács, M; Salamon, D; Salamon, F; Simon, K; Speer, G; Szekeres, O; Winkler, G | 1 |
| Bjerre-Knudsen, L; Deacon, C; Holst, JJ; Toft-Nielsen, MB | 1 |
| De Ore, KA; Egan, JM; Garant, MJ; Greig, NH; Holloway, HW; Jani, D; Wang, Y; Zhou, J | 1 |
| Chang, SL; Cheng, JT; Chi, TC; Lin, JG; Liu, IM | 1 |
| Domschke, W; Fischer, H; Heidemann, T; Hengst, K; Konturek, JW | 1 |
| Carpentier, A; Giacca, A; Lewis, GF; Vranic, M | 1 |
| Armstrong, E; Blackshaw, PE; Buchanan, KD; Horowitz, M; King, P; Kong, MF; Macdonald, IA; Perkins, AC; Tattersall, RB | 1 |
| Binder, C; Dinesen, B; Hartling, SG; Houssa, P; Røder, ME; Sodoyez-Goffaux, F; Vestergaard, H | 1 |
| Barrett, EJ; Miers, WR | 1 |
| Beglinger, C; Drewe, J; Göke, B; Gutzwiller, JP; Lareida, J; Rohrer, B; Schmidt, H | 1 |
| Brubaker, PL; Efendic, S; Giacca, A; Irwin, DM; MacDonald, PE; McCall, RH; Rashid, S; Sandhu, H; Satkunarajah, M; Shi, ZQ; Tchipashvili, V; Vranic, M; Wheeler, MB; Wiesenthal, SR | 1 |
| Hamaguchi, T; Hanafusa, T; Higashiyama, S; Horikawa, Y; Imagawa, A; Iwahashi, H; Matsuzawa, Y; Miyagawa, J; Miyazaki, J; Nakajima, H; Namba, M; Okita, K; Oue, T; Satoh, T; Yamagata, K; Yamamoto, K; Yamasaki, T; Yang, Q; Yoshiuchi, I | 1 |
| Burton, PS; Colca, JR; Elhammer, AP; Meurer, JA | 1 |
| Holst, JJ; Madsbad, S; Toft-Nielsen, MB | 2 |
| Basu, A; Basu, R; Nielsen, M; Rizza, RA; Shah, P | 1 |
| Burcelin, R; Carrel, V; Dolci, W; Germain, S; Rolland, E; Thorens, B | 1 |
| Endo, T; Funo, S; Iizuka, S; Kawamura, H; Kimura, M; Sato, T; Suzuki, W; Tabuchi, M; Yanagisawa, T | 1 |
| Mason, EE | 1 |
| Adamson, U; Landstedt-Hallin, L; Lins, PE | 1 |
| Gallwitz, B; Schmidt, WE | 1 |
| Alvarsson, M; Clauson, P; Grill, V | 1 |
| Feinglos, MN; Hughes, AT; Luna, B | 1 |
| Dela, F; Galbo, H; Larsen, JJ; Madsbad, S; Vibe-Petersen, J | 1 |
| Alberti, KG; Gravholt, CH; Holst, JJ; Nyholm, B; Schmitz, O; Shearing, PA; Sturis, J; Walker, M | 1 |
| Freeman, DJ; Leclerc, I; Rutter, GA | 1 |
| Bonner-Weir, S; Habener, JF; Stoffers, DA; Xu, G | 1 |
| Burge, MR; Rassam, AG; Schade, DS; Sobhy, TA; Zeise, TM | 1 |
| Ban, N; Fujimoto, S; Hashimoto, H; Ihara, Y; Jomori, T; Kajikawa, M; Kubota, A; Kuroe, A; Miyawaki, K; Miyazaki, J; Niwa, H; Seino, Y; Tashiro, F; Tsuda, K; Yamada, Y; Yamashita, T; Yano, H | 1 |
| Fölsch, UR; Gallwitz, B; Schmidt, WE; Siegel, EG | 1 |
| Carlsson, A; Groop, L; Sundkvist, G; Tuomi, T | 1 |
| Caro, J; Wishner, KL | 1 |
| Ahrén, B; Efendic, S; Holst, JJ | 1 |
| Bosch, F; Casellas, A; Devedjian, JC; George, M; Gros, L; Pelegrín, M; Pujol, A; Visa, J | 1 |
| Sélam, JL | 1 |
| Abdel-Halim, SM; Efendić, S; Grimelius, L; Guenifi, A; Portela-Gomes, GM | 1 |
| Agersø, H; Huusfeldt, PO; Johansen, NL; Knudsen, LB; Madsen, K; Nielsen, PF; Pedersen, FZ; Thøgersen, H; Wilken, M | 1 |
| Fritsche, A; Hardt, E; Häring, H; Schützenauer, S; Stefan, N; Stumvoll, M | 1 |
| Hahn, S; Nauck, M; Sauerwald, A; Schmiegel, W | 1 |
| Dinesen, B; Holst, JJ; Krarup, T; Madsbad, S; Toft-Nielsen, MB; Vilsbøll, T | 1 |
| Holst, JJ; Juhl, CB; Pincus, S; Pørksen, N; Schmitz, O; Veldhuis, J | 1 |
| Bell, GI; D'Souza, E; Fajans, SS; Herman, WH; Ilag, LL; Tabaei, BP; Zawacki, CM | 1 |
| Basu, A; Basu, R; Jensen, MD; Johnson, CM; Nair, KS; Rizza, RA; Schwenk, WF; Shah, P; Vella, A | 1 |
| Basu, A; Basu, R; Holst, JJ; Rizza, RA; Shah, P; Vella, A | 1 |
| Baldi, S; Camastra, S; Ferrannini, E; Gastaldelli, A; Landau, BR; Natali, A; Pettiti, M; Toschi, E | 1 |
| Birkeland, K; Dejgaard, A; Hanssen, KF; Kjems, L; Madsbad, S; Rosenfalck, AM; Thorsby, P | 1 |
| Fosgerau, K; Grunnet, N; Kristiansen, M; Lundgren, K; Quistorff, B; Westergaard, N | 1 |
| Cancelas, J; Garcia-Martinez, JA; Malaisse, WJ; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Moller, DE; Zhang, BB | 1 |
| Barazzoni, R; Carraro, P; Davanzo, G; Kiwanuka, E; Tessari, P; Tiengo, A; Zanetti, M | 1 |
| Bloom, SR; Brynes, AE; Edwards, CM; Frost, GS; Ghatei, MA; Jadhav, A | 1 |
| Barilli, AL; Dei Cas, A; Dell'Anna, C; Gnudi, A; Iotti, M; Lugari, R; Marani, B; Orlandini, A; Ugolotti, D; Zandomeneghi, R | 1 |
| Chin, GA; Clarke, WL; Clocquet, AR; Egan, JM; Elahi, D; Habener, JF; Hanks, JB; Muller, DC; Stoffers, DA; Wideman, L | 1 |
| Brubaker, PL; Joseph, JW; Kalitsky, J; St-Pierre, S | 1 |
| Basu, A; Basu, R; Rizza, RA; Schwenk, WF; Shah, P; Vella, A | 1 |
| Bardini, G; Ciani, S; Cremasco, F; Fanelli, A; Mannucci, E; Mencucci, A; Messeri, G; Ognibene, A; Pierazzuoli, E; Rotella, CM | 1 |
| Daimon, M; Igarashi, M; Kato, T; Manaka, H; Ohnuma, H; Sasaki, H; Yamatani, K | 1 |
| Flatt, PR; Kelly, CM; McKillop, AM; Mooney, MH; O'Harte, FP | 1 |
| Guenat, E; Jequier, E; Philippe, J; Seematter, G; Tappy, L; Temler, E | 2 |
| Boden, G; Chen, X; Stein, TP | 1 |
| Amiel, S; Hattersley, AT; MacDonald, IA; MacLeod, KM; Spyer, G | 1 |
| Dralyuk, F; Mittal, AA; Polonsky, KS; Pugh, WL; Roe, MW; Sreenan, SK | 1 |
| Arakawa, K; Ishihara, T; Kitamura, K; Matsumoto, M; Nawano, M; Oku, A; Saito, A; Ueta, K | 1 |
| Bailbe, D; Marie, JC | 1 |
| Nakata, M; Shioda, S; Yada, T | 1 |
| Buckingham, RE; Lister, CA; Smith, SA; Toseland, CD | 1 |
| Baraldi, L; Bianchi, G; Brizi, M; Forlani, G; Marchesini, G; Melchionda, N; Natale, S; Zaccheroni, V | 1 |
| Dharmalingam, M; Kumar, P | 1 |
| Damberg, G; Gannon, MC; Gupta, V; Nuttall, FQ; Nuttall, JA | 1 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
| Cherrington, AD; Dixon, K; Fujimoto, Y; Grimsby, J; Grippo, JF; Jetton, TL; Magnuson, MA; Pan, D; Postic, C; Shiota, M | 1 |
| Brubaker, PL; Giguere, J; Jeng, W; Parisien, M; St-Pierre, SA; Wheeler, MB; Xiao, Q | 1 |
| Cerasi, E; Efendic, S; Kaiser, N; Khan, A; Nesher, R; Warwar, N | 1 |
| Miralles, F; Portha, B | 1 |
| Holst, JJ; Juhl, C; März, W; Nauck, MA; Nauck, MS; Pørksen, N; Ritzel, R; Schmiegel, WH; Schmitz, O; Schulte, M | 1 |
| AvRuskin, TW; Banerji, MA; Bastian, W; Castells, S; Taha, D; Umpaichitra, V | 1 |
| Holst, JJ; Madsbad, S; Taskiran, M; Toft-Nielsen, MB; Zander, M | 1 |
| Alford, FP; Barton, J; Boston, RC; Walters, JM; Ward, GM | 1 |
| Egan, JM; Elahi, D; Gingerich, R; Habener, JF; McIntosh, CH; Meneilly, GS; Pederson, RA | 2 |
| Basu, A; Basu, R; Jensen, MD; Rizza, RA; Shah, P; Vella, A | 1 |
| Cancelas, J; Malaisse, WJ; Valverde, I; Villanueva-Peñacarrillo, ML | 2 |
| Beck-Nielsen, H; Holst, JJ; Hother-Nielsen, O; Levin, K; Staehr, P | 1 |
| Contesse, J; Reinhart, WH; Rohrer, A; Schnyder, L; Walter, R | 1 |
| Chung, P; Harding, HP; Jungries, R; Plesken, H; Ron, D; Sabatini, DD; Zeng, H; Zhang, Y | 1 |
| Stubbs, RS; Wickremesekera, SK | 1 |
| Adner, N; Ahrén, B; Gutniak, MK; Hellström, PM; Holst, JJ; Svartberg, J | 1 |
| Creutzfeldt, W | 2 |
| Kuwajima, M; Lan, MS; Mizuno, A; Murakami, T; Noma, Y; Shima, K; Zhu, M | 1 |
| Hansen , AP; Juhl, CB; Pincus, SM; Pørksen, N; Schmitz, O; Veldhuis, JD | 1 |
| Damsbo, P; Hylleberg, B; Larsen, J; Ng, K | 1 |
| Damholt, MB; Hilsted, LM; Holst, JJ; Hughes, TE; Madsbad, S; Michelsen, BK; Toft-Nielsen, MB | 1 |
| Doi, Y; Iwai, M; Matsuura, B; Onji, M | 1 |
| Kimura, I; Kobayashi, M; Ohgaku, S; Sasamoto, H; Sasamura, T; Sugihara, Y | 1 |
| Ackermans, MT; Arias, AM; Bisschop, PH; Endert, E; Nijpels, G; Romijn, JA; Sauerwein, HP | 1 |
| Hietaniemi, K; Kiviluoto, T; Mäkimattila, S; Timonen, T; Yki-Järvinen, H | 1 |
| Barilli, AL; Dei Cas, A; Gnudi, A; Iotti, M; Lugari, R; Marani, B; Orlandini, A; Ugolotti, D; Zandomeneghi, R | 1 |
| Bernier, M; Betkey, JA; Doyle, ME; Egan, JM; Greig, NH; Holloway, HW | 1 |
| Gjinovci, A; Hagenfeldt-Johansson, KA; Herrera, PL; Ishihara, H; Wang, H; Wollheim, CB | 1 |
| Clemente, F; Puente, J; Redondo, A; Valverde, I; Villanueva-Peñacarrillo, ML | 1 |
| Ackermans, MT; Bisschop, PH; Endert, E; Pereira Arias, AM; Romijn, JA; Sauerwein, HP | 1 |
| González, N; Márquez, L; Puente, J; Valverde, L; Villanueva-Peñacarrillo, ML | 1 |
| Agersø, H; Hollingdal, M; Jakobsen, G; Juhl, CB; Pørksen, N; Schmitz, O; Sturis, J; Veldhuis, J | 1 |
| Banerji, MA; Bastian, W; Castells, S; Taha, DR; Umpaichitra, V | 1 |
| Chung, YS; Hong, EG; Kim, HM; Lee, KW; Lee, SK; Noh, HL | 1 |
| Andres, R; Egan, JM; Elahi, D; Meneilly, GS; Muller, DC; Veldhuist, J | 1 |
| Gabriely, I; Hawkins, M; Rossetti, L; Shamoon, H; Vilcu, C; Wozniak, R | 1 |
| Cryer, PE; Paramore, DS; Segel, SA | 1 |
| Abdulkadir, J; Faiman, C; Hammel, JP; Reddy, SS; Scherbaum, WA; Siraj, ES | 1 |
| Dirlewanger, M; Lefèbvre, PJ; Paquot, N; Scheen, AJ; Tappy, L | 1 |
| Albert, SG; Chandurkar, V; DeLeon, MJ; Mooradian, AD | 1 |
| Holst, JJ; Madsbad, S; Madsen, JL; Zander, M | 1 |
| Castro, A; Fernández-Real, JM; García-Bragado, F; Hernández-Aguado, I; Peñarroja, G; Ricart, W | 1 |
| Alstrup, KK; Gregersen, S; Hermansen, K; Jeppesen, PB | 1 |
| Cooper, BP; Fucetola, R; Haupt, DW; Melson, AK; Newcomer, JW; Schweiger, JA; Selke, G | 1 |
| Andersson, G; Efendic, S; Grill, V; Kärvestedt, L | 1 |
| Chacra, AR; Dib, SA; Kasamatsu, T; Moisés, RS; Shiota, D | 1 |
| Kieffer, TJ; Lam, NT | 1 |
| Barilli, AL; Dei Cas, A; Finardi, L; Gnudi, A; Luciani, A; Lugari, R; Ognibene, C; Ugolotti, D; Zandomeneghi, R | 1 |
| Bailbe, D; Kergoat, M; Lacorne, M; Meile, MJ; Portha, B; Tourrel, C | 1 |
| Ashworth, D; Aubert, ML; Broqua, P; Evans, DM; Haigh, R; Junien, JL; Sudre, B; White, RB | 1 |
| Richardson, AP; Tayek, JA | 1 |
| Fujii, S; Hosoi, M; Ishii, T; Miyamoto, M; Onishi, S; Sato, T; Tanaka, S; Yamagami, K; Yamakita, T; Yamamoto, T; Yoshioka, K | 1 |
| Chen, J; Ding, P; Li, C; Ma, Y | 1 |
| AvRuskin, TW; Juan, CS | 1 |
| Banerji, MA | 1 |
| Göke, B; Hoppe, B; Konrad, A; Schirra, J | 1 |
| Geronooz, I; Jandrain, B; Letiexhe, MR; Paquot, N; Scheen, AJ | 1 |
| Gabriely, I; Hawkins, M; Reddy, K; Rossetti, L; Shamoon, H; Wozniak, R | 1 |
| Bhattacharyya, PK; Mohan, V; Ramachandran, A; Snehalatha, C; Viswanathan, M | 1 |
| Fehmann, HC; Habener, JF | 1 |
| Alberti, KG; Catalano, C; Farrer, M; Fulcher, GR; Walker, M | 1 |
| Tang, S | 1 |
| Ahrén, B; Efendic, S; Gutniak, M; Holst, JJ; Orskov, C | 1 |
| Itakura, C; Katsuta, O; Narama, I; Tsuchitani, M; Wako, Y; Yamagishi, Y | 1 |
| Huang, HS; Huang, MJ; Juang, JH | 1 |
| Imura, H; Ishida, H; Kato, S; Kurose, T; Okamoto, Y; Seino, Y; Tsuda, K; Tsuji, K; Tsuura, Y; Usami, M | 1 |
| Hanafusa, T; Itoh, N; Katsura, H; Kono, N; Tarui, S | 1 |
| Burmeister, LA; Gannon, MC; Lane, JT; Nuttall, FQ | 1 |
| Houslay, MD; Palmer, TM; Taberner, PV | 1 |
| Minamori, Y; Takeda, N; Tanaka, A; Yammoto, M; Yasuda, K | 1 |
| Atiea, JA; Luzio, S; Owens, DR | 1 |
| Menheere, PP; Nieuwenhuijzen Kruseman, AC; Nijst, L; Rondas-Colbers, GJ; Sels, JP; Wolffenbuttel, BH | 1 |
| Chiou, GC; Chuang, LM; Wu, HP | 1 |
| Cha, T; Ikegami, H; Kawaguchi, Y; Ogihara, T; Tahara, Y; Yamamoto, Y; Yamato, E; Yoneda, H | 1 |
| Garg, A; Grundy, SM; Koffler, M | 1 |
| Fujii, S; Komatsu, R; Matsuyama, T; Miki, H; Nishioeda, Y; Omae, T | 1 |
| Kobayashi, K; Miyakoshi, H; Miyamoto, I; Nagai, Y; Nishimura, Y; Noto, Y; Ohsawa, K | 1 |
| Basabe, JC; Capucchio, M; Cardoso, AI; Fabiano de Bruno, LE; Fainboim, L; Mota, AH; Poskus, E; Zavala, AV | 1 |
| Nicod, P; Waeber, G | 1 |
| Xiong, MQ | 1 |
| Ceriello, A; D'Onofrio, F; Giugliano, D; Paolisso, G; Saccomanno, F; Torella, R; Varricchio, M | 1 |
| Christensen, SE; Flyvbjerg, A; Frystyk, J; Harris, AG; Ledet, T; Møller, N; Orskov, H | 1 |
| Brunetti, P; Misericordia, P; Santeusanio, F; Santucci, A; Scionti, L | 1 |
| Aburaya, J; Enoki, S; Matsukara, S; Mitsukawa, T; Nakazato, M; Takemura, J; Toshimori, H | 1 |
| Birkeland, KI; Chatzipanagiotou, F; Hanssen, KF; Vaaler, S | 1 |
| Gumbiner, B; Nolan, JJ; Olefsky, JM; Suter, SL; Wallace, P | 1 |
| Fogel, H; Habener, JF; Mojsov, S; Nathan, DM; Schreiber, E | 1 |
| Berne, C; Boberg, M; Karlström, B; Lithell, H; Vessby, B | 1 |
| D'Alessio, DA; Ensinck, JW | 1 |
| Cortinovis, F; Lepore, G; Maglio, ML; Nosari, I; Pagani, G | 1 |
| Burmeister, LA; Gannon, MC; Lane, JT; Nuttall, FQ; Pyzdrowski, KL | 1 |
| Bressler, R; Johnson, D | 1 |
| Akinmokun, A; Alberti, KG; Ramaiya, K; Selby, PL | 1 |
| Funahashi, M; Koons, J; Winter, WE | 1 |
| Bierman, EL; Childs, MT; Ensinck, JW; Friday, KE; Fujimoto, WY; Zambon, S | 1 |
| Arnqvist, HJ; Lindström, T; Ludvigsson, J; von Schenck, HH | 1 |
| Damjanović, S; Devecerski, M; Djordjević, P; Lalić, N; Ribarac-Stepić, N; Zamaklar, M | 1 |
| Gerich, J; Kelley, D; Mitrakou, A; Mokan, M; Pangburn, T; Reilly, J; Veneman, T | 1 |
| Consoli, A; Gerich, J; Nurjhan, N | 1 |
| Bailey, DJ; Blackard, WG; Clore, JN; Nestler, JE; Post, EP | 1 |
| Maezawa, H; Sugiyama, H; Uchimura, I; Watanabe, T | 1 |
| Fukushima, H; Hamaguchi, T; Ichinose, K; Kishikawa, H; Shichiri, M; Shirotani, T; Uehara, M; Wada, S; Yamaguchi, K | 1 |
| Creutzfeldt, W; Nauck, MA; Siegel, EG | 1 |
| Borkman, M; Bruce, DG; Chisholm, DJ; Kraegen, EW; Storlien, LH | 1 |
| Kawai, K; Murayama, Y; Suzuki, S; Watanabe, Y; Yamashita, K | 1 |
| Chi, Z; Kan, Y | 1 |
| Halter, JB; Herman, WH; Ortiz-Alonso, FJ; Perry, TJ; Smith, MJ; Zobel, DL | 1 |
| Efendic, S; Grill, V; Ostenson, CG | 1 |
| Brechtel, G; Henry, RR; Lim, KH | 1 |
| Besenthal, I; Eggstein, M; Jakober, B; Nordt, TK | 1 |
| Blackman, J; Bosson, D; Copinschi, G; Lewis, G; Polonsky, KS; Shapiro, ET; Tillil, H; Van Cauter, E | 1 |
| Holst, JJ; Jeppesen, J; Madsbad, S; Orskov, C | 1 |
| Butler, PC; Rizza, RA | 1 |
| Matsuda, A | 1 |
| Komi, N; Muñoz, NA; Nishi, M; Takehara, H | 1 |
| Abdulkadir, J; Bekele, A; Gebre, P; Keen, H; Mengesha, B; Taddesse, AS; Urga, K; Welde Gebriel, Z; Worku, Y | 1 |
| Gerich, J; Greenawalt, K; Mitrakou, A; Stanko, RT | 1 |
| Aslan, SM; Atiea, JA; Luzio, S; Owens, DR | 1 |
| Beard, JC; Johnston, C; McKnight, B; Porte, D; Ward, WK | 1 |
| Reckless, JP; Simpson, HC; Stirling, CA; Sturley, R | 1 |
| Ayzac, L; Charrie, A; Fleury, MC; Jouve, M; Rebattu, B; Sabot, O; Tourniaire, J | 1 |
| Chen, YD; Hollenbeck, C; Johnston, P; Reaven, GM; Sheu, W | 1 |
| Chiba, Y; Ito, S; Kamoi, K; Momotsu, T; Nakamura, H; Shibata, A; Tamura, N; Yamaji, T; Yamazaki, M | 1 |
| Chari, S; Madanagopalan, N; Mohan, V; Ramachandran, A; Snehalatha, C; Viswanathan, M | 1 |
| Doi, K; Morita, S | 1 |
| Frey-Hewitt, B; Galbo, H; Haskell, W; Hollenbeck, CB; Kjaer, M; Reaven, GM | 1 |
| Wang, Z; Yin, Z | 1 |
| Aguilar, M; Escobar-Jiménez, F; Gómez-Villalba, R; Herrera Pombo, JL; Nuñez del Carril, J; Rovira, A | 1 |
| Flynn, T; Gumbiner, B; Henry, RR; Thorburn, AW | 1 |
| Bier, DM; Consoli, A; Gerich, JE; Nurjhan, N; Reilly, JJ | 1 |
| Bonner-Weir, S; Leahy, JL; Weir, GC | 1 |
| Kanter, Y; Piell, E; Santo, M | 1 |
| Marsh, HM; McMahon, M; Rizza, RA | 1 |
| Fujita, Y; Kawaji, K; Kubo, H; Shirataka, M; Yajima, Y | 1 |
| Bretzel, RG; Cohen, AM; Federlin, K; Wiegand, S | 1 |
| Fujishima, M; Iwase, M; Kikuchi, M; Kodama, T; Maki, Y; Nunoi, K; Sadoshima, S | 1 |
| De Leeuw, I; Nobels, F; Rillaerts, E; Van Gaal, L | 1 |
| Bhathena, SJ; Carswell, N; Hansen, CT; Jones, J; Kennedy, BW; Michaelis, OE; Recant, L; Smith, PM; Voyles, NR | 1 |
| Bell, PM; Firth, RG; Rizza, RA | 1 |
| D'Onofrio, F; Paolisso, G; Passariello, N; Pizza, G; Sgambato, S; Varricchio, M | 1 |
| Filer, LJ; Stegink, LD | 1 |
| Capani, F; Consoli, A; Gerich, J; Nurjhan, N | 1 |
| Helve, E; Karonen, SL; Nikkilä, EA; Sane, T; Taskinen, MR; Yki-Järvinen, H | 1 |
| Kawai, K; Murayama, Y; Watanabe, Y; Yamashita, K; Yoshikawa, H | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| D'Onofrio, F; Giunta, R; Marrazzo, G; Paolisso, G; Passariello, N; Pizza, G; Sgambato, S; Varricchio, M | 1 |
| Faber, OK; Frøland, A; Gjessing, HJ; Matzen, LE | 1 |
| Bisacchi, U; Gianni, R; Maggi, L; Santoro, E; Tomassini, CR | 1 |
| Lefèbvre, P; Paolisso, G; Scheen, A | 1 |
| Epstein, PN; Means, AR; Overbeek, PA | 1 |
| Gannon, MC; Neil, BJ; Nuttall, FQ; Seaquist, ER; Westphal, SA | 1 |
| Antoniello, S; Auletta, M; Cacciatore, L; Cavalcanti, E; La Rocca, S; Salvatore, F | 1 |
| Gjessing, HJ; Pedersen, O; Reinholdt, B | 1 |
| Atley, L; Balasz, N; McDonald, J; Simpson, RW; Sissons, M; Wahlqvist, ML | 1 |
| Cryer, PE; Gerich, JE | 1 |
| Best, JD; Halter, JB; Pfeifer, MA; Porte, D; Ward, WK | 1 |
| Efendić, S; Grill, V; Gutniak, M | 1 |
| Doorenbos, H | 1 |
| Bonner-Weir, S; Samols, E; Weir, GC | 1 |
| Cavalie, G; Lachkar, H; Mirouze, J; Monnier, L; Orsetti, A; Richard, JL; Rodier, M | 1 |
| Pipeleers, D | 1 |
| Bloom, SR; Fuessl, H; Kraenzlin, M; Williams, G | 1 |
| Chen, JJ; Chen, YD; Ho, LT; Reaven, GM; Wu, MS | 1 |
| Burrin, JM; Cloke, HR; Kohner, EM; Maneschi, F; Mohan, V; Sharp, PS; Vitelli, F | 1 |
| Baron, AD; Kolterman, OG; Schaeffer, L; Shragg, P | 1 |
| Lasichak, A; Lo, GS; Tsai, AC; Vinik, AI | 1 |
| Clark, A; Hosker, JP; Matthews, DR; Naylor, BA; Turner, RC; Wells, CA | 1 |
| Alberti, KG; Davies, RR; Johnston, DG; McGill, A; Miller, M; Orskov, H; Turner, SJ; Watson, M | 1 |
| Bloom, SR; Burrin, JM; Chilvers, E; Füessl, HS; Williams, G | 1 |
| Ching, KN; Ho, LT; Lam, HC; Tang, KT; Wang, JT; Wang, LM | 1 |
| Ceriello, A; D'Onofrio, F; Giugliano, D; Lefèbvre, P; Paolisso, G; Salvatore, T | 1 |
| Ceriello, A; Cozzolino, D; D'Onofrio, F; Giugliano, D; Salvatore, T; Torella, R | 1 |
| Alford, FP; Best, JD; Crock, PA; Ley, CJ; Martin, IK | 1 |
| Gragnoli, G; Signorini, AM; Tanganelli, I | 1 |
| Asp, NG; Björck, I; Hagander, B; Lundquist, I; Nilsson-Ehle, P; Scherstén, B; Schrezenmeir, J | 1 |
| Arner, P; Einarsson, K; Ewerth, S; Livingston, JN | 1 |
| Irjala, KM; Koskinen, PJ; Viikari, JS | 1 |
| Campbell, PJ; Gerich, JE; Kennedy, FP | 1 |
| Crapo, PA; Henry, RR | 1 |
| Horwitz, DL; Kobe, P; McLane, M | 1 |
| Hashimoto, N; Iwaoka, H; Kanatsuka, A; Makino, H; Sakurada, M; Taira, M; Yamaguchi, T; Yoshida, A; Yoshida, S | 1 |
| Erkelens, DW | 1 |
| D'Onofrio, F; Gentile, S; Giugliano, D; Memoli, P; Paolisso, G; Sgambato, S; Varricchio, M | 1 |
| Ellyin, FE; Gilden, JL; Kumar, Y; Singh, SP; Snyder, AK | 1 |
| Acheson, K; Curchod, B; DeFronzo, RA; Felber, JP; Ferrannini, E; Golay, A; Jéquier, E; Simonson, DC; Thiébaud, D; Thorin, D | 1 |
| Damsgaard, EM; Faber, OK; Frøland, A; Gjessing, HJ; Matzen, LE | 1 |
| Fujiwara, H; Uchida, K | 1 |
| Fujishima, M; Iwase, M; Kikuchi, M; Maki, Y; Nunoi, K; Wada, M; Wakisaka, M | 1 |
| Ho, LT; Jap, TS; Tai, WH | 1 |
| Alberti, KG; Hanning, I; Leslie, RD; Orskov, H; Poncher, M; Volkmann, HP | 1 |
| Borisova, AM; Kirilov, G; Koev, D | 1 |
| DeFronzo, RA; Groop, L; Groop, PH; Luzi, L; Melander, A; Ratheiser, K; Simonson, DC | 1 |
| Lockwood, D; Nair, KS; Welle, S | 1 |
| Bierwolf, B; Brunner, E; Danneberg, G; Pohl, A; Verlohren, HJ | 1 |
| Bol'shakova, TD; Diuzheva, TG; Gal'perin, EI; Gitel', EP; Kuzovlev, NF | 1 |
| Bottazzo, GF; Groop, L; Groop, PH; Koskimies, S; Meri, S; Miettinen, A | 1 |
| Hakala, P; Korhonen, T; Laakso, M; Majander, H; Pyörälä, K; Sarlund, H; Uusitupa, M; Voutilainen, E | 1 |
| Albisser, AM; Gulan, M; Perlman, K; Sole, M; Zinman, B | 1 |
| Brechtel, G; Griver, K; Henry, RR | 1 |
| Hasselstrøm, K; Lumholtz, IB; Siersbaek-Nielsen, K; Snorgaard, O; Thorsteinsson, B | 1 |
| Bruce, DG; Chisholm, DJ; Kraegen, EW; Storlien, LH | 1 |
| Efendic, S; Karlander, S; Vranic, M | 1 |
| Binder, C; Cerasi, E; Glaser, B; Hartling, S; Leibovich, G; Nesher, R | 1 |
| Laakso, M; Penttilä, I; Pyörälä, K; Sarlund, H | 2 |
| Brechtel, G; Glauber, H; Wallace, P | 1 |
| Koskinen, P; Rönnemaa, T; Viikari, J | 1 |
| Hsieh, SD; Iwamoto, Y; Kuzuya, T; Matsuda, A | 2 |
| Kawai, K; Murayama, Y; Okuda, Y; Yamashita, K | 1 |
| Heller, SR; Macdonald, IA; Tattersall, RB | 1 |
| Kissebah, AH; Schectman, G | 1 |
| Buoninconti, R; D'Onofrio, F; Paolisso, G; Sgambato, S; Torella, R; Varricchio, M | 1 |
| Bell, PM; Firth, RG; Hansen, I; Marsh, HM; Rizza, RA | 1 |
| Castells, S; Rao, SP | 1 |
| Esteva de Antonio, I; Soriguer Escofet, FJ | 1 |
| Gerich, JE | 1 |
| Ahrén, B; Lundquist, I; Scherstén, B | 1 |
| Atiea, J; Hayes, TM; Luzio, S; Morris, T; Owens, DR; Ryder, RE; Vora, J | 1 |
| Karam, JH; Nolte, MS; Salamon, E; Sanz, N | 1 |
| Chen, YD; Golay, A; Jaspan, JB; Reaven, GM; Swislocki, AL | 1 |
| Balázsi, I; Nagy, K; Varsányi-Nagy, M | 1 |
| Irjala, K; Kaihola, HL; Koskinen, P; Seppälä, P; Viikari, J | 2 |
| Katsura, M | 1 |
| Holland, GC; Osei, K | 1 |
| Ceriello, A; Consoli, G; D'Onofrio, F; Giugliano, D; Quatraro, A; Torella, R | 1 |
| Perusicová, J | 1 |
| Bezwoda, WR; Bothwell, TH; Joffe, BI; Kalk, WJ; Rumbak, MJ; Seftel, HC | 1 |
| Biso, P; Buratti, P; Capelli, M; Melchionda, N; Pasquali, R; Pasqui, F; Patrono, D | 1 |
| Disilvio, L; Featherbe, D; Hawa, MI; Jackson, RA; Jaspan, JB; Kurtz, AB; Sim, BM | 1 |
| Franzen, A; Gries, FA; Hübinger, A | 1 |
| Elfving, S; Kyllästinen, M | 1 |
| Laakso, M; Pyörälä, K; Sarlund, H; Siitonen, O | 1 |
| Laakso, M; Pyörälä, K; Sarlund, H | 1 |
| Franz, MJ | 1 |
| Fyhrquist, F; Groop, LC; Groop, PH | 1 |
| Dimitriadis, GD; Gerich, JE; Pehling, GB | 1 |
| Unger, RH | 1 |
| Colman, PG; Harrison, LC; Tait, BD | 1 |
| Abadie, E; Fiet, J; Gauville, C; Passa, P; Tabuteau, F; Villette, JM | 1 |
| Beard, JC; Benedetti, TJ; Halter, JB; Johnston, CL; Porte, D; Ward, WK | 1 |
| Raskin, P | 1 |
| Habich, K; Heitz, PU; Klöppel, G; Löhr, M; Oberholzer, M | 1 |
| Cohen, MJ; Naliboff, BD; Sowers, JD | 1 |
| Casamitjana, R; Coves, MJ; Figuerola, D; Guillén, M; Peig, M; Soriano, G | 1 |
| Lohmann, D; Verlohren, HJ; Wünsch, C | 1 |
| Błasiak, M; Kokot, F; Kuska, J | 1 |
| Abe, H; Kawamori, R; Kikuchi, M; Shichiri, M; Yamasaki, Y | 1 |
| Iwamoto, Y; Kamata, I; Kuzuya, T; Matsuda, A; Sakamoto, Y | 1 |
| Groop, L; Harno, K; Nikkilä, EA; Pelkonen, R; Tolppanen, EM | 1 |
| Bowers, CY; Kosola, JW; Prosser, PR | 1 |
| Fajardo, F; Ginier, P; Levin, SR; Madan, S | 1 |
| Fyhrqvist, F; Groop, L; Groop, PH; Melander, A; Tolppanen, EM; Tötterman, KJ; Wåhlin-Boll, E | 1 |
| Billesbølle, P; Kølendorf, K; Poulsen, S; Thorsteinsson, B | 1 |
| Alcántara, A; Clemente, F; López-Delgado, MI; Luque, MA; Malaisse, WJ; Márquez, L; Morales, M; Puente, J; Valverde, I; Villanueva-Peñacarrillo, ML; Viñambres, C | 1 |
334 review(s) available for glucagon and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror.
Topics: Animals; Autocrine Communication; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Paracrine Communication | 2021 |
New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
Topics: Administration, Intranasal; Adult; Child; Critical Care; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin, Regular, Human; Powders; Sulfonylurea Compounds; Treatment Outcome | 2021 |
Pathways of Glucagon Secretion and Trafficking in the Pancreatic Alpha Cell: Novel Pathways, Proteins, and Targets for Hyperglucagonemia.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Hyperglycemia; Insulin Resistance; Signal Transduction | 2021 |
The incretin/glucagon system as a target for pharmacotherapy of obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Obesity | 2022 |
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Obesity | 2022 |
Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans | 2022 |
Physiological significance of bistable circuit design in metabolic homeostasis: role of integrated insulin-glucagon signalling network.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Homeostasis; Humans; Insulin; Insulin Resistance; Signal Transduction | 2022 |
The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice.
Topics: Atherosclerosis; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Myocardial Infarction; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The Liver-α-Cell Axis in Health and in Disease.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Hepatocytes; Humans; Insulin; Non-alcoholic Fatty Liver Disease | 2022 |
Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1.
Topics: Calcium; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Inositol 1,4,5-Trisphosphate Receptors; Lipid Metabolism; Lipids; Liver; Non-alcoholic Fatty Liver Disease | 2022 |
Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Receptors, Neurotransmitter | 2022 |
The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Topics: Alzheimer Disease; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Humans | 2023 |
Antagonistic Effect and In Vitro Activity of Dauricine on Glucagon Receptor.
Topics: Benzylisoquinolines; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; HEK293 Cells; Humans; Molecular Docking Simulation; Receptors, Glucagon; Tetrahydroisoquinolines | 2022 |
New Developments in Glucagon Treatment for Hypoglycemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemia; Insulin | 2022 |
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Incretins; Peptides; Proglucagon | 2022 |
The Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell.
Topics: Diabetes Mellitus, Type 2; Enteroendocrine Cells; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Peptide Fragments; Peptides; Secretagogues | 2022 |
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon; Humans; Hypoglycemic Agents; Male; Secretagogues | 2022 |
The past, present, and future physiology and pharmacology of glucagon.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Receptors, Glucagon | 2022 |
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease.
Topics: Amino Acids; Animals; Diabetes Mellitus, Type 2; Feedback; Glucagon; Glucose; Humans; Hyperglycemia; Lipids; Non-alcoholic Fatty Liver Disease | 2023 |
Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin | 2023 |
Glucagon, from past to present: a century of intensive research and controversies.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemia; Receptors, Glucagon | 2023 |
[Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases].
Topics: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins | 2023 |
Glucagon in type 2 diabetes: Friend or foe?
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease | 2023 |
Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Obesity; Oxyntomodulin | 2023 |
The relationship between glucose and the liver-alpha cell axis - A systematic review.
Topics: Adult; Amino Acids; Child; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Liver | 2022 |
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin; Metabolic Diseases | 2023 |
The molecular pharmacology of glucagon agonists in diabetes and obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Mice; Obesity; Receptors, Glucagon | 2023 |
The human α cell in health and disease.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin; Insulin-Secreting Cells; Islets of Langerhans | 2023 |
[Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Metabolic Syndrome; Peptides; Venoms | 2023 |
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Obesity | 2023 |
Gut hormone co-agonists for the treatment of obesity: from bench to bedside.
Topics: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Obesity; United States | 2023 |
100 years of glucagon and 100 more.
Topics: Amino Acids; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hyperglycemia; Non-alcoholic Fatty Liver Disease | 2023 |
Postprandial plasma GLP-1 levels are elevated in individuals with postprandial hypoglycaemia following Roux-en-Y gastric bypass - a systematic review.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Insulin | 2023 |
Whey Protein Premeal Lowers Postprandial Glucose Concentrations in Adults Compared with Water-The Effect of Timing, Dose, and Metabolic Status: a Systematic Review and Meta-analysis.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Postprandial Period; Water; Whey Proteins | 2023 |
The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins | 2023 |
The role of glucagon after bariatric/metabolic surgery: much more than an "anti-insulin" hormone.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Proglucagon | 2023 |
The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms.
Topics: Amino Acids; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin | 2023 |
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Receptors, Gastrointestinal Hormone | 2019 |
The role of GIP in α-cells and glucagon secretion.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Agents; Glucagon; Glucagon-Secreting Cells; Humans; Insulin-Secreting Cells; Receptors, Gastrointestinal Hormone | 2020 |
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Design; Gastric Inhibitory Polypeptide; Glucagon; Humans; Obesity; Peptide Fragments; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Structure-Activity Relationship | 2020 |
Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon.
Topics: Animals; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dogs; Glucagon; Hypoglycemia; Hypoglycemic Agents; Insulin | 2020 |
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Humans; Hypoglycemia; Insulin | 2020 |
Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Receptors, Glucagon | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Microbiome; Glucagon; Glucagon-Like Peptide 1; Humans; Obesity; Peptide YY | 2020 |
Mutual regulation of metabolic processes and proinflammatory NF-κB signaling.
Topics: Animals; Biomarkers; Carrier Proteins; Cyclic AMP; Diabetes Mellitus, Type 2; Disease Management; Disease Susceptibility; Energy Metabolism; Glucagon; Humans; I-kappa B Kinase; Inflammation; Insulin; Mitochondria; Molecular Targeted Therapy; NF-kappa B; Protein Binding; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Diet, Reducing; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Mucosa; Meals; Nutritional Physiological Phenomena; Obesity | 2020 |
Dietary protein intake and obesity-associated cardiometabolic function.
Topics: Animals; Blood Glucose; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diet, High-Protein; Diet, High-Protein Low-Carbohydrate; Dietary Proteins; Glucagon; Humans; Insulin; Non-alcoholic Fatty Liver Disease; Obesity; Triglycerides | 2020 |
CNS control of the endocrine pancreas.
Topics: Animals; Autonomic Nervous System; Blood Glucose; Central Nervous System; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Sensory Receptor Cells | 2020 |
Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice.
Topics: Administration, Intravenous; Adult; Aged; Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Middle Aged | 2021 |
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
Topics: Asia, Eastern; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Metformin | 2021 |
SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2021 |
Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucosides; Humans; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Proglucagon-Derived Peptides as Therapeutics.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Proglucagon | 2021 |
Altered islet prohormone processing: a cause or consequence of diabetes?
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Proglucagon; Proinsulin; Protein Precursors | 2022 |
Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Homeostasis; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Pancreas; Proglucagon | 2021 |
Potential for Gut Peptide-Based Therapy in Postprandial Hypotension.
Topics: Acarbose; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Agents; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypotension; Insulin; Peptides; Postprandial Period; Somatostatin; Splanchnic Circulation | 2021 |
On the role of the gut in diabetic hyperglucagonaemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptides; Glucagon-Secreting Cells; Humans; Hyperglycemia; Insulin | 2017 |
Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1.
Topics: Animals; Diabetes Mellitus, Type 2; Fasting; Gastric Emptying; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Gluconeogenesis; Glucose; Homeostasis; Humans; Hyperglycemia; Kinetics; Liver; Receptors, Glucagon; Satiation | 2017 |
cAMP signalling in insulin and glucagon secretion.
Topics: Adenylyl Cyclases; Animals; Calcium Signaling; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Exocytosis; Glucagon; Glucagon-Secreting Cells; Glucose; Guanine Nucleotide Exchange Factors; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Paracrine Communication; Phosphoric Diester Hydrolases; Second Messenger Systems | 2017 |
The role of incretin hormones and glucagon in patients with liver disease.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Intolerance; Humans; Incretins; Insulin; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2017 |
The Gut: A Key to the Pathogenesis of Type 2 Diabetes?
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Gastrointestinal Tract; Glucagon; Humans; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Intestines; Postprandial Period | 2017 |
A shared comparison of diabetes mellitus and neurodegenerative disorders.
Topics: Amyloid; Animals; Brain; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin-Secreting Cells; Kidney Glomerulus; Neurodegenerative Diseases | 2018 |
NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions.
Topics: Animals; Apoptosis; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Drug Design; Drug Resistance, Multiple; Drugs, Investigational; Glucagon; Glucagon-Secreting Cells; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Neuralgia; Receptors, N-Methyl-D-Aspartate | 2017 |
Glucagon, a key factor in the pathophysiology of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Humans; Hyperglycemia; Liver; Rodentia | 2017 |
Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Molecular Targeted Therapy; Receptors, Glucagon | 2017 |
Genetic determinants of circulating GIP and GLP-1 concentrations.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enteroendocrine Cells; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Gastrointestinal Tract; Genetic Variation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-2 Receptor; Glucose; Glucose Tolerance Test; Homeodomain Proteins; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Prospective Studies; Receptors, Gastrointestinal Hormone; RNA, Messenger; Sodium-Glucose Transporter 1 | 2017 |
Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 2; Drug Discovery; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Obesity; Peptides | 2018 |
Simultaneous Glucagon and Vasoactive Intestinal Peptide Producing Pancreatic Neuroendocrine Tumors in a Patient With Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review.
Topics: Aged; Diabetes Mellitus, Type 2; Glucagon; Humans; Male; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Treatment Outcome; Vasoactive Intestinal Peptide | 2018 |
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Insulin | 2018 |
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptides; Proteolysis | 2018 |
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Topics: Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Receptors, Gastrointestinal Hormone | 2018 |
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes.
Topics: Cholecystokinin; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Obesity; Peptides; Receptor, Cholecystokinin B | 2018 |
Glucagon receptor signaling in metabolic diseases.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemia; Hypoglycemic Agents; Obesity; Receptors, Glucagon; Signal Transduction | 2018 |
Problem or solution: The strange story of glucagon.
Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Humans; Hyperglycemia; Incretins; Insulin; Obesity; Receptors, Glucagon | 2018 |
Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Peptides | 2018 |
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Insulin; Myocardium; Oxidation-Reduction | 2018 |
Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Peptides; Postprandial Period; Treatment Outcome | 2018 |
Hemodynamic Effects of Glucagon: A Literature Review.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Glucagon; Heart; Heart Rate; Hemodynamics; Humans | 2018 |
Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
Topics: Adjuvants, Pharmaceutic; Administration, Intranasal; beta-Cyclodextrins; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Compounding; Emergency Treatment; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Phosphorylcholine; Powders; Severity of Illness Index | 2018 |
The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Topics: Cardiovascular Diseases; Cardiovascular System; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Natriuretic Peptide, Brain; Neuropeptide Y; Practice Guidelines as Topic; Proteolysis; Receptors, CXCR4 | 2018 |
EJE PRIZE 2018: A gut feeling about glucagon.
Topics: Diabetes Mellitus, Type 2; Enteroendocrine Cells; Fasting; Fatty Liver; Gastrointestinal Tract; Glucagon; Glucagon-Secreting Cells; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Liver; Proglucagon | 2018 |
[Role of Paradoxical Hypersecretion of Glucagon in the Pathogenesis of Type 2 Diabetes Mellitus].
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Resistance | 2018 |
SGLT2 inhibition and glucagon secretion in humans.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Water intake keeps type 2 diabetes away? Focus on copeptin.
Topics: Animals; Arginine Vasopressin; Biomarkers; Diabetes Mellitus, Type 2; Drinking; Glucagon; Glycopeptides; Humans; Insulin; Vasopressins | 2018 |
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide | 2018 |
The α-cell in diabetes mellitus.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Insulin-Secreting Cells; Male; Role; Sensitivity and Specificity | 2018 |
Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Postprandial Period | 2018 |
Management of hypoglycemia in older adults with type 2 diabetes.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Blood Glucose; Blood Glucose Self-Monitoring; Cardiovascular Diseases; Continuity of Patient Care; Dementia; Diabetes Complications; Diabetes Mellitus, Type 2; Glucagon; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Patient-Centered Care; Practice Guidelines as Topic; Risk Factors; Time Factors | 2019 |
The Liver-α-Cell Axis and Type 2 Diabetes.
Topics: Amino Acids; Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin; Insulin Resistance; Liver | 2019 |
Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia.
Topics: Administration, Intranasal; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemia; Risk; Treatment Outcome | 2019 |
Cell Autonomous Dysfunction and Insulin Resistance in Pancreatic α Cells.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin; Insulin Resistance; Liver | 2019 |
Type 2 diabetes and the evolving paradigm in glucose regulation.
Topics: Adipocytes; Appetite; Brain; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Humans; Insulin Resistance; Insulin-Secreting Cells; Kidney; Liver; Muscle, Skeletal; Obesity; Sodium-Glucose Transport Proteins | 2013 |
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.
Topics: Animals; Blood Glucose; Body Weight; Central Nervous System; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Leptin; Obesity | 2013 |
[Type LADA diabetes--interrogation points].
Topics: Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Disease Progression; Glucagon; Humans; Insulin; Islets of Langerhans | 2013 |
Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Hyperglycemia; Hypertension; Insulin | 2013 |
Melatonin and glucose metabolism: clinical relevance.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucose; Homeostasis; Humans; Insulin; Insulin Secretion; Melatonin; Polymorphism, Genetic; Receptors, Melatonin | 2014 |
Metformin--mode of action and clinical implications for diabetes and cancer.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Gluconeogenesis; Humans; Liver; Metformin; Signal Transduction | 2014 |
[The cutting-edge of medicine; glucagon renaissance].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin-Secreting Cells | 2013 |
Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptides; Postprandial Period; Randomized Controlled Trials as Topic | 2014 |
Energy metabolism in the liver.
Topics: Circadian Rhythm; Cytokines; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Energy Metabolism; Fatty Acids; Glucagon; Gluconeogenesis; Glucose; Human Growth Hormone; Humans; Insulin; Lipogenesis; Liver; Non-alcoholic Fatty Liver Disease; Obesity | 2014 |
Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?
Topics: Adolescent; Adult; Child; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Male; Pediatric Obesity; Randomized Controlled Trials as Topic; Receptors, Glucagon | 2014 |
Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Female; Glucagon; Glucose; Glucose Tolerance Test; Guidelines as Topic; Homeostasis; Humans; Insulin; Insulin Resistance; Male; Mice; Phenotype; Pregnancy; Pregnancy in Diabetics; Rats; Somatostatin | 2014 |
[New therapies for type 2 diabetes mellitus].
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Drugs, Investigational; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucokinase; Gluconeogenesis; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Insulin, Long-Acting; Molecular Targeted Therapy; Obesity; Phosphofructokinase-2; Sodium-Glucose Transport Proteins; Weight Loss | 2015 |
Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism.
Topics: Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Microcirculation; Muscle, Skeletal | 2014 |
Glucagon and type 2 diabetes: the return of the alpha cell.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans | 2014 |
How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Topics: Anti-Obesity Agents; Bariatric Surgery; Biological Transport; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Kidney Tubules, Proximal; Microvilli; Multicenter Studies as Topic; Obesity; Peptides; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Weight Loss | 2015 |
Glucagon--Early breakthroughs and recent discoveries.
Topics: Animals; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Glucagon; Glucose; History, 20th Century; History, 21st Century; Humans; Hypoglycemia; Protein Processing, Post-Translational | 2015 |
Islet α cells and glucagon--critical regulators of energy homeostasis.
Topics: Adipose Tissue; Blood Glucose; Brain; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Secreting Cells; Homeostasis; Hormones; Humans; Hypoglycemic Agents; Insulin; Liver; Myocardium | 2015 |
Experimental and clinical aspects of melatonin and clock genes in diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Melatonin | 2015 |
Glucagon - the new 'insulin' in the pathophysiology of diabetes.
Topics: CREB-Binding Protein; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Gluconeogenesis; Histone Acetyltransferases; Humans; Insulin; Insulin-Secreting Cells; Liver; Phosphorylation; Transcription Factors | 2015 |
Role of the clock gene Rev-erbα in metabolism and in the endocrine pancreas.
Topics: Adipocytes; Blood Glucose; Circadian Clocks; Circadian Rhythm; Diabetes Mellitus, Type 2; Feedback, Physiological; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Lipid Metabolism; Mitochondria; Muscle, Skeletal; Nuclear Receptor Subfamily 1, Group D, Member 1; Thermogenesis | 2015 |
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastric Emptying; Glucagon; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Postprandial Period; Randomized Controlled Trials as Topic | 2015 |
Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
Topics: Diabetes Mellitus, Type 2; Fasting; Gastric Emptying; Gastrointestinal Agents; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestine, Small; Liver; Postprandial Period | 2016 |
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion | 2016 |
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
Topics: Area Under Curve; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Lipids; Liraglutide; Liver Failure; Renal Insufficiency; Sex Factors | 2016 |
Glucagon therapeutics: Dawn of a new era for diabetes care.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents | 2016 |
Glucagon orchestrates stress-induced hyperglycaemia.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hyperglycemia; Stress, Physiological | 2016 |
Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemia; Insulin; Insulin Secretion; Male; Randomized Controlled Trials as Topic | 2016 |
Glucagon secretion from pancreatic α-cells.
Topics: Animals; Diabetes Mellitus, Type 2; Electrophysiology; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Hyperglycemia; Insulin; Islets of Langerhans; Mice; Models, Theoretical; Rats; Receptors, Somatostatin; Signal Transduction; Somatostatin | 2016 |
Glucagon: acute actions on hepatic metabolism.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucose; Homeostasis; Humans; Liver | 2016 |
Hormonal and Metabolite Regulation of Hepatic Glucokinase.
Topics: Adaptor Proteins, Signal Transducing; Animals; Diabetes Mellitus, Type 2; Gene Expression Regulation, Enzymologic; Glucagon; Glucokinase; Homeostasis; Humans; Liver; Models, Biological; Non-alcoholic Fatty Liver Disease; Phosphofructokinase-2; Postprandial Period; Protein Transport | 2016 |
Searching for the physiological role of glucose-dependent insulinotropic polypeptide.
Topics: Animals; Bone and Bones; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Gastric Inhibitory Polypeptide; Glucagon; Humans; Lipid Metabolism; Receptors, Gastrointestinal Hormone | 2016 |
Contribution of the distal small intestine to metabolic improvement after bariatric/metabolic surgery: Lessons from ileal transposition surgery.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Endotoxemia; Enteroendocrine Cells; Gastric Bypass; Gastrointestinal Microbiome; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Ileum; Insulin; Insulin Resistance; Insulin Secretion; Rats | 2016 |
Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy.
Topics: Animals; Blood Glucose; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Glucagon; Glucose; Homeostasis; Humans; Insulin; Islets of Langerhans; Liver; Molecular Targeted Therapy; Muscle, Skeletal; Organ Specificity; Signal Transduction | 2016 |
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
Topics: Amino Acid Sequence; Bariatric Surgery; Diabetes Mellitus, Type 2; Glucagon; Humans; Obesity; Peptides; Polypharmacy | 2016 |
Glucagon and heart in type 2 diabetes: new perspectives.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Influence of Bisphenol A on Type 2 Diabetes Mellitus.
Topics: Air Pollutants, Occupational; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin Antagonists; Male; Phenols; Plastics; Polycarboxylate Cement | 2016 |
Physiological and pathophysiological aspects of incretin hormones and glucagon.
Topics: Animals; Appetite; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Oxyntomodulin; Peptide Fragments | 2017 |
Exenatide: its position in the treatment of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptides; Venoms | 2008 |
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
An overview of incretin hormones.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Incretins; Insulin Resistance; Insulin-Secreting Cells | 2008 |
Glucotoxicity and pancreatic proteomics.
Topics: Adipose Tissue; Animals; Brain; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Islets of Langerhans; Liver; Muscles; Pancreas; Proteome | 2009 |
The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
Topics: Adipose Tissue; Body Weight; Diabetes Mellitus, Type 2; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Insulin; Insulin Secretion; Overweight; Receptors, Glucagon | 2008 |
Hypoglycaemia in Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemia | 2008 |
Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Endocrine System; Glucagon; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Mice; Pancreas; Pituitary Adenylate Cyclase-Activating Polypeptide; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Receptors, Vasoactive Intestinal Peptide, Type II | 2008 |
Glucose sensing and the pathogenesis of obesity and type 2 diabetes.
Topics: Animals; Appetite Regulation; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Fatty Acids; Glucagon; Insulin; Mice; Obesity; Pancreas; Portal System; Rats | 2008 |
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Humans; Hyperglycemia; Receptors, Glucagon | 2009 |
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucose; Humans; Islets of Langerhans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2009 |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glutaminase; Humans; Hypoglycemic Agents; Insulin; Intracellular Signaling Peptides and Proteins | 2009 |
The role of the pancreatic endocannabinoid system in glucose metabolism.
Topics: Amides; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Ethanolamines; Glucagon; Glucose; Glycerides; Homeostasis; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2009 |
Exenatide: a review from pharmacology to clinical practice.
Topics: Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Peptides; Randomized Controlled Trials as Topic; Venoms; Weight Loss | 2009 |
Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Middle Aged; Nurse Practitioners; Patient Selection; Primary Health Care | 2008 |
Pathomechanisms of type 2 diabetes genes.
Topics: Adiposity; Animals; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Glucagon; Humans; Insulin; Insulin Secretion; Polymorphism, Single Nucleotide | 2009 |
Zinc, alpha cells and glucagon secretion.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cation Transport Proteins; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Homeostasis; Humans; Potassium Channels; Rats; Zinc | 2010 |
The evolving place of incretin-based therapies in type 2 diabetes.
Topics: Adolescent; Adult; Animals; Child; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion | 2010 |
Meta-analysis and functional effects of the SLC30A8 rs13266634 polymorphism on isolated human pancreatic islets.
Topics: Arginine; Asian People; Cation Transport Proteins; Diabetes Mellitus, Type 2; Genotype; Glucagon; Glucose; Glyburide; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Polymorphism, Genetic; Risk; White People; Zinc Transporter 8 | 2010 |
Pathophysiology of type 2 diabetes: targeting islet cell dysfunction.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disease Progression; Endocrine Cells; Genetic Predisposition to Disease; Global Health; Glucagon; Glucose; Humans; Incidence; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Risk Assessment | 2010 |
The perspectives of adjunctive drugs usage in the treatment of glucose metabolism disturbances in adolescent patients.
Topics: Adipose Tissue; Adolescent; Adult; Amyloid; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Male; Receptors, Cannabinoid | 2009 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Pro-insulin, C peptide, glucagon, adiponectin, TNF alpha, AMPK: neglected players in type 2 diabetes mellitus.
Topics: Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Tumor Necrosis Factor-alpha | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Liraglutide: the therapeutic promise from animal models.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Mice; Mice, Obese; Peptides; Rats; Rats, Zucker; Receptors, Glucagon; Swine; Swine, Miniature; Venoms | 2010 |
Pathophysiology of prediabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin Resistance; Insulin-Secreting Cells; Lipids; Liver; Prediabetic State; Risk Factors | 2011 |
Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Topics: Biphenyl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucagon-Secreting Cells; Humans; Hyperglycemia; Hypoglycemic Agents; Liver; Receptors, Glucagon; Signal Transduction | 2011 |
Type 2 diabetes across generations: from pathophysiology to prevention and management.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Retinopathy; Epigenesis, Genetic; Female; Fetal Development; Genetic Predisposition to Disease; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Incretins; Insulin Resistance; Insulin-Secreting Cells; Life Style; Liver; Muscle, Skeletal; Myocardium; Obesity; Prediabetic State; Pregnancy | 2011 |
Growth factor signalling in the regulation of α-cell fate.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Mice; Mice, Knockout; Signal Transduction | 2011 |
Brain glucose sensing and neural regulation of insulin and glucagon secretion.
Topics: Autonomic Nervous System; Biological Transport; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Glucagon; Glucose Transporter Type 2; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Signal Transduction | 2011 |
Regulation of glucagon secretion by incretins.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Rats; Receptors, Glucagon | 2011 |
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?
Topics: Animals; Biological Transport; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; KATP Channels; Mice | 2011 |
Regulation of glucagon secretion by zinc: lessons from the β cell-specific Znt8 knockout mouse model.
Topics: Animals; Cation Transport Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Knockout; Zinc; Zinc Transporter 8 | 2011 |
The role of dysregulated glucagon secretion in type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Hyperglycemia; Insulin-Secreting Cells; Liver; Mice | 2011 |
Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Hypoglycemia; Insulin; Insulin-Secreting Cells; Postprandial Period | 2011 |
Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Hyperglycemia; Hypoglycemia; Insulin; Mice; Models, Biological; Rats; Somatostatin | 2012 |
Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Receptors, Glucagon | 2011 |
The alpha-cell as target for type 2 diabetes therapy.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Receptors, Glucagon | 2011 |
Insulin sensitivity and secretion modifications after bariatric surgery.
Topics: Animals; Bariatric Surgery; Body Mass Index; Diabetes Mellitus, Type 2; Gastric Mucosa; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Incretins; Insulin Resistance; Insulin-Secreting Cells; Intestinal Mucosa; Obesity, Morbid | 2012 |
Insulin resistance in type 2 diabetic youth.
Topics: Adolescent; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Exercise Tolerance; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Metformin; Obesity; Phenotype; Young Adult | 2012 |
Contrasting effects of type 2 and type 1 diabetes on plasma RBP4 levels: the significance of transthyretin.
Topics: Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon; Humans; Insulin; Pancreas; Prealbumin; Protein Multimerization; Protein Structure, Quaternary; Retinol-Binding Proteins, Plasma; Signal Transduction; Vitamin A | 2012 |
The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Treatment Outcome | 2012 |
Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Pituitary Adenylate Cyclase-Activating Polypeptide; Vasoactive Intestinal Peptide | 2013 |
Dysglycaemia in the critically ill - significance and management.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Critical Illness; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Risk Factors | 2013 |
Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Humans; Hypoglycemia; Insulin | 2002 |
Gastric inhibitory polypeptide: the neglected incretin revisited.
Topics: Adipose Tissue; Amino Acid Sequence; Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Lipids; Models, Biological; Molecular Sequence Data; Pancreatic Hormones; Peptide Fragments; Postprandial Period; Protein Precursors; Secretin; Sequence Homology, Amino Acid; Stomach | 2002 |
[Glucagon-like peptide-1 (GLP-1) receptor].
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Peptide Fragments; Peptides; Polymorphism, Genetic; Protein Precursors; Receptors, Glucagon; Venoms | 2002 |
Preclinical developments in type 2 diabetes.
Topics: Acetyl-CoA Carboxylase; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fatty Acids, Nonesterified; Glucagon; Glucagon-Like Peptide 1; I-kappa B Kinase; Insulin Resistance; Peptide Fragments; Protein Precursors; Protein Serine-Threonine Kinases | 2002 |
Glucagon receptor antagonists for the treatment of type II diabetes: current prospects.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 2; Glucagon; Humans; Molecular Sequence Data; Receptors, Glucagon | 2002 |
Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Topics: Amyloid; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Design; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Peptide Fragments; Peptides; Postprandial Period; Protein Precursors; Venoms | 2002 |
Aging and insulin secretion.
Topics: Adult; Aged; Aged, 80 and over; Aging; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Intolerance; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Middle Aged; Nutrition Surveys; Peptide Fragments | 2003 |
Insulin sensitisation in the treatment of Type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-3 Receptor Agonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hydroxysteroid Dehydrogenases; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors | 2003 |
Glucagon and regulation of glucose metabolism.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Receptors, Glucagon | 2003 |
Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Peptide Fragments; Peptides; Protease Inhibitors; Protein Precursors; Venoms | 2003 |
Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
Topics: Appetite; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2003 |
Pancreatic and extrapancreatic effects of GLP-1.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Pancreas; Peptide Fragments; Protein Precursors | 2002 |
NN-2211 Novo Nordisk.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Liraglutide; Technology, Pharmaceutical | 2003 |
Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
Topics: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Peptide Fragments; Protein Precursors; Secretory Rate; Signal Transduction | 2003 |
The glucagon-like peptides: a double-edged therapeutic sword?
Topics: Amino Acid Sequence; Animals; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2003 |
Gut peptides and type 2 diabetes mellitus treatment.
Topics: Diabetes Mellitus, Type 2; Gastric Emptying; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Peptide Fragments; Protein Precursors; Satiation | 2003 |
Enhancing incretin action for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Peptide Fragments; Protein Precursors | 2003 |
Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2003 |
Incretins and their analogues as new antidiabetic drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Therapy; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptide Fragments; Protein Precursors | 2003 |
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Topics: Amino Acid Sequence; Animals; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Molecular Sequence Data; Nutritional Physiological Phenomena; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Venoms | 2004 |
Incretins, insulin secretion and Type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 2004 |
Gut peptides in the treatment of diabetes mellitus.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Peptide Fragments; Peptide Hormones; Protease Inhibitors; Protein Precursors; Receptors, Gastrointestinal Hormone; Receptors, Glucagon | 2004 |
Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2004 |
Novel strategies for the pharmacological management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptide Fragments; Protein Precursors; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Transcription Factors | 2004 |
The potential role of glucagon-like peptide 1 in diabetes.
Topics: Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Injections, Intravenous; Injections, Subcutaneous; Insulin; Peptide Fragments; Protein Precursors | 2004 |
Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
Topics: Animals; Cell Division; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Islets of Langerhans Transplantation; Peptide Fragments; Protein Precursors | 2004 |
[Future targets in the treatment of type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Glycogen Synthase Kinase 3; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Peroxidation; Metabolic Syndrome; Mice; Oxazines; Peptide Fragments; Phenylpropionates; Protein Precursors; Rats; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors | 2004 |
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Afferent Pathways; Animals; Appetite; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Hypothalamus; Insulin; Insulin Secretion; Intestinal Mucosa; Islets of Langerhans; Liraglutide; Lizards; Maleimides; Mice; Mice, Knockout; Mice, Obese; Peptide Fragments; Peptides; Proglucagon; Protein Precursors; Rats; Rats, Zucker; Receptors, Glucagon; Venoms | 2004 |
The gastrointestinal tract and glucose tolerance.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 2004 |
[Glucagon-like peptide-1(GLP-1)].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Peptide Fragments; Protein Precursors | 2004 |
[GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Knockout; Peptide Fragments; Protein Precursors; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction | 2004 |
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Neurosecretory Systems; Peptide Fragments; Peptide Hormones; Protein Precursors | 2004 |
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Molecular Sequence Data; Peptide Fragments; Protein Precursors; Structure-Activity Relationship | 2004 |
Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success?
Topics: Acyl Coenzyme A; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Lipolysis; Obesity, Morbid; Peptide Fragments; Peptide Hormones; Peptide YY; Protein Precursors | 2004 |
Therapeutic strategies based on glucagon-like peptide 1.
Topics: Amino Acid Sequence; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Molecular Sequence Data; Peptide Fragments; Protein Precursors | 2004 |
Gut-derived incretin hormones and new therapeutic approaches.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Follow-Up Studies; Forecasting; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Peptide Fragments; Peptides; Protein Precursors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Venoms | 2004 |
[Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Peptide Fragments; Protein Precursors | 2004 |
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors; United Kingdom | 2004 |
Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
Topics: Animals; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose; Humans; Nervous System Physiological Phenomena; Peptide Fragments; Peptides; Protein Precursors | 2004 |
Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucose; Humans; Insulin; Lipid Metabolism; Peptides | 2004 |
[Oral diabetes treatment. Which substance is indicated at which time?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Germany; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Obesity; Peptide Fragments; Peptides; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome | 2004 |
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 2004 |
The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Peptide Fragments; Protein Precursors | 2004 |
Incretin mimetics as emerging treatments for type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2005 |
Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
Topics: Adenosine Triphosphate; Animals; Calcium; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Insulin; Insulin Secretion; Ion Channels; Islets of Langerhans; Peptide Fragments; Protein Precursors; Receptors, Glucagon | 2004 |
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Topics: Animals; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptide Fragments; Protein Precursors; Structure-Activity Relationship | 2004 |
Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity.
Topics: Aged; Aging; Blood Glucose; Diabetes Mellitus, Type 2; Geriatrics; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Peptide Fragments; Protein Precursors | 2005 |
Islet adaptation to insulin resistance: mechanisms and implications for intervention.
Topics: Adaptation, Physiological; Animals; Blood Glucose; Cholinergic Agonists; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds | 2005 |
Novel pharmacologic agents for type 2 diabetes.
Topics: Amyloid; Antigens, Neoplasm; Biomarkers, Tumor; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Islet Amyloid Polypeptide; Lectins, C-Type; Pancreatitis-Associated Proteins; Peptide Fragments; Polymers; Protein Precursors; Thiazolidinediones | 2005 |
Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Peptide Fragments; Protein Precursors | 2002 |
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Topics: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Neurotransmitter Agents; Peptide Fragments; Proglucagon; Protein Precursors | 2005 |
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Mice; Mice, Knockout; Pancreas; Peptide Fragments; Protein Precursors; Receptors, Gastrointestinal Hormone; Receptors, Glucagon | 2005 |
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Topics: Amino Acid Sequence; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Molecular Sequence Data; Peptide Fragments; Protein Precursors; Receptors, Glucagon | 2005 |
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2005 |
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Obesity; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2003 |
Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Male; Obesity, Morbid; Peptide Fragments; Peptide Hormones; Prognosis; Protein Precursors; Treatment Outcome; Weight Loss | 2005 |
Glucagon as a target for the treatment of Type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Receptors, Glucagon | 2005 |
Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Triglycerides | 2005 |
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Nerve Degeneration; Peptide Fragments; Protein Precursors; Risk Factors; Signal Transduction | 2005 |
[Therapeutic potential of DPP-IV inhibitor for the treatment of Type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Nitriles; Peptide Fragments; Protein Precursors; Pyrrolidines | 2005 |
Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Mice; Models, Biological; Molecular Sequence Data; Peptide Fragments; Protein Precursors; Satiation | 2005 |
Alpha cell function in health and disease: influence of glucagon-like peptide-1.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Insulin; Islets of Langerhans | 2005 |
Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Infusions, Intra-Arterial; Insulin; Insulin Secretion; Intestine, Small; Peptide Fragments; Protein Precursors | 2005 |
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestinal Diseases; Peptide Fragments; Peptides; Proglucagon; Protease Inhibitors; Protein Precursors; Receptors, Glucagon | 2005 |
Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin-Secreting Cells; Satiety Response | 2005 |
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Topics: Amyloid; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Glucagon; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Postprandial Period | 2005 |
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Tolerance Test; Humans; Molecular Sequence Data; Peptide Fragments; Protease Inhibitors | 2006 |
Glucagon: the effects of its excess and deficiency on insulin action.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Insulin | 2006 |
[Gluco-incretin hormones in insulin secretion].
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Islets of Langerhans | 2005 |
Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Protein Synthesis Inhibitors; Satiety Response | 2006 |
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Peptides; Randomized Controlled Trials as Topic; Receptors, Glucagon; Venoms | 2006 |
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
Topics: Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Type 2; Drugs, Investigational; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Venoms | 2006 |
Pramlintide: A new tool in diabetes management.
Topics: Amyloid; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Models, Biological; Pancreas | 2006 |
Exenatide: a novel approach for treatment of type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Nitriles; Peptides; Pyrrolidines; Treatment Outcome; Venoms; Vildagliptin | 2006 |
Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Topics: Animals; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pancreas; Peptides; Receptors, Glucagon; Second Messenger Systems; Venoms | 2007 |
Incretins: a new treatment option for type 2 diabetes?
Topics: Adenosine Deaminase; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Receptors, Glucagon; Satiety Response | 2007 |
The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.
Topics: Animals; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucagon-Secreting Cells; Humans; Hyperglycemia; Postprandial Period; Receptors, Glucagon | 2007 |
Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon; Humans; Hypoglycemic Agents; Metabolic Syndrome; Receptors, Glucagon; Signal Transduction | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
New hepatic targets for glycaemic control in diabetes.
Topics: Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fructose-Bisphosphatase; Glucagon; Glucokinase; Gluconeogenesis; Glucose-6-Phosphatase; Glycogen Phosphorylase; Humans; Hypoglycemic Agents; Liver | 2007 |
New treatments of diabetes: the beta-amylin agonists.
Topics: Amyloid; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eating; Glucagon; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide | 2008 |
GLP-1: physiological effects and potential therapeutic applications.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Islets of Langerhans; Receptors, Glucagon; Satiety Response; Weight Loss | 2008 |
[Peptide hormones of the digestive organs (review of the literature)].
Topics: Cholecystokinin; Diabetes Mellitus, Type 2; Digestive System Physiological Phenomena; Gastric Inhibitory Polypeptide; Gastrins; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptides; Humans; Insulin; Motilin; Neurotensin; Obesity; Pancreatic Polypeptide; Pentagastrin; Secretin; Somatostatin; Vasoactive Intestinal Peptide | 1983 |
Metabolic effects of sulfonylurea drugs. A review.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Humans; Insulin; Insulin Resistance; Insulin Secretion; Liver; Somatostatin; Sulfonylurea Compounds | 1983 |
New pharmacologic approaches to the treatment of diabetes.
Topics: Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Pyrrolidines; Somatostatin; Sulfonylurea Compounds | 1984 |
Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Feedback; Glucagon; Humans; Hyperglycemia; Hypoxia; Insulin; Insulin Secretion; Islets of Langerhans; Myocardial Infarction; Physical Exertion; Stress, Physiological; Surgical Procedures, Operative; Sympathetic Nervous System; Wounds and Injuries | 1984 |
Does adult-onset diabetes mellitus begin in childhood?: the Bogalusa Heart Study.
Topics: Adolescent; Adult; Blood Glucose; Child; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin | 1995 |
Glucose metabolism and liver cirrhosis.
Topics: Catecholamines; Chronic Disease; Diabetes Mellitus, Type 2; Fatty Acids; Glucagon; Glucose; Humans; Hyperglycemia; Hyperinsulinism; Insulin Resistance; Insulin-Like Growth Factor I; Liver Cirrhosis; Nutrition Disorders | 1995 |
The genetics of non-insulin-dependent diabetes mellitus.
Topics: Amyloid; Animals; Base Sequence; Carrier Proteins; Chromosome Mapping; Cloning, Molecular; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Glucose Transporter Type 4; Glycogen Synthase; Humans; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Molecular Sequence Data; Monosaccharide Transport Proteins; Muscle Proteins; Neoplasm Proteins; Peptide Fragments; Protein Precursors; Receptor, Insulin; Selection, Genetic; Tumor Suppressor Proteins | 1995 |
[Insulin resistance: role in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Fatty Acids; Glucagon; Glucose; Humans; Insulin Resistance; Liver; Muscle, Skeletal; Oxidation-Reduction | 1994 |
[GLP-1 and the control of insulin secretion].
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors; Signal Transduction; Structure-Activity Relationship | 1994 |
Hormonal responses and future treatment of non-insulin-dependent diabetes mellitus (NIDDM).
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Resistance; Insulin Secretion; Pancreatic Hormones; Prediabetic State; Somatostatin | 1993 |
["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
Topics: Animals; B-Lymphocytes; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors; Rats; Receptors, Cell Surface; Receptors, Glucagon | 1994 |
The incretin notion and its relevance to diabetes.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Molecular Sequence Data; Peptide Fragments; Protein Precursors | 1993 |
[Dysfunction of the pancreatic beta cells observed in non-insulin-dependent diabetes].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Insulin Secretion; Islets of Langerhans; Monosaccharide Transport Proteins; Peptide Fragments; Protein Precursors | 1993 |
Glucose metabolism during physical exercise in patients with noninsulin-dependent (type II) diabetes.
Topics: Blood Glucose; Catecholamines; Diabetes Mellitus, Type 2; Exercise; Glucagon; Glucose; Hormones; Humans; Insulin | 1993 |
Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
Topics: Animals; Cloning, Molecular; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Peptide Fragments; Peptides; Protein Precursors; Signal Transduction | 1993 |
[Biochemical bases of abnormalities of glucose metabolism in non-insulin-dependent diabetes].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Models, Biological; Muscles; Protein-Tyrosine Kinases; Receptor, Insulin | 1993 |
[Role of C-peptide determination in the diagnosis of diabetes mellitus].
Topics: C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Prognosis; Radioimmunoassay | 1993 |
Glucagon-like peptide-1 and control of insulin secretion.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors; Receptors, Glucagon; Secretory Rate; Signal Transduction | 1995 |
The metabolic role of GIP: physiology and pathology.
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Diet; Digestive System Physiological Phenomena; Energy Metabolism; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Mice; Mice, Inbred NOD; Models, Biological; Obesity; Organ Specificity; Peptide Fragments; Protein Precursors; Rats; Rats, Zucker; Receptors, Gastrointestinal Hormone; Receptors, Glucagon | 1996 |
The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals.
Topics: Animals; Aspartic Acid Endopeptidases; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Islets of Langerhans; Obesity; Organ Specificity; Proinsulin; Proprotein Convertase 2; Proprotein Convertases; Subtilisins | 1996 |
Nutrient-induced secretion and metabolic effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
Topics: Adaptation, Physiological; Adipose Tissue; Animals; Coronary Disease; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Obesity; Peptide Fragments | 1996 |
Amylin, amyloid and age-related disease.
Topics: Amyloid; Diabetes Mellitus, Type 2; Glucagon; Humans; Islet Amyloid Polypeptide | 1996 |
Modulation of gastric emptying as a therapeutic approach to glycaemic control.
Topics: Amino Acid Sequence; Amyloid; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Humans; Hyperglycemia; Islet Amyloid Polypeptide; Molecular Sequence Data; Postprandial Period; Rats | 1996 |
Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Infusions, Intravenous; Injections, Subcutaneous; Peptide Fragments; Postprandial Period; Protein Precursors | 1996 |
GLP-1 in NIDDM.
Topics: Animals; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestine, Small; Islets of Langerhans; Pancreas; Peptide Fragments; Protein Precursors | 1996 |
Regulation, perturbation, and correction of metabolic events in pancreatic islets.
Topics: Adenosine; Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Glycerolphosphate Dehydrogenase; Hexoses; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mitochondria; Oxidative Phosphorylation; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds | 1996 |
Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Design; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Peptide Fragments; Protein Precursors | 1996 |
[The pathogenesis of NIDDM: genetic defects and environmental factors].
Topics: Diabetes Mellitus, Type 2; Diet; DNA, Mitochondrial; Exercise; Glucagon; Glucokinase; Glycogen Synthase; Humans; Insulin; Mutation; Obesity; Receptor, Insulin; Receptors, Adrenergic, beta; Stress, Physiological | 1996 |
New treatments for patients with type 2 diabetes mellitus.
Topics: Amyloid; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islet Amyloid Polypeptide; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds | 1996 |
Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
Topics: Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion | 1996 |
[Glucagon-like peptide-1 (GLP-1) receptor gene].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Peptide Fragments; Protein Precursors; Receptors, Glucagon | 1997 |
Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Topics: Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Peptide Fragments; Protein Precursors; Receptors, Glucagon | 1997 |
[Leanness and diabetes mellitus].
Topics: Biomarkers; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Nutritional Status; Protein Precursors; Thinness | 1997 |
Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.
Topics: Animals; Calcium; Diabetes Mellitus, Type 2; Exocytosis; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Ion Channels; Islets of Langerhans; Pancreatic Hormones; Peptide Fragments; Protein Precursors; Receptors, Glucagon | 1998 |
Glucagon-like peptides.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Humans; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon | 1998 |
Dietary interventions in noninsulin-dependent diabetes mellitus: new approaches.
Topics: Cholecystokinin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 1998 |
[GLP-1 (7-36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Peptide Fragments | 1998 |
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Peptide Fragments; Peptides; Protease Inhibitors; Protein Precursors | 1998 |
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
Topics: Animals; Cerebral Ventricles; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Feeding Behavior; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Models, Biological; Peptide Fragments; Proinsulin; Protein Precursors | 1998 |
[Physiopathological fundamentals of type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Humans; Insulin; Insulin Resistance; Obesity | 1999 |
On the treatment of diabetes mellitus with glucagon-like peptide-1.
Topics: Administration, Oral; Animals; Appetite Depressants; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptide Fragments; Protein Precursors | 1998 |
Is glucagon-like peptide 1 an incretin hormone?
Topics: Animals; Diabetes Mellitus, Type 2; Digestion; Gastric Emptying; Gastrointestinal Hormones; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 1999 |
The role of insulin and other hormones in the regulation of amino acid and protein metabolism in humans.
Topics: Amino Acids; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Gonadal Steroid Hormones; Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin-Like Growth Factor I; Male; Muscle, Skeletal; Proteins; Receptor, IGF Type 1; Thyroid Hormones | 1998 |
Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Genetic Engineering; Glucagon; Glucagon-Like Peptide 1; Humans; Membranes, Artificial; Mice; Mutation; Peptide Fragments; Protein Precursors | 1999 |
Ileal [correction of ilial] transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery.
Topics: Animals; Biliopancreatic Diversion; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Ileum; Obesity, Morbid; Peptide Fragments; Protein Precursors; Rats | 1999 |
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Piperidines; Protein Precursors; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Present and potential future use of gene therapy for the treatment of non-insulin dependent diabetes mellitus (Review).
Topics: Adult; Animals; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Cell Transplantation; Diabetes Mellitus, Type 2; Gene Expression Regulation; Genes, Synthetic; Genetic Therapy; Genetic Vectors; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Glucose Transporter Type 2; Homeodomain Proteins; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Lectins, C-Type; Mice; Middle Aged; Monosaccharide Transport Proteins; Muscle Contraction; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pancreatitis-Associated Proteins; Peptide Fragments; Promoter Regions, Genetic; Protein Precursors; Proteins; Rats; Trans-Activators | 1999 |
[Hepatogenic diabetes--the current concepts of its pathophysiology and therapy].
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Diseases; Peptide Fragments; Receptor, Insulin | 1999 |
Research advances in the treatment of type 2 diabetes mellitus.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptide Fragments; Protein Kinase C; Protein Precursors; Research; Thiazoles; Thiazolidinediones | 1999 |
New approaches in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Liver; Molecular Structure; Peptide Fragments; Protein Precursors; Protein Tyrosine Phosphatases; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Receptors, Glucagon; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Topics: Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Peptide Fragments; Protein Precursors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Glucagon-like peptide-1.
Topics: Age Factors; Aged; Aging; Animals; Cell Line; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Glucose Transporter Type 2; Homeodomain Proteins; Humans; Insulin; Islets of Langerhans; Models, Biological; Monosaccharide Transport Proteins; Peptide Fragments; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Time Factors; Trans-Activators; Up-Regulation | 2001 |
The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Intestines; Islets of Langerhans; Peptide Fragments; Protein Precursors | 2001 |
Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Delivery Systems; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Peptide Fragments; Peptides; Protein Precursors; Receptors, Glucagon; Technology, Pharmaceutical; Venoms | 2001 |
Incretin hormones--an update.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Humans; Insulin; Insulin Secretion; Intestinal Mucosa; Peptide Fragments; Protein Precursors | 2001 |
Glucose tolerance, glucose utilization and insulin secretion in ageing.
Topics: Aging; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Tolerance Test; Humans; Insulin; Islets of Langerhans; Liver; Peptide Fragments | 2002 |
Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Brief Psychiatric Rating Scale; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Hydrocortisone; Insulin; Male; Obesity; Schizophrenia | 2002 |
The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Administration Routes; Gastric Emptying; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Intestine, Small; Islets of Langerhans; Peptide Fragments; Protein Precursors; Rats; Receptors, Glucagon; Satiety Response; Signal Transduction | 2002 |
Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".
Topics: Adolescent; Adult; Black People; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Food; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Puberty | 2002 |
Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; History, 20th Century; History, 21st Century; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2002 |
[A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptide Fragments; Protein Precursors | 2002 |
[Postprandial hyperglycemia. II. Pharmacological approaches].
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Enzyme Inhibitors; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Intestinal Absorption; Postprandial Period | 2002 |
Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 2002 |
Entero-insular axis and diabetes mellitus.
Topics: Animals; Cholecystokinin; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Intestines; Islets of Langerhans; Peptide Fragments | 1992 |
[Various molecular mechanisms involved in the pathogenesis of type II diabetes and their potential therapeutic importance].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Monosaccharide Transport Proteins; Peptide Fragments; Protein Precursors; RNA, Messenger; Transcription, Genetic | 1992 |
Octreotide and diabetes: theoretical and experimental aspects.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Octreotide; Vascular Diseases | 1992 |
New pharmacological approaches to therapy of NIDDM.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Feedback; Glucagon; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion | 1992 |
[Regulation of glucose metabolism during exercise and after exercise in normal and diabetic subjects].
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Glucagon; Glucose; Glycogen; Hormones; Humans; Insulin; Muscles; Time Factors | 1990 |
Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Arginine; Blood Glucose; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Synergism; Glucagon; Glucose; Glucose Tolerance Test; Histocytochemistry; Humans; Immunologic Techniques; In Vitro Techniques; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pancreatectomy; Rats; Rats, Inbred Strains | 1986 |
[Pulsatory secretion of pancreatic hormones].
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Secretion; Time Factors | 1989 |
Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Glucose; Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemia; Insulin; Islets of Langerhans; Liver; Neurotransmitter Agents | 1985 |
Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver.
Topics: Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Feedback; Glucagon; Gluconeogenesis; Glucose; Glycogen; Homeostasis; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Liver; Somatostatin; Sulfonylurea Compounds | 1985 |
Intra-islet insulin-glucagon-somatostatin relationships.
Topics: Animals; Autonomic Nervous System; Cell Communication; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Intercellular Junctions; Islets of Langerhans; Pancreatic Polypeptide; Rats; Somatostatin | 1986 |
Purified islet cells in diabetes research.
Topics: Alloxan; Animals; Antigens, Surface; Cell Separation; Cells, Cultured; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Flavin-Adenine Dinucleotide; Flow Cytometry; Glucagon; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; NADP; Somatostatin; Streptozocin | 1986 |
Non-beta-cell islet abnormalities in noninsulin-dependent diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucagon; Hormones; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Pancreatic Polypeptide; Reference Values | 1988 |
Hormones and lipoprotein metabolism.
Topics: Catecholamines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucocorticoids; Gonadal Steroid Hormones; Growth Hormone; Hormones; Humans; Hyperinsulinism; Insulin; Lipoproteins; Menopause; Obesity; Thyroxine | 1987 |
Insulin-dependent diabetes mellitus: pathophysiology.
Topics: Autoimmune Diseases; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Diagnosis, Differential; Glucagon; Humans; Insulin; Insulin Resistance | 1986 |
Islet-cell abnormalities in non-insulin-dependent diabetes mellitus.
Topics: Alanine; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Proteins; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans | 1985 |
Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Islets of Langerhans | 1985 |
326 trial(s) available for glucagon and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes.
Topics: Adult; Aged; Biphenyl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Postprandial Period; Receptors, Glucagon | 2022 |
Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients.
Topics: Area Under Curve; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Male; Meals; Middle Aged; Nutrients; Time Factors | 2022 |
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin | 2021 |
Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Insulin; Lipid Metabolism; Male | 2022 |
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulins; Islets of Langerhans; Treatment Outcome | 2022 |
A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Peptides; Receptors, Glucagon; Recombinant Fusion Proteins | 2022 |
Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients: A Prospective Cohort Study.
Topics: Adipokines; Adolescent; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Gastric Bypass; Gastrointestinal Hormones; Glucagon; Glycated Hemoglobin; Humans; Insulin; Liver Diseases; Middle Aged; Obesity, Morbid; Prospective Studies; Sirtuin 1; Young Adult | 2022 |
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Topics: Biphenyl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Incretins; Insulin; Receptors, Glucagon | 2022 |
MicroRNA Changes Up to 24 h following Induced Hypoglycemia in Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Gene Expression Profiling; Glucagon; Humans; MicroRNAs; Prospective Studies | 2022 |
Beneficial effects of premeal almond load on glucose profile on oral glucose tolerance and continuous glucose monitoring: randomized crossover trials in Asian Indians with prediabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Postprandial Period; Prediabetic State; Prunus dulcis | 2023 |
Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Glucagon; Glucose; Humans; Hypoglycemic Agents; Liraglutide; Weight Loss | 2023 |
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glucagon; Humans; Hypertension; Hypoglycemic Agents; Morbidity; Obesity; Overweight; Weight Loss | 2023 |
The entero-endocrine response following a mixed-meal tolerance test with a non-nutritive pre-load in participants with pre-diabetes and type 2 diabetes: A crossover randomized controlled trial proof of concept study.
Topics: Child, Preschool; Diabetes Mellitus, Type 2; Excipients; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Humans; Non-Nutritive Sweeteners; Prediabetic State; Proof of Concept Study | 2023 |
Changes in Bone Mineral Density in Patients with Type 2 Diabetes After Different Bariatric Surgery Procedures and the Role of Gastrointestinal Hormones.
Topics: Adult; Bariatric Surgery; Bone and Bones; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Female; Femur Neck; Follow-Up Studies; Gastrointestinal Hormones; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Obesity, Morbid; Treatment Outcome | 2020 |
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Male; Middle Aged; Obesity; Overweight; Peptides; Prognosis; Receptors, Glucagon | 2020 |
Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Male; Mass Spectrometry; Metformin; Middle Aged; Prospective Studies; Pyrimidines; Young Adult | 2019 |
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Meals; Peptides; Postprandial Period | 2020 |
Postprandial Lipemia Modulates Pancreatic Alpha-Cell Function in the Prediction of Type 2 Diabetes Development: The CORDIOPREV Study.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucagon; Glucagon-Secreting Cells; Humans; Hyperlipidemias; Lipid Metabolism; Male; Middle Aged; Postprandial Period; Prospective Studies; Triglycerides | 2020 |
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
Topics: Adult; Aged; Appetite; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Energy Intake; Energy Metabolism; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged | 2020 |
Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male | 2020 |
Late-night-dinner deteriorates postprandial glucose and insulin whereas consuming dinner dividedly ameliorates them in patients with type 2 diabetes: A randomized crossover clinical trial.
Topics: Aged; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Japan; Male; Meals; Middle Aged; Postprandial Period | 2020 |
Effect of short-term intensive insulin therapy on α-cell function in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Aged; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Placebos; Postprandial Period; Time Factors | 2020 |
Topics: Adipose Tissue, White; Adult; Aged; Air Pollutants; Animals; Anti-Inflammatory Agents; Arginine; bcl-2-Associated X Protein; Biofuels; Biological Products; Blood Glucose; Breast Neoplasms; Caspases; CD36 Antigens; Cell Communication; Cell Proliferation; Cell Survival; Cooking; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diphtheria Toxin; Double-Blind Method; Exenatide; Extracellular Polymeric Substance Matrix; Feasibility Studies; Female; Filgrastim; Fruit; Galactose; Gene Deletion; Gene Knockdown Techniques; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glycated Hemoglobin; Hematopoietic Stem Cell Mobilization; Household Articles; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Lung; Lymphoma; Male; Metals, Heavy; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Nanoparticles; Neoplasms; Obesity; Obstetrics; Odds Ratio; Oxygen; Peripheral Blood Stem Cell Transplantation; Photochemotherapy; Plant Extracts; Polyethylene Glycols; Polyglutamic Acid; Porosity; Postprandial Period; Prospective Studies; Quality of Life; Receptors, Glucagon; Receptors, LDL; Receptors, Somatostatin; Registries; Rhodophyta; Rhodotorula; Risk Factors; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Signal Transduction; Somatostatin; Stilbenes; Terminalia; Treatment Outcome; United States; Venoms | 2021 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
Effects of intragastric administration of L-tryptophan on the glycaemic response to a nutrient drink in men with type 2 diabetes - impacts on gastric emptying, glucoregulatory hormones and glucose absorption.
Topics: 3-O-Methylglucose; Aged; Beverages; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Routes; Gastric Emptying; Glucagon; Glucose; Humans; Insulin; Intestinal Absorption; Male; Middle Aged; Nutrients; Obesity; Postprandial Period; Tryptophan | 2021 |
β-Lactoglobulin Elevates Insulin and Glucagon Concentrations Compared with Whey Protein-A Randomized Double-Blinded Crossover Trial in Patients with Type Two Diabetes Mellitus.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Humans; Insulin; Lactoglobulins; Male; Middle Aged; Postprandial Period; Whey Proteins | 2021 |
Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects.
Topics: Blood Glucose; Denmark; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Healthy Volunteers; Humans; Male; Middle Aged; Treatment Outcome | 2021 |
Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes.
Topics: Adult; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diagnostic Techniques, Endocrine; Eating; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin-Secreting Cells; Male; Meals; Stimulation, Chemical | 2017 |
Glucose metabolism during rotational shift-work in healthcare workers.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Health Personnel; Humans; Insulin; Male; Postprandial Period; Shift Work Schedule; Young Adult | 2017 |
Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome | 2017 |
Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
Topics: Adamantane; Aged; Blood Glucose; C-Peptide; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Placebo Effect; Treatment Outcome | 2017 |
Pre-Meal Effect of Whey Proteins on Metabolic Parameters in Subjects with and without Type 2 Diabetes: A Randomized, Crossover Trial.
Topics: Acetaminophen; Aged; Apolipoprotein B-48; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet; Fatty Acids, Nonesterified; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Male; Meals; Middle Aged; Postprandial Period; Triglycerides; Whey Proteins | 2018 |
Zinc Supplementation Does Not Affect Glucagon Response to Intravenous Glucose and Insulin Infusion in Patients with Well-Controlled Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Dietary Supplements; Female; Glucagon; Glucose; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Zinc | 2018 |
Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.
Topics: Aged; Area Under Curve; Bile Acids and Salts; Blood Glucose; C-Peptide; Chelating Agents; Cholecystokinin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism; Female; Fibroblast Growth Factors; Gastric Emptying; Gastric Inhibitory Polypeptide; Gastrointestinal Microbiome; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; RNA, Ribosomal, 16S; Sequestering Agents; Sevelamer; Triglycerides | 2018 |
Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers.
Topics: Adult; Autonomic Nervous System; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Gastrointestinal Tract; Glucagon; Humans; Male; Middle Aged; Postprandial Period; Receptors, Nicotinic; Smoking | 2018 |
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aging; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Meals; Metformin; Risk; Sitagliptin Phosphate; Sweden | 2018 |
Rate of appearance of amino acids after a meal regulates insulin and glucagon secretion in patients with type 2 diabetes: a randomized clinical trial.
Topics: Aged; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Protein; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged | 2018 |
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2019 |
Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazoles; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2019 |
Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet, Mediterranean; Disease-Free Survival; Female; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Prediabetic State | 2018 |
A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial.
Topics: Aged; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Intake; Female; Galactans; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Mannans; Metformin; Middle Aged; Plant Gums; Postprandial Period; Single-Blind Method; Whey Proteins | 2019 |
Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Middle Aged; Prediabetic State; Severity of Illness Index; Young Adult | 2019 |
Impaired early-phase suppression of glucagon secretion after glucose load is associated with insulin requirement during pregnancy in gestational diabetes.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Pregnancy; Prognosis; Prospective Studies | 2020 |
Early postprandial glucagon surge affects postprandial glucose levels in obese and non-obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Meals; Middle Aged; Obesity; Postprandial Period; Up-Regulation | 2013 |
A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Colon; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Ileum; Insulin; Lauric Acids; Male; Metformin; Middle Aged; Tablets, Enteric-Coated; Time Factors | 2013 |
Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glutamine; Healthy Volunteers; Humans; Incretins; Insulin; Insulin Secretion; Male | 2013 |
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Gastric Emptying; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period | 2013 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Metformin; Middle Aged; Peptides; Postprandial Period; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Topics: Adult; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Missouri; Neurotensin; Postprandial Period; Receptors, Neurotensin; Time Factors; Treatment Outcome | 2014 |
Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hyperglycemia; Hypoglycemia; Insulin; Insulin Secretion; Male; Middle Aged | 2014 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Insulin Secretion; Male; Peptides; Postprandial Period; Treatment Outcome | 2014 |
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Topics: Adamantane; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes.
Topics: Administration, Intranasal; Aged; Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Prospective Studies | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.
Topics: Aged; Blood Glucose; Chromatography, Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Glucagon; Glucose Clamp Technique; Glycemic Index; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Middle Aged; Tandem Mass Spectrometry | 2014 |
Estimated proinsulin processing activity of prohormone convertase (PC) 1/3 rather than PC2 is decreased in pancreatic β-cells of type 2 diabetic patients.
Topics: Administration, Intravenous; Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin-Secreting Cells; Middle Aged; Proinsulin; Proprotein Convertase 1; Proprotein Convertase 2; Protein Processing, Post-Translational; Statistics as Topic | 2014 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study.
Topics: Adult; Aged; Blood Glucose; Breakfast; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Reducing; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Lunch; Male; Meals; Middle Aged; Treatment Outcome | 2014 |
Impaired incretin secretion and pancreatic dysfunction with older age and diabetes.
Topics: Adiponectin; Adipose Tissue; Adult; Aged; Aging; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Pancreas; Postprandial Period; Up-Regulation | 2014 |
The acute effects of interval- Vs continuous-walking exercise on glycemic control in subjects with type 2 diabetes: a crossover, controlled study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Exercise; Female; Glucagon; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Oxygen Consumption; Walking | 2014 |
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Topics: Azetidines; Blood Glucose; Body Mass Index; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Activators; Fasting; Female; Glucagon; Glucokinase; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period | 2014 |
Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Topics: Adult; Aged; Area Under Curve; Bile; Biomarkers; Blood Glucose; C-Peptide; Case-Control Studies; Cholecystokinin; Denmark; Diabetes Mellitus, Type 2; Dietary Fats; Female; Gallbladder Emptying; Gastric Emptying; Gastric Inhibitory Polypeptide; Gastrins; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged; Postprandial Period; Receptors, G-Protein-Coupled | 2014 |
Comparison of the effects of slowly and rapidly absorbed carbohydrates on postprandial glucose metabolism in type 2 diabetes mellitus patients: a randomized trial.
Topics: Blood Glucose; C-Peptide; Carbohydrate Metabolism; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Isomaltose; Male; Middle Aged; Postprandial Period; Sucrose | 2014 |
Glucose counterregulation in advanced type 2 diabetes: effect of β-adrenergic blockade.
Topics: Adrenergic beta-Antagonists; C-Peptide; Case-Control Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Single-Blind Method | 2014 |
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Female; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Models, Biological; Receptors, Glucagon | 2014 |
First proof of pharmacology in humans of a novel glucagon receptor antisense drug.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Glucagon; Healthy Volunteers; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Liver; Male; Middle Aged; Netherlands; Phosphorothioate Oligonucleotides; Receptors, Glucagon; Young Adult | 2015 |
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Food; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Topics: Acetylcholine; Aged; Blood Glucose; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Lipids; Liraglutide; Male; Middle Aged; Nitroprusside; Plethysmography | 2014 |
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Pancreas; Recombinant Proteins; Up-Regulation | 2015 |
Sucralose enhances GLP-1 release and lowers blood glucose in the presence of carbohydrate in healthy subjects but not in patients with type 2 diabetes.
Topics: Adult; Area Under Curve; Aspartame; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Healthy Volunteers; Humans; Insulin; Male; Middle Aged; Sucrose; Sweetening Agents | 2015 |
Genotype-based treatment of type 2 diabetes with an α2A-adrenergic receptor antagonist.
Topics: Adrenergic alpha-2 Receptor Antagonists; Aged; Alleles; Blood Pressure; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gene Expression; Genetic Variation; Genotype; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Norepinephrine; Receptors, Adrenergic, alpha-2; Translational Research, Biomedical; Yohimbine | 2014 |
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2015 |
Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; China; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Male; Middle Aged; Postprandial Period; Predictive Value of Tests; Time Factors; Young Adult | 2015 |
Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Food; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2014 |
Comparison of a carbohydrate-free diet vs. fasting on plasma glucose, insulin and glucagon in type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Caloric Restriction; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Diet, Reducing; Fasting; Glucagon; Hospitals, Veterans; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Weight Loss | 2015 |
The effect of metformin on glucose homeostasis during moderate exercise.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Glucagon; Homeostasis; Hormones; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2015 |
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
Topics: Adult; Aged; Biphenyl Compounds; Cohort Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Half-Life; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Molecular Targeted Therapy; Receptors, Glucagon; Risk; Single-Blind Method | 2015 |
Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucose Clamp Technique; Hepatobiliary Elimination; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Triazines | 2015 |
A high-protein breakfast induces greater insulin and glucose-dependent insulinotropic peptide responses to a subsequent lunch meal in individuals with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Breakfast; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet; Diet Records; Dietary Carbohydrates; Dietary Proteins; Energy Intake; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Lunch; Male; Middle Aged; Postprandial Period; Single-Blind Method; Young Adult | 2015 |
Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass.
Topics: Adiponectin; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Obesity; Treatment Outcome; Weight Loss | 2015 |
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Male; Middle Aged; Postprandial Period | 2015 |
Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Detemir; Insulin, Long-Acting; Insulin, Regular, Human; Male; Middle Aged; Pancreatic Diseases; Up-Regulation | 2015 |
Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Limosilactobacillus reuteri; Male; Middle Aged; Obesity; Oxidative Stress; Pilot Projects; Probiotics; Prospective Studies; Protein Precursors | 2015 |
Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Breakfast; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Lunch; Male; Meals; Middle Aged; Postprandial Period | 2015 |
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Treatment Outcome | 2015 |
Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Topics: Academic Dissertations as Topic; Adult; Blood Glucose; Cross-Over Studies; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Islets of Langerhans; Male; Postprandial Period | 2015 |
Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Peptides | 2016 |
Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Topics: Adult; Aged; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Japan; Male; Meals; Middle Aged; Postprandial Period | 2016 |
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Topics: Adult; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Incretins; Insulin; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2016 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Fiber; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Intestinal Mucosa; Male; Middle Aged; ROC Curve | 2016 |
Impact of protein-rich meals on glycaemic response of rice.
Topics: Adult; Amino Acids; Animals; Blood Glucose; Chickens; China; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Proteins; Egg White; Fishes; Glucagon; Humans; Insulin; Kinetics; Male; Meals; Oryza; Postprandial Period; Risk Factors; Soy Foods | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2016 |
GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Incretins; Infusions, Intravenous; Insulin; Insulin Secretion; Kidney Transplantation; Male; Middle Aged; Proinsulin | 2016 |
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
Topics: Adipose Tissue; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Liraglutide; Magnetic Resonance Imaging; Male; Middle Aged | 2016 |
Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Alanine Transaminase; Amino Acids; Aspartate Aminotransferases; beta-Alanine; Blood Glucose; C-Peptide; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazoles; Receptors, Glucagon; Sulfonylurea Compounds | 2016 |
Exercise-Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes.
Topics: Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Exercise; Fibroblast Growth Factors; Follistatin; Glucagon; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Male; Pancreas; Young Adult | 2016 |
Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Humans; Insulin; Leptin; Male; Middle Aged | 2016 |
Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Neuropeptide Y; Neurotensin; Pancreatic Polypeptide | 2016 |
Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
Topics: Administration, Oral; Adult; Bethanechol; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Hormones; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Muscarinic Agonists; Neurotensin; Non-Randomized Controlled Trials as Topic; Pancreatic Polypeptide; Postprandial Period | 2016 |
Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism.
Topics: Adult; Bariatric Surgery; Blood Glucose; Device Removal; Diabetes Mellitus, Type 2; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hormones; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Male; Middle Aged; Obesity, Morbid; Prosthesis Implantation | 2017 |
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Calorimetry, Indirect; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Glucagon; Glucosides; Humans; Insulin; Insulin Resistance; Ketones; Lipid Metabolism; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2016 |
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Epinephrine; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Japan; Linagliptin; Liraglutide; Male; Middle Aged; Norepinephrine | 2017 |
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Blood Glucose; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endotoxemia; Endotoxins; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Male; Middle Aged; Piperidones; Postprandial Period; Pyrimidines; RNA, Messenger; Subcutaneous Fat, Abdominal; Transcriptome; Triglycerides; Tumor Necrosis Factor-alpha | 2017 |
Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
Topics: Adult; Area Under Curve; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucagon-Like Peptides; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Infusions, Intravenous; Injections, Subcutaneous; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome | 2017 |
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome | 2017 |
Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
Topics: Abdominal Fat; Adult; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Pioglitazone; Postprandial Period; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms | 2008 |
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Topics: Adamantane; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Digestion; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Satiety Response; Vildagliptin | 2009 |
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Topics: Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Exenatide; Female; Glucagon; Half-Life; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Japan; Male; Middle Aged; Nausea; Peptides; Single-Blind Method; Time Factors; Treatment Outcome; Venoms; Vomiting | 2008 |
KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Infusion Pumps; Insulin; Insulin Resistance; Ion Channel Gating; KATP Channels; Male; Middle Aged; Sulfonylurea Compounds | 2009 |
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glutamine; Humans; Insulin; Insulin Secretion; Male; Obesity; Thinness | 2009 |
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Cross-Over Studies; Cyclic AMP; Diabetes Mellitus, Type 2; Diet, Diabetic; Glucagon; Glutaminase; Humans; Hyperglycemia; Hypoglycemic Agents; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Metformin; Placebos; Postprandial Period; Sulfonylurea Compounds | 2009 |
Administration of a new diabetes-specific enteral formula results in an improved 24h glucose profile in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enteral Nutrition; Female; Glucagon; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Insulin; Male; Monitoring, Ambulatory; Nutritive Value; Postprandial Period; Reproducibility of Results; Sensitivity and Specificity | 2009 |
Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Topics: Adolescent; Area Under Curve; Blood Glucose; Child; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Peptides; Postprandial Period; Single-Blind Method; Venoms | 2009 |
Acute effects of casein on postprandial lipemia and incretin responses in type 2 diabetic subjects.
Topics: Aged; Biomarkers; Blood Glucose; Caseins; Chylomicrons; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Diterpenes; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Postprandial Period; Retinyl Esters; Time Factors; Triglycerides; Vitamin A | 2010 |
[Effects of glucagon on plasma ghrelin level in type 2 diabetes mellitus].
Topics: Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Ghrelin; Glucagon; Humans; Male; Middle Aged | 2009 |
Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Body Composition; C-Peptide; Calorimetry, Indirect; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet; Dinoprost; Double-Blind Method; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Female; Glucagon; Glucose Clamp Technique; Humans; Infusions, Intravenous; Insulin; Insulin Resistance; Isoprostanes; Male; Middle Aged; Oxidative Stress | 2009 |
Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Infusions, Intravenous; Insulin; Male; Middle Aged | 2009 |
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2010 |
Dose-response effects of insulin glargine in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged | 2010 |
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Male; Middle Aged; Pancreatitis, Chronic | 2010 |
Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes.
Topics: Administration, Inhalation; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Delivery Systems; Energy Intake; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments | 2010 |
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged | 2010 |
Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Prospective Studies; Treatment Outcome; Weight Loss | 2011 |
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Insulin; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Hydrolyzed casein decreases postprandial glucose concentrations in T2DM patients irrespective of leucine content.
Topics: Aged; Analysis of Variance; Blood Glucose; Caseins; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Leucine; Male; Middle Aged; Postprandial Period; Protein Hydrolysates | 2011 |
Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Neurotensin | 2012 |
Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.
Topics: Adult; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hyperglycemia; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Obesity; Obesity, Morbid; Postprandial Period; Time Factors | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Clamp Technique; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Peptide Fragments; Receptors, Glucagon | 2012 |
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Blood Glucose; Body Weight; C-Peptide; Cyclopropanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycated Hemoglobin; Glycerol; Homeostasis; Humans; Insulin; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sample Size | 2012 |
Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucagon; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged | 2012 |
Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Clamp Technique; Humans; Hyperglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Pancreatic Hormones | 2012 |
The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; C-Peptide; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Postprandial Period | 2013 |
Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Activators; Female; Glucagon; Glucokinase; Glucose; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Models, Biological; Research Design | 2013 |
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Activators; Female; Glucagon; Glucokinase; Glucose; Humans; Insulin; Liver; Male; Middle Aged | 2013 |
Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine.
Topics: Adult; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Glucagon; Glucagon-Secreting Cells; Glucose; Glycine; Humans; Insulin-Secreting Cells; Male; Middle Aged; Receptors, GABA; Receptors, Glycine; Sodium Oxybate | 2013 |
Fibroblast growth factor 21 mediates specific glucagon actions.
Topics: Adult; Animals; Anti-Obesity Agents; Cells, Cultured; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibroblast Growth Factors; Glucagon; HEK293 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Knockout; Mice, Mutant Strains; Molecular Targeted Therapy; Obesity; Peptides; Rats; Receptors, Glucagon; Recombinant Proteins | 2013 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Peptide Fragments; Protein Precursors | 2002 |
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Appetite; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Middle Aged; Obesity; Peptide Fragments; Postprandial Period; Protein Precursors | 2002 |
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Hormones; Humans; Lactic Acid; Liver; Male; Middle Aged; Osmolar Concentration; Reference Values; Time Factors | 2002 |
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Topics: Adult; Amyloid; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Male; Middle Aged; Postprandial Period | 2002 |
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
Topics: Aged; Blood Glucose; Body Composition; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Islets of Langerhans; Male; Middle Aged; Peptides; Venoms | 2003 |
Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Butter; Cholesterol, HDL; Chylomicrons; Coronary Artery Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Monounsaturated; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Obesity; Olive Oil; Peptide Fragments; Plant Oils; Postprandial Period; Protein Precursors; Triglycerides | 2003 |
Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Peptide Fragments; Protein Precursors | 2003 |
Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Erythromycin; Female; Gastric Emptying; Gastrointestinal Agents; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Morphine; Placebo Effect; Postprandial Period; Radionuclide Imaging; Stomach | 2003 |
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Injections, Intravenous; Male; Middle Aged; Osmolar Concentration; Peptide Fragments; Postprandial Period; Protein Precursors; Time Factors | 2003 |
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Liraglutide; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Reference Values | 2003 |
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Fasting; Female; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period; Triglycerides; Venoms | 2003 |
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.
Topics: Adult; Aged; Amyloid; Blood Glucose; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Proinsulin; Quality of Life | 2003 |
Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus.
Topics: Autonomic Nervous System; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Enzyme Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Gastric Mucosa; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Hemodynamics; Humans; Insulin; Lactones; Lipase; Male; Middle Aged; Orlistat; Peptide Fragments; Peptides | 2003 |
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Injections, Subcutaneous; Insulin; Kinetics; Middle Aged; Pancreatitis; Peptide Fragments; Protein Precursors | 2003 |
Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Implants; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin; Male; Peptide Fragments; Protein Precursors; Treatment Outcome | 2003 |
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Humans; Hyperglycemia; Insulin; Islets of Langerhans; Male; Middle Aged; Neurotransmitter Agents; Nuclear Proteins; Pancreatitis; Peptide Fragments; Phenotype; Protein Precursors; Transcription Factors | 2003 |
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin; Metformin; Peptide Fragments; Placebos; Recombinant Proteins; Sulfonylurea Compounds | 2003 |
Antihyperglycemic effects of stevioside in type 2 diabetic subjects.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Diuresis; Fatty Acids, Nonesterified; Female; Food; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Triglycerides | 2004 |
Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients.
Topics: Aged; Alcohol Drinking; Butter; Cholesterol; Cholesterol, HDL; Chylomicrons; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Energy Intake; Ethanol; Fatty Acids; Fatty Acids, Nonesterified; Food; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Lipids; Middle Aged; Peptide Fragments; Protein Precursors; Triglycerides | 2004 |
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Humans; Hyperglycemia; Infusions, Intravenous; Insulin; Male; Middle Aged; Parenteral Nutrition, Total; Peptide Fragments; Placebos | 2004 |
Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glucose Clamp Technique; Humans; Insulin; Male; Middle Aged; Severity of Illness Index | 2004 |
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Male; Middle Aged; Peptide Fragments; Postoperative Care; Postoperative Complications; Protein Precursors | 2004 |
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Topics: Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liraglutide; Male; Middle Aged | 2004 |
Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
Topics: Adult; Aged; Anti-Obesity Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Lactones; Male; Middle Aged; Obesity; Orlistat; Peptide Fragments; Protein Precursors; Single-Blind Method; Weight Loss | 2004 |
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Circadian Rhythm; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Enzyme Inhibitors; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Pyrrolidines | 2004 |
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Topics: Blood Glucose; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Liraglutide; Male; Middle Aged; Placebos; Treatment Outcome | 2004 |
Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes.
Topics: Biological Availability; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Duodenum; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Intestine, Small; Middle Aged; Osmolar Concentration; Peptide Fragments; Protein Precursors | 2004 |
Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Pioglitazone; Protein Precursors; Thiazolidinediones | 2004 |
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
Topics: Blood Glucose; Body Composition; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Male; Middle Aged; Placebos | 2004 |
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Topics: Adult; Brachial Artery; Coronary Circulation; Coronary Disease; Coronary Vessels; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Endothelium, Vascular; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Male; Middle Aged; Nitroglycerin; Peptide Fragments; Pilot Projects; Protein Precursors; Receptors, Glucagon; Regional Blood Flow; Vasodilation | 2004 |
Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Lispro; Insulin, Isophane; Male; Middle Aged | 2004 |
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Oxidation-Reduction; Piperidines; Postprandial Period | 2005 |
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Gastric Emptying; Glucagon; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Nausea; Peptides; Postprandial Period; Single-Blind Method; Venoms; Vomiting | 2005 |
alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Postprandial Period; Protein Precursors | 2005 |
Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hyperglycemia; Insulin; Intestine, Small; Male; Peptide Fragments; Postprandial Period; Protein Precursors; Reference Values | 2005 |
Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged | 2005 |
Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Proteins; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycemic Index; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Milk Proteins; Peptide Fragments; Postprandial Period; Protein Precursors; Whey Proteins | 2005 |
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged | 2005 |
Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Homeostasis; Human Growth Hormone; Humans; Insulin; Liver; Male; Middle Aged; Sodium Bicarbonate; Sodium Lactate | 2005 |
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Topics: Adult; Aged; Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Infusions, Parenteral; Insulin; Islet Amyloid Polypeptide; Male; Middle Aged; Peptides; Proinsulin; Venoms | 2005 |
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Exercise Test; Glucagon; Glucagon-Like Peptide 1; Heart; Heart Failure; Humans; Infusions, Parenteral; Injections, Subcutaneous; Insulin; Male; Myocardial Contraction; Pilot Projects; Recombinant Proteins; Time Factors | 2004 |
The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Activation; Enzyme Inhibitors; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Nitriles; Peptides; Pyrrolidines | 2006 |
Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Test; Female; Glucagon; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2006 |
Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?
Topics: Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Homeostasis; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Nonlinear Dynamics; Suprachiasmatic Nucleus | 2006 |
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Topics: Adamantane; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Mucosa; Intestines; Lipids; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Triglycerides; Vildagliptin | 2006 |
Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Tolerance Test; Glycated Hemoglobin; Glycolysis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lactates; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2007 |
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Follow-Up Studies; Glucagon; Glyburide; Glycated Hemoglobin; Health Status Indicators; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Insulin, Long-Acting; Lipids; Male; Middle Aged; Proinsulin; Quality of Life | 2008 |
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Evaluation of beta-cell function in diabetic Taiwanese children using a 6-min glucagon test.
Topics: Adolescent; C-Peptide; Child; Child, Preschool; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Evaluation Studies as Topic; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Infant; Islets of Langerhans; Male; ROC Curve; Taiwan | 2008 |
Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glycerol; Glycogenolysis; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Liver; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones | 2008 |
Weight loss therapy improves pancreatic endocrine function in obese older adults.
Topics: Aged; Aging; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Reducing; Exercise; Female; Glucagon; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Male; Obesity; Risk Factors; Weight Loss | 2008 |
[The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication].
Topics: Adult; Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Resistance; Somatostatin; Time Factors | 1984 |
Effects of high fiber breakfasts on glucose metabolism in noninsulin-dependent diabetics.
Topics: Absorption; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dietary Fiber; Edible Grain; Female; Fruit; Glucagon; Growth Hormone; Humans; Insulin; Male; Middle Aged; Xylose | 1984 |
Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged; Oligosaccharides; Random Allocation; Trisaccharides | 1984 |
Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in type 2 diabetic subjects.
Topics: Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type 2; Diastole; Diet, Diabetic; Dietary Fats, Unsaturated; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated; Female; Glucagon; Glucose Tolerance Test; Growth Hormone; Heart Rate; Humans; Lipids; Male; Middle Aged; Pulse; Systole; Triglycerides | 1995 |
Differences in substrate metabolism between self-perceived 'large-eating' and 'small-eating' women.
Topics: Adult; Appetite; Basal Metabolism; Calorimetry, Indirect; Carbon Dioxide; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Diabetes Mellitus, Type 2; Eating; Energy Metabolism; Female; Glucagon; Humans; Insulin; Insulin-Like Growth Factor I; Middle Aged; Obesity; Oxygen Consumption; Rest; Self Concept | 1995 |
Importance of early insulin levels on prandial glycaemic responses and thermogenesis in non-insulin-dependent diabetes mellitus.
Topics: Aged; Basal Metabolism; Blood Glucose; Body Temperature Regulation; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Food; Glucagon; Humans; Insulin; Male; Middle Aged; Time Factors | 1995 |
Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus.
Topics: Autonomic Nervous System; Diabetes Mellitus, Type 2; Eating; Female; Gastric Emptying; Gastrointestinal Motility; Glucagon; Glucose; Humans; Hyperglycemia; Insulin; Liver; Male; Middle Aged; Muscle Contraction; Stomach | 1995 |
Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes.
Topics: Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Emulsions; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Heparin; Humans; Infusions, Intravenous; Insulin, Isophane; Male; Middle Aged; Phospholipids; Recombinant Proteins; Safflower Oil; Soybean Oil | 1995 |
Insulin response after treatment depends on fasting plasma glucose level in NIDDM.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle Aged | 1994 |
[Effect of misoprostol, a synthetic prostaglandin E analog, on levels of serum C-peptide in serum and glucose tolerance].
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Duodenal Ulcer; Glucagon; Humans; Male; Misoprostol; Radioimmunoassay; Stomach Ulcer | 1994 |
Improved metabolic control does not reverse left ventricular filling abnormalities in newly diagnosed non-insulin-dependent diabetes patients.
Topics: Adult; Blood Glucose; Blood Pressure; C-Peptide; Chlorpropamide; Cholesterol; Diabetes Mellitus, Type 2; Diet, Diabetic; Echocardiography, Doppler; Female; Follow-Up Studies; Glucagon; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Male; Middle Aged; Reference Values; Triglycerides; Ventricular Function, Left | 1994 |
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus.
Topics: Age of Onset; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Liver; Middle Aged; Obesity; Reference Values; Triglycerides; Tritium; Twins, Monozygotic | 1995 |
Glycemic response to stress is altered in euglycemic Pima Indians.
Topics: Adolescent; Adult; Blood Glucose; Catecholamines; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hydrocortisone; Indians, North American; Insulin; Insulin Resistance; Male; Mathematics; Obesity; Prevalence; Radioimmunoassay; Risk Factors; Software; Stress, Psychological; White People | 1994 |
Differential effects of human and animal insulin on the responses to hypoglycemia in elderly patients with NIDDM.
Topics: Aged; Animals; Blood Glucose; Cattle; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Infusions, Intravenous; Insulin; Male; Neuropsychological Tests; Norepinephrine; Recombinant Proteins; Risk Factors; Swine; Time Factors | 1995 |
Prevalence and predictive value of islet cell antibodies and insulin autoantibodies in women with gestational diabetes.
Topics: Autoantibodies; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Glucagon; Glucose Tolerance Test; Histocompatibility Testing; Humans; Insulin Antibodies; Islets of Langerhans; Predictive Value of Tests; Pregnancy; Prevalence; Reference Values; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Time Factors | 1994 |
Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Injections, Subcutaneous; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors; Radioimmunoassay; Time Factors | 1994 |
Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.
Topics: Amino Acids; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Food; Glucagon; Humans; Kinetics; Male; Metformin; Middle Aged; Phenylalanine; Placebos; Proteins; Tritium | 1994 |
Effects on blood pressure, glucose, and lipid levels of a high-monounsaturated fat diet compared with a high-carbohydrate diet in NIDDM subjects.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 2; Diastole; Diet, Diabetic; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Female; Glucagon; Glycated Hemoglobin; Glycosuria; Growth Hormone; Humans; Insulin; Lipids; Male; Middle Aged; Pulse; Systole; Triglycerides | 1993 |
Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Calcifediol; Calcitriol; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucagon; Humans; Insulin; Insulin Secretion; Male; Middle Aged | 1994 |
Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Erythrocytes; Female; Glucagon; Glucose; Humans; Insulin; Magnesium; Male; Oxidation-Reduction | 1994 |
Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Topics: Analysis of Variance; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Lactates; Lipolysis; Liver; Male; Middle Aged; Oxygen Consumption; Pyrazines; Tritium | 1993 |
Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Female; Glucagon; Growth Hormone; Hormones; Humans; Hydrocortisone; Insulin; Insulin-Like Growth Factor I; Kinetics; Leucine; Male; Middle Aged; Norepinephrine; Recombinant Proteins | 1993 |
The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Blood Pressure; C-Peptide; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Female; Follow-Up Studies; Glucagon; Glycated Hemoglobin; Humans; Male; Middle Aged; Sex Factors; Triglycerides | 1993 |
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Topics: Blood Glucose; Calorimetry; Chromatography, High Pressure Liquid; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Pyrazines; Time Factors | 1993 |
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Kinetics; Male; Middle Aged; Peptide Fragments; Time Factors | 1993 |
Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Proteins; Glomerular Filtration Rate; Glucagon; Humans; Insulin; Kidney; Middle Aged; Proteinuria | 1993 |
Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.
Topics: Algorithms; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Outpatients; Triglycerides | 1993 |
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Peptide Fragments; Protein Precursors; Reference Values; Time Factors | 1993 |
Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Topics: Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Homeostasis; Humans; Islets of Langerhans; Lipids; Male; Metformin; Middle Aged; Obesity; Prospective Studies; Risk Factors; Single-Blind Method | 1993 |
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Nitrogen; Oxygen Consumption; Pyrazines; Reference Values | 1993 |
Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. The GL-G Hypoglycemia Study Group.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Intramuscular; Injections, Intravenous; Insulin; Male; Middle Aged; Recombinant Proteins | 1993 |
Dose-dependency of the glycemic response to starch-rich meals in non-insulin-dependent diabetic subjects: studies with varying amounts of white rice.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Glucagon; Humans; Insulin; Male; Middle Aged; Oryza; Starch | 1993 |
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Topics: Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Lipid Metabolism; Male; Oxidation-Reduction; Pyrazines; Pyruvates; Radioimmunoassay; Time Factors | 1993 |
Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.
Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Cyclohexanols; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Insulin; Male; Peptide Fragments; Protein Precursors | 1995 |
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Peptide Fragments; Protein Precursors | 1996 |
Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients.
Topics: Analysis of Variance; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Monounsaturated; Female; Glucagon; Humans; Insulin; Male; Middle Aged; Obesity; Time Factors; Triglycerides; Weight Loss | 1996 |
Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.
Topics: Antibodies; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Epinephrine; Fatty Acids, Nonesterified; Female; Glucagon; Homeostasis; Humans; Injections, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Norepinephrine; Placebos; Protein Engineering; Recombinant Proteins; Time Factors; Tumor Necrosis Factor-alpha | 1996 |
Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Topics: Adult; Analysis of Variance; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Male; Peptide Fragments; Protein Precursors; Time Factors | 1996 |
Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Topics: Analysis of Variance; Animals; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glyburide; Humans; In Vitro Techniques; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Middle Aged; Peptide Fragments; Perfusion; Protein Precursors; Rats; Rats, Sprague-Dawley; Treatment Failure | 1996 |
The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
Topics: Amyloid; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Fasting; Female; Glipizide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Male; Middle Aged; Placebos; Postprandial Period; Single-Blind Method | 1996 |
Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon; Glucose; Hormones; Humans; Hypoglycemic Agents; Insulin; Kinetics; Liver; Male; Middle Aged; Osmolar Concentration; Somatostatin | 1996 |
The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
Topics: Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperlipoproteinemias; Hypoglycemic Agents; Insulin; Lipoproteins, VLDL; Male; Middle Aged; Peptide Fragments; Protein Precursors; Time Factors; Triglycerides | 1996 |
Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose; Homeostasis; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Insulin; Insulin Infusion Systems; Insulin, Regular, Pork; Kinetics; Male; Middle Aged; Recombinant Proteins; Time Factors | 1996 |
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Emptying; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Peptide Fragments; Peptides | 1996 |
Secretory protein 7B2 response to oral glucose loading and intravenous glucagon injection in patients with diabetes mellitus.
Topics: Administration, Oral; Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Injections, Intravenous; Islets of Langerhans; Male; Middle Aged; Nerve Tissue Proteins; Neuroendocrine Secretory Protein 7B2; Pancreatic Function Tests; Pituitary Hormones | 1996 |
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Topics: Adult; Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infusions, Intravenous; Islets of Langerhans; Male; Middle Aged; Peptide Fragments; Prospective Studies; Protein Precursors | 1997 |
Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Pharmaceutical Preparations; Proinsulin; Sulfonylurea Compounds | 1997 |
Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Peptides | 1997 |
Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Injections, Intravenous; Injections, Subcutaneous; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Reference Values | 1997 |
Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.
Topics: Acarbose; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Metformin; Middle Aged; Peptide Fragments; Protein Precursors; Regression Analysis; Sulfonylurea Compounds; Trisaccharides | 1997 |
GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Topics: Absorption; Administration, Buccal; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Half-Life; Humans; Insulin; Male; Middle Aged; Peptide Fragments; Postprandial Period; Protein Precursors; Tablets | 1997 |
No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes.
Topics: Adult; Amyloid; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Islet Amyloid Polypeptide; Male; Middle Aged; Peptide Fragments; Protein Precursors | 1997 |
The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Catecholamines; Computer Simulation; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Models, Biological; Neurotransmitter Agents; Norepinephrine; Time Factors | 1997 |
Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Breath Tests; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Neurotransmitter Agents; Pancreatic Polypeptide; Peptide Fragments; Postprandial Period; Regression Analysis | 1998 |
Influence of food on glycemia, insulin, C-peptide and glucagon levels in diabetic patients treated with antidiabetic metformin at steady-state.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged | 1997 |
The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exercise; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Lactic Acid; Middle Aged | 1998 |
Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Peptide Fragments; Postprandial Period; Protein Precursors; Single-Blind Method; Time Factors; Treatment Outcome | 1998 |
Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Topics: Acarbose; Administration, Oral; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Sucrose; Time Factors; Trisaccharides | 1998 |
Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Norepinephrine; Oxidation-Reduction | 1998 |
Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Topics: Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Peptide Fragments; Postprandial Period; Protein Precursors | 1998 |
The effect of low intensity bicycle exercise on the insulin-induced glucose uptake in obese patients with type 2 diabetes.
Topics: Adult; Bicycling; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Exercise; Glucagon; Glucose Clamp Technique; Humans; Insulin; Male; Norepinephrine | 1998 |
Acute metabolic response to high-carbohydrate, high-starch meals compared with moderate-carbohydrate, low-starch meals in subjects with type 2 diabetes.
Topics: Aged; Blood Glucose; Blood Urea Nitrogen; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Energy Intake; Fatty Acids, Nonesterified; Fructose; Galactose; Glucagon; Glucose; Glycosuria; Humans; Insulin; Insulin Secretion; Middle Aged; Starch; Triglycerides | 1998 |
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Oxygen Consumption; Placebos; Pyrazines | 1998 |
Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Topics: Aged; Blood Glucose; C-Peptide; Calorimetry, Indirect; Cholesterol; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Postprandial Period; Proinsulin; Protein Precursors; Sulfonylurea Compounds; Triglycerides | 1998 |
Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Topics: Age of Onset; Aged; Blood Glucose; C-Peptide; Calorimetry, Indirect; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Peptide Fragments; Peptides; Triglycerides | 1998 |
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
Topics: Appetite; Blood Glucose; Brain Chemistry; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Infusions, Intravenous; Insulin; Male; Middle Aged; Obesity; Peptide Fragments; Protein Precursors; Satiation | 1999 |
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Topics: Adult; Aged; Appetite; Appetite Depressants; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Drug Delivery Systems; Energy Intake; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Infusion Pumps; Insulin; Lipids; Middle Aged; Peptide Fragments; Peptides; Pilot Projects; Postprandial Period; Protein Precursors | 1999 |
Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Ethanol; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Male; Sulfonylurea Compounds; Time Factors | 1999 |
Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA).
Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Insulin; Male | 2000 |
Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Pancreas; Peptide Fragments; Postprandial Period; Protein Precursors; Sincalide | 2000 |
A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Clamp Technique; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Peptide Fragments; Protein Precursors; Reproducibility of Results | 2000 |
Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Middle Aged; Peptide Fragments; Periodicity; Protein Precursors | 2000 |
Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Food; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Human Growth Hormone; Humans; Hydrocortisone; Insulin; Kinetics; Peptide Fragments; Somatostatin | 2000 |
Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Aspart; Insulin, Regular, Pork; Male; Middle Aged; Postprandial Period | 2000 |
Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations.
Topics: Adult; Blood Glucose; Capillaries; Diabetes Mellitus, Type 2; Fibrinogen; Glucagon; Humans; Insulin; Kinetics; Leucine; Lipids; Male; Middle Aged | 2000 |
Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Fats, Unsaturated; Double-Blind Method; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Linoleic Acid; Oleic Acid; Peptide Fragments; Protein Precursors; Triglycerides | 2000 |
Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eating; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Male; Middle Aged; Peptide Fragments; Radioimmunoassay | 2000 |
Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Deuterium; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glycolysis; Human Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Ketone Bodies; Male; Middle Aged; Tritium | 2001 |
Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control.
Topics: Aged; Alanine; Alprostadil; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Infusions, Intravenous; Insulin; Liver; Male; Middle Aged; Nitrogen; Time Factors; Urea | 2001 |
Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes.
Topics: Adult; Aged; Animals; Blood Glucose; C-Peptide; Cattle; Circadian Rhythm; Diabetes Mellitus, Type 2; Dietary Proteins; Drinking; Fatty Acids, Nonesterified; Glucagon; Humans; Insulin; Male; Meat; Middle Aged; Triglycerides; Uric Acid | 2001 |
Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Entropy; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Hormones; Humans; Injections, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Osmolar Concentration; Peptide Fragments; Protein Precursors; Pulsatile Flow; Reference Values | 2001 |
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Infusions, Parenteral; Insulin; Insulin Secretion; Kinetics; Male; Metformin; Middle Aged; Peptide Fragments; Placebos; Research Design | 2001 |
Physiologic modeling of the intravenous glucose tolerance test in type 2 diabetes: a new approach to the insulin compartment.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Infusions, Intravenous; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Models, Biological | 2001 |
Systemic and regional free fatty acid metabolism in type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Hormones; Human Growth Hormone; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipolysis; Male; Middle Aged; Obesity; Palmitates; Protein Synthesis Inhibitors; Somatostatin; Tritium | 2001 |
Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Peptide Fragments; Protein Precursors; Time Factors | 2001 |
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Entropy; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Middle Aged; Placebos; Prospective Studies; Time Factors | 2001 |
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infusions, Intravenous; Inpatients; Insulin; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Sulfonylurea Compounds; Time Factors | 2001 |
Aminophylline stimulates insulin secretion in patients with type 2 diabetes mellitus.
Topics: Aged; Aminophylline; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Humans; Hydrocortisone; Infusions, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Norepinephrine; Purinergic P1 Receptor Antagonists | 2001 |
Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
Topics: Aged; Biological Transport, Active; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Clamp Technique; Humans; Insulin; Peptide Fragments; Peptides | 2001 |
Indomethacin does not affect endogenous glucose production in type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Reactive Protein; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Indomethacin; Insulin; Male; Middle Aged; Random Allocation; Somatostatin; Statistics, Nonparametric | 2001 |
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Topics: Aged; Blood Glucose; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Insulin Secretion; Liraglutide; Male; Middle Aged; Osmolar Concentration; Postprandial Period | 2002 |
Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Black or African American; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Islets of Langerhans; Male; Metformin; Pancreatic Function Tests | 2002 |
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Peptide Fragments; Pilot Projects; Protein Precursors | 2002 |
Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function.
Topics: Analysis of Variance; Area Under Curve; Blood Glucose; Blood Pressure; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Ferritins; Glucagon; Glycated Hemoglobin; Hematocrit; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Phlebotomy; Smoking; Transferrin | 2002 |
A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glucagon; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged | 2002 |
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glycerol; Humans; Hydrocortisone; Hydroxybutyrates; Hypolipidemic Agents; Lipolysis; Male; Middle Aged; Norepinephrine; Pyrazines | 1992 |
Nicardipine does not cause deterioration of glucose homoeostasis in man: a placebo controlled study in elderly hypertensives with and without diabetes mellitus.
Topics: Aged; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Homeostasis; Humans; Hypertension; Insulin; Male; Nicardipine; Reproducibility of Results | 1992 |
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Kinetics; Male; Middle Aged; Peptide Fragments; Peptides; Reference Values; Time Factors | 1992 |
The metabolic response to various doses of fructose in type II diabetic subjects.
Topics: Aged; Amino Acids; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Fructose; Glucagon; Humans; Insulin; Middle Aged; Nitrogen; Osmolar Concentration | 1992 |
The short insulin tolerance test for determination of insulin sensitivity: a comparison with the euglycaemic clamp.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Growth Hormone; Humans; Hydrocortisone; Insulin; Male; Norepinephrine; Reference Values | 1992 |
Effect of glyburide and omega 3 fatty acid dietary supplements on glucose and lipid metabolism in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Omega-3; Glucagon; Glucose; Glyburide; Humans; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged | 1992 |
C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Food; Glucagon; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male | 1992 |
Meal-time intranasal insulin delivery in type 2 diabetes.
Topics: Administration, Intranasal; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Insulin; Kinetics; Male; Time Factors | 1991 |
Comparison between a glucose-fructose-xylitol solution and a sole glucose solution for surgical patients with glucose tolerance impairment.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructose; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged; Postoperative Care; Randomized Controlled Trials as Topic; Surgical Procedures, Operative; Xylitol | 1990 |
Effect of dihydroxyacetone and pyruvate on plasma glucose concentration and turnover in noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dihydroxyacetone; Female; Food, Formulated; Glucagon; Glucose Tolerance Test; Humans; Insulin; Isotope Labeling; Middle Aged; Pyruvates | 1990 |
Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol Esters; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glucagon; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipoproteins; Male; Middle Aged; Sulfonylurea Compounds | 1990 |
Metabolic effects of hyperglycemia and hyperinsulinemia on fate of intracellular glucose in NIDDM.
Topics: Blood Glucose; C-Peptide; Calorimetry; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Insulin; Lipid Metabolism; Male; Middle Aged; Obesity; Oxidation-Reduction | 1990 |
Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Interactions; Erythrocytes; Female; Glucagon; Humans; Insulin; Kinetics; Magnesium; Male; Obesity | 1989 |
Dietary magnesium supplements improve B-cell response to glucose and arginine in elderly non-insulin dependent diabetic subjects.
Topics: Aged; Arginine; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Magnesium; Male; Random Allocation | 1989 |
[Comparison of biosynthetic human insulin and purified pork insulin. Studies in insulin-resistant obese patients using the insulin suppression test].
Topics: Adult; Aged; Animals; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Insulin; Insulin Resistance; Insulin, Regular, Pork; Male; Middle Aged; Obesity; Recombinant Proteins; Somatostatin; Swine | 1986 |
Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fiber; Female; Glucagon; Glycine max; Humans; Insulin; Male; Middle Aged; Obesity; Pancreatic Hormones; Pancreatic Polypeptide; Polysaccharides; Somatostatin; Triglycerides | 1987 |
Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Growth Hormone; Humans; Insulin; Male; Middle Aged; Octreotide; Somatostatin; Thyrotropin; Thyroxine | 1986 |
Hormonal and metabolic responses to breakfast meals in niddm: comparison of white and whole-grain wheat bread and corresponding extruded products.
Topics: Adult; Aged; Blood Glucose; Bread; C-Peptide; Diabetes Mellitus, Type 2; Dietary Fiber; Female; Gastric Inhibitory Polypeptide; Glucagon; Glycerol; Humans; Insulin; Male; Middle Aged; Triglycerides; Triticum | 1985 |
Postprandial metabolic responses to the influence of food form.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Glucagon; Humans; Insulin; Kinetics; Male; Middle Aged; Oryza; Solanum tuberosum; Starch | 1988 |
Response to single dose of aspartame or saccharin by NIDDM patients.
Topics: Adult; Aspartame; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucagon; Humans; Insulin; Kinetics; Male; Middle Aged; Reference Values; Saccharin | 1988 |
[Plasma glucagon and insulin profile in obese non-diabetic and non-insulin-dependent diabetic patients on a daily 800 calorie diet].
Topics: Adult; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Energy Intake; Female; Glucagon; Humans; Insulin; Male; Middle Aged; Obesity | 1986 |
[Effects of nifedipine on carbohydrate metabolism in the non-insulin dependent diabetic].
Topics: Adult; Aged; Arginine; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glucose Tolerance Test; Growth Hormone; Humans; Insulin; Male; Middle Aged; Nifedipine; Prospective Studies; Random Allocation | 1985 |
Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone.
Topics: Blood Glucose; Body Weight; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glyburide; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Lipids; Male; Middle Aged | 1985 |
The 24-hour effects of glyburide and chlorpropamide after chronic treatment of type II diabetic patients.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Cholesterol; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Glucagon; Glyburide; Growth Hormone; Humans; Insulin; Male; Middle Aged; Radioimmunoassay; Random Allocation; Time Factors; Triglycerides | 1985 |
Once-daily use of glyburide.
Topics: Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glucagon; Glyburide; Glycosuria; Humans; Insulin | 1985 |
Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Erythrocytes; Female; Gastric Inhibitory Polypeptide; Glipizide; Glucagon; Glyburide; Glycosuria; Humans; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Random Allocation; Sulfonylurea Compounds | 1985 |
972 other study(ies) available for glucagon and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Measurement of Plasma Glucagon Levels Using Mass Spectrometry in Patients with Type 2 Diabetes on Maintenance Hemodialysis.
Topics: Aged; Chromatography, Liquid; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Male; Mass Spectrometry; Middle Aged; Renal Dialysis | 2021 |
Impact of the different biliopancreatic limb length on diabetes and incretin hormone secretion following distal gastrectomy in gastric cancer patients.
Topics: Aged; Anastomosis, Roux-en-Y; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gastrectomy; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Male; Middle Aged; Postoperative Period; Prospective Studies; Stomach Neoplasms; Treatment Outcome | 2021 |
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Insulin | 2022 |
On the Electrophysiological Component of Pancreatic Alpha-Cell Models.
Topics: Calcium; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Membrane Potentials | 2021 |
Intra-islet glucagon confers β-cell glucose competence for first-phase insulin secretion and favors GLP-1R stimulation by exogenous glucagon.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Inbred C57BL; Rats | 2022 |
Pancreatic and gut hormone responses to mixed meal test in post-chronic pancreatitis diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Pancreatitis, Chronic; Peptide YY | 2022 |
Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Sorbitol | 2022 |
Main glucose hepatic fluxes in healthy subjects predicted from a phenomenological-based model.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Healthy Volunteers; Humans; Insulin; Liver | 2022 |
Hypoglycemic Events in the Emergency Department.
Topics: Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Retrospective Studies; United States | 2022 |
Heterogenous impairment of α cell function in type 2 diabetes is linked to cell maturation state.
Topics: Animals; Diabetes Mellitus, Type 2; Exocytosis; Glucagon; Glucagon-Secreting Cells; Insulin; Islets of Langerhans; Mice | 2022 |
Pancreatic cancer-associated diabetes mellitus is characterized by reduced β-cell secretory capacity, rather than insulin resistance.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Pancreatic Neoplasms | 2022 |
Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia.
Topics: Adiposity; Adolescent; Blood Glucose; Body Mass Index; Cardiometabolic Risk Factors; Cardiovascular Diseases; Child; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hyperglycemia; Insulin; Insulin Resistance; Overweight; Pediatric Obesity; Risk Factors; Young Adult | 2022 |
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
Topics: Cryoelectron Microscopy; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Peptides; Receptors, G-Protein-Coupled; Receptors, Glucagon | 2022 |
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Nicotinic Agonists; Pyridines; Sitagliptin Phosphate; Tyrosine | 2022 |
Assessment of Two Different Glucagon Assays in Healthy Individuals and Type 1 and Type 2 Diabetes Patients.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Glucagon; Humans; Radioimmunoassay | 2022 |
Design, synthesis, and biological evaluation of a small molecule oral agonist of the glucagon-like-peptide-1 receptor.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Design; Glucagon; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Secretion; Insulin-Secreting Cells; Streptozocin | 2022 |
Protein Kinase C (Pkc)-δ Mediates Arginine-Induced Glucagon Secretion in Pancreatic α-Cells.
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Mice; Protein Kinase C-delta | 2022 |
A Study of Correlation of Glucagon-Insulin Ratio with Hba1c in Diabetic Patients in a Tertiary Care Hospital.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Middle Aged; Prospective Studies; Tertiary Care Centers | 2022 |
Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: Results of the LEGEND-A pilot study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Pilot Projects | 2022 |
Targeting hyperglucagonaemia in T2DM.
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin | 2022 |
Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin Resistance; Meals; Pituitary ACTH Hypersecretion; Somatostatin | 2022 |
Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Hyperglycemia; Insulin | 2022 |
Cyclocarya paliurus triterpenoids suppress hepatic gluconeogenesis via AMPK-mediated cAMP/PKA/CREB pathway.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Glucose; Juglandaceae; Liver; Mice; RNA, Messenger; Triterpenes | 2022 |
Positive association of glucagon with bone turnover markers in type 2 diabetes: A cross-sectional study.
Topics: Biomarkers; Bone Density; Bone Remodeling; China; Collagen Type I; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon; Humans; Osteocalcin; Peptide Fragments; Procollagen | 2022 |
Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation.
Topics: alpha-Synuclein; Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Hyperplasia; Insulin; Insulin-Secreting Cells; Insulysin; Mice | 2022 |
Inhibition of basal and glucagon-induced hepatic glucose production by 991 and other pharmacological AMPK activators.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Glucose; Lactic Acid; Liver; Mice; Pyruvic Acid | 2022 |
Glucagon-like peptide-1 effect on β-cell function varies according to diabetes remission status after Roux-en-Y gastric bypass.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Intolerance; Humans; Insulin; Retrospective Studies | 2022 |
The rs10830963 Polymorphism of the MTNR1B Gene: Association With Abnormal Glucose, Insulin and C-peptide Kinetics.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Intolerance; Humans; Insulin; Insulin Resistance; Kinetics; Male; Prediabetic State; Receptor, Melatonin, MT2 | 2022 |
The relationship between insulin and glucagon concentrations in non-diabetic humans.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Hyperglycemia; Insulin; Middle Aged; Reproducibility of Results | 2022 |
Transgenic overexpression of microRNA-30d in pancreatic beta-cells progressively regulates beta-cell function and identity.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Insulin-Secreting Cells; Mice; MicroRNAs | 2022 |
Disrupted and Elevated Circadian Secretion of Glucagon-Like Peptide-1 in a Murine Model of Type 2 Diabetes.
Topics: Animals; Circadian Rhythm; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Insulin; Mice | 2022 |
RhoA as a Signaling Hub Controlling Glucagon Secretion From Pancreatic α-Cells.
Topics: Actins; Animals; Calcium; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ephrins; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin; Islets of Langerhans; Ligands; Mice; Receptors, Eph Family; rhoA GTP-Binding Protein | 2022 |
Islet Gene View-a tool to facilitate islet research.
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Islets of Langerhans; Serpin E2 | 2022 |
Comparative Effects of Co-Ingesting Whey Protein and Glucose Alone and Combined on Blood Glucose, Plasma Insulin and Glucagon Concentrations in Younger and Older Men.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hyperglycemia; Insulin; Male; Postprandial Period; Whey Proteins | 2022 |
Heterogeneity and altered β-cell identity in the TallyHo model of early-onset type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Insulin-Secreting Cells; Male; Mice; Transcription Factors; Vimentin | 2022 |
Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
Topics: Adult; Alanine; Amino Acids; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Liver; Male; Middle Aged; Overweight | 2022 |
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose; Guanidines; Humans; Hypoglycemic Agents; Insulin; Metformin; Receptors, Glucagon | 2022 |
Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events.
Topics: Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Lipids; Risk Factors; Triglycerides | 2022 |
The Different Insulin-Sensitising and Anti-Inflammatory Effects of Palmitoleic Acid and Oleic Acid in a Prediabetes Model.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Cytokines; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Glucagon; Glucose; Inflammation; Insulin; Insulin Resistance; Lipoprotein Lipase; Oleic Acid; Prediabetic State; Rats | 2022 |
Characteristic changes in plasma glutamate levels and free amino acid profiles in Japanese patients with type 1 diabetes mellitus.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; East Asian People; Glucagon; Glutamic Acid; Humans; Insulin | 2023 |
When insulin isn't enough: targeting glucagon in type 1 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin | 2022 |
SMALL INTESTINAL L CELL DENSITY IN PATIENTS WITH SEVERE OBESITY AFTER ROUX-EN-Y GASTRIC BYPASS.
Topics: Anastomosis, Roux-en-Y; Diabetes Mellitus, Type 2; Enteroendocrine Cells; Gastric Bypass; Glucagon; Humans; Incretins; Obesity, Morbid; Treatment Outcome | 2022 |
Organ-specific metabolic pathways distinguish prediabetes, type 2 diabetes, and normal tissues.
Topics: Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Metabolic Networks and Pathways; Prediabetic State; Proteome; Proteomics | 2022 |
Lipid droplet accumulation in β cells in patients with type 2 diabetes is associated with insulin resistance, hyperglycemia and β cell dysfunction involving decreased insulin granules.
Topics: Blood Glucose; Boron Compounds; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Insulin Resistance; Lipid Droplets | 2022 |
Surfactin Mitigates a High-Fat Diet and Streptozotocin-Induced Type 2 Diabetes through Improving Pancreatic Dysfunction and Inhibiting Inflammatory Response.
Topics: Animals; Blood Glucose; Claudin-1; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Glucose; Inflammation; Insulin Resistance; Mice; Occludin; Pancreas; Pancreatic Hormones; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Proto-Oncogene Proteins c-akt; Streptozocin | 2022 |
Hepatic Sam68 Regulates Systemic Glucose Homeostasis and Insulin Sensitivity.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Cycle Proteins; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Type 2; Gene Expression; Glucagon; Gluconeogenesis; Glucose; Hepatocytes; Homeostasis; Hyperglycemia; Insulin; Insulin Resistance; Liver; Mice; RNA-Binding Proteins; src-Family Kinases; Transcription Factors | 2022 |
Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes.
Topics: Animals; Diabetes Mellitus, Type 2; Endosomal Sorting Complexes Required for Transport; Endosomes; Glucagon; Glucose; Lipids; Liver; Mammals; Mice; Mice, Inbred C57BL; Receptors, Glucagon | 2022 |
Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China.
Topics: Acarbose; Blood Glucose; China; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Insulins | 2022 |
An emerging direction in glucagon-based therapy.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Liver; Receptors, Glucagon | 2022 |
The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
Topics: Animals; Body Weight; Complement C4; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Lipids; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, Glucagon | 2023 |
GC-Globulin/Vitamin D-Binding Protein Is Required for Pancreatic α-Cell Adaptation to Metabolic Stress.
Topics: Animals; Diabetes Mellitus, Type 2; Globulins; Glucagon; Mice; Stress, Physiological; Vitamin D-Binding Protein | 2023 |
Altered chronic glycemic control in a clinically relevant model of rat thoracic spinal contusion.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycemic Control; Humans; Insulin; Rats | 2023 |
Inhibition of stearoyl-CoA desaturase 1 in the mouse impairs pancreatic islet morphogenesis and promotes loss of β-cell identity and α-cell expansion in the mature pancreas.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Insulin; Islets of Langerhans; Mice; Morphogenesis; Stearoyl-CoA Desaturase | 2023 |
The 'early' postprandial glucagon response is related to the rate of gastric emptying in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Postprandial Period | 2023 |
Glucagon 100 years. Important, but still enigmatic.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hyperglycemia; Insulin | 2023 |
Human pancreatic capillaries and nerve fibers persist in type 1 diabetes despite beta cell loss.
Topics: Animals; Capillaries; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Islets of Langerhans; Mice; Nerve Fibers | 2023 |
Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Hypoglycemia; Insulin Aspart; Male; Prediabetic State; Rats; Rats, Sprague-Dawley | 2023 |
Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucagon concentration in healthy humans.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Insulin Resistance | 2023 |
Somatostatin Containing δ-Cell Number Is Reduced in Type-2 Diabetes.
Topics: Cell Count; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Islets of Langerhans; Somatostatin | 2023 |
Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose; Humans; Insulin; Ketones; Norepinephrine | 2023 |
Implication of sugar, protein and incretins in excessive glucagon secretion in type 2 diabetes after mixed meals.
Topics: Blood Glucose; Caseins; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Meals; Obesity; Sucrose; Sugars | 2023 |
Short-term high-fat diet feeding of mice suppresses catecholamine-stimulated Ca
Topics: Animals; Catecholamines; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Hepatocytes; Inositol 1,4,5-Trisphosphate; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Norepinephrine | 2023 |
Synthalin: a lost lesson for glucagon suppression in diabetes therapeutics.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Islets of Langerhans; Mammals | 2023 |
Determinants of blood glucose concentrations following a high carbohydrate meal in type 2 diabetes: A multiple linear regression analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Humans; Insulin; Postprandial Period; Regression Analysis | 2023 |
MafB-dependent neurotransmitter signaling promotes β cell migration in the developing pancreas.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin-Secreting Cells; Islets of Langerhans; MafB Transcription Factor; Mice; Pancreas | 2023 |
Upregulated TGF-β1 contributes to hyperglycaemia in type 2 diabetes by potentiating glucagon signalling.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Glucose; Hepatocytes; Humans; Hyperglycemia; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Transforming Growth Factor beta1 | 2023 |
Circulating levels of gastrointestinal hormones in prediabetes reversing to normoglycemia or progressing to diabetes in a year-A cross-sectional and prospective analysis.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glicentin; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Insulin; Prediabetic State | 2023 |
Alterations of adipokines, pancreatic hormones and incretins in acute and convalescent COVID-19 children.
Topics: Adipokines; Adiponectin; C-Peptide; Child; Complement Factor D; COVID-19; Cytokines; Diabetes Mellitus, Type 2; Ghrelin; Glucagon; Granulocyte Colony-Stimulating Factor; Humans; Incretins; Interleukin-12; Interleukin-17; Interleukin-6; Leptin; Pancreatic Hormones; SARS-CoV-2; Tumor Necrosis Factor-alpha | 2023 |
Perspectives in weight control in diabetes - SGLT2 inhibitors and GLP-1-glucagon dual agonism.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2023 |
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Obesity; Receptors, Glucagon | 2023 |
Designer GLP1 poly-agonist peptides in the management of diabesity.
Topics: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins | 2023 |
Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Out-of-Hospital Cardiac Arrest; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Hepatic p38α MAPK controls gluconeogenesis via FOXO1 phosphorylation at S273 during glucagon signalling in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; Glucagon; Gluconeogenesis; Glucose; Hepatocytes; Insulin; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 14; p38 Mitogen-Activated Protein Kinases; Phosphorylation | 2023 |
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Receptors, Glucagon | 2023 |
Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion.
Topics: Animals; Blood Glucose; Cation Transport Proteins; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Macaca mulatta; Mice; Obesity | 2023 |
Lower serum zinc level is associated with higher fasting insulin in type 2 diabetes mellitus (T2DM) and relates with disturbed glucagon suppression response in male patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Male | 2023 |
The effect of hormones insulin and glucagon on ubiquitin modifications elucidated by proteomics in liver cells.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Liver Neoplasms; Proteomics; Tandem Mass Spectrometry; Ubiquitin; Ubiquitination | 2023 |
Glucagon prescribing and prevention of hospitalization for hypoglycemia in a large health system.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Glucagon; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Retrospective Studies | 2023 |
Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production.
Topics: Adult; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hyperglycemia; Mammals; Mechanistic Target of Rapamycin Complex 1 | 2023 |
Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea-treated KCNJ11 neonatal diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Infant, Newborn; Insulin | 2023 |
PECULIARITIES OF FORMATION OF CARBOHYDRATE METABOLISM DISORDERS WITH COMORBID CHRONIC PANCREATITIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Glucagon; Humans; Pancreatitis, Chronic; Pulmonary Disease, Chronic Obstructive | 2023 |
Serum alanine transaminase is predictive of fasting and postprandial insulin and glucagon concentrations in type 2 diabetes.
Topics: Alanine Transaminase; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Humans; Insulin | 2023 |
Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
Topics: Blood Glucose; Deafness; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon; Glycemic Control; Humans; Hypoglycemic Agents; Maternal Inheritance; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Type 1 and Type 2 Diabetes Mellitus: Commonalities, Differences and the Importance of Exercise and Nutrition.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin | 2023 |
TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice.
Topics: Animals; Blood Glucose; Circadian Clocks; Circadian Rhythm; Cryptochromes; Diabetes Mellitus, Type 2; Fasting; Glucagon; Mammals; Mice; Mice, Obese | 2023 |
Glucagon as the First Incretin: Objects (in the Rearview Mirror) Are Closer Than They Appear.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Humans; Incretins; Insulin | 2023 |
Diabetes News.
Topics: Administration, Intranasal; Biomedical Research; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endocrinology; Glucagon; Humans; Hypoglycemic Agents; Injections | 2019 |
The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.
Topics: Adiposity; Anti-Obesity Agents; Appetite Depressants; Diabetes Mellitus, Type 2; Drug Synergism; Estradiol; Female; Glucagon; Glucagon-Like Peptide 1; Gonadal Steroid Hormones; Humans; Hypoglycemic Agents; Insulin; Male; Menstrual Cycle; Models, Biological; Overweight; Pancreas; Risk Factors; Secretory Rate; Testosterone; Weight Loss | 2019 |
Obesity dysregulates fasting-induced changes in glucagon secretion.
Topics: Adult; Animals; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Hyperglycemia; Insulin; Insulin Resistance; Male; Mice, Inbred C57BL; Middle Aged; Obesity; Pancreas | 2019 |
Effect of diabetes-specific nutrition formulas on satiety and hunger hormones in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cholecystokinin; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Food, Formulated; Ghrelin; Glucagon; Humans; Hunger; Islet Amyloid Polypeptide; Leptin; Male; Middle Aged; Peptide YY; Postprandial Period; Satiation | 2019 |
Sustained ER stress promotes hyperglycemia by increasing glucagon action through the deubiquitinating enzyme USP14.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Glucagon; Gluconeogenesis; Glucose; Glucose Intolerance; Hyperglycemia; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Ubiquitin Thiolesterase | 2019 |
Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes:a retrospective study from glucagon stimulation test.
Topics: Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon; Gluconeogenesis; Hormones; Humans; Incidence; Japan; Kidney Function Tests; Male; Middle Aged; Prognosis; Retrospective Studies | 2019 |
Dendrobium officinale polysaccharide ameliorates diabetic hepatic glucose metabolism via glucagon-mediated signaling pathways and modifying liver-glycogen structure.
Topics: Animals; Dendrobium; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Glucose; Glycogen; Hypoglycemic Agents; Liver; Male; Mice, Inbred C57BL; Molecular Structure; Plant Extracts; Polysaccharides; Signal Transduction; Streptozocin | 2020 |
Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin Secretion; Male; Middle Aged | 2019 |
Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetes.
Topics: Adolescent; Adult; Anastomosis, Roux-en-Y; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Insulin; Kisspeptins; Liver; Male; Middle Aged; Obesity, Morbid; Treatment Outcome; Young Adult | 2020 |
Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes.
Topics: Animals; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 2; Glucagon; Humans; Immunoblotting; Insulin Secretion; Insulin-Secreting Cells; Male; Mass Spectrometry; Mice; Nicotinamide Phosphoribosyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Structure-Activity Relationship | 2020 |
Therapeutic Ultrasound-Induced Insulin Release in Vivo.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Insulin; Mice; Pancreas; Random Allocation; Ultrasonic Therapy | 2020 |
Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Carbohydrate Metabolism; Case-Control Studies; Cells, Cultured; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucagon; Glucose; Humans; Lipolysis; Male; Middle Aged; Primary Cell Culture; Receptors, Glucagon | 2020 |
Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study.
Topics: Adult; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Organ Transplantation; Recombinant Fusion Proteins; Retrospective Studies | 2020 |
Hepatic TET3 contributes to type-2 diabetes by inducing the HNF4α fetal isoform.
Topics: Animals; Diabetes Mellitus, Type 2; Dioxygenases; Disease Models, Animal; DNA Demethylation; DNA Methylation; DNA-Binding Proteins; Fasting; Gene Expression Regulation; Glucagon; Glucose; Hepatocyte Nuclear Factor 3-beta; Hepatocyte Nuclear Factor 4; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Promoter Regions, Genetic; Protein Isoforms; Transcriptional Activation; Transcriptome; Up-Regulation | 2020 |
In pancreatic islets from type 2 diabetes patients, the dampened circadian oscillators lead to reduced insulin and glucagon exocytosis.
Topics: Adult; Animals; Circadian Rhythm; Diabetes Mellitus, Type 2; Exocytosis; Female; Flavones; Glucagon; Humans; In Vitro Techniques; Insulin; Islets of Langerhans; Male; Mice; Middle Aged; Young Adult | 2020 |
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Blood Glucose; Cell Proliferation; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Mice, Inbred C57BL; Mice, Transgenic; Sitagliptin Phosphate | 2020 |
Molecular changes in hepatic metabolism in ZDSD rats-A new polygenic rodent model of obesity, metabolic syndrome, and diabetes.
Topics: Amino Acids; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Humans; Hypertension; Insulin; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Multifactorial Inheritance; Obesity; Pancreas; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Rats, Zucker | 2020 |
Somatostatin secretion by Na
Topics: Animals; Calcium; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hypoglycemia; Insulin; Mice; Sodium; Somatostatin; Somatostatin-Secreting Cells | 2020 |
Reduced Expression of the Co-regulator TLE1 in Type 2 Diabetes Is Associated with Increased Islet α-Cell Number.
Topics: Adult; Aged; Co-Repressor Proteins; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Humans; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged | 2020 |
[Tanatogenetic role of type 2 diabetes in neurosurgical patients].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Middle Aged; Pancreas; Young Adult | 2020 |
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.
Topics: Acetyl Coenzyme A; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; Glucagon; Gluconeogenesis; Inositol 1,4,5-Trisphosphate Receptors; Lipase; Lipolysis; Liver; Mice, Knockout; Mitochondria; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction | 2020 |
Loss of EGR-1 uncouples compensatory responses of pancreatic β cells.
Topics: Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Early Growth Response Protein 1; Glucagon; Glucose; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout | 2020 |
Beginning of a new era in glucagon research: Breakthrough by the new glucagon assay.
Topics: Biological Assay; Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Prognosis | 2020 |
Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exocytosis; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Hyperglycemia; Insulin; Optical Imaging; Receptors, Somatostatin; Somatostatin | 2020 |
Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
Topics: Amino Acid Sequence; Animals; Anti-Obesity Agents; Apoptosis; Blood Glucose; Body Weight; Cell Proliferation; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Transporter Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Neoplasm Proteins; Obesity; Receptors, Glucagon; Structure-Activity Relationship | 2020 |
Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Treatment Outcome | 2020 |
Novel Insights Into Effects of Cortisol and Glucagon on Nocturnal Glucose Production in Type 2 Diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Gluconeogenesis; Humans; Hydrocortisone; Hyperglycemia; Male; Middle Aged; Time Factors | 2020 |
Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Topics: Aged; Biological Assay; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Male; Prognosis; Receptors, Gastrointestinal Hormone | 2020 |
Effect of Glucagon on Ischemic Heart Disease and Its Risk Factors: A Mendelian Randomization Study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Genome-Wide Association Study; Glucagon; Humans; Insulin; Male; Mendelian Randomization Analysis; Middle Aged; Myocardial Ischemia; Polymorphism, Single Nucleotide; Risk Factors | 2020 |
Human islets contain a subpopulation of glucagon-like peptide-1 secreting α cells that is increased in type 2 diabetes.
Topics: Animals; Biomarkers; Diabetes Mellitus, Type 2; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Humans; Immunophenotyping; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Mice | 2020 |
Plasma glucagon levels measured by sandwich ELISA are correlated with impaired glucose tolerance in type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged | 2020 |
A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Proteins; Endothelium, Vascular; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Postprandial Period; Young Adult | 2020 |
Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.
Topics: Adult; Bile Acids and Salts; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged | 2020 |
In vivo studies of glucagon secretion by human islets transplanted in mice.
Topics: Adult; Animals; CRISPR-Cas Systems; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Islets of Langerhans; Islets of Langerhans Transplantation; Liver; Liver Glycogen; Male; Mice; Mice, Knockout; Middle Aged | 2020 |
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endocrine Cells; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glucosides; Insulin; Insulin-Secreting Cells; Male; Mice; Proprotein Convertase 1; Regeneration; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Glucagon stimulation test as a possible predictor of residual β-cell function.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Infant, Newborn; Insulin; Insulin-Secreting Cells; Male; Retrospective Studies | 2021 |
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Topics: Benzhydryl Compounds; Biphenyl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Gastric Emptying; Glucagon; Glucosides; Glycerol; Half-Life; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; C-Peptide; Calcinosis; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Fibrosis; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Pancreatitis, Chronic; Time Factors; Young Adult | 2021 |
Amylase-Dependent Regulation of Glucose Metabolism and Insulin/Glucagon Secretion in the Streptozotocin-Induced Diabetic Pig Model and in a Rat Pancreatic Beta-Cell Line, BRIN-BD11.
Topics: Amylases; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Infusions, Intravenous; Insulin; Insulin-Secreting Cells; Rats; Secretory Pathway; Streptozocin; Sus scrofa; Time Factors | 2020 |
Development and characterisation of novel, enzymatically stable oxytocin analogues with beneficial antidiabetic effects in high fat fed mice.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Energy Intake; Female; Glucagon; Half-Life; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Mice; Obesity; Oligopeptides; Oxytocin; Protein Stability; Triglycerides | 2021 |
Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin-Secreting Cells; Male; Meals; Middle Aged; Prospective Studies | 2021 |
Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test.
Topics: Adult; Diabetes Mellitus, Type 2; Genome-Wide Association Study; Glucagon; Glucose Tolerance Test; Humans; Male; Middle Aged | 2021 |
Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetes.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Cell Dedifferentiation; Chromogranin A; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Pancreas, Exocrine | 2021 |
Structure-Activity Relationship and Biological Investigation of SR18292 (
Topics: Adipocytes, Brown; Animals; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Hepatocytes; Hypoglycemic Agents; Indoles; Lipolysis; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Propanols; Receptors, Adrenergic, beta; Signal Transduction; Structure-Activity Relationship; Sympathetic Nervous System | 2021 |
Pharmacology Update: Emergency Medications for Hypoglycemia in Diabetes.
Topics: Administration, Intranasal; Adult; Blood Glucose; Child; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemia; School Nursing | 2021 |
Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Clamp Technique; Glucose Intolerance; Glucose Tolerance Test; Hispanic or Latino; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Obesity; Prediabetic State; United States; Veterans | 2021 |
Optogenetic stimulation of cholinergic fibers for the modulation of insulin and glycemia.
Topics: Animals; Axons; Blood Glucose; Channelrhodopsins; Choline O-Acetyltransferase; Cholinergic Fibers; Cholinergic Neurons; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Optogenetics; Pancreas; Vagus Nerve; Vagus Nerve Stimulation | 2021 |
Glucagon use by U.S. adults with type 1 and type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Retrospective Studies; United States | 2021 |
Effect of Therapeutic Ultrasound on the Release of Insulin, Glucagon, and Alpha-Amylase from Ex Vivo Pancreatic Models.
Topics: alpha-Amylases; Animals; Diabetes Mellitus, Type 2; Glucagon; Insulin; Pancreas; Rabbits | 2021 |
Genetic activation of α-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fasting; Female; Glucagon; Glucagon-Secreting Cells; Glucokinase; Glucose; Glucose Intolerance; Hyperinsulinism; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Mice | 2021 |
Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion.
Topics: Adult; Blood Glucose; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Germany; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Pancreas | 2021 |
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.
Topics: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Humans; Incretins; Receptors, G-Protein-Coupled; Receptors, Gastrointestinal Hormone | 2021 |
Vitamin D binding protein/GC-globulin: a novel regulator of alpha cell function and glucagon secretion.
Topics: Actins; Diabetes Mellitus, Type 2; Globulins; Glucagon; Glucose; Humans; Vitamin D; Vitamin D-Binding Protein | 2022 |
Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucagon; Humans | 2021 |
Physicochemical characterization and the hypoglycemia effects of polysaccharide isolated from
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Fatty Acids, Volatile; Glucagon; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Intestinal Mucosa; Mice; Passiflora; Polysaccharides; Proprotein Convertase 1; Triglycerides; Up-Regulation; Weight Gain | 2021 |
Lack of Improvement in Insulin Sensitivity After Pancreas Transplantation in Recipients With a High Level of Calcineurin Inhibitors.
Topics: Adult; Blood Glucose; Calcineurin Inhibitors; Cyclosporine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas Transplantation; Tacrolimus | 2021 |
Thermo-Responsive self-assembly of a dual glucagon-like peptide and glucagon receptor agonist.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Pharmaceutical Preparations; Receptors, Glucagon | 2021 |
Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Topics: Adult; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Japan; Liraglutide; Male; Middle Aged; Peptides; Postprandial Period; Prospective Studies; Recombinant Fusion Proteins | 2021 |
GRK2 contributes to glucose mediated calcium responses and insulin secretion in pancreatic islet cells.
Topics: Animals; Calcium; Cell Line; Cyclic AMP; Diabetes Mellitus, Type 2; Diet, High-Fat; Down-Regulation; G-Protein-Coupled Receptor Kinase 2; Glucagon; Glucose; Glucose Intolerance; Glucose Tolerance Test; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Lipid Peroxidation; Mice; Mice, Knockout; Obesity | 2021 |
Comparative Effects of the Branched-Chain Amino Acids, Leucine, Isoleucine and Valine, on Gastric Emptying, Plasma Glucose, C-Peptide and Glucagon in Healthy Men.
Topics: Adult; Amino Acids, Branched-Chain; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Insulin; Isoleucine; Leucine; Male; Middle Aged; Postprandial Period; Valine; Whey Proteins; Young Adult | 2021 |
Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls.
Topics: Aged; Arrhythmias, Cardiac; Blood Pressure; Diabetes Mellitus, Type 2; Electrocardiography; Female; Glucagon; Growth Hormone; Heart Rate; Humans; Hydrocortisone; Hypoglycemia; Male; Middle Aged; Norepinephrine; Potassium | 2021 |
Sam68 promotes hepatic gluconeogenesis via CRTC2.
Topics: Adaptor Proteins, Signal Transducing; Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Gene Expression Regulation; Glucagon; Gluconeogenesis; Glucose; Hepatocytes; Homeostasis; Humans; Hyperglycemia; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; RNA-Binding Proteins; Transcription Factors; Up-Regulation | 2021 |
Disordered branched chain amino acid catabolism in pancreatic islets is associated with postprandial hypersecretion of glucagon in diabetic mice.
Topics: Amino Acids, Branched-Chain; Animals; Calcium; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Palmitates; Postprandial Period | 2021 |
Whey protein preload enhances the active GLP-1 response and reduces circulating glucose in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Proteins; Dietary Supplements; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hyperglycemia; Incretins; Insulin; Polycystic Ovary Syndrome; Postprandial Period; Whey Proteins; Young Adult | 2021 |
A method for constructing GLP-1 overexpression intestinal organoids.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Insulin; Mice; Organoids | 2021 |
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Fats; DNA, Bacterial; Gastrointestinal Microbiome; Glucagon; Glycogen; Hypoglycemic Agents; Insulin; Lacticaseibacillus casei; Liver; Male; Metformin; Mice; Probiotics; Random Allocation; RNA, Bacterial; RNA, Ribosomal, 16S | 2021 |
Synthesis and anti-diabetic activity of novel biphenylsulfonamides as glucagon receptor antagonists.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Mice, Inbred C57BL; Molecular Structure; Receptors, Glucagon; Structure-Activity Relationship; Sulfonamides | 2021 |
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucagon; Hyperglycemia; Lacticaseibacillus rhamnosus; Mice; Signal Transduction | 2021 |
Hormonal regulation of glycine decarboxylase and its relationship to oxidative stress.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastrointestinal Agents; Gene Expression Regulation, Enzymologic; Glucagon; Glutathione; Glycine; Glycine Dehydrogenase (Decarboxylating); HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2021 |
Defective insulin maturation in patients with type 2 diabetes.
Topics: Adult; Aldehyde Oxidoreductases; Case-Control Studies; Cell Dedifferentiation; China; Diabetes Mellitus, Type 2; Female; Glucagon; Homeodomain Proteins; Humans; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prediabetic State; Proinsulin; Protein Processing, Post-Translational | 2021 |
Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression.
Topics: Adult; China; Diabetes Mellitus, Type 2; Glucagon; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2021 |
O-GlcNAcylated p53 in the liver modulates hepatic glucose production.
Topics: Acetylglucosamine; Animals; Base Sequence; Caloric Restriction; Cell Line; Colforsin; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Glucocorticoids; Gluconeogenesis; Glucose; Glycosylation; Hepatocytes; Humans; Hydrocortisone; Hyperglycemia; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Liver; Mice, Inbred C57BL; Mice, Knockout; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Promoter Regions, Genetic; Protein Binding; Protein Stability; Pyruvic Acid; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Protein p53 | 2021 |
The Human and Mouse Islet Peptidome: Effects of Obesity and Type 2 Diabetes, and Assessment of Intraislet Production of Glucagon-like Peptide-1.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Islets of Langerhans; Mice; Obesity | 2021 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic | 2017 |
Normal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivity.
Topics: Blood Glucose; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Male; Middle Aged; Postprandial Period; Retrospective Studies; Sensitivity and Specificity | 2018 |
Circadian orchestration of insulin and glucagon release.
Topics: Circadian Clocks; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Insulin-Secreting Cells; Suprachiasmatic Nucleus | 2017 |
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rodentia; Signal Transduction; Sodium-Glucose Transporter 2 | 2017 |
Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes.
Topics: Brain; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Obesity; Precision Medicine | 2017 |
How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?
Topics: Blood Glucose; Brain; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Glucose; Homeostasis; Humans; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans | 2017 |
Hepatic β-arrestin 2 is essential for maintaining euglycemia.
Topics: Animals; beta-Arrestin 1; beta-Arrestin 2; Blood Glucose; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Deletion; Gene Expression Regulation; Glucagon; Hepatocytes; Homeostasis; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Receptors, Glucagon; Signal Transduction | 2017 |
Recycling of glucagon receptor to plasma membrane increases in adipocytes of obese rats by soy protein; implications for glucagon resistance.
Topics: Adipocytes; Adipose Tissue, White; Animals; Cell Membrane; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Gene Expression Regulation; Glucagon; Hyperglycemia; Male; Obesity; rab GTP-Binding Proteins; Rats; Rats, Zucker; Receptors, Glucagon; Soybean Proteins; Triglycerides | 2017 |
Comparison of pancreatic beta cells and alpha cells under hyperglycemia: Inverse coupling in pAkt-FoxO1.
Topics: Adenoma; Animals; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; Glucagon; Glucagon-Secreting Cells; Glucose; Hydrogen Peroxide; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Insulinoma; Mice; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt | 2017 |
Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Pancreatitis, Chronic | 2017 |
Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.
Topics: Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Linagliptin | 2017 |
Rebirth of the Incretin Concept: Its conception and early development.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hyperglycemia; Incretins; Insulin; Peptide Fragments | 2018 |
Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.
Topics: Blood Glucose; Cohort Studies; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Female; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Insulin; Insulin Secretion; London; Male; Middle Aged; Monitoring, Ambulatory; Obesity; Postoperative Complications; Postprandial Period; Prevalence; Risk Factors | 2017 |
Incretins and Their Endocrine and Metabolic Functions.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Tract; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells | 2017 |
Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Postprandial Period | 2019 |
Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Male; Middle Aged; Obesity; Pancreas; Somatostatin | 2017 |
Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
Topics: Adult; Aged; Amino Acids; Biomarkers; Body Mass Index; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Insulin Resistance; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Up-Regulation | 2018 |
Involvement of stanniocalcins in the deregulation of glycaemia in obese mice and type 2 diabetic patients.
Topics: Adult; Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Obese; Middle Aged; Organ Size; Pancreas | 2018 |
[Effect of Electroacupuncture at "Weiwanxiashu" (EX-B 3) on Islet Morphology and the Expression of Pancreatic Glucagon-like Peptide-1 Receptor in Type 2 Diabetes Rats].
Topics: Acupuncture Points; Animals; Diabetes Mellitus, Type 2; Electroacupuncture; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Islets of Langerhans; Male; Pancrelipase; Rats; Rats, Sprague-Dawley | 2017 |
Differential associations of lower cardiac vagal tone with insulin resistance and insulin secretion in recently diagnosed type 1 and type 2 diabetes.
Topics: Adolescent; Adult; Aged; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Clamp Technique; Heart; Heart Rate; Humans; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Vagus Nerve; Young Adult | 2018 |
Measurement of Gastrointestinal Hormones.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Mass Spectrometry; Neuropeptides; Obesity; Oxyntomodulin; Specimen Handling | 2017 |
Honokiol protects pancreatic β cell against high glucose and intermittent hypoxia-induced injury by activating Nrf2/ARE pathway in vitro and in vivo.
Topics: Animals; Apoptosis; Biphenyl Compounds; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Free Radical Scavengers; Glucagon; Hypoxia; Insulin; Insulin Resistance; Insulin-Secreting Cells; Lignans; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sleep Apnea, Obstructive | 2018 |
Enteroendocrine and adipokine associations with type 2 diabetes: Phenotypic risk scoring approaches.
Topics: Adipokines; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Metabolic Syndrome; Middle Aged; Phenotype; Risk Assessment; Young Adult | 2018 |
Patterns of Plasma Glucagon Dynamics Do Not Match Metabolic Phenotypes in Young Women.
Topics: Adult; Blood Glucose; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucagon; Glucose Tolerance Test; Humans; Phenotype; Prediabetic State; Pregnancy | 2018 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure.
Topics: Adolescent; Adult; Body Mass Index; Child; Cystic Fibrosis; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin-Secreting Cells; Interleukin-1beta; Lung Transplantation; Male; Pancreas; Pancreatic Polypeptide; Retrospective Studies; Somatostatin; Young Adult | 2018 |
Islet proteomics reveals genetic variation in dopamine production resulting in altered insulin secretion.
Topics: Animals; Diabetes Mellitus, Type 2; Dopamine; Female; Genetic Variation; Glucagon; Insulin Secretion; Islets of Langerhans; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Phenotype; Proteome; Proteomics | 2018 |
Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission.
Topics: Blood Glucose; Caloric Restriction; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liver; Male; Middle Aged; Obesity; Peptide YY; Postprandial Period; Remission Induction | 2018 |
Neprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Deletion; Glucagon; Glucagon-Secreting Cells; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neprilysin; Organ Size; Pancreas | 2018 |
Human pancreatic α- to β-cell area ratio increases after type 2 diabetes onset.
Topics: Aged; Cell Proliferation; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin-Secreting Cells; Male; Middle Aged | 2018 |
Secretagogin is increased in plasma from type 2 diabetes patients and potentially reflects stress and islet dysfunction.
Topics: Adult; Aged; Animals; Biomarkers; Cell Nucleus; Cohort Studies; Cytokines; Cytoplasm; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Middle Aged; Secretagogins | 2018 |
Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glucagon-Like Peptide 1; Humans; Obesity; Overweight; Peptides; Receptors, Glucagon | 2018 |
[Life-threatening ketoacidosis in patients with type 2 diabetes on LCHF diet].
Topics: Adult; Critical Illness; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diet, Ketogenic; Glucagon; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Paradigm Shifts in Nocturnal Glucose Control in Type 2 Diabetes.
Topics: Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Body Mass Index; C-Peptide; Case-Control Studies; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucagon; Homeostasis; Humans; Insulin; Male; Middle Aged; Prognosis; Sleep | 2018 |
GLUCAGON PRESCRIPTIONS FOR DIABETES PATIENTS AFTER EMERGENCY DEPARTMENT VISITS FOR HYPOGLYCEMIA.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Emergencies; Emergency Service, Hospital; Female; Glucagon; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies | 2018 |
Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
Topics: Administration, Intravenous; Arginine; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eating; Enteroendocrine Cells; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin-Secreting Cells; Peptide YY; Postprandial Period; Prediabetic State; Time Factors; United States | 2018 |
Pancreatic β-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Flow Cytometry; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Mice | 2019 |
Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production.
Topics: Adenosine Triphosphate; Animals; Cell Line; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Hyperglycemia; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Potassium Channels; Rats; Rats, Wistar; Sodium | 2019 |
Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Topics: Adiposity; Adult; Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prognosis; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Ultrasonography | 2019 |
Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection?
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pancreatic Neoplasms; Pioglitazone | 2019 |
Gut Hormone Responses to Mixed Meal Test in New-Onset Prediabetes/Diabetes After Acute Pancreatitis.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Magnetic Resonance Imaging; Male; Meals; Middle Aged; Oxyntomodulin; Pancreatitis; Peptide YY; Postprandial Period; Prediabetic State; Subcutaneous Fat | 2019 |
Dynamic changes in insulin and glucagon during disease progression in rhesus monkeys with obesity-related type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Glucagon; Glucose Tolerance Test; Insulin; Macaca mulatta; Male; Monitoring, Physiologic; Obesity | 2019 |
Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysis.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2019 |
Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
Topics: Administration, Intranasal; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastrointestinal Agents; Glucagon; Humans; Hypoglycemia; Injections; Models, Economic | 2019 |
PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Type 2; Fasting; Female; Gene Expression Regulation; Glucagon; Gluconeogenesis; Glucose; Hepatocytes; Homeostasis; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Liver Diseases; Male; Mice; Models, Animal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
A novel measure of glucose homeostasis (or loss thereof) comprising the joint dynamics of glucose, insulin, glucagon, and cortisol.
Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Glucagon; Homeostasis; Humans; Hydrocortisone; Insulin; Insulin Resistance; Insulin Secretion; Prediabetic State | 2019 |
Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.
Topics: Ampulla of Vater; Bariatric Surgery; Bile; Bile Acids and Salts; Bilirubin; Blood Glucose; Cholestasis, Extrahepatic; Diabetes Mellitus, Type 2; Duodenal Neoplasms; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Pancreaticoduodenectomy; Postprandial Period | 2019 |
Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly.
Topics: Acromegaly; Adult; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hyperglycemia; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Prospective Studies; Receptors, Gastrointestinal Hormone | 2019 |
Study of Possible Relation between Fasting Plasma Glucagon, Gestational Diabetes and Development of Type 2 DM.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fasting; Female; Glucagon; Humans; Insulin; Predictive Value of Tests; Pregnancy; Young Adult | 2020 |
Glucagon secretions are impaired in patients with fulminant type 1 diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Islets of Langerhans; Prognosis | 2019 |
Oxygen dependence of glucose sensing: role in glucose homeostasis and related pathology.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucokinase; Glucose; Homeostasis; Humans; Hyperglycemia; Insulin; Oxidative Phosphorylation; Oxygen; Pancreas; Regional Blood Flow; Vascular Diseases | 2019 |
Cellular stressors may alter islet hormone cell proportions by moderation of alternative splicing patterns.
Topics: Alternative Splicing; Cell Line; Cytokines; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Gene Expression; Gene Expression Profiling; Glucagon; Glucose; Humans; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Neuroendocrine Cells; Protein Kinase Inhibitors; Stress, Physiological | 2019 |
Induction of α cell-restricted Gc in dedifferentiating β cells contributes to stress-induced β-cell dysfunction.
Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Epigenomics; Female; Forkhead Box Protein O1; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; Histones; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Knockout; Parity; Transcriptome; Vitamin D-Binding Protein | 2019 |
A brief interactive training with medical students improves their diabetes knowledge about hypoglycemia.
Topics: Adult; Clinical Competence; Curriculum; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemia; Learning; Male; Primary Health Care; Students, Medical; Surveys and Questionnaires; Young Adult | 2019 |
Pancreatic fat is related to the longitudinal decrease in the increment of C-peptide in glucagon stimulation test in type 2 diabetes patients.
Topics: Adipose Tissue; Aged; Biomarkers; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fatty Liver; Female; Follow-Up Studies; Gastrointestinal Agents; Glucagon; Glucose Tolerance Test; Humans; Longitudinal Studies; Male; Pancreatic Diseases; Prognosis | 2020 |
Proinsulin associates with poor β-cell function, glucose-dependent insulinotropic peptide, and insulin resistance in persistent type 2 diabetes after Roux-en-Y gastric bypass in humans.
Topics: Adult; Blood Glucose; Body Weight; C-Peptide; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Recurrence | 2020 |
Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery.
Topics: Adolescent; Adult; Balloon Enteroscopy; Biomarkers; Blood Glucose; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Intestines; Male; Meals; Middle Aged; Obesity, Morbid; Postprandial Period; Prognosis; Prospective Studies; Young Adult | 2019 |
Biomarkers of insulin action during single soccer sessions before and after a 12-week training period in type 2 diabetes patients on a caloric-restricted diet.
Topics: Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Diet, Reducing; Exercise Therapy; Female; Glucagon; Humans; Insulin; Insulin Resistance; Lactic Acid; Leptin; Male; Middle Aged; Physical Conditioning, Human; Soccer; Treatment Outcome | 2019 |
The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes.
Topics: Blood Glucose; Cardiology; Diabetes Mellitus, Type 2; Glucagon; Heart Failure; Humans; Insulin; Translational Research, Biomedical | 2020 |
Response to 'The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes'.
Topics: Blood Glucose; Cardiology; Diabetes Mellitus, Type 2; Glucagon; Heart Failure; Humans; Insulin; Translational Research, Biomedical | 2020 |
Relationships between Body Composition and Plasma Levels of Pancreatic, Gut, and Adipose Tissue Hormones in db/db Mice, a Model of Type 2 Diabetes Mellitus.
Topics: Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Leptin; Male; Mice; Mice, Inbred NOD; Pancreatic Hormones; Plasminogen Activators; Resistin | 2019 |
The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes.
Topics: Adult; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Republic of Korea | 2014 |
The impact of the repair of staple line dehiscence in post-RYGB patients on glucose homeostasis and gut hormones--a preliminary study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Gastrointestinal Hormones; Ghrelin; Glucagon; Glucose Tolerance Test; Homeostasis; Humans; Insulin; Leptin; Male; Middle Aged; Obesity, Morbid; Secondary Prevention; Surgical Stapling; Surgical Wound Dehiscence | 2013 |
Glucose homeostasis, obesity and diabetes.
Topics: Aging; Body Mass Index; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Intolerance; Glucose Transport Proteins, Facilitative; Glycogen; Homeostasis; Humans; Inflammation Mediators; Insulin; Insulin Resistance; Metabolic Syndrome; Obesity; Obesity, Abdominal; Sodium-Glucose Transport Proteins | 2013 |
Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.
Topics: Adolescent; Adult; Aged; Area Under Curve; Bariatric Surgery; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Duodenum; Eating; Endoscopy; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Jejunum; Male; Middle Aged; Netherlands; Obesity; Pilot Projects; Postprandial Period; Remission Induction; Time Factors; Treatment Outcome; Weight Loss | 2013 |
GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Blood Glucose; Body Composition; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity, Morbid; Treatment Outcome | 2013 |
Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Male; Middle Aged | 2013 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Bypass; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Peptide Fragments; Receptors, Glucagon | 2013 |
Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Topics: Animals; C-Peptide; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Treatment Outcome; Triazoles; Umbilical Cord | 2014 |
Impairment of pancreatic β-cell function by chronic intermittent hypoxia.
Topics: Animals; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Glucagon; Homeostasis; Humans; Hypoxia; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mitochondria; Models, Biological; Proinsulin; Reactive Oxygen Species; Sleep Apnea Syndromes | 2013 |
A mixed mirror-image DNA/RNA aptamer inhibits glucagon and acutely improves glucose tolerance in models of type 1 and type 2 diabetes.
Topics: Animals; Aptamers, Nucleotide; Blood Glucose; Body Weight; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Glucagon; Glucose Tolerance Test; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; RNA | 2013 |
Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats.
Topics: Administration, Intravenous; Animals; Blood Glucose; Bone Marrow; C-Peptide; Culture Media, Conditioned; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rats; Rats, Sprague-Dawley; Streptozocin | 2013 |
Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Obesity; Obesity, Morbid; Weight Loss | 2013 |
RNAi screening in primary human hepatocytes of genes implicated in genome-wide association studies for roles in type 2 diabetes identifies roles for CAMK1D and CDKAL1, among others, in hepatic glucose regulation.
Topics: Calcium-Calmodulin-Dependent Protein Kinase Type 1; Cyclic AMP-Dependent Protein Kinases; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Type 2; Extracellular Signal-Regulated MAP Kinases; Gene Knockdown Techniques; Genome-Wide Association Study; Genome, Human; Glucagon; Glucose; Glycogen; Hep G2 Cells; Hepatocytes; Homeostasis; Humans; Intracellular Signaling Peptides and Proteins; Phosphoenolpyruvate Carboxykinase (GTP); Phosphorylation; Polymorphism, Single Nucleotide; Primary Cell Culture; Protein Processing, Post-Translational; Protein Transport; Pyruvic Acid; Ribosomal Protein S6 Kinases; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factors; tRNA Methyltransferases | 2013 |
Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats.
Topics: Animals; Blood Glucose; Cannabinoid Receptor Agonists; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dronabinol; Drug Evaluation, Preclinical; Glucagon; Insulin; Islets of Langerhans; Lipid Metabolism; Lipoproteins; Male; Rats, Sprague-Dawley | 2014 |
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Topics: Animals; Benzofurans; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Glucagon; Glycated Hemoglobin; Homeodomain Proteins; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Proliferating Cell Nuclear Antigen; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; Sulfones; Time Factors; Trans-Activators | 2013 |
Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT.
Topics: Adult; Aged; Alanine Transaminase; Area Under Curve; Biomarkers; Diabetes Mellitus, Type 2; Eating; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Incretins; Lipid Metabolism; Male; Middle Aged; Triglycerides | 2013 |
Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet.
Topics: Animals; Blood Glucose; Body Weight; Cell Dedifferentiation; Densitometry; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Fluorescent Antibody Technique; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Glycated Hemoglobin; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Macaca mulatta; Nuclear Proteins; Protective Agents; Resveratrol; Sirtuin 1; Stilbenes; Transcription Factors | 2013 |
Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Male; Rats; Rats, Zucker | 2013 |
Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists.
Topics: Animals; Blood Glucose; Cell Line; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Evaluation, Preclinical; Glucagon; HEK293 Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Obese; Proteolysis; Receptors, Glucagon | 2013 |
The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance.
Topics: Adult; Animals; Cation Transport Proteins; Diabetes Mellitus, Type 2; Endocytosis; Genotype; Glucagon; Hep G2 Cells; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Protein Transport; Receptor, Insulin; Sequence Analysis, DNA; Zinc; Zinc Transporter 8 | 2013 |
Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Gastrectomy; Gastric Bypass; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glycemic Index; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Middle Aged; Obesity, Morbid; Pancreatic Polypeptide; Peptide YY; Remission Induction | 2013 |
Expression of mesenchymal and α-cell phenotypic markers in islet β-cells in recently diagnosed diabetes.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Insulin-Secreting Cells; Mesoderm; Middle Aged; Young Adult | 2013 |
Glucagon gene polymorphism modifies the effects of smoking and physical activity on risk of type 2 diabetes mellitus in Han Chinese.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alleles; Asian People; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Glucagon; Humans; Male; Middle Aged; Motor Activity; Polymorphism, Single Nucleotide; Risk; Smoking; Young Adult | 2014 |
The mammalian INDY homolog is induced by CREB in a rat model of type 2 diabetes.
Topics: Animals; Chromatin Immunoprecipitation; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucagon; Hep G2 Cells; Hepatocytes; Humans; Male; Promoter Regions, Genetic; Rats; Rats, Wistar; Symporters | 2014 |
Are we overestimating the loss of beta cells in type 2 diabetes?
Topics: Aged; Chromogranin A; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Male; Microscopy, Electron; Pancreas | 2014 |
Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channels; Diabetes Mellitus, Type 2; Exocytosis; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; In Vitro Techniques; KATP Channels; Membrane Potentials; Mice; Mutation; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Tissue Donors; Tolbutamide | 2013 |
The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Breakfast; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Lunch; Male; Meals; Middle Aged; Postprandial Period; Triglycerides | 2014 |
[The effects of gastric bypass procedures on blood glucose, gastric inhibitory polypeptide and glucagon-like peptide-1 of normal glucose tolerance dogs].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin | 2013 |
Study of CRTC2 pharmacology using antisense oligonuceotides.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Fats; Gene Expression Regulation; Glucagon; Hepatocytes; High-Throughput Screening Assays; Liver; Mice; Mice, Inbred NOD; Oligonucleotides; Oligonucleotides, Antisense; Primary Cell Culture; RNA, Messenger; Transcription Factors | 2014 |
Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans.
Topics: Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Glucagon; Humans; Oxyntomodulin; Radioimmunoassay; Sensitivity and Specificity | 2014 |
Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prediabetic State | 2014 |
Progressive change of intra-islet GLP-1 production during diabetes development.
Topics: Algorithms; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Immunohistochemistry; Islets of Langerhans; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Mutant Strains; Prediabetic State; Proprotein Convertase 1; Up-Regulation | 2014 |
The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
Topics: Animals; Benzamides; Blood Glucose; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Discovery; Glucagon; Mice; Mice, Inbred ICR; Obesity; Prediabetic State; Receptors, Glucagon; Spiro Compounds; Structure-Activity Relationship | 2014 |
Enzogenol improves diabetes-related metabolic change in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Flavonoids; Glucagon; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Quercetin | 2014 |
Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.
Topics: Administration, Intravenous; Administration, Oral; Adult; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucokinase; Glucose; Hepatocyte Nuclear Factor 1-alpha; Humans; Incretins; Insulin Resistance; Male; Middle Aged | 2014 |
Abnormal alpha cell function in diabetics response to insulin.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin | 1972 |
Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes.
Topics: Animals; Blood Glucose; Body Mass Index; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Incretins; Insulin; Male | 2014 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Diabetes. Attenuated incretin effect after glucose loading in monogenic HNF1A diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Incretins; Male | 2014 |
Glycoprotein 130 receptor signaling mediates α-cell dysfunction in a rodent model of type 2 diabetes.
Topics: Animals; Cytokine Receptor gp130; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Glucagon-Secreting Cells; Interleukin-6; Male; Mice; Mice, Knockout; Phosphorylation; Rats; STAT3 Transcription Factor | 2014 |
Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.
Topics: Animals; Binding Sites; Blood Glucose; Catalytic Domain; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastric Emptying; Genetic Predisposition to Disease; Glucagon; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulysin; Islet Amyloid Polypeptide; Macrocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Obesity; Signal Transduction; Thinness | 2014 |
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Infusions, Intravenous; Insulin; Middle Aged | 2014 |
[Changes of plasma glucagon level in individuals with different glucose metabolism].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance | 2014 |
PTEN deletion in pancreatic α-cells protects against high-fat diet-induced hyperglucagonemia and insulin resistance.
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Glucagon; Glucagon-Secreting Cells; Hyperglycemia; Insulin Resistance; Insulin-Secreting Cells; Male; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction | 2015 |
Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells.
Topics: Animals; Blood Glucose; Body Temperature; Body Weight; Cell Line; Ceramides; Cricetinae; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Secreting Cells; Hyperglycemia; Hyperinsulinism; Insulin; Insulin-Secreting Cells; Lipogenesis; Male; Mice, Inbred C57BL; Rats; Receptors, Glucagon; RNA, Messenger | 2014 |
Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonylurea Compounds; Treatment Outcome | 2014 |
[Study on correlation of glucagons, type 2 diabetes and impaired glucose regulation].
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged | 2014 |
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Topics: Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Japan; Middle Aged; Monitoring, Ambulatory; Postprandial Period; Pyrazoles; Thiazolidines | 2015 |
[Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
Topics: Appetite; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastric Emptying; Glucagon; Glucagon-Like Peptide-1 Receptor; Hormones; Humans; Hypoglycemic Agents; Insulin; Receptors, Glucagon; Treatment Outcome | 2014 |
Glucagon secretion after metabolic surgery in diabetic rodents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gastrectomy; Gastric Bypass; Glucagon; Glucose Tolerance Test; Humans; Insulin; Male; Postprandial Period; Random Allocation; Rats; Rats, Wistar; Time Factors; Treatment Outcome | 2014 |
[The elderly diabetic patient. Hypoglycemia under control].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Sucrose; Glucagon; Hospitalization; Humans; Hypoglycemia; Nursing Diagnosis; Quality of Life; Reference Values; Risk Factors; Self Care | 2014 |
Postprandial lipemia induces pancreatic α cell dysfunction characteristic of type 2 diabetes: studies in healthy subjects, mouse pancreatic islets, and cultured pancreatic α cells.
Topics: Animals; Blood Glucose; Cell Survival; Cells, Cultured; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Acids, Nonesterified; Glucagon; Glucagon-Secreting Cells; Healthy Volunteers; Hyperlipidemias; Insulin; Insulin Secretion; Lipoproteins; Male; Meals; Mice; Mice, Inbred C57BL; Postprandial Period; Triglycerides | 2014 |
Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Gene Deletion; Genetic Loci; Genome-Wide Association Study; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Secretion; Insulin-Secreting Cells; Integrases; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Weight; Pancreas; Polymorphism, Single Nucleotide; Receptors, Glucagon; Transcription Factor 7-Like 2 Protein; Wnt Signaling Pathway | 2015 |
Effects of acute exercise on pancreatic endocrine function in subjects with type 2 diabetes.
Topics: Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hyperglycemia; Infusions, Intravenous; Injections; Insulin; Insulin Secretion; Male; Pancreas; Treatment Outcome | 2015 |
[The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Topics: Animals; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Homeostasis; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Malabsorption Syndromes; Mice; Mice, Knockout; Models, Biological; Obesity; Receptors, Glucagon | 2014 |
The constitutive activation of Egr-1/C/EBPa mediates the development of type 2 diabetes mellitus by enhancing hepatic gluconeogenesis.
Topics: Animals; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Early Growth Response Protein 1; Glucagon; Gluconeogenesis; Glucose; Liver; Male; Mice | 2015 |
Vitamin A deficiency causes hyperglycemia and loss of pancreatic β-cell mass.
Topics: Animals; Apoptosis; Cell Proliferation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Hyperglycemia; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Retinoic Acid 4-Hydroxylase; Retinoids; Retinol-Binding Proteins, Cellular; Signal Transduction; Vitamin A Deficiency | 2015 |
Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
Topics: Diabetes Mellitus, Type 2; Dynamin I; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Humans; Incretins; Islets of Langerhans; Ligands; Protein Transport; Receptors, G-Protein-Coupled; Receptors, Glucagon; Signal Transduction | 2015 |
Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.
Topics: Animals; Apoptosis; Blood Glucose; Caspases; Cell Proliferation; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Liraglutide; Male; Mice; Mice, Transgenic; Organ Size; Pioglitazone; Proto-Oncogene Proteins c-bcl-2; RNA, Ribosomal, 18S; Thiazolidinediones; Time Factors; Triglycerides | 2015 |
Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.
Topics: beta-Alanine; Blood Glucose; Computational Biology; Diabetes Mellitus, Type 2; Glucagon; High-Throughput Screening Assays; Humans; Liver; Molecular Dynamics Simulation; Peptide Library; Pharmaceutical Preparations; Protein Binding; Protein Conformation; Pyrazoles; Receptors, Glucagon | 2014 |
Patients with psoriasis are insulin resistant.
Topics: Adult; Anthropometry; Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glucose Intolerance; Humans; Hyperinsulinism; Inflammation; Insulin; Insulin Resistance; Male; Middle Aged; Prediabetic State; Psoriasis; Risk | 2015 |
Correlation of circulating betatrophin concentrations with insulin secretion capacity, evaluated by glucagon stimulation tests.
Topics: Aged; Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Biomarkers; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Multivariate Analysis; Peptide Hormones; Stimulation, Chemical; Time Factors | 2015 |
Inhibition of the malate-aspartate shuttle in mouse pancreatic islets abolishes glucagon secretion without affecting insulin secretion.
Topics: Animals; Aspartic Acid; Cell Line; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Glycerophosphates; Glycolysis; In Vitro Techniques; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Kinetics; Malates; Male; Membrane Transport Proteins; Metabolome; Mice; Mice, Inbred C3H; Mice, Transgenic; Mitochondria | 2015 |
Effects of autologous adipose-derived stem cell infusion on type 2 diabetic rats.
Topics: Adipocytes; Adipose Tissue; Adult Stem Cells; Animals; Autografts; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Insulin; Male; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation | 2015 |
Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area.
Topics: Aged; Blood Glucose; C-Peptide; Cell Count; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged | 2015 |
[Significance of glucagon control in the diabetes treatment].
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans | 2015 |
Orexin A regulates plasma insulin and leptin levels in a time-dependent manner following a glucose load in mice.
Topics: Animals; Blood Glucose; Calcium; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Glucose; Glucose Tolerance Test; Guanine Nucleotide Exchange Factors; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Leptin; Mice; Mice, Inbred C57BL; Orexin Receptors; Orexins | 2015 |
Calcium release channel RyR2 regulates insulin release and glucose homeostasis.
Topics: Adult; Amino Acid Substitution; Animals; Calcium; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Female; Glucagon; Glucose; Glucose Intolerance; Homeostasis; Humans; Insulin; Insulin Secretion; Ion Transport; Islets of Langerhans; Male; Mice, Obese; Mice, Transgenic; Mitochondria; Mutation, Missense; Nitrosation; Oxidation-Reduction; Point Mutation; Ryanodine Receptor Calcium Release Channel; Tachycardia, Ventricular; Young Adult | 2015 |
Association of LRP5, TCF7L2, and GCG variants and type 2 diabetes mellitus as well as fasting plasma glucose and lipid metabolism indexes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; DNA Mutational Analysis; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Glucagon; Humans; Lipid Metabolism; Low Density Lipoprotein Receptor-Related Protein-5; Male; Middle Aged; Polymorphism, Single Nucleotide; Risk; Severity of Illness Index; Transcription Factor 7-Like 2 Protein; Triglycerides; Wnt Signaling Pathway; Young Adult | 2015 |
A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Exenatide; Glucagon; Insulin; Mice; Obesity; Peptides; Satiation; Sincalide; Venoms | 2015 |
Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes.
Topics: Adolescent; Analysis of Variance; Asian People; Blood Glucose; Body Mass Index; C-Peptide; Case-Control Studies; Child; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Male; Obesity; Republic of Korea | 2016 |
Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Macaca fascicularis; Macaca mulatta; Male; Plaque, Amyloid | 2015 |
Improvement of glycemic control in streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the dipeptidyl-peptidase IV inhibitor.
Topics: Animals; British Columbia; Diabetes Mellitus, Type 2; Dietary Supplements; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endopeptidases; Fish Proteins; Food-Processing Industry; Gelatin; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Industrial Waste; Insulin; Insulin Secretion; Male; Protein Hydrolysates; Rats, Sprague-Dawley; Salmo salar; Skin | 2015 |
Relationship between circadian blood pressure variability and function of islet α and β cell in type 2 diabetes with dyssomnia.
Topics: Administration, Oral; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Dyssomnias; Female; Glucagon; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Prehypertension; Retrospective Studies | 2015 |
[Association between sleep disorders and dawn phenomenon in patients with type 2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Sleep Wake Disorders | 2015 |
Association of Canonical Wnt/β-Catenin Pathway and Type 2 Diabetes: Genetic Epidemiological Study in Han Chinese.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Asian People; beta Catenin; Body Mass Index; Case-Control Studies; China; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genotyping Techniques; Glucagon; Haplotypes; Humans; Linkage Disequilibrium; Logistic Models; Low Density Lipoprotein Receptor-Related Protein-5; Male; Middle Aged; Polymorphism, Single Nucleotide; Transcription Factor 7-Like 2 Protein; Wnt Signaling Pathway; Young Adult | 2015 |
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gastrointestinal Tract; Glucagon; Glucose; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prediabetic State; Psoriasis; Reproducibility of Results; Severity of Illness Index | 2015 |
Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT2A; Signal Transduction | 2015 |
A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Insulin-Secreting Cells; Mice; Postprandial Period; Receptors, G-Protein-Coupled | 2015 |
Six and 12 Weeks of Caloric Restriction Increases β Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Caloric Restriction; Diabetes Mellitus, Type 2; Energy Intake; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Postprandial Period; Time Factors | 2015 |
Cross-sectional and Longitudinal Analyses of Factors Contributing to the Progressive Loss of the β-cell Function in Type 2 Diabetes.
Topics: Adult; Aged; Body Mass Index; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Longitudinal Studies; Male; Middle Aged; Overweight; Regression Analysis; Thinness; Triglycerides | 2015 |
Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Proteins; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Healthy Volunteers; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Meals; Middle Aged; Postprandial Period | 2016 |
Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Topics: Animals; Animals, Newborn; Apoptosis; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Islets of Langerhans; Rats; Rats, Wistar; Sitagliptin Phosphate; Somatostatin | 2015 |
GLUCAGON PRESCRIPTION PATTERNS IN PATIENTS WITH EITHER TYPE 1 OR 2 DIABETES WITH NEWLY PRESCRIBED INSULIN.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Young Adult | 2016 |
Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Immunohistochemistry; Incretins; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Ducts; Proinsulin; Young Adult | 2015 |
Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Liraglutide; Male | 2015 |
Response to the Letter by Kalra S. et al.
Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Liraglutide; Male | 2015 |
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia.
Topics: Anemia; Diabetes Mellitus, Type 2; Fatty Liver; Glucagon; Glucagon-Secreting Cells; Humans; Models, Biological | 2016 |
Ellagic acid in Emblica officinalis exerts anti-diabetic activity through the action on β-cells of pancreas.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ellagic Acid; Fruit; Glucagon; Glutathione; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Phyllanthus emblica; Phytotherapy; Plant Extracts; Rats; Thiobarbituric Acid Reactive Substances | 2017 |
Comparison of gut hormones and adipokines stimulated by glucagon test among patients with type II diabetes mellitus after metabolic surgery.
Topics: Adipokines; Adult; Aged; Bariatric Surgery; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Gastrointestinal Hormones; Glucagon; Humans; Insulin Resistance; Male; Middle Aged; Obesity, Morbid | 2016 |
[Significance of the regulation of hyperglucagonemia in type 2 diabetes mellitus].
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Humans; Insulin; Insulin Secretion; Pancreas | 2015 |
The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers.
Topics: Adolescent; Adult; Bed Rest; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Glucose Tolerance Test; Healthy Volunteers; Humans; Incretins; Insulin; Insulin Resistance; Male; Young Adult | 2016 |
Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Intolerance; Glucose Tolerance Test; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Receptors, Glucagon | 2016 |
[Association between retinopathy and sleep disorder in patients with type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Postprandial Period; Sleep Wake Disorders | 2015 |
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes.
Topics: Cell Dedifferentiation; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; Forkhead Transcription Factors; Glucagon; Glucagon-Secreting Cells; Homeodomain Proteins; Humans; Immunohistochemistry; Insulin; Insulin Secretion; Insulin-Secreting Cells; Microscopy, Electron; Somatostatin; Somatostatin-Secreting Cells | 2016 |
Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Case-Control Studies; Child; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glicentin; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Male; Pediatric Obesity; Sweden | 2016 |
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hyperglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Secretion; Recombinant Fusion Proteins | 2016 |
Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
Topics: Adult; Aged; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Male; Middle Aged; Predictive Value of Tests | 2016 |
Glucagon secretion is increased in patients with Type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucagon; Humans; Male; Middle Aged | 2016 |
Niclosamide blocks glucagon phosphorylation of Ser552 on β-catenin in primary rat hepatocytes via PKA signalling.
Topics: Animals; beta Catenin; Bucladesine; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Glucagon; Hepatocytes; Male; Niclosamide; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-myc; Rats; Rats, Sprague-Dawley; Signal Transduction | 2016 |
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Activation and conformational dynamics of a class B G-protein-coupled glucagon receptor.
Topics: Catalytic Domain; Diabetes Mellitus, Type 2; Glucagon; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Receptors, Glucagon | 2016 |
Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
Topics: Animals; Cell Line; Cyclic AMP; Diabetes Mellitus, Type 2; Diet, High-Fat; Energy Metabolism; Gastric Inhibitory Polypeptide; Glucagon; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Mice, Obese; Motor Activity; Obesity; Rats; Receptors, Glucagon | 2016 |
Changes in obestatin gene and GPR39 receptor expression in peripheral tissues of rat models of obesity, type 1 and type 2 diabetes.
Topics: Analysis of Variance; Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Expression; Ghrelin; Glucagon; Insulin; Male; Obesity; Peptide Hormones; Rats, Wistar; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; Triglycerides | 2017 |
PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Peptide YY; Rats, Wistar; Transcription, Genetic | 2016 |
[In silico diabetology].
Topics: Computer Simulation; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Kinetics; Models, Biological; User-Computer Interface | 2016 |
Human Type 1 Diabetes Is Characterized by an Early, Marked, Sustained, and Islet-Selective Loss of Sympathetic Nerves.
Topics: Adolescent; Adult; Autonomic Nervous System; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemia; Immunohistochemistry; Islets of Langerhans; Male; Middle Aged; Pancreas; Sympathetic Nervous System; Young Adult | 2016 |
The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.
Topics: Adiposity; Adolescent; Biomarkers; Blood Glucose; Body Composition; Body Mass Index; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin Secretion; Male; Pediatric Obesity; Risk Factors | 2016 |
Effects of flavonoid-rich Chinese bayberry (Morella rubra Sieb. et Zucc.) fruit extract on regulating glucose and lipid metabolism in diabetic KK-A(y) mice.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Flavonoids; Fruit; Glucagon; Glucose-6-Phosphatase; Glutathione Peroxidase; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Lipid Metabolism; Lipids; Liver; Mice; Myrica; Organ Size; Plant Extracts; Transcription Factors | 2016 |
Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay.
Topics: Adult; Aged; Antibodies, Monoclonal; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Glucagon; Glucose Tolerance Test; Humans; Male; Middle Aged; Proglucagon; Young Adult | 2016 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
PAX4 R192H and P321H polymorphisms in type 2 diabetes and their functional defects.
Topics: Alleles; Amino Acid Substitution; Animals; Blood Glucose; Case-Control Studies; Cell Line; Cell Survival; Codon; Diabetes Mellitus, Type 2; Exons; Female; Gene Expression; Gene Frequency; Genetic Association Studies; Genotype; Glucagon; Homeodomain Proteins; Humans; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Male; Mice; Odds Ratio; Paired Box Transcription Factors; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Transport; RNA, Messenger; Stress, Physiological; Transcriptional Activation | 2016 |
CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion.
Topics: Animals; Blotting, Western; Calcium Signaling; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Electrophysiology; Exocytosis; Female; Glucagon; Glucagon-Secreting Cells; Glucose; Homeostasis; Humans; Immunohistochemistry; In Situ Hybridization; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Nerve Tissue Proteins; Real-Time Polymerase Chain Reaction | 2016 |
Cocaine- and amphetamine-regulated transcript: a novel regulator of energy homeostasis expressed in a subpopulation of pancreatic islet cells.
Topics: Animals; Brain; Diabetes Mellitus, Type 2; Glucagon; Homeostasis; Humans; Hyperglycemia; Insulin; Islets of Langerhans; Nerve Tissue Proteins | 2016 |
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Alkanesulfonates; Benzamides; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Healthy Volunteers; Humans; Hypoglycemia; Male; Middle Aged; Postprandial Period; Receptors, Glucagon; Young Adult | 2017 |
Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Prediabetic State | 2016 |
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin | 2016 |
Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Enteroendocrine Cells; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Hyperglycemia; Insulin-Secreting Cells; Male; Mice, Inbred C57BL; Mice, Transgenic; Obesity; Peptide Fragments; Phenotype | 2016 |
Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders.
Topics: Adiposity; Adult; Aged; Bariatric Surgery; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Duodenum; Female; Follow-Up Studies; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Jejunum; Male; Middle Aged; Obesity, Morbid; Treatment Outcome; Weight Loss | 2016 |
Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
Topics: Adipose Tissue; Animals; Azepines; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucose; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Orexin Receptor Antagonists; Orexins; Receptors, Leptin; Sleep; Triazoles; Triglycerides; Wakefulness | 2016 |
Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Topics: Acarbose; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Education as Topic; Weight Loss | 2017 |
Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
Topics: Animals; Atherosclerosis; Body Weight; Bone and Bones; Chemical Engineering; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Drug Synergism; Glucagon; Hyperglycemia; Liver; Metabolic Diseases; Mice; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Obesity; Triiodothyronine | 2016 |
Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Remission Induction | 2016 |
Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Topics: Biphenyl Compounds; Diabetes Mellitus, Type 2; Glucagon; Humans; Receptors, Glucagon | 2016 |
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Topics: Biphenyl Compounds; Diabetes Mellitus, Type 2; Glucagon; Humans; Receptors, Glucagon | 2016 |
Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Female; Finland; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Resistance; Life Style; Longitudinal Studies; Male; Middle Aged | 2017 |
Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes.
Topics: Animals; Body Composition; Body Weight; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Agents; Glucagon; Glucose; Insulin; Mice, Obese; Niclosamide; Treatment Outcome | 2017 |
Metabolic Syndrome: One Speckled Stone Kills a Flock of Birds?
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Liver; Glucagon; Hormones; Humans; Metabolic Syndrome; Triiodothyronine | 2017 |
Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibody Specificity; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Image Processing, Computer-Assisted; Immunohistochemistry; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pancreas; Tissue Banks; Young Adult | 2017 |
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Ketones; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Hybrid peptides in the landscape of drug discovery.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Discovery; Estrogens; Glucagon; Glucagon-Like Peptide 1; Humans; Ligands; Models, Animal; Obesity; Peptide Hormones; Recombinant Fusion Proteins | 2017 |
Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucokinase; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Rats; Rats, Sprague-Dawley; Triglycerides | 2017 |
Gastric bypass in the pig increases GIP levels and decreases active GLP-1 levels.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Obesity; Sus scrofa | 2017 |
FAM3D inhibits glucagon secretion via MKP1-dependent suppression of ERK1/2 signaling.
Topics: Animals; Cell Line; Cytokines; Diabetes Mellitus, Type 2; Dual Specificity Phosphatase 1; Enzyme Induction; Glucagon; Glucagon-Secreting Cells; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Pancreas; Proprotein Convertase 2; Receptors, Formyl Peptide | 2017 |
High-fidelity
Topics: 3' Untranslated Regions; Animals; CRISPR-Cas Systems; Diabetes Mellitus, Type 2; Gene Knock-In Techniques; Gene Targeting; Genetic Engineering; Genetic Techniques; Glucagon; Glucagon-Secreting Cells; Islets of Langerhans; Mice; Mice, Transgenic; Tamoxifen; Transgenes | 2017 |
Beneficial effect of chungkukjang on regulating blood glucose and pancreatic beta-cell functions in C75BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fermentation; Glucagon; Glucokinase; Glycated Hemoglobin; Glycine max; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Isoflavones; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Pancreas; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2008 |
Effects of glucagon on islet beta cell function in patients with diabetes mellitus.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 2008 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Glycerol; Heparin; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat.
Topics: Adipokines; Adiposity; Age Factors; Aging; Animals; Blood Glucose; Crosses, Genetic; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Female; Fertility; Ghrelin; Glucagon; Glucose Intolerance; Insulin; Insulin Resistance; Insulin-Secreting Cells; Intra-Abdominal Fat; Lipids; Male; Obesity; Rats; Rats, Sprague-Dawley; Rats, Zucker; Triglycerides | 2008 |
Insulitis in type 2 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Immunohistochemistry; Insulin; Interleukin-1beta; Islets of Langerhans; Male; Mice; Rats | 2008 |
Impaired islet turnover in human donor pancreata with aging.
Topics: Adolescent; Adult; Aged; Aging; Cell Division; Cellular Senescence; Child; Diabetes Mellitus, Type 2; Female; Glucagon; Homeodomain Proteins; Humans; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Prevalence; Risk Factors; Tissue Donors; Trans-Activators; Young Adult | 2009 |
What is known, new and controversial about GLP-1? Minutes of the 1st European GLP-1 Club Meeting, Marseille, 28-29 May 2008.
Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; France; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; L Cells; Mice | 2008 |
Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Postprandial Period | 2008 |
The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats.
Topics: Animals; Cats; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Male; Nitriles; Pyrrolidines | 2010 |
Metabolic fate of plasma glucose during hyperglycemia in impaired glucose tolerance: evidence for further early defects in the pathogenesis of type 2 diabetes.
Topics: Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Glucose Intolerance; Glycogen; Glycolysis; Humans; Hyperglycemia; Lactic Acid; Male; Middle Aged; Oxidation-Reduction | 2009 |
Adoptive transfer of syngeneic bone marrow-derived cells in mice with obesity-induced diabetes: selenoorganic antioxidant ebselen restores stem cell competence.
Topics: Adoptive Transfer; Amyloid; Animals; Antioxidants; Azoles; Bone Marrow Cells; Bone Marrow Transplantation; Cytokines; Diabetes Mellitus, Type 2; Flow Cytometry; Fluorescent Antibody Technique; Glucagon; Immunohistochemistry; Insulin; Islet Amyloid Polypeptide; Isoindoles; Mice; Mice, Mutant Strains; Obesity; Organoselenium Compounds; Stem Cells; Transplantation, Isogeneic; Vasodilation | 2009 |
Transgenic expression of insulin-response element binding protein-1 in beta-cells reproduces type 2 diabetes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Secreting Cells; Glucose; Hyperinsulinism; Insulin; Insulin Resistance; Insulin-Secreting Cells; Iron Regulatory Protein 1; Mice; Mice, Transgenic; Obesity; Phenotype; Rats; Rats, Zucker; Somatostatin-Secreting Cells | 2009 |
Attenuated sympathoadrenal responses, but not severe hypoglycemia, during aggressive glycemic therapy of early type 2 diabetes.
Topics: Adrenal Glands; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Muscle, Skeletal; Sympathetic Nervous System | 2009 |
Additional evidence that transaldolase exchange, isotope discrimination during the triose-isomerase reaction, or both occur in humans: effects of type 2 diabetes.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Deuterium; Diabetes Mellitus, Type 2; Galactose; Glucagon; Gluconeogenesis; Humans; Insulin; Isotope Labeling; Middle Aged; Obesity; Reference Values; Transaldolase; Triose-Phosphate Isomerase | 2009 |
The second-meal phenomenon in type 2 diabetes.
Topics: Arginine; Blood Glucose; C-Peptide; Catecholamines; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feeding Behavior; Glucagon; Humans; Insulin; Postprandial Period | 2009 |
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Degranulation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Eating; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Mice; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein.
Topics: Aged; Animals; Blood Glucose; Caseins; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Proteins; Diterpenes; Fatty Acids, Nonesterified; Female; Fishes; Glucagon; Glutens; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Meat; Middle Aged; Milk Proteins; Postprandial Period; Retinyl Esters; Triglycerides; Vitamin A; Whey Proteins | 2009 |
[Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Topics: Aged; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Costs; Female; Germany; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Needles; Patient Satisfaction; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2009 |
Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Awareness; Blood Glucose; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Male; Middle Aged; Norepinephrine; Reaction Time; Sensory Thresholds | 2009 |
[Indicators for insulin therapy in late elderly patients with type 2 diabetes mellitus--the relationship between plasma C-peptide on glucagon load test and insulin therapy].
Topics: Aged; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Sensitivity and Specificity | 2009 |
Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Immunohistochemistry; Insulin; Male; Middle Aged; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate | 2009 |
Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Case-Control Studies; Cognition; Diabetes Mellitus, Type 2; Epinephrine; Fasting; Glucagon; Glucose Clamp Technique; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Middle Aged; Norepinephrine; Sulfonylurea Compounds; Tremor | 2009 |
Pancreatic function of spontaneously diabetic torii rats in pre-diabetic stage.
Topics: Animals; Arginine; Benzoates; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Obesity; Organ Culture Techniques; Pancreas; Peptide Fragments; Rats; Rats, Sprague-Dawley; Tolbutamide | 2009 |
Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?
Topics: Diabetes Mellitus, Type 2; Digestion; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Humans; Intestine, Small; Jejunum; Models, Biological; Proglucagon; Signal Transduction | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2009 |
ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation.
Topics: Animals; Calcium Channels; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemia; Insulin; Insulin Secretion; KATP Channels; Male; Mice; Mice, Inbred C57BL; Nifedipine; Rats; Signal Transduction; Zinc | 2010 |
Age dependence of glucose tolerance in adult KK-Ay mice, a model of non-insulin dependent diabetes mellitus.
Topics: Age Factors; Amyloid; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Islet Amyloid Polypeptide; Leptin; Male; Mice; Mice, Inbred ICR | 2009 |
Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.
Topics: Algorithms; Animals; Antibodies, Blocking; Antibodies, Monoclonal; Blood Glucose; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Glucagon; Humans; Immunoglobulin G; Male; Mice; Mice, Obese; Models, Statistical; Postprandial Period; Receptors, Glucagon | 2009 |
Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise.
Topics: Adult; Bicycling; Blood Glucose; Catecholamines; Diabetes Mellitus, Type 2; Exenatide; Exercise; Glucagon; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Lactates; Male; Oxygen Consumption; Peptides; Reference Values; Venoms | 2010 |
Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report.
Topics: Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Enteral Nutrition; Fatty Acids, Nonesterified; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Male; Middle Aged; Obesity, Morbid; Peptide YY; Postoperative Period; Postprandial Period | 2010 |
Diabetes mellitus decreases the expression of calcitonin-gene related peptide, gamma-amino butyric acid and glutamic acid decarboxylase in human pancreatic islet cells.
Topics: Calcitonin Gene-Related Peptide; Diabetes Mellitus, Type 2; Fluorescent Antibody Technique; gamma-Aminobutyric Acid; Glucagon; Glutamate Decarboxylase; Humans; Insulin; Insulin-Secreting Cells; Pancreatectomy; Pancreatic Neoplasms | 2009 |
The time has come for incretins, a long time coming.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon; Humans; Incretins; Mice; Models, Biological; Pancreas | 2010 |
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Peptides; Phenotype; Receptors, Glucagon; Venoms | 2009 |
Targeted disruption of the CREB coactivator Crtc2 increases insulin sensitivity.
Topics: Animals; Blood Glucose; Chromatin Immunoprecipitation; Diabetes Mellitus, Type 2; DNA Primers; Electrophoresis, Polyacrylamide Gel; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; Gene Silencing; Glucagon; Gluconeogenesis; Immunoblotting; Luciferases; Mice; Mice, Knockout; Polymerase Chain Reaction; Trans-Activators; Transcription Factors | 2010 |
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
Topics: Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Time Factors; Treatment Outcome | 2010 |
Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Amyloid; Biomarkers, Tumor; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Immunoenzyme Techniques; Insulin; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Morphogenesis; Pancreas; Pancreatic Neoplasms; Pancreatic Polypeptide; Somatostatin | 2010 |
Glucose flux in controlled hyperglycaemia before and after oral glucose ingestion in men with mild type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Statistics, Nonparametric | 2010 |
Pathologic changes and glucose homeostasis according to expression of human islet amyloid polypeptide in type 2 diabetic patients.
Topics: Adult; Aged; Amyloid; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucagon; Glucose Tolerance Test; Humans; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Pancreas | 2010 |
Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
Topics: Aged; Analysis of Variance; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Insulin; Male; Middle Aged; Postprandial Period | 2010 |
Evidence for epithelial-mesenchymal transition in adult human pancreatic exocrine cells.
Topics: Adult; Amylases; Biomarkers; Cell Dedifferentiation; Cell Proliferation; Cell Transdifferentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Epithelial Cells; Glucagon; Humans; Islets of Langerhans; Mesenchymal Stem Cells; Mesoderm; Middle Aged; Pancreas, Exocrine; Pancreatic Ducts; Stem Cells; Young Adult | 2010 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2010 |
Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin | 2010 |
Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Leptin; Middle Aged; Obesity, Morbid; Postoperative Period; Stomach; Weight Loss | 2010 |
Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Glucagon; Gluconeogenesis; Glucose; Glycosuria; Humans; Hyperglycemia; Insulin Resistance; Intestinal Absorption; Liver; Postprandial Period; Reference Values; Uridine Diphosphate Glucose | 2010 |
Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Insulin; Male | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Raldh3 expression in diabetic islets reciprocally regulates secretion of insulin and glucagon from pancreatic islets.
Topics: 3T3-L1 Cells; Animals; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Isotretinoin; Mice; Mice, Inbred C57BL; Retinal Dehydrogenase | 2010 |
Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose Transporter Type 2; Insulin; Male; Melatonin; Pineal Gland; Rats; Rats, Transgenic; Rats, Wistar; Receptor, Insulin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Somatostatin | 2010 |
Delayed onset of hyperglycaemia in a mouse model with impaired glucagon secretion demonstrates that dysregulated glucagon secretion promotes hyperglycaemia and type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Glucagon; Glycogen; Hyperglycemia; Male; Mice; Mice, Knockout; Synaptotagmins | 2011 |
Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion.
Topics: Animals; Cell Line; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin-Secreting Cells; Islets of Langerhans; Mice; Mice, Mutant Strains; Models, Biological; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Rats | 2011 |
Sustained glucagon-like peptide 1 expression from encapsulated transduced cells to treat obese diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Muscle, Smooth, Vascular; Obesity; Rats; Rats, Wistar; Receptors, Leptin; Transduction, Genetic | 2011 |
Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β- and MIN6 cells.
Topics: Animals; Calcium-Binding Proteins; Cell Line; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Glucagon; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Nucleobindins; Obesity | 2011 |
Pancreatic volume and endocrine and exocrine functions in patients with diabetes.
Topics: Adult; Aged; Atrophy; C-Peptide; Chymotrypsin; Cohort Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Feces; Female; Glucagon; Humans; Islets of Langerhans; Male; Middle Aged; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Elastase; Tomography, X-Ray Computed | 2011 |
Insulin and glucagon regulate pancreatic α-cell proliferation.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucagon; Glucagon-Secreting Cells; Hypertrophy; Insulin; Mice; Mice, Inbred Strains | 2011 |
Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass.
Topics: Animals; Blood Glucose; Cell Count; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Infusions, Parenteral; Insulin; Insulin-Secreting Cells; Mice; Streptozocin | 2011 |
Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion.
Topics: Animals; Cell Line; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Humans; Insulin-Secreting Cells; Islets of Langerhans; Mice; Mice, Mutant Strains; Protein Serine-Threonine Kinases; Rats | 2011 |
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides | 2011 |
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period; Venoms | 2011 |
GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disulfides; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Half-Life; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Molecular Sequence Data; Peptides; Protein Binding; Protein Stability; Rats; Venoms | 2011 |
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women.
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucagon; Humans; Insulin; Insulin Resistance; Insulin Secretion; Liver; Male | 2011 |
A diabetes drug, sitagliptin, also has a potential to prevent diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis.
Topics: Acetylation; AMP-Activated Protein Kinases; Animals; Cell Nucleus; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; Forkhead Transcription Factors; Glucagon; Gluconeogenesis; Glucose; Histone Deacetylases; Homeostasis; Mice; Phosphorylation; Protein Serine-Threonine Kinases; Signal Transduction | 2011 |
Abnormally decreased NO and augmented CO production in islets of the leptin-deficient ob/ob mouse might contribute to explain hyperinsulinemia and islet survival in leptin-resistant type 2 obese diabetes.
Topics: Animals; Blood Glucose; Carbon Monoxide; Diabetes Mellitus, Type 2; Enzyme Assays; Female; Glucagon; Glucose; Humans; Hyperinsulinism; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Leptin; Mice; Mice, Inbred C57BL; Mice, Obese; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II | 2011 |
Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period | 2011 |
Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.
Topics: Adolescent; Adult; Age of Onset; Aged; Case-Control Studies; Child; Child, Preschool; Czechoslovakia; Denmark; Diabetes Mellitus, Type 2; Europe; Female; Genetic Association Studies; Glucagon; Glucagon-Like Peptide 1; Homozygote; Humans; Infant; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Obesity; Polymorphism, Single Nucleotide | 2011 |
Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice.
Topics: Adenosine; Animals; Cell Line; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Type 2; Genes, Reporter; Glucagon; Glucose; HEK293 Cells; Humans; Mice; Mice, Knockout; Mice, Transgenic; Nerve Tissue Proteins; Nucleic Acid Conformation; Proinsulin; Protein Biosynthesis; Recombinant Fusion Proteins; RNA, Transfer, Amino Acyl; Threonine; tRNA Methyltransferases | 2011 |
The message for MODY.
Topics: Autoantibodies; C-Peptide; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Glucagon; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Immunologic Factors; Male; Mutation; RNA, Messenger; Transcription, Genetic | 2011 |
Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes.
Topics: Age of Onset; Aged; C-Peptide; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Male; Middle Aged; Sensitivity and Specificity | 2011 |
Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats.
Topics: Animals; Blood Glucose; Body Weight; Corticosterone; Diabetes Mellitus, Type 2; Eating; eIF-2 Kinase; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; Glucagon; Gluconeogenesis; Glycated Hemoglobin; Injections, Subcutaneous; Insulin; Insulin-Like Growth Factor I; Janus Kinase 2; Leptin; Lipid Metabolism; Male; Rats; Signal Transduction | 2011 |
Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Topics: Adipose Tissue; Animals; Biological Transport; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Transporter Type 2; Glucose Transporter Type 4; Glycogen Synthase; Insulin Resistance; Liver; Male; Mitogen-Activated Protein Kinases; Muscle, Skeletal; Peptides; Phosphatidylinositol 3-Kinases; Rats; Rats, Wistar; Venoms | 2012 |
Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects.
Topics: Animals; Calcium-Binding Proteins; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Glucagon; Humans; Immunohistochemistry; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Nucleobindins; Rats; Rats, Sprague-Dawley | 2011 |
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Obesity | 2012 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Blood Glucose; Cross Reactions; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Time Factors; Treatment Outcome; Venoms | 2012 |
Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gastrectomy; Gastric Bypass; Gastrointestinal Hormones; Glucagon; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Obesity, Morbid; Prospective Studies | 2012 |
Effects of duodenal-jejunal exclusion on beta cell function and hormonal regulation in Goto-Kakizaki rats.
Topics: Animals; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Insulin; Insulin-Secreting Cells; Leptin; Male; Models, Animal; Pancreas; Random Allocation; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans.
Topics: Adult; Biomarkers; Blood Glucose; C-Peptide; Computer Simulation; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Infusion Systems; Insulin Secretion; Male; Pancreatic Hormones; Pituitary Hormones; Postprandial Period; Pulsatile Flow; Research Design; Time Factors | 2012 |
[Important therapy goal in diabetics. Intercept hypoglycemias!].
Topics: Aged; Autonomic Nervous System; Awareness; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Epinephrine; Glucagon; Glycated Hemoglobin; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Risk Factors | 2012 |
Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Genetic Variation; Genotype; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Clamp Technique; Humans; Hyperglycemia; Insulin; Insulin-Secreting Cells; KCNQ1 Potassium Channel; Membrane Proteins; Transcription Factor 7-Like 2 Protein | 2012 |
Novel pancreatic beta cell-specific proteins: antibody-based proteomics for identification of new biomarker candidates.
Topics: Antibodies; Biomarkers; Databases, Protein; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Guanine Nucleotide Exchange Factors; Humans; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Membrane Glycoproteins; Microscopy, Confocal; Platelet Glycoprotein GPIb-IX Complex; Proteomics; Receptors, Immunologic; Receptors, Prostaglandin; Serpins | 2012 |
Isosteviol has beneficial effects on palmitate-induced α-cell dysfunction and gene expression.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diterpenes, Kaurane; Fatty Acids; Female; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Hypoglycemic Agents; Insulin; Mice; Palmitates | 2012 |
Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Gαq protein-coupled and PI3K signaling pathways.
Topics: Animals; Cell Line; Cyclic AMP; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; GTP-Binding Protein alpha Subunits, Gq-G11; Liver; Male; Melanins; Mice; Mice, Knockout; Pertussis Toxin; Phosphatidylinositol 3-Kinase; Rats; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptors, Glucagon; RNA, Messenger; Signal Transduction; Tetrahydronaphthalenes; Tissue Culture Techniques; Tryptamines; Type C Phospholipases | 2012 |
Pancreatic β-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin-Secreting Cells; Mice; Microscopy, Confocal; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Rats | 2012 |
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
Topics: Animals; Area Under Curve; beta-Alanine; Blood Glucose; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Dogs; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Inhibitory Concentration 50; Macaca mulatta; Mice; Mice, Obese; Microsomes, Liver; Pyrazoles; Rats; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Receptors, Vasoactive Intestinal Peptide, Type II; Receptors, Vasoactive Intestinal Polypeptide, Type I | 2012 |
[Dysregulation of glucagon secretion in diabetes and intra-islet insulin effect on alpha-cells].
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Humans; Insulin | 2012 |
[Glucose tolerance test, glucagon stimulation test, arginine stimulation test].
Topics: Arginine; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Humans | 2012 |
Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens.
Topics: Aged; Biopsy; Diabetes Mellitus, Type 2; Female; Glucagon; Homeodomain Proteins; Humans; Hypertrophy; Insulin; Islets of Langerhans; Ki-67 Antigen; Liver Cirrhosis; Male; Middle Aged; Proliferating Cell Nuclear Antigen; Retrospective Studies; Somatostatin; Trans-Activators | 2013 |
Antidiabetic activities of oligosaccharides of Ophiopogonis japonicus in experimental type 2 diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Oligosaccharides; Ophiopogon; Organ Size; Proteinuria; Rats; Rats, Sprague-Dawley | 2012 |
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Apoptosis; Cell Proliferation; Deoxyguanosine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Rats; Time Factors; Vildagliptin | 2012 |
Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gastrins; Glucagon; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred Strains; Mice, Obese; Obesity; Omeprazole; Peptides; Venoms | 2013 |
Beta cell nuclear musculoaponeurotic fibrosarcoma oncogene family A (MafA) is deficient in type 2 diabetes.
Topics: Aged; Animals; Blood Glucose; Cell Nucleus; Cells, Cultured; Diabetes Mellitus, Type 2; Embryonic Stem Cells; Female; Glucagon; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Maf Transcription Factors, Large; Male; Middle Aged; Rats; Rats, Nude | 2012 |
Elevated NEFA levels impair glucose effectiveness by increasing net hepatic glycogenolysis.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Glucagon; Glucose Clamp Technique; Glycogen; Glycogenolysis; Human Growth Hormone; Humans; Hyperglycemia; Insulin; Liver; Male; Somatostatin | 2012 |
In vivo hyperpolarized carbon-13 magnetic resonance spectroscopy reveals increased pyruvate carboxylase flux in an insulin-resistant mouse model.
Topics: Animals; Aspartic Acid; Carbon Isotopes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucagon; Gluconeogenesis; Insulin Resistance; Liver; Magnetic Resonance Spectroscopy; Malates; Male; Mice; Mice, Inbred C57BL; Pyruvate Carboxylase; Pyruvic Acid | 2013 |
A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.
Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Immunohistochemistry; Insulin; Male; Mass Spectrometry; Middle Aged; Pancreas | 2012 |
Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy.
Topics: Algorithms; Blood Glucose; Carbohydrate Metabolism; Computer Simulation; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Glucose; Glycogen; Hepatocytes; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Liver; Models, Biological; Phosphorylation; Postprandial Period; Protein Processing, Post-Translational | 2012 |
C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Liraglutide; Male; Middle Aged; Receptors, Glucagon | 2012 |
Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
Topics: Animals; Artificial Intelligence; Diabetes Mellitus, Type 2; Exenatide; Expert Systems; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; High-Throughput Screening Assays; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Obesity; Pattern Recognition, Automated; Peptides; Rats; Rats, Zucker; Somatostatin; Somatostatin-Secreting Cells; Venoms | 2013 |
Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy.
Topics: Adiponectin; Age Factors; Aged; Blood Pressure; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Clamp Technique; Homeostasis; Humans; Insulin; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Models, Biological; Reproducibility of Results; Triglycerides; Waist Circumference | 2013 |
Impact of incretin on early-phase insulin secretion and glucose excursion.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged | 2013 |
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.
Topics: Adenylyl Cyclases; AMP-Activated Protein Kinases; Animals; Biguanides; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Enzyme Activation; Glucagon; Glucose; Hepatocytes; Hypoglycemic Agents; Liver; Metformin; Mice; Phenformin; Phosphorylation; Signal Transduction | 2013 |
Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbon Isotopes; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glucose Intolerance; Glycogenolysis; Humans; Hyperglycemia; Hyperinsulinism; Insulin; Liver; Male; Middle Aged; Prediabetic State | 2013 |
The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
Topics: Animals; Animals, Newborn; Biomarkers; Blood Glucose; Body Weight; Cell Proliferation; Clusterin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gene Expression; Glucagon; Homeodomain Proteins; Hypoglycemic Agents; In Situ Hybridization; Insulin-Secreting Cells; Peptides; Rats; Rats, Wistar; Regeneration; RNA, Messenger; Trans-Activators; Venoms | 2013 |
GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptide Fragments | 2013 |
Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: a long-term follow-up study.
Topics: Aged; Aged, 80 and over; Asian People; C-Peptide; Diabetes Mellitus, Type 2; Diagnostic Techniques, Endocrine; Disease Progression; Female; Follow-Up Studies; Glucagon; Humans; Injections; Insulin; Insulin Secretion; Male; Middle Aged; Treatment Outcome; Up-Regulation | 2013 |
On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Protein Precursors | 2002 |
Glycemic, hormone, and appetite responses to monosaccharide ingestion in patients with type 2 diabetes.
Topics: Adult; Aged; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fructose; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Humans; Insulin; Male; Middle Aged; Peptide Fragments | 2002 |
Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2002 |
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Male; Middle Aged; Obesity; Peptide Fragments; Protein Precursors; Reference Values; Time Factors | 2002 |
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
Topics: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Eating; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Islets of Langerhans; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2002 |
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Liraglutide; Male; Peptide Fragments; Protein Precursors; Swine, Miniature | 2002 |
Insulin and glucagon impairments in relation with islet cells morphological modifications following long term pancreatic duct ligation in the rabbit--a model of non-insulin-dependent diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Insulin; Islets of Langerhans; Male; Pancreatic Ducts; Rabbits; Time Factors | 2001 |
An etiologic model proposing that non-insulin-dependent diabetes mellitus is chronic hypoxic stress hyperglycemia.
Topics: Anemia; Arteriosclerosis; Arthritis, Rheumatoid; Blood Glucose; Brain; Catecholamines; Diabetes Mellitus, Type 2; Edema; Endothelins; Endothelium, Vascular; Ephedrine; Glucagon; Hemorheology; Hydrocortisone; Hyperglycemia; Hyperplasia; Hypothalamo-Hypophyseal System; Hypoxia; Mitosis; Models, Biological; Muscle, Smooth, Vascular; Pituitary-Adrenal System; Sympathetic Nervous System; Vasodilation | 2002 |
Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet.
Topics: Animals; Base Sequence; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; DNA Primers; Fatty Acids, Nonesterified; Glucagon; Insulin; Insulin Secretion; Ion Channels; Membrane Transport Proteins; Mice; Mice, Knockout; Mitochondrial Proteins; Proteins; Triglycerides; Uncoupling Protein 2; Weight Gain | 2002 |
Reduction of plasma leptin concentrations by arginine but not lipid infusion in humans.
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Glucagon; Glycerol; Heparin; Humans; Insulin; Kinetics; Leptin; Male; Middle Aged; Somatostatin | 2002 |
Theratechnologies expands peptide portfolio in endocrinology.
Topics: Administration, Cutaneous; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptide Fragments; Protein Precursors | 2002 |
Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Proteins; Energy Intake; Exercise; Fasting; Fatty Acids; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Proinsulin; Pyrazines | 2003 |
Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptide Fragments; Protein Precursors | 2003 |
Combined pancreas and kidney transplantation in a lean type 2 diabetic patient. Effects on insulin secretion and sensitivity.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Kidney Function Tests; Kidney Transplantation; Middle Aged; Pancreas Transplantation | 2002 |
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
Topics: Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Injections, Intravenous; Male; Middle Aged; Obesity; Osmolar Concentration; Peptide Fragments; Protein Precursors; Reference Values | 2003 |
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Topics: Actins; Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Proglucagon; Protease Inhibitors; Protein Precursors; Pyrroles; Valine | 2003 |
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Topics: Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Peptide Fragments; Protein Precursors; Reference Values | 2003 |
Pharmacologic treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Monosaccharide Transport Proteins; Obesity; Peptide Fragments; Peptide Hormones; Peptides; Peroxisome Proliferators; Protein Precursors; Receptors, Cell Surface; Thiazoles; Venoms | 2003 |
[Optimal drug therapy of glucose intolerance is a guarantee of successful prevention of type 2 diabetes mellitus].
Topics: Acarbose; Adult; Age Factors; Aged; Blood Glucose; Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucagon; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Life Style; Middle Aged; Multicenter Studies as Topic; Placebos; Risk Factors; Smoking Prevention | 2002 |
Residual C-peptide secretion and endothelial function in patients with Type II diabetes.
Topics: Aged; Analysis of Variance; Area Under Curve; Brachial Artery; C-Peptide; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glucagon; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Nitroglycerin; Oxidative Stress; Regional Blood Flow; Thiobarbituric Acid Reactive Substances; Ultrasonography; Vasodilator Agents | 2003 |
Glucagon-like peptide 1 content of intestinal tract in adult rats injected with streptozotocin either during neonatal period or 7 d before sacrifice.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Cecum; Colon; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Ileum; Insulin; Intestines; Jejunum; Male; Pancreas; Peptide Fragments; Protein Precursors; Proteins; Rats; Rats, Inbred BB; Rats, Wistar; Streptozocin | 2002 |
Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cell Line; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Fasting; Gene Expression Profiling; Glucagon; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Islets of Langerhans; Kinetics; Male; Rats; Rats, Wistar | 2003 |
Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects.
Topics: Adult; Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Clamp Technique; Humans; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged | 2003 |
PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets.
Topics: Animals; Colforsin; Cyclic AMP; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucagon; Glucose; Humans; Immunohistochemistry; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Microscopy, Immunoelectron; Neuropeptides; Pancreas; Pituitary Adenylate Cyclase-Activating Polypeptide; Rats; Rats, Wistar | 2003 |
GLP-1 gene delivery for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Cell Culture Techniques; Cell Line; Diabetes Mellitus, Type 2; Genetic Vectors; Glucagon; Glucagon-Like Peptide 1; Injections, Intravenous; Islets of Langerhans; Peptide Fragments; Plasmids; Protein Precursors; Rats | 2003 |
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Feeding Behavior; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Obesity; Peptide Fragments; Protein Precursors; Random Allocation | 2003 |
Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes.
Topics: Amino Acids; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fibrinogen; Glucagon; Humans; Insulin; Male; Middle Aged; Reference Values; Triglycerides | 2003 |
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Insulin; Islets of Langerhans; Male; Peptide Fragments; Protein Precursors; Rats; Rats, Sprague-Dawley; Rats, Zucker | 2003 |
Does overnight normalization of plasma glucose by insulin infusion affect assessment of glucose metabolism in Type 2 diabetes?
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Humans; Insulin; Insulin Infusion Systems; Male; Obesity; Predictive Value of Tests; Statistics, Nonparametric | 2003 |
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Topics: Amino Acid Substitution; Animals; Cells, Cultured; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzymes; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Insulin; Insulin Secretion; Mice; Mice, Obese; Peptide Fragments; Receptors, Glucagon; Spectrometry, Mass, Electrospray Ionization | 2003 |
Drug discovery and development for metabolic diseases.
Topics: Adult; Animals; Appetite; Child; Congresses as Topic; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Obesity; Peptide Fragments; Peptide YY; Pharmacology, Clinical; Protein Precursors; Receptors, Glucocorticoid | 2003 |
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Topics: Adenosine Deaminase; Amino Acid Substitution; Animals; Binding, Competitive; Blood Glucose; Cell Line, Tumor; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fibroblasts; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glutamine; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Obese; Peptide Fragments; Phenylalanine; Proline; Protein Precursors; Rats; Receptors, Glucagon; Spectrometry, Mass, Electrospray Ionization; Transformation, Genetic; Tyrosine | 2003 |
Can amylin analogue lead to better diabetes control?
Topics: Amyloid; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Management; Glucagon; Humans; Hypoglycemic Agents; Insulin; Managed Care Programs; United States; Weight Gain | 2003 |
Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus.
Topics: Adult; Anastomosis, Roux-en-Y; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hydrocortisone; Insulin; Male; Middle Aged; Obesity, Morbid; Peptide Fragments; Protein Precursors | 2004 |
Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population.
Topics: Adult; Body Mass Index; Cohort Studies; Denmark; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Gestational Age; Glucagon; Glucose Tolerance Test; Humans; Incidence; Infant, Newborn; Middle Aged; Pregnancy; Time Factors | 2004 |
A gut response. The next generation of type 2 drugs.
Topics: Diabetes Mellitus, Type 2; Exenatide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Peptide Fragments; Peptide Hormones; Peptide YY; Peptides; Protein Precursors; United States; Venoms | 2004 |
Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes.
Topics: Aged; Base Sequence; Denmark; Diabetes Mellitus, Type 2; DNA; Female; Gastric Inhibitory Polypeptide; Genetic Predisposition to Disease; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Male; Middle Aged; Molecular Sequence Data; Peptide Fragments; Phenotype; Polymerase Chain Reaction; Predictive Value of Tests; Protein Precursors; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Sequence Analysis, DNA; White People | 2004 |
Defect in glucokinase translocation in Zucker diabetic fatty rats.
Topics: Animals; Biological Transport; Blood Glucose; Carrier Proteins; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Glucokinase; Glucose; Glucose-6-Phosphate; Glycogen; Insulin; Intracellular Membranes; Intracellular Signaling Peptides and Proteins; Liver; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Thinness; Tissue Distribution | 2004 |
GLP-1: target for a new class of antidiabetic agents?
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2004 |
Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Excipients; Glucagon; Glucagon-Like Peptide 1; Hydrogels; Hypoglycemic Agents; Insulin; Lactic Acid; Male; Peptide Fragments; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Protein Precursors; Rats; Rats, Zucker; Solubility | 2004 |
Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1.
Topics: Animals; Arginine; Cathepsin A; Chromatography, Affinity; Chromatography, Ion Exchange; Cyanogen Bromide; Diabetes Mellitus, Type 2; Escherichia coli; Female; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucose; Glutathione Transferase; Humans; Insulin; Leucine; Peptide Fragments; Protein Precursors; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins | 2004 |
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.
Topics: Anastomosis, Surgical; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Female; Follow-Up Studies; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Jejunum; Male; Peptide Fragments; Protein Precursors; Rats; Rats, Inbred Strains | 2004 |
Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes.
Topics: Biological Transport; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucagon; Glycolysis; Humans; Insulin; Kinetics; Reference Values; Splanchnic Circulation | 2004 |
Novel "second-generation" approaches for the control of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptide Fragments; Protease Inhibitors; Protein Precursors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
[New diabetes therapy in clinical trial: will need adapted insulin supply be available soon? (interview by Dr. Judith Neumaier)].
Topics: Animals; Clinical Trials, Phase I as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Mice; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2004 |
A gut feeling.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2004 |
Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Family; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors | 2004 |
Orlistat augments postprandial increases in glucagon-like peptide-1 in obese type 2 diabetic patients: response to Damci et al.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Lactones; Obesity; Orlistat; Peptide Fragments; Postprandial Period; Protein Precursors | 2004 |
Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet; Energy Intake; Family; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Intolerance; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Linear Models; Male; Models, Biological; Multivariate Analysis; Peptide Fragments; Protein Precursors | 2005 |
[Risk for patients often underestimated].
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; First Aid; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Patient Education as Topic; Risk | 2004 |
A case of type 2 diabetes with high levels of plasma and urinary C-peptide.
Topics: Adult; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Fatty Liver; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Kidney; Male; Radiography | 2004 |
Glucagon-like peptide: the time is near.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Genetic Therapy; Glucagon; Glucagon-Like Peptide 1; Half-Life; Humans; Insulin; Insulin Secretion; Peptide Fragments; Protein Precursors | 2004 |
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Binding Sites; Biochemistry; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Precursors; Pyrazines; Rats; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2005 |
Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
Topics: Adult; Area Under Curve; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin; Peptide Fragments; Pregnancy; Protein Precursors; Secretory Rate | 2005 |
Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Enzyme Inhibitors; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Heart Rate; Humans; Insulin; Insulin Secretion; Lactones; Lipase; Male; Middle Aged; Orlistat; Peptide Fragments; Protein Precursors | 2004 |
A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk.
Topics: Chlorogenic Acid; Coffee; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Peptide Fragments; Protein Precursors | 2005 |
Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
Topics: Animals; Cell Proliferation; Cell Survival; Diabetes Mellitus, Type 2; Diet; Female; Gerbillinae; Glucagon; Hypoglycemic Agents; Insulin; Islets of Langerhans; Leptin; Male; Models, Animal; Peptide Fragments; Protein Precursors | 2005 |
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glycoproteins; Homeostasis; Humans; Models, Biological; Nausea; Peptide Fragments; Protein Precursors; Vomiting | 2005 |
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glycoproteins; Homeostasis; Humans; Nausea; Peptide Fragments; Protein Precursors; Vomiting | 2005 |
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoproteins; Humans; Insulin; Insulin Secretion; Models, Biological; Nerve Growth Factors; Neuropeptides; Neurotransmitter Agents; Peptide Fragments; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Precursors; Time Factors | 2005 |
What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoproteins; Glycosylation; Humans; Metformin; Mice; Nerve Growth Factors; Neuropeptides; Neurotransmitter Agents; Peptide Fragments; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Precursors | 2005 |
Proceedings from the GLP1 Meeting on the Occasion of the 80th Birthday of Prof. Dr. med. Dr. hc (em.) Werner Creutzfeldt.
Topics: Animals; Diabetes Mellitus, Type 2; Gastroenterology; Gastrointestinal Diseases; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; History, 20th Century; History, 21st Century; Humans; Liver Diseases; Pancreatic Diseases; Peptide Fragments; Peptides; Protein Precursors | 2005 |
Characterization of an N-acylated glucagon-like peptide-1 derivative by electron capture dissociation.
Topics: Acylation; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Peptide Fragments; Protein Precursors; Spectroscopy, Fourier Transform Infrared | 2005 |
[The role of incretins. Type 2 diabetes with new beginnings].
Topics: Diabetes Mellitus, Type 2; Disease Progression; Exenatide; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Peptide Fragments; Peptides; Protein Precursors; Venoms | 2005 |
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptide Fragments; Protein Precursors | 2005 |
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Insulin; Male; Mice; Mice, Obese; Obesity; Peptide Fragments; Protein Precursors; Receptors, Glucagon; Time Factors | 2005 |
Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Peptide Fragments; Protein Precursors | 2004 |
Participation of protein kinases in the stimulant action of GLP-1 on 2-deoxy-D-glucose uptake by normal rat skeletal muscle.
Topics: Animals; Biological Transport; Deoxyglucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Muscle, Skeletal; Organ Culture Techniques; Peptide Fragments; Protein Kinases; Protein Precursors; Rats; Rats, Wistar | 2005 |
On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans.
Topics: Adult; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Male; Middle Aged; Niacin; Triglycerides | 2005 |
Symlin for adults with type 1 and type 2 diabetes.
Topics: Adult; Amyloid; Appetite; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Administration Schedule; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Metabolic Clearance Rate; Nurse Practitioners; Nurse's Role; Patient Education as Topic; Patient Selection | 2005 |
Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Genetic Vectors; Glucagon; Glucagon-Like Peptide 1; Injections, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Plasmids; Protein Precursors | 2005 |
Exenatide.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Molecular Sequence Data; Peptides; Sulfonylurea Compounds; Venoms | 2005 |
Modulation of carbohydrate metabolism and peptide hormones by soybean isoflavones and probiotics in obesity and diabetes.
Topics: Adrenocorticotropic Hormone; Animals; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Glucagon; Glycine max; Insulin; Isoflavones; Leptin; Male; Obesity; Peptide Hormones; Phytoestrogens; Probiotics; Rats; Rats, Inbred SHR; Triglycerides | 2005 |
Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation; Glucagon; Glucose; Glucose Tolerance Test; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Sirtuin 1; Sirtuins | 2005 |
Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.
Topics: Alanine; Blood Glucose; Carbon Dioxide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glycerol; Glycogenolysis; Glycolysis; Humans; Hyperglycemia; Insulin; Lactic Acid; Male; Middle Aged; Oxidation-Reduction; Postprandial Period; Viscera; Water | 2006 |
KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Topics: Animals; Blood Glucose; Caco-2 Cells; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Nitriles; Peptide Fragments; Peptide Hydrolases; Protein Precursors; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine | 2005 |
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Proteins; Fasting; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Multivariate Analysis; Postprandial Period | 2005 |
[Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin Resistance; Lizards; Peptide Fragments; Peptides; Protein Precursors; Time Factors; Venoms | 2005 |
Pathophysiology of ketoacidosis in Type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Islets of Langerhans; Ketones; Middle Aged; Norepinephrine | 2005 |
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Biopsy; Diabetes Mellitus, Type 2; Duodenum; Enteroendocrine Cells; Enzyme-Linked Immunosorbent Assay; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Tolerance Test; Humans; Immunohistochemistry; Insulin; Insulin Resistance; Male; Middle Aged; Peptide Fragments; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Tolbutamide | 2005 |
New ways in which GLP-1 can regulate glucose homeostasis.
Topics: Animals; Brain; Central Nervous System; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Insulin; Models, Biological; Peptide Fragments; Proglucagon | 2005 |
Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Dietary Sucrose; Disease Models, Animal; Glucagon; Glucose; Homeostasis; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred Strains; Receptor, Insulin | 2006 |
Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gene Expression Profiling; Gene Expression Regulation; Glucagon; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; SNARE Proteins | 2006 |
Albumin and fibrinogen synthesis and insulin effect in type 2 diabetic patients with normoalbuminuria.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Fibrinogen; Glucagon; Humans; Hypertension; Hypoglycemic Agents; Insulin; Leucine; Male; Serum Albumin | 2006 |
Insulin's effect on the liver: "direct or indirect?" continues to be the question.
Topics: Animals; Diabetes Mellitus, Type 2; Dogs; Glucagon; Gluconeogenesis; Glucose; Humans; Insulin; Liver; Mice | 2006 |
Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus.
Topics: Adult; C-Reactive Protein; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Norepinephrine; Regression Analysis | 2006 |
Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice.
Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Diet; Eating; Genistein; Glucagon; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Insulin; Isoflavones; Leptin; Lipid Metabolism; Liver; Liver Glycogen; Mice; Mice, Inbred C57BL; Phytoestrogens; Receptors, Cell Surface; Receptors, Leptin | 2006 |
Hypoglycemic and hypolipidemic action of Du-zhong (Eucommia ulmoides Oliver) leaves water extract in C57BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Eucommiaceae; Glucagon; Gluconeogenesis; Glucose; Glucose Tolerance Test; Glycolysis; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pancreas; Plant Leaves; Time Factors | 2006 |
Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Glucagon; Growth Hormone; Hypoglycemic Agents; In Vitro Techniques; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Rats; Receptors, Somatostatin | 2006 |
NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Glucagon; Gluconeogenesis; Glucose; Humans; Hyperglycemia; Liver; Male; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Nuclear Receptor Subfamily 4, Group A, Member 2; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Transcription Factors | 2006 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Mellitus, Type 2; Endocrine System; Energy Intake; Glucagon; Haloperidol; Hyperinsulinism; Insulin; Insulin Resistance; Insulin Secretion; Lipid Metabolism; Male; Obesity; Rats; Rats, Sprague-Dawley; Risperidone; Species Specificity; Testosterone; Weight Gain | 2006 |
Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Carbonates; Carrier Proteins; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucokinase; Glucose; Glucose-6-Phosphatase; Glucosides; Glycogen; Glycogen Synthase; Hyperglycemia; Insulin; Liver; Liver Glycogen; Male; Muscle, Skeletal; Phosphorylases; Rats; Rats, Zucker | 2006 |
Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
Topics: Animals; Bioreactors; Blood Glucose; Cell Line; Chlorocebus aethiops; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Genetic Therapy; Glucagon; Glucagon-Like Peptide 1; Half-Life; Immunoglobulin Fc Fragments; Immunoglobulin G; Insulin; Mice; Mice, Obese; Models, Animal; Recombinant Fusion Proteins; Transfection | 2007 |
Distribution of pancreatic endocrine cells including IAPP-expressing cells in non-diabetic and type 2 diabetic cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amyloid; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Secreting Cells; Humans; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Pancreatic Polypeptide; Pancreatic Polypeptide-Secreting Cells; Reference Values; Somatostatin; Somatostatin-Secreting Cells | 2007 |
Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Hyperglycemia; Liver; Liver Glycogen; Male; Mice; Mice, Obese | 2006 |
For the ZDF rat, "Breaking up is hard to do": dissociation of the GK:GKRP complex.
Topics: Adaptor Proteins, Signal Transducing; Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucokinase; Glucose; Glucose-6-Phosphatase; Glycogen; Insulin; Liver; Phosphorylation; Rats; Rats, Zucker; Sorbitol; Time Factors | 2007 |
A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetes.
Topics: Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucokinase; Glucose; Glucose-6-Phosphatase; Glycogen; Insulin; Liver; Liver Glycogen; Male; Phosphorylation; Rats; Rats, Zucker; Sorbitol; Time Factors | 2007 |
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged; Time Factors | 2007 |
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Insulin; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; Peptide Fragments; Peptides; Polyethylene Glycols; Rats; Rats, Wistar; Receptors, Glucagon | 2007 |
Awareness of pathophysiological concepts of type 2 diabetes: a survey in 847 physicians.
Topics: Clinical Competence; Diabetes Mellitus, Type 2; Family Practice; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Humans; Insulin Resistance; Insulin-Secreting Cells; Liver; Online Systems; Primary Health Care; Surveys and Questionnaires | 2007 |
Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Male; Mexican Americans | 2007 |
Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.
Topics: Administration, Oral; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Infusions, Intravenous; Insulin; Male; Middle Aged; Time Factors | 2007 |
Multi-organ failure after a glucagon test.
Topics: Adrenal Gland Neoplasms; Adult; Diabetes Mellitus, Type 2; Diagnosis, Differential; Glucagon; Humans; Hypertension; Injections, Intravenous; Male; Multiple Organ Failure; Pheochromocytoma; Treatment Outcome | 2007 |
Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Middle Aged; Postprandial Period; Predictive Value of Tests; Reference Values; Sensitivity and Specificity | 2007 |
T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.
Topics: Adult; Aged; Antigens; Autoantibodies; C-Peptide; Cell Proliferation; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Humans; Islets of Langerhans; Male; Middle Aged; Phenotype; T-Lymphocytes | 2007 |
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Topics: Aged; Area Under Curve; Diabetes Mellitus, Type 2; Fibrinolysis; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Tissue Plasminogen Activator | 2007 |
Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease.
Topics: Acidosis, Lactic; Animals; Antiporters; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Glucagon; Glucose-6-Phosphatase; Glycogen; Glycogen Storage Disease; Hyperlipidemias; Hyperuricemia; Hypoglycemia; Kidney; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Monosaccharide Transport Proteins; Oligoribonucleotides, Antisense; RNA, Messenger | 2007 |
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Insulin; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Models, Biological | 2007 |
The common C49620T polymorphism in the sulfonylurea receptor gene (ABCC8), pancreatic beta cell function and long-term diabetic complications in obese patients with long-lasting type 2 diabetes mellitus.
Topics: Aged; ATP-Binding Cassette Transporters; Chronic Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Injections, Intravenous; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Obesity; Polymorphism, Single Nucleotide; Potassium Channels; Potassium Channels, Inwardly Rectifying; Prevalence; Receptors, Drug; Stroke; Sulfonylurea Receptors; Time Factors | 2007 |
Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
Topics: Animal Feed; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glycogen; Glycogen Synthase; Glycogenolysis; Homeostasis; Hyperglycemia; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Obese; Obesity; Receptors, Somatostatin; Triglycerides | 2007 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Homeostasis; Insulin; Leptin; Male; Rats; Rats, Inbred Strains | 2007 |
Recurrent intermittent restraint delays fed and fasting hyperglycemia and improves glucose return to baseline levels during glucose tolerance tests in the Zucker diabetic fatty rat--role of food intake and corticosterone.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Corticosterone; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucose Tolerance Test; Hormones; Hyperglycemia; Insulin; Leptin; Lipids; Male; Organ Size; Rats; Rats, Zucker; Regression Analysis; Restraint, Physical; Stress, Psychological | 2007 |
Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Arginine; Body Mass Index; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin Resistance; Insulin-Secreting Cells; Japan; Male; Middle Aged; Reference Values | 2007 |
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.
Topics: Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Postprandial Period; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Sulfonylurea Compounds | 2007 |
Susceptibility to oxidative stress, insulin resistance, and insulin secretory response in the development of diabetes from obesity.
Topics: Adult; Antioxidants; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Resistance; Insulin Secretion; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Obesity; Oxidative Stress | 2007 |
Hyperglucagonaemia is not a primary metabolic defect in non-diabetic first-degree relatives from Type 2 diabetic families.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Glucagon; Humans; Male; Pedigree | 2007 |
Association of fasting glucagon and proinsulin concentrations with insulin resistance.
Topics: Adolescent; Adult; Analysis of Variance; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperinsulinism; Insulin Resistance; Male; Multivariate Analysis; Proinsulin | 2007 |
Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice.
Topics: Albuminuria; Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Type 2; Extracellular Signal-Regulated MAP Kinases; Glucagon; Glucose; Glucose Tolerance Test; Insulin; Kidney; Liver; Male; Mice; Mice, Inbred C57BL; Models, Animal; Oncogene Protein v-akt; Phosphorylation; Receptors, Glucagon; Time | 2008 |
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Male; Middle Aged; Triglycerides | 2008 |
Gender and neurogenin3 influence the pathogenesis of ketosis-prone diabetes.
Topics: Adult; Anovulation; Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Black People; C-Peptide; Case-Control Studies; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Gene Expression; Genotype; Glucagon; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Nerve Tissue Proteins; Promoter Regions, Genetic; Sex Factors | 2008 |
Postprandial paradoxical IGFBP-1 response in obese patients with Type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 1; Male; Middle Aged; Obesity; Postprandial Period; Somatostatin | 2008 |
Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Hormones; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Reproducibility of Results | 2008 |
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Female; Gastric Emptying; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Postprandial Period; Triglycerides; Venoms | 2008 |
Automated, high-throughput assays for evaluation of human pancreatic islet function.
Topics: Animals; Autoanalysis; Calcium; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Living Donors; Macaca fascicularis; Pancreatic Hormones; Perfusion; Species Specificity | 2008 |
Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Calcium-Binding Proteins; Cardiomyopathies; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Glucagon; Insulin; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Mice; Mice, Transgenic; Obesity; Pancreas; Promoter Regions, Genetic; Receptors, Leptin; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transgenes | 2008 |
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Reducing; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Incretins; Male; Middle Aged; Obesity; Weight Loss | 2008 |
Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Male; Microscopy, Confocal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2008 |
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon; Glucagon-Like Peptide 1; Insulin; Male; Mice; Mice, Obese; Piperidines; Triglycerides; Uracil | 2008 |
Diabetes mellitus: customizing management.
Topics: Adult; Aging; Biguanides; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Male; Monitoring, Physiologic; Pregnancy; Pregnancy in Diabetics; Sulfonylurea Compounds | 1984 |
Blood glycerol levels in type-2 diabetics after beta-1-blockade and alpha-2 adrenergic stimulation.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Clonidine; Diabetes Mellitus, Type 2; Female; Glucagon; Glycerol; Humans; Male; Metoprolol; Middle Aged | 1984 |
Decreased glucagon-stimulated cyclic AMP production by isolated liver cells of rats with type 2 diabetes.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Animals; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; In Vitro Techniques; Insulin; Liver; Rats; Rats, Inbred Strains | 1983 |
Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus.
Topics: Aged; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Type 2; Endorphins; Female; Glucagon; Humans; Insulin; Male; Middle Aged | 1984 |
Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients.
Topics: Adult; Aged; Catecholamines; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Growth Hormone; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Norepinephrine | 1983 |
Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Endorphins; Glucagon; Glucose; Glucose Tolerance Test; Growth Hormone; Heroin Dependence; Humans; Insulin; Male | 1983 |
[Mechanism of action of sulfonylureas at the pancreatic and extra-pancreatic levels in prolonged treatment in noninsulin-dependent diabetic patients].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Erythrocytes; Female; Glipizide; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1983 |
Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Iodine Radioisotopes; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 1984 |
[Long-term effects of glipizide at the pancreatic and extra-pancreatic level in non-insulin dependent diabetics].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Erythrocytes; Female; Glipizide; Glucagon; Glycated Hemoglobin; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Receptor, Insulin; Sulfonylurea Compounds | 1984 |
Factors influencing beta-cell function and insulin sensitivity in patients with type 2 (non-insulin-dependent) diabetes.
Topics: Adult; Age Factors; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 1984 |
[Glucose tolerance and insulin secretion in relation to age in type-II diabetes--a contribution to the pathogenesis of type-II diabetes mellitus].
Topics: Aged; Aging; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Antibodies; Insulin Secretion; Middle Aged | 1984 |
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
Topics: Adult; Aging; Arginine; Blood Glucose; Catecholamines; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Obesity | 1984 |
Lack of relationship between plasma insulin and glucagon levels and angiographically-documented coronary atherosclerosis.
Topics: Blood Glucose; Cardiac Catheterization; Cholesterol; Coronary Angiography; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Male; Middle Aged; Triglycerides | 1984 |
Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Epinephrine; Female; Glucagon; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Pancreatectomy | 1984 |
Effect of sodium salicylate on hormonal responses to hypoglycaemia in type II diabetics.
Topics: Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Hormones; Humans; Hypoglycemia; Insulin; Middle Aged; Norepinephrine; Pancreatic Polypeptide; Secretory Rate; Sodium Salicylate | 1984 |
[Islet beta-cell function in failures following sulfonylurea therapy in diabetics, by determination of serum C-peptide].
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Islets of Langerhans; Male; Middle Aged; Sulfonylurea Compounds | 1984 |
Glucagon secretion in rats with non-insulin-dependent diabetes: an in vivo and in vitro study.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; In Vitro Techniques; Male; Pancreas; Rats; Rats, Inbred Strains | 1984 |
[Glucagon peptide--new treatment for late-onset diabetes?].
Topics: C-Peptide; Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Pancreatic Hormones; Peptides; Protein Precursors | 1994 |
Abnormal transient rise in hepatic glucose production after oral glucose in non-insulin-dependent diabetic subjects.
Topics: Animals; Blood Glucose; Deuterium; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Tolerance Test; Humans; Insulin; Liver; Male; Middle Aged; Models, Biological; Radioisotope Dilution Technique; Rats; Rats, Zucker; Reference Values; Time Factors; Tritium | 1995 |
Chronic calcific pancreatitis of the tropics (CCPT): spectrum and correlates of exocrine and endocrine pancreatic dysfunction.
Topics: Adolescent; Adult; Age of Onset; Analysis of Variance; Blood Glucose; C-Peptide; Calcinosis; Chronic Disease; Chymotrypsin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Islets of Langerhans; Male; Pancreas; Pancreatitis; Reference Values; Tropical Climate; Ultrasonography | 1995 |
Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin.
Topics: Alanine; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Fatty Acids, Nonesterified; Femoral Vein; Glucagon; Glucose; Glucose Clamp Technique; Infusions, Intravenous; Insulin; Lactates; Liver; Male; Models, Biological; Portal Vein; Signal Transduction; Somatostatin; Time Factors | 1995 |
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.
Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Peptide Fragments; Radioimmunoassay; Reference Values; Sensitivity and Specificity; Time Factors | 1995 |
C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Regression Analysis; Sulfonylurea Compounds | 1994 |
Diabetes mellitus carrying a mutation in the mitochondrial tRNA(Leu(UUR)) gene.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genetic Variation; Glucagon; Humans; Male; MELAS Syndrome; Middle Aged; Mitochondria; Molecular Sequence Data; Pedigree; Point Mutation; Polymorphism, Restriction Fragment Length; RNA, Transfer, Leu | 1995 |
A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; DNA Primers; Female; Genetic Linkage; Glucagon; Heterozygote; Humans; Male; Pedigree; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Receptors, Glucagon | 1995 |
Glucagon-like peptide-1 (GLP-1): a piece of the incretin puzzle.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Peptide Fragments; Peptides; Protein Precursors; Rodentia | 1995 |
Increased plasma gluconeogenic and system A amino acids in patients with pancreatic diabetes due to chronic pancreatitis in comparison with primary diabetes.
Topics: Amino Acids; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Male; Middle Aged; Pancreatectomy; Pancreatitis | 1994 |
Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats.
Topics: Animals; Antibodies, Monoclonal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Insulin; Male; Rats; Rats, Sprague-Dawley; Streptozocin | 1994 |
Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity: application to obesity, insulin-dependent diabetes mellitus, and noninsulin-dependent diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Obesity | 1995 |
The possible role of age-related increase in the plasma glucagon/insulin ratio in the enhanced hepatic gluconeogenesis and hyperglycemia in genetically diabetic (C57BL/KsJ-db/db) mice.
Topics: Age Factors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Fructose-Bisphosphatase; Glucagon; Gluconeogenesis; Glucose-6-Phosphatase; Hyperglycemia; Insulin; Liver; Mice; Mice, Inbred C57BL | 1994 |
Glucagon-like peptide: a therapeutic glimmer.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Peptide Fragments; Protein Precursors | 1994 |
Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Food; Glucagon; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hydroxybutyrates; Insulin; Lactates; Lactic Acid; Liver; Male; Middle Aged; Obesity | 1994 |
Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus.
Topics: Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucose; Humans; Insulin; Lactates; Lactic Acid; Lipid Metabolism; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Viscera | 1994 |
[Diabetes and hypoglycemia].
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Glucagon; Humans; Hyperinsulinism; Hypoglycemia | 1994 |
Glucose-dependent alterations of intracellular free calcium by glucagon-like peptide-1(7-36amide) in individual ob/ob mouse beta-cells.
Topics: Animals; Calcium; Cyclic AMP; Diabetes Mellitus, Type 2; Felodipine; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; In Vitro Techniques; Islets of Langerhans; Mice; Mice, Inbred C57BL; Peptide Fragments | 1994 |
The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Injections, Intravenous; Insulin; Male; Peptide Fragments; Peptides | 1994 |
Effects of glipizide on glucose metabolism and muscle content of the insulin-regulatable glucose transporter (GLUT 4) and glycogen synthase activity during hyperglycaemia in type 2 diabetic patients.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glipizide; Glucagon; Glucose; Glucose Clamp Technique; Glucose Transporter Type 4; Glycogen Synthase; Humans; Hyperglycemia; Male; Middle Aged; Monosaccharide Transport Proteins; Muscle Proteins; Muscles | 1994 |
Short cycles of very low calorie diet in the therapy of obese type II diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Reducing; Energy Intake; Female; Glucagon; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Receptor, Insulin; Weight Loss | 1994 |
Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Humans; Insulin; Male; Middle Aged; Somatostatin | 1993 |
Plasma glucagon responses to insulin-induced hypoglycemia and arginine in spontaneous non-insulin-dependent diabetes mellitus (NIDDM) rats, Otsuka Long Evans Tokushima Fatty (OLETF) strain.
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Glucagon; Hypoglycemia; Immunohistochemistry; Infusions, Intravenous; Insulin; Male; Pancreas; Pancreatic Hormones; Physical Conditioning, Animal; Radioimmunoassay; Rats; Rats, Inbred Strains; Rats, Mutant Strains | 1993 |
[Effects of insular hormones on the secretion of atrial natriuretic factor].
Topics: Adolescent; Adult; Atrial Natriuretic Factor; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperinsulinism; Insulin; Male; Middle Aged; Obesity; Potassium; Secretory Rate; Sodium | 1993 |
Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels.
Topics: Adult; Apolipoproteins B; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glucagon; Humans; Hyperlipidemias; Insulin; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Triglycerides | 1994 |
Enhancement by succinic acid dimethyl ester of insulin release evoked by D-glucose and glimepiride in the perfused pancreas of normoglycemic and hyperglycemic rats.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon; Glucose; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Pancreas; Rats; Rats, Wistar; Succinates; Sulfonylurea Compounds | 1994 |
Effects of glucose, galactose, and lactose ingestion on the plasma glucose and insulin response in persons with non-insulin-dependent diabetes mellitus.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Eating; Fatty Acids, Nonesterified; Galactose; Glucagon; Glucose; Humans; Insulin; Kinetics; Lactose; Male; Middle Aged; Time Factors | 1993 |
[C-peptide levels in secondary sulfonylurea resistant diabetics].
Topics: Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Resistance; Female; Glucagon; Glyburide; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1993 |
Suppression of gluconeogenesis after a 3-day fast does not deplete liver glycogen in patients with NIDDM.
Topics: Adult; Alanine; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Ethanol; Fasting; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Humans; Lactates; Liver; Liver Glycogen; Obesity; Reference Values | 1994 |
Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration.
Topics: Blood Glucose; C-Peptide; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Eating; Female; Forearm; Glucagon; Glucose; Humans; Insulin; Lactates; Liver; Male; Middle Aged; Palmitic Acid; Palmitic Acids; Reference Values; Time Factors | 1994 |
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Insulin; Male; Psychomotor Performance | 1994 |
Effect of added fat on plasma glucose and insulin response to ingested potato in individuals with NIDDM.
Topics: Aged; Blood Glucose; Butter; C-Peptide; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Nonesterified; Glucagon; Humans; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Reference Values; Solanum tuberosum; Time Factors; Triglycerides | 1993 |
Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.
Topics: Adolescent; Adult; Age Factors; Autoantibodies; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Follow-Up Studies; Glucagon; Glycated Hemoglobin; Humans; Insulin; Islets of Langerhans; Middle Aged; Reference Values; Time Factors | 1993 |
Transient state of NIDDM in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Pentamidine; Proinsulin | 1993 |
Pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Italy; Pheochromocytoma; Prevalence | 1993 |
Intracellular glucose metabolism after long term metabolic control with glyburide: improved glucose oxidation with unchanged glycogen synthase activity.
Topics: Blood Glucose; Body Composition; Body Mass Index; C-Peptide; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Glyburide; Glycogen Synthase; Humans; Insulin; Male; Middle Aged; Muscles; Obesity; Oxidation-Reduction; Pyruvate Dehydrogenase Complex | 1993 |
Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fasting; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycated Hemoglobin; Humans; Hypertension; Insulin; Insulin Resistance; Lipids; Liver; Middle Aged; Reference Values; Triglycerides | 1993 |
Improvement in blunted glucagon response to insulin-induced hypoglycemia by strict glycemic control in diabetics.
Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Insulin Infusion Systems; Insulin Secretion; Male; Middle Aged; Reference Values; Time Factors | 1993 |
Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Growth Hormone; Humans; Hydrocortisone; Hypertension; Insulin; Insulin Resistance; Male; Norepinephrine; Obesity; Polycystic Ovary Syndrome; Reference Values; Sex Factors | 1993 |
Response of glomerular filtration rate to protein load in diabetic patients varies according to severity of proteinuria.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucagon; Humans; Male; Middle Aged; Proteins; Proteinuria | 1993 |
Diagnosis of naturally acquired type-I and type-II diabetes mellitus in cats.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Insulin; Obesity | 1993 |
Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects.
Topics: Adult; Aged; Amyloid; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Islet Amyloid Polypeptide; Male; Middle Aged; Reference Values | 1993 |
A longitudinal study of plasma insulin and glucagon in women with previous gestational diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Glucagon; Glucose Tolerance Test; Humans; Incidence; Insulin; Longitudinal Studies; Parity; Pregnancy; Reference Values; Regression Analysis; Risk Factors; Time Factors | 1995 |
Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Male; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds | 1995 |
The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Exons; Glucagon; Glycine; Humans; Insulin; Insulin Secretion; Insulinoma; Kidney; Kinetics; Molecular Sequence Data; Pancreatic Neoplasms; Point Mutation; Protein Structure, Secondary; Rats; Receptors, Glucagon; Recombinant Proteins; Serine; Transfection | 1996 |
Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity | 1996 |
NMR studies of muscle glycogen synthesis in insulin-resistant offspring of parents with non-insulin-dependent diabetes mellitus immediately after glycogen-depleting exercise.
Topics: Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose; Glucose-6-Phosphate; Glucosephosphates; Glycogen; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Insulin; Insulin Resistance; Lactates; Magnetic Resonance Spectroscopy; Male; Muscle Contraction; Muscle, Skeletal; Nuclear Family; Phosphates; Phosphocreatine; Physical Exertion; Reference Values | 1996 |
Glutamine and alanine metabolism in NIDDM.
Topics: Alanine; Blood Glucose; C-Peptide; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Forearm; Glucagon; Glucose; Glutamine; Humans; Insulin; Male; Middle Aged; Phenylalanine; Radioisotope Dilution Technique; Reference Values; Tritium | 1996 |
Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production.
Topics: Alanine; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Growth Hormone; Humans; Hydrocortisone; Insulin; Lactates; Liver; Male; Middle Aged; Sleep | 1996 |
Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits.
Topics: Alloxan; Animals; Antibodies, Monoclonal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Immunization, Passive; Male; Rabbits | 1996 |
Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide.
Topics: Aging; Amyloid; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Mice; Mice, Transgenic; Microscopy, Electron; Promoter Regions, Genetic; Rats; Sex Characteristics | 1996 |
Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Female; Food; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Linear Models; Male; Middle Aged; Obesity; Stimulation, Chemical; Treatment Outcome | 1996 |
The possible role of insulin release in cardiovascular morbidity and mortality in NIDDM patients.
Topics: Age Factors; Aged; Analysis of Variance; Blood Pressure; Body Mass Index; C-Peptide; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Glucagon; Humans; Insulin; Insulin Secretion; Male; Morbidity; Myocardial Ischemia; Obesity; Risk Factors; Sex Factors | 1995 |
Proinsulin secretion during the first 3 years after diagnosis in diabetic patients with and without islet cell antibodies.
Topics: Autoantibodies; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Follow-Up Studies; Glucagon; Humans; Insulin; Islets of Langerhans; Middle Aged; Proinsulin; Reference Values; Retrospective Studies; Time Factors | 1996 |
Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects.
Topics: Administration, Oral; Adult; Analysis of Variance; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Fructose; Glucagon; Gluconeogenesis; Glucose; Glycogen; Humans; Infusions, Intravenous; Kinetics; Male; Middle Aged; Models, Theoretical; Obesity; Reference Values | 1996 |
Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Mice; Mice, Inbred NOD; Mice, Mutant Strains; Pancreas; Peptide Fragments; Time Factors | 1996 |
Nuclear protein binding and functional activity of a variant insulin gene found in non-insulin-dependent diabetes mellitus.
Topics: Animals; Base Sequence; Cell Line; Diabetes Mellitus, Type 2; Enhancer Elements, Genetic; Genetic Variation; Glucagon; Humans; Insulin; Islets of Langerhans; Molecular Sequence Data; Nuclear Proteins; Oligodeoxyribonucleotides; Promoter Regions, Genetic; Rats; Recombinant Proteins; Regulatory Sequences, Nucleic Acid; Repetitive Sequences, Nucleic Acid; Somatostatin; Transcription, Genetic; Transfection | 1996 |
Pancreatic endocrine dysfunction in rats not expressing the cholecystokinin-A receptor.
Topics: Animals; Base Sequence; Blood Glucose; Blotting, Northern; Cholecystokinin; Diabetes Mellitus, Type 2; Food; Gene Expression; Glucagon; Insulin; Insulin Secretion; Male; Molecular Sequence Data; Pancreatic Diseases; Perfusion; Rats; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; RNA, Messenger | 1996 |
Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Homeostasis; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Models, Biological; Neurotransmitter Agents; Peptide Fragments; Reference Values; Time Factors | 1996 |
Metabolic and endocrine effects of interleukin-1 in obese, diabetic Zucker fa/fa rats.
Topics: Animals; Blood Glucose; Cholesterol; Corticosterone; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified; Glucagon; Humans; Injections, Intraperitoneal; Insulin; Interleukin-1; Lactic Acid; Lipid Metabolism; Lipids; Male; Obesity; Rats; Rats, Zucker; Recombinant Proteins; Time Factors; Triglycerides | 1996 |
The effect of L-tryptophan load on endocrine system of pancreas in diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastrins; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Reference Values; Tryptophan | 1996 |
Abnormal characteristics in young offspring of parents with non-insulin-dependent diabetes mellitus. The Bogalusa Heart Study.
Topics: Adipose Tissue; Adolescent; Adult; Anthropometry; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Male; Triglycerides | 1996 |
Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Topics: Administration, Oral; Area Under Curve; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Intestinal Mucosa; Male; Middle Aged; Neurotransmitter Agents; Peptide Fragments; Protein Precursors; Sex Characteristics | 1996 |
Pancreatic A-cell function in the partially pancreatectomized Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus.
Topics: Animals; Arginine; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Insulin; Islets of Langerhans; Male; Niacinamide; Organ Size; Pancreatectomy; Rats | 1996 |
The effects of acute hyperglycemia and hyperinsulinemia on plasma leptin levels: its relationships with body fat, visceral adiposity, and age in women.
Topics: Adipose Tissue; Adolescent; Adult; Age Factors; Aged; Diabetes Mellitus, Type 2; Exercise; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hyperinsulinism; Leptin; Middle Aged; Peptide Fragments; Protein Precursors; Proteins; Weight Loss | 1996 |
Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement.
Topics: Adult; Age of Onset; Body Mass Index; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Male; Obesity | 1996 |
Exhaustion of blood glucose response and enhancement of insulin response after repeated glucagon injections in type-2 diabetes: potentiation by progressive hyperglycemia.
Topics: Aged; Analysis of Variance; B-Lymphocytes; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastrointestinal Agents; Glucagon; Humans; Hyperglycemia; Injections, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged | 1996 |
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dogs; Glucagon; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Peptides | 1997 |
Physiological and genetic characterization of the Gly40Ser mutation in the glucagon receptor gene in the Sardinian population. The Sardinian Diabetes Genetic Study Group.
Topics: Aged; Base Sequence; Blood Glucose; Chromosomes, Human, Pair 17; Cohort Studies; Diabetes Mellitus, Type 2; DNA Primers; Dose-Response Relationship, Drug; Exons; Female; Gene Frequency; Glucagon; Heterozygote; Humans; Infusions, Intravenous; Insulin; Italy; Male; Middle Aged; Mutation; Prevalence; Receptors, Glucagon | 1997 |
Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycolysis; Human Growth Hormone; Humans; Insulin; Kinetics; Male; Mathematics; Middle Aged; Models, Biological; Reference Values; Somatostatin | 1997 |
Incretin hormone expression in the gut of diabetic mice and rats.
Topics: Animals; Blotting, Northern; Colon; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastric Inhibitory Polypeptide; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Intestinal Mucosa; Intestine, Small; Intestines; Mice; Mice, Inbred NOD; Peptide Fragments; Proglucagon; Protein Precursors; Rats; Rats, Zucker; Rectum; RNA, Messenger; Tissue Distribution | 1997 |
Increased alanine uptake and lipid synthesis from alanine in isolated hepatocytes of Wistar-Kyoto fatty rats: an inhibitory effect of biguanides.
Topics: Aging; Alanine; Animals; Body Weight; Buformin; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucagon; Hypoglycemic Agents; Lipids; Liver; Male; Metformin; Rats; Rats, Inbred WKY | 1997 |
Abnormal myocardial kinetics of 123I-heptadecanoic acid in subjects with impaired glucose tolerance.
Topics: Adult; Analysis of Variance; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Echocardiography; Fatty Acids; Fatty Acids, Nonesterified; Glucagon; Glucose Intolerance; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Models, Cardiovascular; Myocardium; Reference Values; Tissue Distribution; Tomography, Emission-Computed; Ventricular Function, Left | 1997 |
Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM.
Topics: Alanine; Blood Glucose; Carbon Radioisotopes; Cohort Studies; Diabetes Mellitus, Type 2; Epinephrine; Fasting; Female; Glucagon; Gluconeogenesis; Glucose; Human Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Insulin; Male; Middle Aged; Reference Values; Tritium | 1997 |
Theoretical analysis of the mechanisms of chronic hyperinsulinemia.
Topics: Adult; Blood Glucose; Computer Simulation; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Liver; Obesity; Software | 1997 |
Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance.
Topics: Adult; Analysis of Variance; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Reference Values; Regression Analysis; Somatostatin | 1997 |
Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Infusion Pumps; Insulin; Male; Pancreas; Peptide Fragments; Protein Precursors; Radioimmunoassay; Rats; Rats, Inbred Strains; Rats, Mutant Strains | 1997 |
Localization of the rat genes encoding glucagon, glucagon receptor, and insulin receptor, candidates for diabetes mellitus susceptibility loci.
Topics: Animals; Chromosome Mapping; Diabetes Mellitus; Diabetes Mellitus, Type 2; DNA Probes; Genetic Markers; Genetic Predisposition to Disease; Glucagon; In Situ Hybridization, Fluorescence; Rats; Receptor, Insulin; Receptors, Glucagon | 1997 |
Modulation of gliquidone action by forskolin in the pancreas of normal and GK rats.
Topics: Animals; Blood Glucose; Colforsin; Diabetes Mellitus, Type 2; Glucagon; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Perfusion; Rats; Rats, Inbred Strains; Rats, Wistar; Reference Values; Sulfonylurea Compounds; Time Factors | 1997 |
Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat.
Topics: Age Factors; Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Female; Glucagon; Guinea Pigs; Immunoglobulin G; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Microscopy, Confocal; Organ Size; Pregnancy; Rabbits; Rats; Rats, Inbred Strains; Rats, Wistar | 1997 |
Diabetes mellitus update.
Topics: Blood Glucose; Dentists; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemia; Insulin; Mouth Diseases; Patient Care Team; Terminology as Topic | 1997 |
Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 2; Glucose Transporter Type 3; Homozygote; Hyperglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Monosaccharide Transport Proteins; Nerve Tissue Proteins | 1997 |
Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Human Growth Hormone; Humans; Insulin; Kinetics; Lactic Acid; Liver; Male; Middle Aged | 1997 |
Anchoring of protein kinase A facilitates hormone-mediated insulin secretion.
Topics: Animals; Calcium; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Insulin; Insulin Secretion; Pancreas; Peptide Fragments; Protein Precursors; Rats | 1997 |
Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Insulin; Male; Splanchnic Circulation | 1997 |
The effect of diet on the Vervet monkey endocrine pancreas.
Topics: Animals; Arteriosclerosis; Cercopithecus; Diabetes Mellitus, Type 2; Dietary Fats; Gene Expression; Glucagon; Insulin; Islets of Langerhans; Male; Pancreatic Polypeptide; Somatostatin | 1997 |
Alterations of insulin and glucagon secretion from the perfused pancreas before, at the onset and after the development of diabetes in male Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose; Immunohistochemistry; Insulin; Insulin Secretion; Male; Obesity; Pancreas; Perfusion; Rats; Rats, Inbred Strains; Time Factors | 1997 |
Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat.
Topics: Animals; Apoptosis; Cohort Studies; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucagon; Glucose; Glucose Intolerance; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Pancreatic Polypeptide; Perfusion; Rats; Rats, Zucker; Somatostatin; Time Factors | 1998 |
Stimulation of insulin secretion by fructose ingested with protein in people with untreated type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Blood Urea Nitrogen; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Proteins; Fructose; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Triglycerides | 1998 |
Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose; Glucose Clamp Technique; Growth Hormone; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Norepinephrine; Psychomotor Performance; Reaction Time | 1998 |
The human glucagon-like peptide-1 (GLP-1) receptor. Cloning and functional expression.
Topics: Amino Acid Sequence; Animals; Binding, Competitive; Calcium; Cloning, Molecular; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Kinetics; Molecular Sequence Data; Peptide Fragments; Peptides; Polymerase Chain Reaction; Protein Precursors; Rats; Receptors, Glucagon; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Transfection | 1997 |
[Glucagon-like peptide-1--a new hormone and a new drug].
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon; Humans; Mice; Receptors, Glucagon | 1998 |
Impact of family history of diabetes on the assessment of beta-cell function.
Topics: Adolescent; Adult; Age Factors; Aged; Biomarkers; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Family Health; Fasting; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Linear Models; Male; Middle Aged | 1998 |
Mapping of murine diabetogenic gene mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and beta cell development during the perinatal period.
Topics: Animals; Blood Glucose; Chromosome Mapping; Crosses, Genetic; Diabetes Mellitus, Type 2; Genetic Linkage; Genetic Markers; Genotype; Glucagon; Heterozygote; Homozygote; Immunohistochemistry; Insulin; Islets of Langerhans; Lod Score; Mice; Mice, Inbred NOD; Microscopy, Electron; Pancreas; Quantitative Trait, Heritable | 1998 |
Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hypertension; Insulin; Lactic Acid; Male; Middle Aged; Obesity | 1998 |
beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes.
Topics: Amyloid; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Gene Expression Regulation; Genes; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glucose Transporter Type 2; Heterozygote; Homeodomain Proteins; Immunohistochemistry; Insulin; Islet Amyloid Polypeptide; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Mutant Strains; Monosaccharide Transport Proteins; Mutagenesis, Site-Directed; Phenotype; Trans-Activators; Transcriptional Activation | 1998 |
Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity.
Topics: Age Factors; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin Resistance; Male; Middle Aged; Obesity; Reference Values; Sex Characteristics; Tumor Necrosis Factor-alpha | 1998 |
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Arteries; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycerol; Humans; Hydroxybutyrates; Insulin; Kidney; Lactic Acid; Liver; Male; Middle Aged; Organ Specificity; Veins | 1998 |
Physiological importance of first-phase insulin release in elderly patients with diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Fatty Acids, Nonesterified; Glucagon; Glucose; Glucose Clamp Technique; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Liver; Obesity; Time Factors | 1998 |
Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM.
Topics: Adrenocorticotropic Hormone; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glycated Hemoglobin; Homeostasis; Hormones; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Male; Middle Aged; Norepinephrine; Reference Values; Regression Analysis; Time Factors | 1998 |
Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Intolerance; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Peptide Fragments; Protein Precursors | 1998 |
Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose Clamp Technique; Glycogen; Glycolysis; Human Growth Hormone; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Somatostatin; Sulfonylurea Compounds | 1998 |
Glucose utilization and production in patients with maturity-onset diabetes of the young caused by a mutation of the hepatocyte nuclear factor-1alpha gene.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Humans; Infusions, Intravenous; Insulin; Kinetics; Male; Middle Aged; Mutation; Nuclear Proteins; Reference Values; Time Factors; Transcription Factors | 1998 |
The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin Secretion; Male; Obesity; Pancreas; Peptide Fragments; Perfusion; Protein Precursors; Rats; Sex Factors | 1998 |
Effects of branched-chain-enriched amino acid solution on insulin and glucagon secretion and blood glucose level in liver cirrhosis.
Topics: Adult; Aged; Amino Acids, Branched-Chain; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucagon; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 1998 |
Integral rein control in physiology.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Homeostasis; Humans; Insulin; Islets of Langerhans; Models, Biological | 1998 |
Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake.
Topics: Blood Glucose; C-Peptide; Carbon Dioxide; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Glycosuria; Human Growth Hormone; Humans; Insulin; Kinetics; Male; Middle Aged; Tritium | 1998 |
The ageing entero-insular axis.
Topics: Acetaminophen; Adult; Aged; Aging; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Intolerance; Humans; Insulin; Insulin Secretion; Peptide Fragments; Postmenopause; Premenopause; Risk Factors | 1998 |
Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Topics: Acarbose; Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Dumping Syndrome; Enzyme Inhibitors; Female; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Insulin; Male; Middle Aged; Postprandial Period; Time; Trisaccharides | 1998 |
Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity.
Topics: Adipose Tissue; Aged; Biomarkers; Body Mass Index; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Male; Middle Aged; Obesity; Reference Values; Tumor Necrosis Factor-alpha | 1998 |
Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Topics: Animals; Blood Glucose; Body Weight; Carrier Proteins; Crosses, Genetic; Cyclic AMP; Diabetes Mellitus, Type 2; Drug Administration Schedule; Energy Intake; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Insulin; Islets of Langerhans; Lizards; Mice; Mice, Inbred C57BL; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Leptin; Venoms | 1999 |
An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats.
Topics: Acupuncture Points; Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Electroacupuncture; Glucagon; Hypoglycemia; Insulin; Insulin Resistance; Male; Naloxone; Narcotic Antagonists; Rats; Rats, Wistar; Tolbutamide | 1999 |
Disturbed gastric motility and pancreatic hormone release in diabetes mellitus.
Topics: Acetates; Aged; Blood Glucose; Breath Tests; Diabetes Mellitus, Type 2; Electrophysiology; Female; Gastric Emptying; Gastrointestinal Motility; Glucagon; Humans; Insulin; Male; Manometry; Middle Aged; Pancreatic Hormones; Pyloric Antrum; Radionuclide Imaging; Reference Values; Stomach | 1998 |
Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes.
Topics: Adult; Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dogs; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Liver; Male; Middle Aged; Portal System; Tolbutamide | 1999 |
Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus.
Topics: Adult; Amyloid; Blood Glucose; C-Peptide; Cholecystokinin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperinsulinism; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Islet Amyloid Polypeptide; Male; Peptide Fragments; Protein Precursors | 1999 |
Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes.
Topics: Body Mass Index; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Fasting; Female; Glucagon; Humans; Islets of Langerhans; Male; Middle Aged; Obesity; Proinsulin; Radioimmunoassay | 1999 |
Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dogs; Fatty Acids, Nonesterified; Female; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Clamp Technique; Glycerol; Insulin; Insulin Secretion; Kinetics; Male; Pancreatectomy; Peptide Fragments; Protein Precursors; Receptors, Glucagon; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin | 1999 |
Three new mutations in the hepatocyte nuclear factor-1alpha gene in Japanese subjects with diabetes mellitus: clinical features and functional characterization.
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA; DNA-Binding Proteins; Female; Glucagon; Glucose Tolerance Test; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Mutation; Nuclear Proteins; Promoter Regions, Genetic; Transcription Factors | 1999 |
Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39).
Topics: Animals; Chlorocebus aethiops; Cyclic AMP; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycosylation; Humans; In Vitro Techniques; Male; Peptide Fragments; Protein Precursors; Rats; Rats, Sprague-Dawley | 1999 |
The European Association for the Study of Diabetes Annual Meeting, 1998. Treatment of type 2 diabetes and the pathogenesis of complications.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Peptide Fragments; Protein Precursors | 1999 |
Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Food; Glucagon; Glucose; Human Growth Hormone; Humans; Insulin; Kinetics; Lactic Acid; Male; Middle Aged; Somatostatin | 1999 |
A new mouse model of spontaneous diabetes derived from ddY strain.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucagon; Glycosuria; Hyperinsulinism; Hypertrophy; Immunohistochemistry; Inbreeding; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Obesity; Pedigree; Pregnancy; Triglycerides | 1999 |
Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged | 1999 |
[Inhibition of incretin degradation--a new therapy principle for treatment of type 2 diabetes?].
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Isoleucine; Peptide Fragments; Rats; Rats, Zucker; Thiazoles | 1999 |
Enhancement of B-cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting C-peptide levels.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 1997 |
Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Exercise; Exercise Test; Glucagon; Glyburide; Homeostasis; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Middle Aged; Norepinephrine; Oxygen Consumption; Physical Exertion; Sulfonylurea Compounds; Time Factors | 1999 |
Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.
Topics: Adult; Blood; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Intestinal Mucosa; Male; Middle Aged; Peptide Fragments; Proinsulin; Reference Values | 1999 |
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Islets of Langerhans; Male; Pancreatectomy; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Venoms | 1999 |
Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dietary Fats; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glucose Intolerance; Glucose Tolerance Test; Homeostasis; Injections, Intraperitoneal; Insulin; Insulin Resistance; Insulin Secretion; Intestines; Islets of Langerhans; Mice; Mice, Knockout; Models, Biological; Peptide Fragments; Protein Precursors; Receptors, Gastrointestinal Hormone | 1999 |
Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Fatty Liver; Gene Expression; Glucagon; Glucose; Glucose Tolerance Test; Hyperinsulinism; Hyperplasia; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Obesity; Promoter Regions, Genetic; Rats; Recombinant Fusion Proteins; RNA, Messenger | 2000 |
[Acute metabolic complications of diabetes mellitus (ketoacidosis, hypoglycemia, hyperosmolarity, lactic acidosis). Etiology, physiopathology, diagnosis, emergency treatment of ketoacidosis with drug posology].
Topics: Acidosis, Lactic; Aged; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Emergencies; Glucagon; Humans; Hyperglycemic Hyperosmolar Nonketotic Coma; Hypoglycemia; Insulin; Models, Biological | 2000 |
Adenylyl cyclase isoform expression in non-diabetic and diabetic Goto-Kakizaki (GK) rat pancreas. Evidence for distinct overexpression of type-8 adenylyl cyclase in diabetic GK rat islets.
Topics: Adenylyl Cyclases; Animals; Antibodies; Antibody Specificity; Diabetes Mellitus, Type 2; Disease Models, Animal; Endocrine Glands; Gene Expression Regulation; Glucagon; Immunohistochemistry; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Pancreas; Protein Isoforms; Rats; Rats, Inbred Strains; Rats, Wistar; Somatostatin | 2000 |
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
Topics: Acylation; Amino Acid Sequence; Animals; Cell Line; Chromatography, High Pressure Liquid; Cricetinae; Diabetes Mellitus, Type 2; Fatty Acids; Glucagon; Glucagon-Like Peptide 1; Kidney; Lysine; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Precursors; Spectrophotometry, Ultraviolet; Structure-Activity Relationship; Swine | 2000 |
Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients.
Topics: Aged; Amino Acid Sequence; Base Sequence; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptide Fragments; Proglucagon; Protein Precursors; Sequence Analysis, DNA | 2000 |
Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Injections, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Peptide Fragments; Postprandial Period; Protein Precursors; Reference Values; Time Factors | 2000 |
Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha/MODY1 gene.
Topics: Adult; Amyloid; Arginine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Glucagon; Hepatocyte Nuclear Factor 4; Humans; Hypoglycemia; Insulin; Islet Amyloid Polypeptide; Male; Mutation; Pancreatic Polypeptide; Phosphoproteins; Transcription Factors | 2000 |
Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucokinase; Glucose; Human Growth Hormone; Humans; Insulin; Leg; Liver; Middle Aged; Muscles; Palmitic Acid; Reference Values; Uridine Diphosphate; Viscera | 2000 |
Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Constitution; Body Mass Index; Deuterium; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Gluconeogenesis; Glucose; Humans; Insulin; Male; Middle Aged; Obesity; Reference Values; Regression Analysis | 2000 |
Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.
Topics: Animals; Arabinose; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glucagon; Glycogen; Hypoglycemic Agents; Imino Furanoses; In Vitro Techniques; Kinetics; Lactic Acid; Liver; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Mice, Obese; Muscles; Phosphorylases; Rabbits; Rats; Sugar Alcohols; Swine | 2000 |
Prolongation of the insulinotropic action of glucagon-like peptide 1 by the dimethyl ester of succinic acid in an animal model of type-2 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Insulin; Male; Pancreas; Peptide Fragments; Protein Precursors; Rats; Succinates | 2000 |
Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene).
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Glucagon; Glucose Clamp Technique; Heterozygote; Homeodomain Proteins; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Metabolic Clearance Rate; Mutation; Pancreas; Pedigree; Trans-Activators | 2000 |
Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice.
Topics: 3-O-Methylglucose; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Carriers; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Kinetics; Mice; Microspheres; Olive Oil; Peptide Fragments; Plant Oils; Polymers; Protein Precursors | 2000 |
Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Galactose; Glucagon; Glycogen; Human Growth Hormone; Humans; Hyperglycemia; Infusions, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period | 2000 |
Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperinsulinism; Insulin; Leptin; Male; Middle Aged; Obesity; Peptide Fragments; Protein Precursors | 2000 |
Impaired neural regulation of insulin secretion related to the leptin receptor gene mutation in Wistar fatty rats.
Topics: Animals; Atropine Derivatives; Blood Glucose; Carrier Proteins; Crosses, Genetic; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Injections, Intraventricular; Insulin; Insulin Resistance; Insulin Secretion; Mutation; Obesity; Peptide Fragments; Protein Precursors; Rats; Rats, Inbred WKY; Rats, Zucker; Receptors, Cell Surface; Receptors, Leptin; Vagotomy; Vagus Nerve | 2000 |
Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
Topics: Animals; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Mice; Mice, Obese; Oligopeptides; Peptide Fragments; Protease Inhibitors; Protein Precursors; Spectrometry, Mass, Electrospray Ionization; Time Factors | 2001 |
Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations.
Topics: Adult; Amino Acid Substitution; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Exons; Female; Glucagon; Glucokinase; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hyperinsulinism; Hypoglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Mutation; Reference Values | 2000 |
Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes.
Topics: Adult; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Male; Middle Aged; Norepinephrine; Pancreatic Polypeptide | 2000 |
Glucagon-like peptide-1 stimulates insulin secretion by a Ca2+-independent mechanism in Zucker diabetic fatty rat islets of Langerhans.
Topics: Animals; Calcium; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Insulin; Insulin Secretion; Islets of Langerhans; Obesity; Peptide Fragments; Protein Precursors; Rats; Rats, Zucker | 2000 |
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Topics: Animals; Blood Glucose; Carbonates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon; Glucose Tolerance Test; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Kidney Glomerulus; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Obese; Microvilli; Monosaccharide Transport Proteins; Pancreas; Phenotype; Sodium-Glucose Transporter 1 | 2001 |
Counterregulatory responses to hypoglycemia in patients with maturity-onset diabetes of the young caused by HNF-1alpha gene mutations (MODY3).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Glucagon; Glucose; Glucose Clamp Technique; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Homeostasis; Humans; Hypoglycemia; Insulin; Male; Mutation; Nuclear Proteins; Transcription Factors | 2001 |
Cytosolic calcium handling in islets of normal Wistar and diabetic Goto Kakizaki rats in the presence of glucose and truncated glucagon-like peptide 1 (7-36) amide.
Topics: Animals; Calcium; Cytosol; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Peptide Fragments; Rats; Rats, Wistar | 2000 |
Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Biological Transport, Active; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Synergism; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Mice; Models, Biological; Neuropeptides; Peptide Fragments; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Precursors; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Receptors, Pituitary Hormone | 2000 |
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Topics: Aging; Animals; Cataract; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Pancreas; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Thirst; Time Factors | 2000 |
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Topics: Aged; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Osmolar Concentration; Peptide Fragments; Postprandial Period; Protein Precursors; Reference Values | 2001 |
Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes.
Topics: Animals; Blood Glucose; Chromosome Mapping; Diabetes Mellitus, Type 2; Dietary Fats; Genetic Predisposition to Disease; Glucagon; Glucokinase; Insulin; Liver; Mice; Mice, Transgenic; Obesity; Reference Values; RNA, Messenger; Transgenes | 2001 |
No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Infusions, Intravenous; Injections, Subcutaneous; Insulin; Kinetics; Male; Middle Aged; Peptide Fragments; Protein Precursors; Reference Values | 2001 |
Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Binding, Competitive; CHO Cells; Cricetinae; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Inbred C57BL; Mice, Obese; Molecular Sequence Data; Peptide Fragments; Protein Precursors; Radioligand Assay; Receptors, Glucagon; Sequence Deletion; Structure-Activity Relationship | 2001 |
Defective stimulus-secretion coupling in islets of Psammomys obesus, an animal model for type 2 diabetes.
Topics: Animals; Colforsin; Diabetes Mellitus, Type 2; Diazoxide; Disease Models, Animal; Disease Susceptibility; Gerbillinae; Glucagon; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Isoenzymes; Oxidation-Reduction; Peptide Fragments; Protein Kinase C; Protein Precursors; Rats; Rats, Sprague-Dawley; Reference Values; Signal Transduction; Tetradecanoylphorbol Acetate | 2001 |
Early development of beta-cells is impaired in the GK rat model of type 2 diabetes.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Division; Culture Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Embryonic and Fetal Development; Female; Fetus; Glucagon; Heart; Immunohistochemistry; Insulin; Islets of Langerhans; Kidney; Liver; Lung; Organ Size; Pregnancy; Rats; Rats, Wistar; Spleen | 2001 |
C-peptide and glucagon profiles in minority children with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Black People; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Eating; Food, Formulated; Glucagon; Glycated Hemoglobin; Hispanic or Latino; Humans; Reference Values; Time Factors; White People | 2001 |
Glucagon-like peptide-1 (7-37) augments insulin release in elderly patients with diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Clamp Technique; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Peptide Fragments; Peptides | 2001 |
Potentiation by methyl pyruvate of GLP-1 insulinotropic action in normal rats.
Topics: Animals; B-Lymphocytes; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Hypoglycemia; Insulin; Male; Peptide Fragments; Protein Precursors; Pyruvates; Rats; Rats, Wistar; Time Factors | 2001 |
Assessment of hepatic insulin action in obese type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Liver; Middle Aged; Obesity | 2001 |
No influence of C-peptide, insulin, and glucagon on blood viscosity in vitro in healthy humans and patients with diabetes mellitus.
Topics: Adult; Aged; Blood Proteins; Blood Viscosity; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Erythrocyte Indices; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged | 2001 |
Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival.
Topics: Animals; Cell Death; Cell Survival; Cells, Cultured; Diabetes Mellitus, Type 2; eIF-2 Kinase; Endoplasmic Reticulum; Female; Glucagon; Hyperglycemia; In Situ Nick-End Labeling; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Pancreas; Phenotype; Phosphorylation; Proinsulin; Protein Biosynthesis; RNA, Messenger; Secretory Vesicles | 2001 |
Insulin resistance and type 2 diabetes: time for a new hypothesis.
Topics: Amyloid; Animals; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Islet Amyloid Polypeptide; Leptin; Mice; Peptide Fragments; Protein Precursors; Tumor Necrosis Factor-alpha | 2001 |
Defective morphogenesis and functional maturation in fetal islet-like cell clusters from OLETF rat, a model of NIDDM.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucagon; Homeodomain Proteins; Insulin; Islets of Langerhans; Morphogenesis; Pregnancy; Rats; Rats, Inbred OLETF; Time Factors; Trans-Activators | 2001 |
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
Topics: Analysis of Variance; Autoantibodies; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Pancreatic Polypeptide; Peptide Fragments; Peptides; Protein Precursors; Reference Values | 2001 |
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
Topics: Area Under Curve; Autoantibodies; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dipeptidyl Peptidase 4; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Infusions, Intravenous; Insulin; Islets of Langerhans; Isoenzymes; Male; Middle Aged; Peptide Fragments; Protein Precursors; Regression Analysis | 2001 |
Glucagon attenuates the action of insulin on glucose output in the liver of the Goto-Kakizaki rat perfused in situ.
Topics: Animals; Cyclic AMP; Diabetes Mellitus, Type 2; Gastrointestinal Agents; Glucagon; Glucose; Glycogen; Hypoglycemic Agents; Insulin; Liver; Male; Microscopy, Electron; Organ Size; Perfusion; Rats; Rats, Mutant Strains | 2001 |
Reduction of incretin-like salivatin in saliva from patients with type 2 diabetes and in parotid glands of streptozotocin-diabetic BALB/c mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Eating; Enzyme-Linked Immunosorbent Assay; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred BALB C; Microscopy, Immunoelectron; Parotid Gland; Peptide Fragments; Peptides; Postprandial Period; Proline-Rich Protein Domains; Saliva; Salivary Proline-Rich Proteins | 2001 |
In vivo glucose-stimulated amylin secretion is increased in nondiabetic patients with pancreatic cancer.
Topics: Adenocarcinoma; Amyloid; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Glucose Transporter Type 2; Humans; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Male; Middle Aged; Monosaccharide Transport Proteins; Pancreas; Pancreatic Neoplasms; Predictive Value of Tests; Reference Values | 2001 |
Urinary excretion of glucagon-like peptide 1 (GLP-1) 7-36 amide in human type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Aged; Albuminuria; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Male; Metabolic Clearance Rate; Middle Aged; Peptide Fragments | 2001 |
Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
Topics: Amino Acid Sequence; Aminocaproic Acid; Animals; Cell Line; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Molecular Sequence Data; Mutagenesis, Insertional; Peptide Fragments; Protein Precursors; Rats; Structure-Activity Relationship | 2001 |
Beta-cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1 alpha induces a maturity-onset diabetes of the young (MODY)3-like phenotype in transgenic mice.
Topics: Animals; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Gene Expression; Gene Targeting; Genes, Dominant; Glucagon; Glucose Intolerance; Glucose Transporter Type 2; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Insulin; Insulin Antagonists; Islets of Langerhans; Male; Mice; Mice, Transgenic; Monosaccharide Transport Proteins; Mutation; Nuclear Proteins; Pancreas; Phenotype; Sex Characteristics; Transcription Factors | 2001 |
Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.
Topics: Adipose Tissue; Animals; Blotting, Northern; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Transporter Type 2; Glucose Transporter Type 4; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Peptide Fragments; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger | 2001 |
GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Topics: Adipocytes; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glycosylphosphatidylinositols; Hepatocytes; Hypoglycemic Agents; Inositol Phosphates; Insulin; Liver; Male; Oligosaccharides; Pancreas; Peptide Fragments; Polysaccharides; Protein Precursors; Rats; Rats, Wistar | 2001 |
Insulin and glucagon secretions, and morphological change of pancreatic islets in OLETF rats, a model of type 2 diabetes mellitus.
Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Insulin; Islets of Langerhans; Male; Rats; Rats, Inbred OLETF | 2002 |
Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Activation; Fatty Acids, Nonesterified; Female; Fructose; Glucagon; Glucokinase; Glucose; Human Growth Hormone; Humans; Hyperglycemia; Insulin; Liver; Male; Middle Aged; Somatostatin; Tritium | 2002 |
Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.
Topics: Adult; Autonomic Nervous System; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Kinetics; Male; Middle Aged; Norepinephrine | 2002 |
Basal and postglucagon C-peptide levels in Ethiopians with diabetes.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ethiopia; Female; Glucagon; Humans; Insulin; Male; Reference Values; Socioeconomic Factors | 2002 |
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Insulin; Insulin Resistance; Liver; Male; Middle Aged; Obesity; Somatostatin | 2002 |
Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of L-glutamic acid in a type 2 diabetes animal model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Glucagon; Glucagon-Like Peptide 1; Glutamates; Injections, Intravenous; Insulin; Peptide Fragments; Protein Precursors; Pyruvates; Rats; Time Factors | 2001 |
Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects.
Topics: Acarbose; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptide Fragments; Postprandial Period; Protein Precursors; Triglycerides | 2002 |
Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats.
Topics: Animals; Area Under Curve; Diabetes Mellitus, Type 2; Disease Models, Animal; Diterpenes; Diterpenes, Kaurane; Glucagon; Glucose; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Injections, Intravenous; Insulin; Male; Phytotherapy; Plant Extracts; Rats; Rats, Inbred Strains; Rats, Wistar; Terpenes | 2002 |
Role of the Gly40Ser mutation in the glucagon receptor gene in Brazilian patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Brazil; Diabetes Mellitus, Type 2; Female; Gastrointestinal Agents; Genetic Testing; Glucagon; Glucose Tolerance Test; Heterozygote; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Mutation, Missense; Receptors, Glucagon | 2002 |
Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Disease Progression; Eating; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors | 2002 |
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Topics: Age Factors; Animals; Animals, Newborn; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Disease Models, Animal; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Insulin; Insulin Secretion; Islets of Langerhans; Longitudinal Studies; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Mutant Strains; Rats, Wistar; Venoms | 2002 |
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Eating; Fatty Acids, Nonesterified; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Insulin; Male; Nitriles; Obesity; Pancreas; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrrolidines; Rats; Rats, Zucker; Receptors, Glucagon; Triglycerides; Weight Gain | 2002 |
Type 2 diabetic patients may have a mild form of an injury response: a clinical research center study.
Topics: Acute-Phase Reaction; Adult; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Glucagon; Gluconeogenesis; Humans; Hydrocortisone; Insulin; Interleukin-6; Leucine; Lung Neoplasms; Middle Aged; Triiodothyronine; Tumor Necrosis Factor-alpha | 2002 |
Glycemic response during exercise after administration of insulin lispro compared with that after administration of regular human insulin.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Exercise; Glucagon; Human Growth Hormone; Humans; Insulin; Insulin Lispro; Kinetics; Norepinephrine | 2002 |
Effect of acupuncture on plasmic levels of insulin, glucagon and hypercoagulability in NIDDM complicated by acute cerebral infarction.
Topics: Acupuncture Therapy; Cerebral Infarction; Diabetes Mellitus, Type 2; Female; Fibrinogen; Glucagon; Humans; Insulin; Male; Middle Aged; Platelet Aggregation | 2001 |
Transient neonatal diabetes mellitus, type 4, type 1 diabetes mellitus, or MODY: which disease is it, anyway?
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Humans; Infant; Insulin; Insulin Secretion; Islets of Langerhans; Male; Tolbutamide | 2002 |
Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Glycerol; Humans; Hyperglycemia; Infusions, Intravenous; Insulin; Lactates; Liver; Middle Aged; Reference Values; Somatostatin | 2002 |
Glucagon response to glucose load in offspring of conjugal type 2 diabetic parents in south India.
Topics: Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; India; Male; Middle Aged | 1992 |
Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.
Topics: Animals; Chloramphenicol O-Acetyltransferase; Cyclic AMP; Diabetes Mellitus, Type 2; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Insulin; Insulin Secretion; Insulinoma; Mice; Pancreatic Neoplasms; Peptide Fragments; Peptides; Proinsulin; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured | 1992 |
[Changes in plasma glucagon concentration in patients with diabetes mellitus and its clinical significance].
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged | 1992 |
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Infusion Systems; Insulin Secretion; Male; Middle Aged; Obesity; Peptide Fragments; Peptides; Somatostatin | 1992 |
Endocrine cell populations in the pancreas of diabetic WBN/Kob rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Rats; Rats, Inbred Strains; Somatostatin | 1992 |
C-peptide response to glucagon in patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Male; Middle Aged | 1992 |
Glucagon, insulin and somatostatin secretion in response to sympathetic neural activation in streptozotocin-induced diabetic rats. A study with the isolated perfused rat pancreas in vitro.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Electric Stimulation; Glucagon; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Neurons; Perfusion; Rats; Rats, Wistar; Somatostatin; Splanchnic Nerves; Streptozocin; Sympathetic Nervous System | 1992 |
Demonstration of islet cell antibodies in apparently non-insulin dependent diabetic patients; a marker for the later development of insulin dependency.
Topics: Autoantibodies; Biomarkers; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucagon; Humans; Islets of Langerhans; Male; Middle Aged; Prognosis | 1991 |
Metabolic response to cottage cheese or egg white protein, with or without glucose, in type II diabetic subjects.
Topics: Aged; Amino Acids; Blood Glucose; Blood Urea Nitrogen; C-Peptide; Cheese; Diabetes Mellitus, Type 2; Egg Proteins; Fatty Acids, Nonesterified; Glucagon; Glucose; Humans; Insulin; Male; Middle Aged; Triglycerides | 1992 |
Alterations in G-protein expression, Gi function and stimulatory receptor-mediated regulation of adipocyte adenylyl cyclase in a model of insulin-resistant diabetes with obesity.
Topics: Adenylyl Cyclases; Adipose Tissue; Animals; Cell Membrane; Cells, Cultured; Colforsin; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; GTP-Binding Proteins; Isoproterenol; Magnesium; Mice; Mice, Inbred CBA; Obesity; Secretin | 1992 |
Hazard of glucagon test in diabetic patients. Hypertensive crisis in asymptomatic pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Hypertension; Islets of Langerhans; Middle Aged; Pheochromocytoma | 1992 |
Discussing the role of glucagonlike peptide-I.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Peptide Fragments; Protein Precursors | 1992 |
The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients.
Topics: Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Glyburide; Glycated Hemoglobin; Growth Hormone; Humans; Hydrocortisone; Insulin; Male; Middle Aged | 1992 |
Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Sulfonylurea Compounds | 1992 |
Increase of blood glucose concentrations in diabetic patients with glucagon eyedrops.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucagon; Humans; Hypoglycemia; Male; Middle Aged; Ophthalmic Solutions | 1992 |
Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Insulin Secretion; Reference Values | 1992 |
Effect of high carbohydrate intake on hyperglycemia, islet function, and plasma lipoproteins in NIDDM.
Topics: Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Monounsaturated; Glucagon; Humans; Hyperglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Lipoproteins; Male; Middle Aged; Triglycerides | 1992 |
Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet, Diabetic; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Middle Aged; Prediabetic State | 1992 |
Characterization of the insulin resistance in liver cirrhosis: a comparison with non-insulin dependent diabetes mellitus.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Erythrocytes; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Growth Hormone; Humans; Hydrocortisone; Insulin; Insulin Resistance; Liver Cirrhosis; Male; Metabolic Clearance Rate; Middle Aged; Receptor, Insulin | 1992 |
Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure.
Topics: Analysis of Variance; Animals; Antibody Formation; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; HLA Antigens; HLA-DQ Antigens; HLA-DR Antigens; Humans; Hypoglycemic Agents; Immunity, Cellular; Insulin; Insulin Antibodies; Insulin Secretion; Islets of Langerhans; Lymphocytes; Male; Middle Aged; Rats; Reference Values; Treatment Failure | 1992 |
[Clinical and experimental study of semen Persical decoction for purgation with addition in type II diabetes mellitus].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Female; Glucagon; Humans; Insulin; Islets of Langerhans; Male; Mice; Middle Aged; Rats; Rats, Inbred Strains | 1992 |
A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.
Topics: Analysis of Variance; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged | 1992 |
Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
Topics: Adult; Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin; Islet Amyloid Polypeptide; Male; Middle Aged; Obesity; Radioimmunoassay; Reference Values | 1992 |
Relationship between blood pressure and in vivo action of insulin in type II (non-insulin-dependent) diabetic subjects.
Topics: Antihypertensive Agents; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glucagon; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypertension; Infusions, Intravenous; Insulin; Male; Metformin; Middle Aged; Regression Analysis | 1992 |
Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1992 |
Polyunsaturated fatty acids may impair blood glucose control in type 2 diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Fats; Fatty Acids; Fatty Acids, Unsaturated; Female; Glucagon; Humans; Insulin; Male; Middle Aged | 1992 |
The enteroinsular axis revisited. A novel role for an incretin.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Secretion; Peptide Fragments; Peptides | 1992 |
The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Male; Middle Aged | 1992 |
Encainide-induced diabetes: analysis of islet cell function.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet; Encainide; Glucagon; Humans; Hyperglycemia; Insulin Resistance; Islets of Langerhans; Male | 1992 |
[The effect of somatostatin on specific binding of insulin to receptors in patients with non-insulin dependent diabetes].
Topics: Diabetes Mellitus, Type 2; Glucagon; Growth Hormone; Humans; Insulin; Receptor, Insulin; Somatostatin | 1991 |
Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Liver; Male; Middle Aged; Muscles; Prediabetic State | 1992 |
Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glycerol; Humans; Infusions, Intravenous; Insulin; Lipolysis; Male; Radioactive Tracers | 1992 |
Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Liver Glycogen; Male; Obesity; Reference Values | 1992 |
Serum ketone response to glucagon as a marker of insulin dependency in diabetics.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fructosamine; Glucagon; Hexosamines; Humans; Hydroxybutyrates; Ketone Bodies; Kinetics; Male; Middle Aged; Regression Analysis | 1991 |
Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.
Topics: Adult; Arginine; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Obesity; Reference Values | 1991 |
Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulinoma; Male; Pancreatic Neoplasms; Proinsulin; Tolbutamide | 1991 |
Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eating; Gliclazide; Glucagon; Glucose Tolerance Test; Insulin; Islets of Langerhans; Male; Pancreas; Rats; Rats, Inbred Strains; Streptozocin; Time Factors | 1991 |
[Clinical significance of measuring serum c-peptide before and after glucagon injection].
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Male; Middle Aged | 1991 |
Effect of epinephrine on pancreatic beta-cell and alpha-cell function in patients with NIDDM.
Topics: Analysis of Variance; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Epinephrine; Glucagon; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Middle Aged; Reference Values | 1991 |
Abnormal regulation by glucose of somatostatin secretion in the perfused pancreas of NIDDM rats.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Rats; Rats, Inbred Strains; Somatostatin | 1990 |
Effects of ketone bodies on carbohydrate metabolism in non-insulin-dependent (type II) diabetes mellitus.
Topics: Acetoacetates; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose; Humans; Ketone Bodies; Liver; Male; Middle Aged; Radioisotope Dilution Technique; Somatostatin; Tritium | 1990 |
Influence of breakfasts with different nutrient contents on glucose, C peptide, insulin, glucagon, triglycerides, and GIP in non-insulin-dependent diabetics.
Topics: Aged; Analysis of Variance; Blood Glucose; C-Peptide; Carbohydrates; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Fats; Dietary Proteins; Female; Gastric Inhibitory Polypeptide; Glucagon; Humans; Insulin; Male; Triglycerides | 1991 |
Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Glucagon; Growth Hormone; Humans; Hydrocortisone; Insulin; Insulin Secretion; Male; Metabolic Clearance Rate; Middle Aged | 1991 |
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
Topics: Administration, Oral; Adult; Aged; Arginine; Chromatography, Gel; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Infusions, Intravenous; Male; Middle Aged; Peptide Fragments; Proglucagon; Protein Precursors; Radioimmunoassay | 1991 |
Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glucagon; Glucose; Humans; Hyperglycemia; Insulin; Kinetics; Liver; Male; Middle Aged; Splanchnic Circulation; Time Factors | 1991 |
[Clinical significance of plasma C-peptide analysis and the analytical method in the diagnosis of diabetes related diseases].
Topics: C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Glucagon; Humans; Hyperinsulinism; Hypoglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Radioimmunoassay; Reference Values | 1990 |
The clinical and hormonal (C-peptide and glucagon) profile and liability to ketoacidosis during nutritional rehabilitation in Ethiopian patients with malnutrition-related diabetes mellitus.
Topics: Adolescent; Adult; C-Peptide; Child; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Ethiopia; Female; Glucagon; Humans; Male; Middle Aged; Nutritional Physiological Phenomena; Protein-Energy Malnutrition; Reference Values | 1990 |
Early morning hyperglycaemia "dawn phenomenon" in non-insulin dependent diabetes mellitus (NIDDM): effects of cortisol suppression by metyrapone.
Topics: Aged; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glycated Hemoglobin; Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Insulin; Male; Metyrapone; Norepinephrine | 1990 |
Islet function and insulin sensitivity in the non-diabetic offspring of conjugal type 2 diabetic patients.
Topics: Adult; Arginine; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Reference Values | 1990 |
[C-peptide assays of the urine and plasma at baseline and under stimulation with glucagon in healthy subjects and diabetics].
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Middle Aged; Reference Values; Stimulation, Chemical | 1990 |
Acute changes in plasma non-esterified fatty acid concentration do not change hepatic glucose production in people with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Humans; Hyperglycemia; Insulin; Lipids; Liver; Male; Middle Aged; Niacin; Safflower Oil | 1990 |
Glomerular filtration response to acute loading with protein from different sources in healthy volunteers and diabetic patients.
Topics: Adult; Albumins; Amino Acids; Atrial Natriuretic Factor; Creatinine; Diabetes Mellitus, Type 2; Dietary Proteins; Female; Glomerular Filtration Rate; Glucagon; Growth Hormone; Humans; Kallikreins; Male; Middle Aged | 1990 |
Plasma glucagon responses in tropical fibrocalculous pancreatic diabetes.
Topics: Adult; Blood Glucose; Calcinosis; Chronic Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Male; Pancreatitis; Reference Values; Tropical Climate | 1990 |
[Plasma pancreatic glucagon assay and the clinical significance].
Topics: Arginine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagonoma; Glucose Tolerance Test; Humans; Insulin; Pancreatic Neoplasms; Radioimmunoassay; Specimen Handling | 1990 |
Glucoregulation and hormonal responses to maximal exercise in non-insulin-dependent diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Exercise; Glucagon; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Norepinephrine | 1990 |
[Effect of ke-tang-Ling administration on the function of pancreatic islets cells in non-insulin-dependent diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 1990 |
Standard breakfast test: an alternative to glucagon testing for C-peptide reserve?
Topics: Adolescent; Adult; C-Peptide; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Food, Formulated; Glucagon; Humans; Islets of Langerhans; Middle Aged | 1990 |
Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism.
Topics: Alanine; Arm; Diabetes Mellitus, Type 2; Female; Glucagon; Gluconeogenesis; Glucose; Humans; Insulin; Lactates; Liver; Male; Muscles | 1990 |
Amylase/creatinine clearance ratio response to hyperglucagonemia in diabetes and obesity.
Topics: Adult; Amylases; Creatinine; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Male; Metabolic Clearance Rate; Obesity | 1986 |
Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM.
Topics: Blood Glucose; C-Peptide; Carbon Dioxide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucose; Humans; Insulin; Insulin, Long-Acting; Lipid Metabolism; Liver; Male; Middle Aged; Obesity | 1989 |
Usefulness of anaerobic threshold in estimating intensity of exercise for diabetics.
Topics: Adult; Anaerobiosis; Blood Glucose; Buformin; Diabetes Mellitus, Type 2; Exercise; Female; Glucagon; Glyburide; Humans; Insulin; Lactates; Male; Middle Aged; Oxygen Consumption; Pyruvates; Reference Values | 1989 |
[Islet transplantation in type II diabetes mellitus--model of the spontaneous diabetic Cohen rat].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Insulin; Islets of Langerhans Transplantation; Rats; Rats, Inbred Strains | 1989 |
Morphometrical and biochemical differences of endocrine pancreata between spontaneously hypertensive and normotensive rats with or without neonatal streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Glucagon; Hypertension; Insulin; Islets of Langerhans; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Streptozocin | 1989 |
Effect of oral antidiabetic drug withdrawal in type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male | 1989 |
Effect of dietary carbohydrates on insulin and glucagon receptors in a new model of noninsulin-dependent diabetes-SHR/N-corpulent rat.
Topics: Animals; Blood Glucose; Cell Membrane; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Glucagon; Insulin; Obesity; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Receptor, Insulin; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Starch; Sucrose; Triglycerides | 1989 |
Assessment of the postprandial pattern of glucose metabolism in nondiabetic subjects and patients with non-insulin-dependent diabetes mellitus using a simultaneous infusion of [2(3)H] and [3(3)H] glucose.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucose; Glycogen; Humans; Insulin; Liver; Male; Middle Aged; Random Allocation; Time Factors | 1989 |
Aspartame metabolism in normal adults, phenylketonuric heterozygotes, and diabetic subjects.
Topics: Adult; Aspartame; Aspartic Acid; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Erythrocytes; Female; Glucagon; Heterozygote; Humans; Insulin; Lipids; Male; Methanol; Phenylalanine; Phenylketonurias; Reference Values | 1989 |
Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM.
Topics: Adult; Alanine; Blood Glucose; Citric Acid Cycle; Diabetes Mellitus, Type 2; Female; Glucagon; Gluconeogenesis; Glucose; Humans; Insulin; Lactates; Liver; Male; Middle Aged | 1989 |
Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Lactates; Lactic Acid; Liver; Male; Middle Aged | 1989 |
Insulin and glucagon secretion are suppressed equally during both hyper- and euglycemia by moderate hyperinsulinemia in patients with diabetes mellitus.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Hyperinsulinism; Insulin; Insulin Infusion Systems; Insulin Secretion; Male; Middle Aged | 1989 |
Insulin-sensitive and insulin-resistant variants in NIDDM.
Topics: Adult; Autoantibodies; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Liver; Male; Middle Aged | 1989 |
Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Insulin; Insulin Secretion; Male | 1989 |
[Evaluation of beta cell function in non-insulin-dependent diabetes mellitus (NIDDM) and its correlations with clinico-metabolic parameters].
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Islets of Langerhans; Middle Aged | 1989 |
Calmodulin-induced early-onset diabetes in transgenic mice.
Topics: Aging; Animals; Blood Glucose; Calmodulin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Genetic Vectors; Glucagon; Insulin; Islets of Langerhans; Mice; Mice, Transgenic; Reference Values; Signal Transduction | 1989 |
Effects of dose of ingested glucose on plasma metabolite and hormone responses in type II diabetic subjects.
Topics: Aged; Amino Acids; Blood Glucose; Blood Urea Nitrogen; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Food; Glucagon; Glucose; Humans; Insulin; Lactates; Male; Middle Aged; Nitrogen; Pancreatic Hormones | 1989 |
Insulin and glucagon degradation in liver are not affected by hepatic cirrhosis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hyperinsulinism; Insulin; Insulin Resistance; Liver; Liver Cirrhosis; Male; Middle Aged | 1989 |
The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glucagon; Glucose Clamp Technique; Humans; Hyperglycemia; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Time Factors | 1989 |
Temporal study of metabolic change when poorly controlled noninsulin-dependent diabetics change from low to high carbohydrate and fiber diet.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fiber; Fasting; Fatty Acids, Nonesterified; Glucagon; Glycosuria; Humans; Insulin; Pancreas; Receptor, Insulin; Time Factors; Triglycerides | 1988 |
Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fasting; Feedback; Female; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hyperglycemia; Insulin; Insulin Infusion Systems; Male; Middle Aged; Somatostatin | 1986 |
[Diabetes mellitus and endocrine balance].
Topics: Adrenocorticotropic Hormone; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Epinephrine; Glucagon; Growth Hormone; Humans; Hydrocortisone; Somatostatin | 1986 |
Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Gastrointestinal Hormones; Glucagon; Humans; Insulin; Male; Middle Aged; Octreotide; Somatostatin | 1986 |
Somatostatin potentiation of insulin-induced glucose uptake in normal individuals.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Kinetics; Male; Middle Aged; Reference Values; Somatostatin | 1986 |
Changes in plasma growth hormone in diabetic and nondiabetic subjects during the glucose clamp.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Growth Hormone; Humans; Hydrocortisone; Insulin; Male; Prolactin; Somatostatin | 1987 |
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hyperglycemia; Insulin; Liver; Middle Aged; Somatostatin | 1987 |
Pancreatic islet amyloid and elevated proinsulin secretion in familial maturity-onset diabetes.
Topics: Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Islets of Langerhans; Pancreatic Polypeptide; Proinsulin; Somatostatin | 1987 |
Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Octreotide; Somatostatin | 1988 |
Two compartment pharmacodynamics of somatostatin in non-obese non-insulin-dependent diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon; Half-Life; Humans; Insulin; Male; Middle Aged; Obesity; Somatostatin | 1987 |
Beta-endorphin infusion restores acute insulin responses to glucose in type-2 diabetes mellitus.
Topics: Arginine; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Type 2; Endorphins; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged | 1987 |
Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to beta-endorphin in human diabetes mellitus.
Topics: Adult; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endorphins; Glucagon; Humans; Hyperglycemia; Infusions, Intravenous; Middle Aged; Obesity | 1987 |
Hormonal and metabolic changes during hypothermic coronary artery bypass surgery in diabetic and non-diabetic subjects.
Topics: Blood Glucose; Catecholamines; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Glucagon; Glucose; Hormones; Humans; Hydrocortisone; Hypothermia, Induced; Insulin; Intraoperative Period | 1988 |
[Behavior of beta-endorphin, GH, cortisol and glucagon during insulin hypoglycemia in type II diabetes].
Topics: Adult; beta-Endorphin; Diabetes Mellitus, Type 2; Female; Glucagon; Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Insulin | 1988 |
Altered action of glucagon on human liver in type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Adenylyl Cyclases; Adult; Aged; Cyclic AMP; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Liver; Male; Middle Aged; Receptors, Gastrointestinal Hormone; Receptors, Glucagon | 1987 |
Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Eating; Fasting; Glucagon; Humans; Insulin; Insulin Secretion; Middle Aged | 1988 |
First-phase insulin response to glucose in nonobese or obese subjects with glucose intolerance: analysis by C-peptide secretion rate.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Obesity | 1988 |
[Choice of therapeutic modality for type II diabetes].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Peptides | 1988 |
Advantageous metabolic effects of pulsatile insulin delivery in noninsulin-dependent diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Infusion Systems; Lipids; Lipoproteins; Male; Middle Aged; Pulsatile Flow; Triglycerides | 1988 |
Effect of alcohol on glucose tolerance in normal and noninsulin-dependent diabetic subjects.
Topics: Alcohol Drinking; C-Peptide; Diabetes Mellitus, Type 2; Erythrocytes; Ethanol; Glucagon; Glucose Tolerance Test; Humans; Insulin; Receptor, Insulin | 1988 |
Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin-dependent) diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycolysis; Humans; Insulin; Insulin Infusion Systems; Male; Middle Aged; Oxygen Consumption; Proteins; Reference Values | 1988 |
The beta-cell response to glucagon and mixed meal stimulation in non-insulin dependent diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Food; Glucagon; Humans; Insulin; Islets of Langerhans | 1988 |
[Pancreatic lesions of small-obese mice (C57BL/6 J-ob/ob) with hyperglucagonemia].
Topics: Age Factors; Animals; Cell Count; Diabetes Mellitus, Type 2; Glucagon; Islets of Langerhans; Mice; Mice, Obese; Microscopy, Electron | 1988 |
Residual B cell function in patients with long-standing NIDDM and its relation to metabolic control and diabetic complications.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Female; Glucagon; Humans; Islets of Langerhans; Male; Middle Aged | 1988 |
Comparison of glucose, glucagon and standard meal-induced insulin release in patients with newly onset non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Glucagon; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Male; Middle Aged | 1988 |
Metabolic abnormalities in children of non-insulin dependent diabetics.
Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male | 1986 |
[Possibility of transferring patients with type-II diabetes mellitus treated with small doses of sulfonylurea preparations to diet therapy].
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucagon; Glyburide; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Sulfonylurea Compounds | 1987 |
Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glipizide; Glucagon; Glucose; Glyburide; Humans; Hyperglycemia; Insulin; Insulin Secretion; Kinetics; Liver; Sulfonylurea Compounds | 1987 |
Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus.
Topics: Blood Glucose; Blood Urea Nitrogen; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Epinephrine; Female; Glucagon; Glyburide; Glycosuria; Humans; Insulin; Male; Middle Aged; Norepinephrine; Obesity | 1988 |
[Insulin therapy of obese diabetic patients? Consequences for the evaluation of insulin secretion and metabolic behavior].
Topics: Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Metabolism; Female; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle Aged; Obesity | 1987 |
[Surgical correction of metabolism in diabetes mellitus].
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Male; Middle Aged; Pancreas; Splenorenal Shunt, Surgical | 1988 |
Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes.
Topics: Autoantibodies; Autoimmune Diseases; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Heterozygote; HLA-D Antigens; HLA-DR Antigens; HLA-DR3 Antigen; HLA-DR4 Antigen; Humans; Insulin; Islets of Langerhans; Male; Parietal Cells, Gastric; Thyroid Gland | 1988 |
Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide. Effect on glycaemic control, serum lipids and lipoproteins.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucagon; Glycated Hemoglobin; Humans; Insulin; Lipids; Lipoproteins; Male; Middle Aged | 1988 |
Counterregulatory hormone responses preserved after long-term intravenous insulin infusion compared to continuous subcutaneous insulin infusion.
Topics: Adult; Diabetes Mellitus, Type 2; Dopamine; Epinephrine; Female; Glucagon; Growth Hormone; Hormones; Humans; Hydrocortisone; Hypoglycemia; Infusions, Intravenous; Insulin; Male; Norepinephrine | 1988 |
Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus.
Topics: Basal Metabolism; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Reducing; Fasting; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Liver; Male; Middle Aged; Obesity; Pancreas | 1988 |
Insulin/C-peptide response to intravenous glucagon. A dose-response study in normal and non-insulin-dependent diabetic subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucagon; Humans; Injections, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male | 1988 |
Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Infusions, Intravenous; Insulin; Insulin Secretion; Male; Middle Aged | 1988 |
Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose; Humans; Infusions, Intravenous; Insulin; Liver; Male; Middle Aged; Obesity | 1988 |
Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Infusion Systems; Islets of Langerhans; Male; Middle Aged; Proinsulin | 1988 |
Association of serum lipids and lipoproteins with plasma C-peptide concentration in non-insulin-dependent diabetic and non-diabetic subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Insulin Secretion; Lipids; Lipoproteins; Male; Middle Aged; Obesity | 1987 |
Effects of fasting on plasma glucose and prolonged tracer measurement of hepatic glucose output in NIDDM.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glycogen; Humans; Insulin; Kinetics; Liver; Male; Middle Aged; Tritium | 1987 |
Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
Topics: Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Glucagon; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Prospective Studies | 1987 |
Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Islets of Langerhans; Middle Aged; Sulfonylurea Compounds | 1987 |
Postprandial glucose, insulin and glucagon responses to meals with different nutrient compositions in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Proteins; Female; Glucagon; Glucose; Humans; Insulin; Male; Middle Aged | 1987 |
Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Female; Glucagon; Growth Hormone; Hemodynamics; Humans; Hydrocortisone; Hydroxybutyrates; Insulin; Male; Middle Aged; Pancreatic Polypeptide | 1987 |
Exaggerated plasma catecholamines and cortisol responses to hypoglycemic stress in essential hypertension.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Epinephrine; Glucagon; Growth Hormone; Humans; Hydrocortisone; Hypertension; Hypoglycemia; Middle Aged; Norepinephrine | 1988 |
Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Gluconeogenesis; Glucose; Humans; Hyperglycemia; Insulin; Liver; Male; Middle Aged; Tritium | 1986 |
Hyperglucagonemia in L-asparaginase induced diabetes mellitus.
Topics: Alanine; Asparaginase; Child; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Insulin; Leukemia, Lymphoid | 1986 |
[The glucagon test as a criterion of insulin administration in clinical practice].
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin | 1986 |
Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Interactions; Female; Food; Glipizide; Glucagon; Glucose; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Sulfonylurea Compounds; Terbutaline | 1986 |
The metabolic response to glucagon and glucagon-(1-21)-peptide in normal subjects and non insulin dependent diabetics.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucagon; Humans; Insulin; Peptide Fragments; Time Factors | 1986 |
Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM.
Topics: Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Islets of Langerhans; Male; Middle Aged; Rats; Sulfonylurea Compounds; Tolazamide; Tolbutamide | 1986 |
Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus.
Topics: Activity Cycles; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Tolerance Test; Growth Hormone; Humans; Insulin; Male; Middle Aged; Obesity | 1987 |
Plasma and urinary C-peptide in the classification of adult diabetics.
Topics: Adolescent; Adult; Aged; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Glucagon; Humans; Insulin; Insulin Secretion; Middle Aged | 1986 |
[Mechanism of the blunted glucagon response to insulin-induced hypoglycemia in diabetics].
Topics: Adolescent; Adult; Aged; Autonomic Nervous System; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Shy-Drager Syndrome | 1986 |
Altered C-peptide/insulin molar ratios and glucose turnover rates after stimulation in nondiabetic offsprings of type II diabetic patients.
Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Liver; Metabolic Clearance Rate; Time Factors | 1987 |
Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non insulin-dependent diabetic subjects.
Topics: Adult; Arginine; Blood Glucose; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Male; Middle Aged | 1987 |
[Present findings on the pathogenesis of type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Secretion | 1987 |
Pancreatic beta-cell secretion after oral glucose and intravenous glucagon: different responses to dietary control of plasma glucose in newly diagnosed patients with NIDDM.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet; Female; Glucagon; Glucose; Humans; Insulin; Islets of Langerhans; Male | 1987 |
Plasma C-peptide and insulin responses to intravenous glucagon stimulation in idiopathic haemochromatosis.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Hemochromatosis; Humans; Insulin; Male; Middle Aged; Time Factors | 1987 |
Estimation of B-cell function by the urinary excretion rate of C-peptide in diabetic patients: comparison with C-peptide response to glucagon and to a mixed meal.
Topics: Adult; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Food; Glucagon; Humans; Islets of Langerhans; Male; Obesity | 1987 |
Mechanism of metformin action in non-insulin-dependent diabetes.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Glycerol; Humans; Insulin; Kinetics; Lactates; Lactic Acid; Liver; Male; Metformin; Middle Aged | 1987 |
Hormonal and metabolic response to physical exercise in hyperinsulinemic and non-hyperinsulinemic type 2 diabetics.
Topics: Blood Glucose; Catecholamines; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Growth Hormone; Homeostasis; Hormones; Humans; Hydrocortisone; Insulin; Lactates; Male; Physical Exertion; Pyruvates | 1987 |
Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged | 1986 |
Repeatability of C-peptide response in glucagon stimulation test.
Topics: Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Injections, Intravenous; Male | 1987 |
Clinical characteristics in the discrimination between patients with low or high C-peptide level among middle-aged insulin-treated diabetics.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Male; Middle Aged; Sex Factors | 1987 |
Exercise and the management of diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Glucagon; Glucose; Humans; Hyperglycemia; Hypoglycemia; Ketone Bodies; Physical Exertion | 1987 |
Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in non-insulin-dependent diabetics and in control subjects.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Humans; Male; Middle Aged | 1987 |
Effect of serial test meals on plasma immunoreactive GIP in non-insulin dependent diabetic patients and non-diabetic controls.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Humans; Immune Sera; Insulin; Isoelectric Focusing; Male; Middle Aged; Radioimmunoassay | 1985 |
Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus.
Topics: Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 1985 |
[New findings on the mechanisms of secretion of glucagon].
Topics: Brain; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Hypoglycemia; Insulin; Ketone Bodies; Liver; Protein Kinases | 1985 |
Insulin secretion and immuno-genetic markers in diabetics with 'secondary failure' of oral hypoglycemic agents.
Topics: Administration, Oral; Adult; Aged; Autoantibodies; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged | 1985 |
Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus.
Topics: Adult; Arginine; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Epinephrine; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Norepinephrine; Obesity; Pregnancy; Pregnancy in Diabetics | 1985 |
Effect of clonidine on glucose, insulin and glucagon responses to a protein meal in type 2 diabetics.
Topics: Adult; Aged; Blood Glucose; Clonidine; Diabetes Mellitus, Type 2; Dietary Proteins; Female; Food; Glucagon; Glucose Tolerance Test; Humans; Hypertension; Insulin; Middle Aged | 1985 |
Physiological and metabolic responses to brief stress in non-insulin dependent diabetic and control subjects.
Topics: Adult; Aged; Arousal; Autonomic Nervous System Diseases; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Epinephrine; Glucagon; Heart Rate; Humans; Insulin; Middle Aged; Norepinephrine; Physical Exertion; Problem Solving; Pulse; Stress, Psychological | 1985 |
C-peptide determination in the choice of treatment in diabetes mellitus.
Topics: Adolescent; Adult; Aged; Body Weight; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Middle Aged | 1985 |
[Glucagon test: criterion for insulin therapy in type II diabetes mellitus].
Topics: C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin | 1985 |
[Effect of sodium salicylate on insulin secretion and blood glucose behavior in metabolically healthy and type II diabetic patients].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged; Sodium Salicylate | 1985 |
Glucose counterregulation in normal and diabetic man.
Topics: Autonomic Nervous System Diseases; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Epinephrine; Glucagon; Humans; Hypoglycemia; Insulin | 1985 |
[Secretion of pancreatic polypeptide and glucagon in patients with diabetes mellitus after the administration of insulin].
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Insulin; Male; Middle Aged; Pancreas; Pancreatic Function Tests; Pancreatic Polypeptide | 1985 |
The mechanism of exaggerated glucagon response to arginine in diabetes mellitus.
Topics: Adult; Aged; Arginine; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Infusion Systems; Kinetics; Middle Aged | 1985 |
A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence.
Topics: C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Glucagon; Humans; Insulin; Kinetics; Sulfonylurea Compounds | 1985 |
The C-peptide response to glucagon injections in IDDM and NIDDM patients.
Topics: C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Glucagon; Humans | 1985 |
Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats.
Topics: Animals; Animals, Newborn; Carbon Radioisotopes; Cells, Cultured; Cohort Studies; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon-Like Peptides; Glucose; Glycogen Synthase; Insulin; Liver; Muscle, Skeletal; Pancreatic Hormones; Peptides; Phosphorylases; Rats; Rats, Wistar | 1997 |